
<html lang="en"     class="pb-page"  data-request-id="a4055781-eb6a-446a-be5c-2bf69f5e5707"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2021.64.issue-10;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.1c00050;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Developing a Novel Anticancer Gold(III) Agent to Integrate Chemotherapy and Immunotherapy" /></meta><meta name="dc.Creator" content="Juzheng  Zhang" /></meta><meta name="dc.Creator" content="Ming  Jiang" /></meta><meta name="dc.Creator" content="Shanhe  Li" /></meta><meta name="dc.Creator" content="Zhenlei  Zhang" /></meta><meta name="dc.Creator" content="Hongbin  Sun" /></meta><meta name="dc.Creator" content="Feng  Yang" /></meta><meta name="dc.Creator" content="Hong  Liang" /></meta><meta name="dc.Description" content="To effectively treat gastric cancer, we innovatively attempted to develop a metal agent to integrate immunotherapy and chemotherapy by dual targeting the cellular components in the tumor microenvir..." /></meta><meta name="Description" content="To effectively treat gastric cancer, we innovatively attempted to develop a metal agent to integrate immunotherapy and chemotherapy by dual targeting the cellular components in the tumor microenvir..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 17, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00050" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00050" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00050" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00050" /></link>
        
    
    

<title>Developing a Novel Anticancer Gold(III) Agent to Integrate Chemotherapy and Immunotherapy | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00050" /></meta><meta property="og:title" content="Developing a Novel Anticancer Gold(III) Agent to Integrate Chemotherapy and Immunotherapy" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0012.jpeg" /></meta><meta property="og:description" content="To effectively treat gastric cancer, we innovatively attempted to develop a metal agent to integrate immunotherapy and chemotherapy by dual targeting the cellular components in the tumor microenvironment (TME) based on the specific residue of human serum albumin (HSA) nanoparticles (NPs). We synthesized a series of Au(III) α-N-heterocyclic thiosemicarbazone compounds and obtained a Au agent (5b) with remarkable cytotoxicity to gastric cancer cells; moreover, we successfully constructed a novel HSA-5b complex NP delivery system. Importantly, the in vivo results showed that 5b/HSA-5b NPs effectively inhibited gastric tumor growth and HSA-5b NPs enhanced the therapeutic efficiency, bioavailability, and targeting ability compared with those of 5b alone. Furthermore, the in vitro/in vivo results revealed that 5b/HSA-5b NPs could integrate chemotherapy and immunotherapy by synergistically attacking two different cellular components in TME at the same time, namely, polarizing the tumor-associated macrophages and inducing apoptosis of gastric cancer cells." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00050"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00050">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00050&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00050&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00050&amp;href=/doi/10.1021/acs.jmedchem.1c00050" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 10</span><span class="cit-fg-pageRange">, 6777-6791</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/10" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00039" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c00052" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Developing a Novel Anticancer Gold(III) Agent to Integrate Chemotherapy and Immunotherapy</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Juzheng Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Juzheng Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin, Guangxi 541004, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Juzheng++Zhang">Juzheng Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ming Jiang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ming Jiang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin, Guangxi 541004, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ming++Jiang">Ming Jiang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shanhe Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shanhe Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin, Guangxi 541004, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shanhe++Li">Shanhe Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhenlei Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhenlei Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin, Guangxi 541004, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhenlei++Zhang">Zhenlei Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hongbin Sun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hongbin Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, Nanjing, Jiangsu 210009, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hongbin++Sun">Hongbin Sun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Feng Yang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Feng Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin, Guangxi 541004, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#76100f171811361b171f1a14190e58110e180358131203581518"><span class="__cf_email__" data-cfemail="a6c0dfc7c8c1e6cbc7cfcac4c9de88c1dec8d388c3c2d388c5c8">[email protected]</span></a>. Phone and fax: 86-773-212-0958.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Feng++Yang">Feng Yang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-4201-1416" title="Orcid link">https://orcid.org/0000-0002-4201-1416</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Hong Liang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hong Liang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin, Guangxi 541004, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#422a2e2b232c25022f232b2e202d3a6c253a2c376c2726376c212c"><span class="__cf_email__" data-cfemail="afc7c3c6cec1c8efc2cec6c3cdc0d781c8d7c1da81cacbda81ccc1">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hong++Liang">Hong Liang</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00050&amp;href=/doi/10.1021%2Facs.jmedchem.1c00050" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 10</span><span class="cit-pageRange">, 6777–6791</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 17, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>12 January 2021</li><li><span class="item_label"><b>Published</b> online</span>17 May 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 May 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00050" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00050</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6777%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJuzheng%2BZhang%252C%2BMing%2BJiang%252C%2BShanhe%2BLi%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D10%26contentID%3Dacs.jmedchem.1c00050%26title%3DDeveloping%2Ba%2BNovel%2BAnticancer%2BGold%2528III%2529%2BAgent%2Bto%2BIntegrate%2BChemotherapy%2Band%2BImmunotherapy%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6791%26publicationDate%3DMay%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00050"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">546</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00050" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Developing a Novel Anticancer Gold(III) Agent to Integrate Chemotherapy and Immunotherapy&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Juzheng&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Ming&quot;,&quot;last_name&quot;:&quot;Jiang&quot;},{&quot;first_name&quot;:&quot;Shanhe&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Zhenlei&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Hongbin&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Feng&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;Liang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;17&quot;,&quot;issue&quot;:&quot;10&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;6777-6791&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00050&quot;},&quot;abstract&quot;:&quot;To effectively treat gastric cancer, we innovatively attempted to develop a metal agent to integrate immunotherapy and chemotherapy by dual targeting the cellular components in the tumor microenvironment (TME) based on the specific residue of human serum albumin (HSA) nanoparticles (NPs). We synthesized a series of Au(III) α-N-heterocyclic thiosemicarbazone compounds and obtained a Au agent (5b) with remarkable cytotoxicity to gastric cancer cells; moreover, we successfully constructed a novel HSA-5b complex NP delivery system. Importantly, the in vivo results showed that 5b/HSA-5b NPs effectively inhibited gastric tumor growth and HSA-5b NPs enhanced the therapeutic efficiency, bioavailability, and targeting ability compared with those of 5b alone. Furthermore, the in vitro/in vivo results revealed that 5b/HSA-5b NPs could integrate chemotherapy and immunotherapy by synergistically attacking two different cellular components in TME at the same time, namely, polarizing the tumor-associated macrophages and ind&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00050&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00050" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00050&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00050" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00050&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00050" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00050&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00050&amp;href=/doi/10.1021/acs.jmedchem.1c00050" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00050" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00050" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00050%26sid%3Dliteratum%253Aachs%26pmid%3D34000198%26genre%3Darticle%26aulast%3DZhang%26date%3D2021%26atitle%3DDeveloping%2Ba%2BNovel%2BAnticancer%2BGold%2528III%2529%2BAgent%2Bto%2BIntegrate%2BChemotherapy%2Band%2BImmunotherapy%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D10%26spage%3D6777%26epage%3D6791%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291909" title="Immunology">Immunology</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=291918" title="Gold">Gold</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/10" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/jmcmar.2021.64.issue-10/20210527/jmcmar.2021.64.issue-10.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/medium/jm1c00050_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00050&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">To effectively treat gastric cancer, we innovatively attempted to develop a metal agent to integrate immunotherapy and chemotherapy by dual targeting the cellular components in the tumor microenvironment (TME) based on the specific residue of human serum albumin (HSA) nanoparticles (NPs). We synthesized a series of Au(III) α-N-heterocyclic thiosemicarbazone compounds and obtained a Au agent (<b>5b</b>) with remarkable cytotoxicity to gastric cancer cells; moreover, we successfully constructed a novel <b>HSA-5b</b> complex NP delivery system. Importantly, the <i>in vivo</i> results showed that <b>5b</b>/<b>HSA-5b</b> NPs effectively inhibited gastric tumor growth and <b>HSA-5b</b> NPs enhanced the therapeutic efficiency, bioavailability, and targeting ability compared with those of <b>5b</b> alone. Furthermore, the <i>in vitro</i>/<i>in vivo</i> results revealed that <b>5b</b>/<b>HSA-5b</b> NPs could integrate chemotherapy and immunotherapy by synergistically attacking two different cellular components in TME at the same time, namely, polarizing the tumor-associated macrophages and inducing apoptosis of gastric cancer cells.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77822" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77822" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Traditional therapeutic approaches, which mainly include chemotherapy, radiotherapy, and surgical resection, play an important role in cancer treatment in the clinical setting. However, they cannot lead to a complete tumor regression, and recurrence and metastasis can occur in a short period of time.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Over the past several decades, many novel and promising strategies, especially immunotherapy, have extensively been studied and explored for treating cancer.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> In fact, many immune inhibitors have been approved by the U.S. Food and Drug Administration for immunotherapy, which provided benefit to many patients with advanced cancer.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Immunotherapy is considered to be one of the most important scientific breakthroughs in the field of cancer treatment, and research on immunotherapy was awarded the Nobel Prize in Physiology and Medicine in 2018.</div><div class="NLM_p">Immunotherapy is a method for improving and restoring the immune system function, maintaining the cancer-immunity cycle, and restoring the normal antitumor immune response of the body.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Although many different types of immune checkpoint inhibitors have been studied and used in the clinical setting,<a onclick="showRef(event, 'ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8">(6−8)</a> they often lead to a low response rate and have therapeutic effects in only a few tumors because they function by activating T cells rather than by directly killing cancer cells.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> Thus, to treat cancer in the clinical context, to overcome the deficiencies of immune checkpoint inhibitors, they are often combined with other anticancer drugs that kill cancer cells. However, the multidrug treatment can lead to serious toxic and side effects.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> Therefore, it is very important and urgent to exploit the novel immunotherapy strategies. Current studies have revealed that regulating and targeting tumor-associated macrophages (TAMs) is a promising and effective strategy for enhancing immunotherapy because TAMs are abundant immune cells in the tumor microenvironment (TME).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Interestingly, when TAMs are activated, they can release a variety of cytotoxic soluble factors (e.g., IL-12 and TNFα), which can consequently activate and recruit multiple effector cells (e.g., CD4<sup>+</sup>/CD8<sup>+</sup>T cells and NK cells) for tumor inhibition.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> For example, Ma et al. reported that Zn protoporphyrin nanoparticles (NPs) were able to polarize TAMs to inhibit tumor growth.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Yu et al. reported that Fe<sub>3</sub>O<sub>4</sub>@D-SiO<sub>2</sub>NPs also inhibited tumor growth by polarizing TAMs.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Indeed, reactive oxygen species (ROS) are necessary modulators for polarizing TAMs.<a onclick="showRef(event, 'ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18">(16−18)</a> Unfortunately, considering that cancer is a very complex disease, agents based on a single target or anticancer mechanism cannot cause complete tumor regression. Thus, to ensure effective tumor regression, it would be useful to design an agent that would integrate chemotherapy and immunotherapy by synergistic and simultaneous attacking of TAMs and cancer cells in the TME.</div><div class="NLM_p">Metal agents not only have good cytotoxic anticancer effects but also can induce long-lasting anticancer immune responses by producing ROS and affecting the TME.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Among them, gold [Au(I/III)] agents have extensively been studied as the promising next-generation anticancer metal drugs that can induce cancer cell apoptosis and affect anticancer immune responses.<a onclick="showRef(event, 'ref20 ref21 ref22 ref23 ref24 ref25 ref26 ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref22 ref23 ref24 ref25 ref26 ref27 ref28 ref29">(20−29)</a> Interestingly, while the Au(I) agent can inhibit the proliferation of T cells,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> the Au(III) agent can create a redox model to activate macrophages and further activate T cells.<a onclick="showRef(event, 'ref19 ref30'); return false;" href="javascript:void(0);" class="ref ref19 ref30">(19,30)</a> Therefore, to overcome the deficiencies of the immune checkpoint inhibitors and multidrug combinations, we may rationally combine the properties of Au and ligands to design a dual-targeting Au(III) agent, which not only can directly kill cancer cells by inducing their apoptosis but also can generate ROS to polarize TAMs. However, there are two key challenges: (1) how to improve the agent’s bioavailability and decrease its side effects <i>in vivo</i> and (2) how to achieve targeted cancer treatment. Excitingly, albumin has become one of the most promising carriers for overcoming the challenges mentioned above.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Recently, albumin NPs have been designed to enhance the therapeutic efficiency and targeting ability <i>in vivo</i>.<a onclick="showRef(event, 'ref32 ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34 ref35">(32−35)</a> Albumin conjugates have been designed to enhance the targeting ability of metal agents for photodynamic therapy.<a onclick="showRef(event, 'ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref36 ref37 ref38">(36−38)</a> HSA–metal agent complex delivery systems have been constructed to improve their targeting ability and decrease their side effects <i>in vivo</i>.<a onclick="showRef(event, 'ref39 ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref39 ref40 ref41 ref42">(39−42)</a></div><div class="NLM_p">Taking into consideration the factors mentioned above, we proposed to design a novel Au(III) thiosemicarbazone agent that can synergistically and simultaneously act against cancer cells and TAMs in the TME, thereby inducing cancer cell apoptosis and polarizing TAMs. Furthermore, an HSA–Au(III) thiosemicarbazone agent NP delivery system should be developed for integration of targeted chemotherapy and immunotherapy (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Thus, we conducted the following four studies. First, we designed and synthesized a series of Au α-N-heterocyclic thiosemicarbazone agents, followed by their optimization, by investigating their structure–activity relationships in gastric cancer cells (MGC-803). Second, we constructed a novel HSA–Au N-heterocyclic thiosemicarbazone agent complex NP delivery system for targeted therapy of cancer. Third, we compared and clarified the antitumor behavior of the Au agent and HSA–Au agent NPs <i>in vivo</i>. Finally, we confirmed and clarified that the anticancer mechanism of the Au agent and HSA–Au agent NPs involved the dual targeting of TAMs and cancer cells of the TME <i>in vitro</i> and <i>in vivo</i>.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/medium/jm1c00050_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Construction of HSA-Au agent complex NPs to integrate chemotherapy and immunotherapy of cancer by dual targeting of two different cellular components in the TME.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00050&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78455" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78455" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.1.  Design and Structure of Au 2-Hydroxy-5-methylbenzaldehyde Thiosemicarbazone Compounds</h3><div class="NLM_p">It is a promising strategy to design a novel anticancer metal agent by rationally combining the properties of the metal ions and ligands.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a> In fact, thiosemicarbazones have been one of the most promising anticancer agents.<a onclick="showRef(event, 'ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref45 ref46">(45,46)</a> To obtain a metal agent that can produce ROS, promote the expression of the immune markers in TAMs, and kill cancer cells by inducing their apoptosis, we designed and synthesized five Au 2-hydroxy-5-methylbenzaldehyde thiosemicarbazone compounds (<b>1b–5b</b>) and then characterized each of them.</div><div class="NLM_p">The structures of the five Au 2-hydroxy-5-methylbenzaldehyde thiosemicarbazone compounds were isomorphs. They all had the same skeleton [one tridentate Schiff base ligand, a Au(III) center, and one coordinated Cl atom] and differed only in the modified group of the ligands. All of the atoms (Au1, O1, N1, S1, and Cl1) were in the same plane as shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>. This tridentate ligand structure was favorable for the formation of five- and six-membered closed-loop rings. The relative crystal data for Au compounds are listed in <a class="ref internalNav" href="#notes1" aria-label="Tables S1 and S2">Tables S1 and S2</a>.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/medium/jm1c00050_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design and structures of 5-methylbenzaldehyde-thiosemicarbazide ligands (<b>1a–5a</b>) and the corresponding Au compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00050&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">2.2.  Structure–Activity Relationships of Au Compounds</h3><div class="NLM_p">The <i>in vitro</i> cytotoxicity of ligands (<b>1a–5a</b>) and the five Au(III) compounds (<b>1b–5b</b>) were examined in the human malignant cell lines MGC-803, MCF-7, SK-N-MC, and HepG-2, as well as in normal HL-7702 cells. The IC<sub>50</sub> values of the Au(III) compounds (1.21–19.39 μM) were significantly lower than those of the ligands (IC<sub>50</sub> > 40 μM). The cytotoxicity of compound <b>1b</b> against MGC-803 cells (IC<sub>50</sub>, 13.91 ± 1.13 μM) was the lowest of those of the five Au compounds. The cytotoxicity of <b>2b</b> was ∼2-fold higher than that of <b>1b</b> when one H atom on N3 of <b>1b</b> was replaced by a benzene group. The cytotoxicity of <b>3b</b> and <b>4b</b> was ∼3-fold higher than that of <b>1b</b> when two H atoms on N3 of <b>1b</b> were replaced by a lipophilic group. The cytotoxicity of <b>5b</b> (1.21 ± 0.15 μM) was increased ∼11-fold compared with that of <b>1b</b> (13.91 ± 1.13 μM) upon modification of two H atoms in N3 of <b>1b</b> by two methyl groups (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). In addition, an extra column with the selectivity index between the gastric cell line MGC-803 and normal cell line HL-7702 is also shown in <a class="ref internalNav" href="#notes1" aria-label="Figure S1">Figure S1</a>. Because <b>5b</b> had the highest cytotoxic activity in MGC-803 cells compared with other Au compounds <i>in vitro</i>, it was selected for subsequent studies.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. IC<sub>50</sub> Values of Au Compounds and HSA Complex NPs in Various Cell Lines after 48 h, as Examined by the MTT Method<a class="ref internalNav" href="#tbl1-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">MCF-7</th><th class="colsep0 rowsep0" align="center" char=".">SK-N-MC</th><th class="colsep0 rowsep0" align="center" char=".">MGC-803</th><th class="colsep0 rowsep0" align="center" char=".">HePG-2</th><th class="colsep0 rowsep0" align="center" char=".">TAMs</th><th class="colsep0 rowsep0" align="center" char=".">HL-7702</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1a</b></td><td class="colsep0 rowsep0" align="char" char=".">>40</td><td class="colsep0 rowsep0" align="char" char=".">>40</td><td class="colsep0 rowsep0" align="char" char=".">>40</td><td class="colsep0 rowsep0" align="char" char=".">>40</td><td class="colsep0 rowsep0" align="char" char=".">>40</td><td class="colsep0 rowsep0" align="char" char=".">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2a</b></td><td class="colsep0 rowsep0" align="char" char=".">>40</td><td class="colsep0 rowsep0" align="char" char=".">>40</td><td class="colsep0 rowsep0" align="char" char=".">>40</td><td class="colsep0 rowsep0" align="char" char=".">>40</td><td class="colsep0 rowsep0" align="char" char=".">>40</td><td class="colsep0 rowsep0" align="char" char=".">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3a</b></td><td class="colsep0 rowsep0" align="char" char=".">>40</td><td class="colsep0 rowsep0" align="char" char=".">>40</td><td class="colsep0 rowsep0" align="char" char=".">>40</td><td class="colsep0 rowsep0" align="char" char=".">>40</td><td class="colsep0 rowsep0" align="char" char=".">>40</td><td class="colsep0 rowsep0" align="char" char=".">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4a</b></td><td class="colsep0 rowsep0" align="char" char=".">>40</td><td class="colsep0 rowsep0" align="char" char=".">>40</td><td class="colsep0 rowsep0" align="char" char=".">>40</td><td class="colsep0 rowsep0" align="char" char=".">>40</td><td class="colsep0 rowsep0" align="char" char=".">>40</td><td class="colsep0 rowsep0" align="char" char=".">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5a</b></td><td class="colsep0 rowsep0" align="char" char=".">>40</td><td class="colsep0 rowsep0" align="char" char=".">>40</td><td class="colsep0 rowsep0" align="char" char=".">>40</td><td class="colsep0 rowsep0" align="char" char=".">>40</td><td class="colsep0 rowsep0" align="char" char=".">>40</td><td class="colsep0 rowsep0" align="char" char=".">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1b</b></td><td class="colsep0 rowsep0" align="char" char=".">10.89 ± 0.91</td><td class="colsep0 rowsep0" align="char" char=".">9.52 ± 1.16</td><td class="colsep0 rowsep0" align="char" char=".">13.91 ± 1.13</td><td class="colsep0 rowsep0" align="char" char=".">10.03 ± 0.52</td><td class="colsep0 rowsep0" align="char" char=".">38.19 ± 2.84</td><td class="colsep0 rowsep0" align="char" char=".">19.39 ± 1.43</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2b</b></td><td class="colsep0 rowsep0" align="char" char=".">7.31 ± 1.32</td><td class="colsep0 rowsep0" align="char" char=".">6.18 ± 0.21</td><td class="colsep0 rowsep0" align="char" char=".">7.76 ± 1.22</td><td class="colsep0 rowsep0" align="char" char=".">5.25 ± 1.13</td><td class="colsep0 rowsep0" align="char" char=".">32.66 ± 1.78</td><td class="colsep0 rowsep0" align="char" char=".">18.69 ± 2.53</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3b</b></td><td class="colsep0 rowsep0" align="char" char=".">4.16 ± 0.54</td><td class="colsep0 rowsep0" align="char" char=".">4.34 ± 0.47</td><td class="colsep0 rowsep0" align="char" char=".">4.42 ± 1.11</td><td class="colsep0 rowsep0" align="char" char=".">3.66 ± 1.42</td><td class="colsep0 rowsep0" align="char" char=".">29.39 ± 2.51</td><td class="colsep0 rowsep0" align="char" char=".">17.08 ± 1.72</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4b</b></td><td class="colsep0 rowsep0" align="char" char=".">4.38 ± 1.31</td><td class="colsep0 rowsep0" align="char" char=".">4.37 ± 1.27</td><td class="colsep0 rowsep0" align="char" char=".">4.76 ± 2.31</td><td class="colsep0 rowsep0" align="char" char=".">3.72 ± 1.32</td><td class="colsep0 rowsep0" align="char" char=".">30.11 ± 2.44</td><td class="colsep0 rowsep0" align="char" char=".">17.26 ± 1.41</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5b</b></td><td class="colsep0 rowsep0" align="char" char=".">3.70 ± 0.07</td><td class="colsep0 rowsep0" align="char" char=".">2.53 ± 0.67</td><td class="colsep0 rowsep0" align="char" char=".">1.21 ± 0.15</td><td class="colsep0 rowsep0" align="char" char=".">2.88 ± 1.12</td><td class="colsep0 rowsep0" align="char" char=".">28.57 ± 2.13</td><td class="colsep0 rowsep0" align="char" char=".">8.66 ± 1.32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>HSA-1b complex NPs</b></td><td class="colsep0 rowsep0" align="char" char=".">6.19 ± 1.29</td><td class="colsep0 rowsep0" align="char" char=".">5.53 ± 1.01</td><td class="colsep0 rowsep0" align="char" char=".">7.61 ± 1.14</td><td class="colsep0 rowsep0" align="char" char=".">6.11 ± 1.08</td><td class="colsep0 rowsep0" align="char" char=".">25.52 ± 1.99</td><td class="colsep0 rowsep0" align="char" char=".">35.39 ± 2.55</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>HSA-2b complex NPs</b></td><td class="colsep0 rowsep0" align="char" char=".">3.44 ± 0.92</td><td class="colsep0 rowsep0" align="char" char=".">3.53 ± 0.14</td><td class="colsep0 rowsep0" align="char" char=".">3.98 ± 1.24</td><td class="colsep0 rowsep0" align="char" char=".">3.15 ± 0.91</td><td class="colsep0 rowsep0" align="char" char=".">22.12 ± 2.41</td><td class="colsep0 rowsep0" align="char" char=".">32.15 ± 3.16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>HSA-3b complex NPs</b></td><td class="colsep0 rowsep0" align="char" char=".">2.42 ± 0.32</td><td class="colsep0 rowsep0" align="char" char=".">2.77 ± 1.11</td><td class="colsep0 rowsep0" align="char" char=".">2.18 ± 0.68</td><td class="colsep0 rowsep0" align="char" char=".">1.77 ± 1.01</td><td class="colsep0 rowsep0" align="char" char=".">20.62 ± 1.37</td><td class="colsep0 rowsep0" align="char" char=".">31.04 ± 2.67</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>HSA-4b complex NPs</b></td><td class="colsep0 rowsep0" align="char" char=".">3.08 ± 0.57</td><td class="colsep0 rowsep0" align="char" char=".">2.81 ± 1.63</td><td class="colsep0 rowsep0" align="char" char=".">2.22 ± 0.45</td><td class="colsep0 rowsep0" align="char" char=".">2.36 ± 0.78</td><td class="colsep0 rowsep0" align="char" char=".">21.29 ± 2.01</td><td class="colsep0 rowsep0" align="char" char=".">29.41 ± 1.51</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>HSA-5b complex NPs</b></td><td class="colsep0 rowsep0" align="char" char=".">2.19 ± 0.15</td><td class="colsep0 rowsep0" align="char" char=".">1.64 ± 0.23</td><td class="colsep0 rowsep0" align="char" char=".">0.60 ± 0.22</td><td class="colsep0 rowsep0" align="char" char=".">1.52 ± 0.84</td><td class="colsep0 rowsep0" align="char" char=".">18.86 ± 1.66</td><td class="colsep0 rowsep0" align="char" char=".">28.17 ± 1.29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Na[AuCl<sub>4</sub>]·2H<sub>2</sub>O</td><td class="colsep0 rowsep0" align="char" char=".">>100</td><td class="colsep0 rowsep0" align="char" char=".">>100</td><td class="colsep0 rowsep0" align="char" char=".">>100</td><td class="colsep0 rowsep0" align="char" char=".">>100</td><td class="colsep0 rowsep0" align="char" char=".">>100</td><td class="colsep0 rowsep0" align="char" char=".">>100</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl1-fn1"><div class="footnote" id="tbl1-fn1"><sup><sup>a</sup></sup><p class="last">The compounds were dissolved in DMSO and then diluted with PBS so that the level of DMSO in the solution was <1%.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">2.3.  Constructing a Novel <b>HSA-Au Agent</b> Complex NP Delivery System</h3><div id="sec2_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i8" class="anchor-spacer"></div><h4 class="article-section__title" id="_i8">2.3.1.  Structural Basis of the <b>HSA-Au Agent</b> Complex</h4><div class="NLM_p">We used surface plasmon resonance (SPR), the MALDI-TOF-MS spectrum, and X-ray crystallography to confirm whether the HSA-Au agent complex was formed. The SPR results demonstrated that the Au agent interacted with HSA (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). The MALDI-TOF-MS spectrum showed an increase in the molecular weight of approximately 432 Da, compared with that of HSA (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B), which corresponded to one Au agent molecule bound to an HSA molecule.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/medium/jm1c00050_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structural basis of the HSA-Au agent complex. (A) SPR of the Au agent bound to HSA. (B) MALDI-TOF-MS spectrum of HSA and the HSA-Au agent complex. (C) Experimental σA-weighted 2<i>F</i><sub>o</sub> – <i>F</i><sub>c</sub> electron density map of the Au agent in the IB subdomain. The Protein Data Bank entry is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7EEK">7EEK</a>. (D) Au agent bound to the hydrophobic cavity in the IB subdomain. (E) Environment for binding of the Au agent to the IB subdomain of HSA. (F) Overall structure of the HSA-Au agent complex.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00050&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To further confirm the site and mode of binding of the Au agent to HSA, we resolved the structure of the HSA-PA-Au agent complex. The electron density maps of the HSA complex clearly revealed the presence of one Au agent molecule at the IB subdomain (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C). In HSA’s IB subdomain, the Au agent bound to the long and narrow hydrophobic cavity (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>D). On one hand, His146 in the IB subdomain of HSA replaced its leaving group (Cl) and was coordinated with the Au(III) center; on the other hand, the other parts of the Au agent mainly form hydrophobic interactions with the residues surrounding HSA (Leu115, Tyr138, Arg145, Phe149, Leu154, Lyr161, and Lys190) (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>E), forming the stable HSA-Au agent complex. The overall structure of the HSA-Au agent complex was heart-shaped (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>F and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Data from Crystallographic Analysis of the HSA-PAL-Au Agent Complex</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">space group</td><td class="colsep0 rowsep0" align="left"><i>P</i>1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cell parameters</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>a</i>, <i>b</i>, <i>c</i> (Å)</td><td class="colsep0 rowsep0" align="left">38.19, 92.21, 95.44</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">α, β, γ</td><td class="colsep0 rowsep0" align="left">105.21, 89.68, 100.10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">resolution range (Å)</td><td class="colsep0 rowsep0" align="left">46.1–2.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">redundancy</td><td class="colsep0 rowsep0" align="left">3.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">completeness (%)</td><td class="colsep0 rowsep0" align="left">96.3 (97.6)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>I</i>/σ</td><td class="colsep0 rowsep0" align="left">14.6 (4.2)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i><sub>merge</sub> (%)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">5.2 (22.6)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i><sub>model</sub> (%)<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">24.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i><sub>free</sub> (%)<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">29.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">root-mean-square deviation from ideal bond lengths (Å)</td><td class="colsep0 rowsep0" align="left">0.003</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">root-mean-square deviation from ideal angles (deg)</td><td class="colsep0 rowsep0" align="left">0.612</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Values for the outermost resolution shell are given in parentheses.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last"><i>R</i><sub>merge</sub> = 100 × ∑<i><sub>h</sub></i>∑<i><sub>j</sub></i>|<i>I</i><sub><i>hj</i></sub> – <i>I</i><sub><i>h</i></sub>|/∑<i><sub>h</sub></i>∑<i><sub>j</sub>I</i><sub><i>hj</i></sub>, where <i>I</i><sub><i>h</i></sub> is the weighted mean intensity of symmetry-related refractions <i>I<sub>hj</sub></i>.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last"><i>R</i><sub>model</sub> = 100 × ∑<i><sub>hkl</sub></i>|<i>F</i><sub>obs</sub> – <i>F</i><sub>calc</sub>|/∑<i><sub>hkl</sub>F</i><sub>obs</sub>, where <i>F</i><sub>obs</sub> and <i>F</i><sub>calc</sub> are the observed and calculated structure factors, respectively.</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last"><i>R</i><sub>free</sub> is the <i>R</i><sub>model</sub> calculated using a randomly selected 5% sample of reflection data omitted from the refinement.</p></div></div></div></div><div id="sec2_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10">2.3.2.  Characterization of the HSA-Au Agent Complex NPs</h4><div class="NLM_p">We also used scanning electron microscopy (SEM) to confirm whether the HSA-Au agent complex NPs were successfully constructed. The SEM images of the HSA-Au agent complex NPs showed that they were spherical in structure and uniform in size with no adhesion and with an average particle size of 60.5 nm, which was in agreement with the dynamic light scattering (DLS) results (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). To test the stability of the HSA-Au agent complex NPs, we incubated them in water at 4 °C for 100 h, and then we detected their size by DLS. <a class="ref internalNav" href="#notes1" aria-label="Figure S2A">Figure S2A</a> shows that no significant changes were observed in the size of the HSA-Au agent complex NPs. The overlay of the HSA-Au agent complex NPs and HSA circular dichroism (CD) spectra in the range of 200–250 nm suggested that the HSA conformation remained unchanged after the HSA-Au agent complex NPs were constructed (<a class="ref internalNav" href="#notes1" aria-label="Figure S2B">Figure S2B</a>). Taken together, the HSA-Au agent complex NPs were homogeneous and stable.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/medium/jm1c00050_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Feasibility of constructing the HSA-Au agent complex NP delivery system. (A) Size and SEM of purified protein NPs. Scale bar, 200 nm. (B) <i>In vitro</i> release of the <b>HSA-5b complex NPs</b>. (C) <b>HSA-5b complex NPs</b> absorbed by MGC-803, HL-7702, and M2 macrophages, as determined by Western blotting. (D) Cellular uptake of the <b>5b</b>/<b>HSA-5b complex NPs</b> and accumulation of the Au agents in the cells, as determined by ICP-MS in HL-7702, MGC-803, and M2 macrophages at different time intervals during the treatment with <b>5b</b>/<b>HSA-5b complex NPs</b> at 8 μM. (E–G) Fluorescence images of the intracellular uptake of Cy5.5-<b>HSA-5b complex NPs</b> in MGC-803 tumor cells, HL-7702 cells, and M2 macrophages, respectively, using fluorescence microscopy. MGC-803 cells, HL-7702 cells, and M2 macrophages were incubated at 37 °C with Cy5.5-<b>HSA-5b complex NPs</b> for the times indicated, followed by staining with a lysosomal marker to show the process of Cy5.5-<b>HSA-5b complex NP</b> cellular trafficking.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00050&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11">2.3.3.  Release of the Au Agent from HSA Complex NPs</h4><div class="NLM_p last">To determine the feasibility of the HSA-Au agent complex NP delivery system, we investigated the behavior of the HSA-Au agent complex NPs by simulating the environments of blood circulation, TAMs, and cancer cells. Thus, we used inductively coupled plasma mass spectrometry (ICP-MS) to measure the content of the Au agent released from the HSA-Au agent NPs in buffers (pH 7.4 and 4.7) and Dulbecco’s modified Eagle’s medium (DMEM). The data showed that only ∼3% of the Au agent was released from the HSA complex NPs within 48 h at pH 7.4 and in DMEM. However, approximately 83% of the Au agent was released from the HSA complex NPs at pH 4.7 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B).</div></div><div id="sec2_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12">2.3.4.  Ability of the HSA Complex NPs to Target TAMs and Cancer Cells</h4><div class="NLM_p">To investigate the targeting ability of the <b>HSA-5b complex NPs</b> to normal cells, cancer cells, and TAMs, we incubated HL-7702, MGC-803, and M2 macrophages [RAW264.7, M2 macrophages were obtained via interleukin 4 (IL-4) treatment] with <b>5b</b> and <b>HSA-5b complex NPs</b> for 48 h. The results of ICP-MS and Western blotting showed that the content of Au and HSA in both MGC-803 and M2 macrophages was higher than in HL-7702 cells (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C,D), indicating that the HSA NPs facilitated the selective accumulation of the Au agent in cancer cells and M2 macrophages.</div><div class="NLM_p last">To further confirm the ability of the <b>HSA-5b complex NPs</b> to target normal cells, cancer cells, and TAMs, we labeled the <b>HSA-5b complex NPs</b> with Cy5.5 and incubated them with HL-7702, MGC-803, and M2 macrophages for fluorescence microscopy observation. The fluorescence intensity of MGC-803 and M2 macrophages was stronger than that of HL-7702 cells (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>E–G), suggesting that MGC-803 and M2 macrophages absorbed more <b>HSA-5b complex NPs</b> than did HL-7702 cells.</div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">2.4.  Antitumor Behavior of the <b>5b</b>/<b>HSA-5b NPs</b><i>In Vivo</i></h3><div id="sec2_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14">2.4.1.  Biosafety of the <b>5b</b>/<b>HSA-5b NPs</b><i>In Vivo</i></h4><div class="NLM_p last">To investigate the biosafety of the <b>5b</b>/<b>HSA-5b complex NPs</b><i>in vivo</i>, we examined the serum levels of blood urea nitrogen (BUN), serum creatinine (CRE), alkaline phosphatase (ALT), aspartate aminotransferase (AST), and creatine kinase (CK) in KM mice 14 days after intravenous injection. The results showed that the <b>5b</b>/<b>HSA-5b complex NPs</b> not only had low nephrotoxicity and cardiotoxicity in mice (considering that the values of BUN, CK, and CRE in the mice treated with <b>5b</b>/<b>HSA-5b complex NPs</b> were similar to those in mice treated with NaCl) but also did not damage the liver, as the levels of ALT and AST in the mice treated with <b>5b</b>/<b>HSA-5b complex NPs</b> were almost the same as those in the NaCl group (<a class="ref internalNav" href="#notes1" aria-label="Table S3">Table S3</a>).</div></div><div id="sec2_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15">2.4.2.  Therapeutic Efficacy of the <b>5b</b>/<b>HSA-5b NPs</b><i>In Vivo</i></h4><div class="NLM_p">To investigate the therapeutic efficacy of the <b>5b</b>/<b>HSA-5b complex NPs</b><i>in vivo</i>, we established a model of mouse gastric cancer (MFC) tumor-bearing 615 mice. These mice were injected with the <b>5b</b>/<b>HSA-5b complex NPs</b>, while the control group mice were injected with 0.9% normal saline. The tumor volume and body weight were monitored every 2 days for 28 days. The tumor growth inhibition rates (TIRs) of <b>5b</b> and <b>HSA-5b complex NPs</b> in mice were 51.1 ± 3.6% and 75.3 ± 4.3%, respectively (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A,B).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/medium/jm1c00050_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Antitumor behavior of the <b>5b</b>/<b>HSA-5b complex NPs</b><i>in vivo</i>. (A) The tumor volume of mouse gastric cancer cell (MFC) tumor-bearing 615 mice after administration of the vehicle control, <b>5b</b>, and <b>HSA-5b complex NPs</b> was measured every 2 days. (B) Tumor weight and tissue 2 days after the last treatment. (C) The average body weight was measured every 2 days for 28 days. (D) The major organs (heart, liver, spleen, lungs, and kidneys) were sliced for histopathological analysis of the H&E-stained sections (400×) 2 days after the last injection. (E) The average organ weight was measured 2 days after the last injection. (F) Au content of specific organs and tumors of the mice treated with <b>5b</b> and <b>HSA-5b complex NPs</b> 2 days after the last injection. *<i>p</i> < 0.05, **<i>p</i> < 0.02, and ***<i>p</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00050&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16">2.4.3.  Bioavailability and Side Effects of <b>5b</b>/<b>HSA-5b NPs</b><i>In Vivo</i></h4><div class="NLM_p">To evaluate the side effects of the <b>5b</b>/<b>HSA-5b complex NPs</b><i>in vivo</i>, we measured the body weight of the mice every 2 days. There was no difference in body weight between the mice treated with the <b>5b</b>/<b>HSA-5b complex NPs</b> and mice treated with NaCl [<i>p</i> > 0.05 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C)]. In addition, hematoxylin and eosin (H&E)-stained tissue sections indicated no significant differences in organ tissue morphology between the NaCl group and the treated groups (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>D). Furthermore, there was no significant weight difference in the organs between mice treated with the <b>5b</b>/<b>HSA-5b complex NPs</b> and the NaCl group (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>E). Both <b>5b</b> and <b>HSA-5b complex NPs</b> produced few side effects in the mice.</div><div class="NLM_p">To determine the bioavailability of the <b>5b</b>/<b>HSA-5b complex NPs</b><i>in vivo</i>, we used ICP-MS to measure the Au content in specific organs and tumors of mice treated with the <b>5b</b>/<b>HSA-5b complex NPs</b>. The results showed that the Au content in the tumors treated with <b>HSA-5b complex NPs</b> was significantly higher than in those treated with <b>5b</b> (<i>p</i> < 0.05). In addition, the <b>HSA-5b complex NPs</b> decreased the rate of accumulation of Au in the main organs of the mice (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>F).</div><div class="NLM_p">To further explore the bioavailability and targeting of the <b>HSA-5b complex NPs</b> in tumor-bearing mice, <i>in vivo</i> tracking experiments were carried out using the Cy5.5-labeled <b>HSA-5b complex NPs</b>. The results showed significant accumulation of the fluorescence signal in the tumor area but a decreased level of accumulation of the fluorescence signal in major organs (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A–C). Quantitative analysis of the fluorescence signal showed that the significant level of accumulation of the Cy5.5-labeled <b>HSA-5b complex NPs</b> in the tumor was more than 6-fold higher than that of free Cy5.5 (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>D) 6–24 h after injection. These observations indicated that the HSA complex NPs facilitated the selective accumulation of the Au agent in the tumor <i>in vivo</i>.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/medium/jm1c00050_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. <i>In vivo</i> fluorescence imaging of the mice bearing MFC tumors after the injection of free Cy5.5 or Cy5.5-<b>HSA-5b complex NPs</b>. <i>In vivo</i> fluorescence imaging results of (A) free Cy5.5 and (B) Cy5.5-<b>HSA-5b complex NPs</b> at different time intervals. (C) <i>Ex vivo</i> fluorescence images of major organs and tumors after the injection of free Cy5.5 and Cy5.5-<b>HSA-5b complex NPs</b> at 48 h. (D) Fluorescence intensity analysis of panels A and B. *<i>p</i> < 0.05, **<i>p</i> < 0.02, and ***<i>p</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00050&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">2.5.  Confirmation of the Mechanism of the <b>5b</b>/<b>HSA-5b NPs</b> Integrating Chemotherapy and Immunotherapy</h3><div id="sec2_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18">2.5.1.  Initiating Chemotherapy by Inducing Cancer Cell Apoptosis in TME</h4><div class="NLM_p">The TUNEL assay, H&E staining, and immunohistochemical analysis of the levels of caspase-3 in the tumor tissues were performed to evaluate apoptosis induced by <b>5b</b> and <b>HSA-5b NPs</b><i>in vivo</i> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). The tumor tissues treated with the <b>HSA-5b NPs</b> showed significant apoptosis and increased levels of caspase-3 compared with the tissues treated with <b>5b</b> and the control group, indicating that <b>HSA-5b NPs</b> had a greater capacity to kill cancer cells than <b>5b</b><i>in vivo</i>. Furthermore, the results of Annexin V-FITC/PI staining (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A) and AO/EB fluorescence probes (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B) showed that the <b>5b</b>/<b>HSA-5b NPs</b> induced MGC-803 cell apoptosis <i>in vitro</i>.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/medium/jm1c00050_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. <b>5b</b>/<b>HSA-5b complex NPs</b> inducing MGC-803 cell apoptosis <i>in vivo</i>. Tumor tissue stained with (A) the TUNEL and (B) the H&E assay (400×) in different groups. (C) Immunohistochemical analysis of caspase-3 levels in the tumor tissue 2 days after the last injections.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00050&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/medium/jm1c00050_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Mechanism by which the <b>5b</b>/<b>HSA-5b NPs</b> induce MGC-803 cell apoptosis. (A) Effect of apoptosis of MGC-803 cells treated with 0.6 μM <b>5b</b>/<b>HSA-5b NPs</b> for 24 h compared with the untreated cells. (B) Fluorescence microscopy of the MGC-803 cells treated with 0.6 μM <b>5b</b>/<b>HSA-5b NPs</b> for 24 h. AO/EB images were determined by using a fluorescence microscope. (C) Loss of mitochondrial membrane protein after treatment with the <b>5b</b>/<b>HSA-5b NPs</b>. The cells were incubated with 0.6 μM <b>5b</b>/<b>HSA-5b NPs</b> for 24 h, treated with JC-1, and examined by confocal microscopy (JC-1 indicator, green). (D) Decrease in cellular ATP levels in MGC-803 cells incubated with <b>5b</b>/<b>HSA-5b complex NPs</b>. The cells were treated with the indicated concentrations of the <b>5b</b>/<b>HSA-5b NPs</b> for 24 h. The luminescence intensity was measured in a microplate reader. (E) Enrichment of ROS in MGC-803 cells treated with the <b>5b</b>/<b>HSA-5b complex NPs</b>. The cells were incubated with 0.6 μM <b>5b</b>/<b>HSA-5b NPs</b> for 24 h, treated with DCFH, and examined by fluorescence microscopy (ROS indicator, green, 20×). (F) Cell death induced by <b>5b</b>/<b>HSA-5b NPs</b> was prevented by Mito-TEMPO. (G) Western blotting analysis of mitochondrion-mediated apoptosis markers in MGC-803 cells treated with 0.6 μM <b>5b</b>/<b>HSA-5b NPs</b> for 48 h. β-Actin was used as the internal control. (H) Expression levels of mitochondrion-mediated apoptosis markers shown as percentages; the values are relative to the control. *<i>p</i> < 0.05, **<i>p</i> < 0.02, and ***<i>p</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00050&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Previous studies have revealed that mitochondrial dysfunction can produce ROS and lead to cell apoptosis.<a onclick="showRef(event, 'ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24">(22−24)</a> To determine whether the Au agent induces apoptosis by mitochondrial dysfunction, we first confirmed that the Au(III) agent could accumulate in the mitochondria (<a class="ref internalNav" href="#notes1" aria-label="Figure S3">Figure S3</a>). The decrease in mitochondrial membrane potential and ATP levels showed that the <b>5b</b>/<b>HSA-5b NPs</b> caused mitochondrial dysfunction (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>C,D).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> In addition, H<sub>2</sub>DCFDA, an indicator of ROS, demonstrated that ROS were produced by the Au agent in cancer cells, which further suggested that the <b>5b</b>/<b>HSA-5b NPs</b> mediate mitochondrial dysfunction, ultimately leading to MGC-803 cell death (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>E,F). To confirm whether the mechanism of <b>5b</b> production of ROS in cancer cells occurred by a change in the valence in the Au agent, we used cyclic voltammetry to measure the Au<sup>I/III</sup> redox potentials of <b>5b</b>. The results showed that <b>5b</b> was within the range accessible to both cellular oxidants and reductants, and the Au(I) and Au(III) forms are chemically stable (<a class="ref internalNav" href="#notes1" aria-label="Figure S4">Figure S4</a>). Thus, <b>5b</b> could redox cycle to generate intracellular ROS.</div><div class="NLM_p last">To further confirm the apoptosis pathway, we next evaluated mitochondrion-mediated apoptotic proteins. The Western blotting results showed that the <b>5b</b>/<b>HSA-5b NPs</b> suppressed the levels of pro-survival proteins, including B cell lymphoma extra-large, B cell lymphoma 2, and inhibitor of apoptosis proteins; moreover, the expression levels of proapoptotic proteins p53, caspase-3/8/9, Bcl-2 homologous antagonist/killer, cytochrome <i>c</i>, and Smac were enhanced (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>G,H).<a onclick="showRef(event, 'ref48 ref49 ref50 ref51 ref52 ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref48 ref49 ref50 ref51 ref52 ref53 ref54">(48−54)</a> Together, these results revealed that the <b>5b</b>/<b>HSA-5b NPs</b> induced the apoptosis of MGC-803 cells via a mitochondrion-mediated pathway.</div></div><div id="sec2_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19">2.5.2.  Initiating Immunotherapy by Polarizing TAMs in TME</h4><div class="NLM_p">To determine whether the Au agent could polarize TAMs, we conducted the following experiment. As shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A, excessive ROS were generated in macrophages, which led to the significant upregulation of nuclear factor κ-light-chain enhancer of activated B cells (NF-κB) and nitric oxide synthase (iNOS), two genes that induce macrophage polarization to the tumor suppression M1 phenotype. However, Msr2 and STAT3, two genes that induce macrophage polarization to the tumor-promoting M2 phenotype, were suppressed <i>in vitro</i> and <i>in vivo</i> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B,C). Furthermore, Western blotting also demonstrated that <b>5b</b> significantly downregulated p-STAT3, STAT3, and programmed cell death protein 1 (PD-1, upregulated in M2 cells), whereas it markedly upregulated tumor necrosis factor (TNF-α, abundantly released when macrophages are polarized to the M1 phenotype) (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>D,E). Immunohistochemical analysis demonstrated that the <b>5b</b>/<b>HSA-5b NPs</b> significantly increased the level of the M1 macrophage marker (CD86) <i>in vivo</i> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>F). The <i>in vivo</i> results of the enzyme-linked immunoassay (ELISA) also showed that the serum levels of TNF-α and IL-12 (abundantly released in serum when macrophages are activated to the M1 phenotype) in the mice treated with the <b>HSA-5b NPs</b> were ∼5- and ∼2-fold higher, respectively, than in the control group (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>G). Together, these <i>in vitro</i> and <i>in vivo</i> results suggested that the <b>HSA-5b NPs</b> promoted the polarization of TAMs to the M1 phenotype.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/medium/jm1c00050_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Mechanism by which the <b>5b</b>/<b>HSA-5b NPs</b> polarized macrophages <i>in vivo</i> and <i>in vitro</i>. (A) Enrichment of ROS in M2 macrophages (RAW264.7) treated with the <b>5b</b>/<b>HSA-5b NPs</b>. M2 macrophages were obtained by IL-4 treatment (20 ng/mL). The cells were incubated with the <b>5b</b>/<b>HSA-5b NPs</b> for 24 h, treated with DCFH, and examined by fluorescence microscopy (ROS indicator, green, 20×). (B and C) Signaling pathway study of M2 macrophages <i>in vitro</i> and <i>in vivo</i> treated with the <b>5b</b>/<b>HSA-5b NPs</b>. Gene expression levels were examined by quantitative RT-PCR (qPCR) relative to the untreated control. (D) Western blot analysis of STAT3, P-STAT3, PD-1, and TNF-α in M2 macrophages treated with the <b>5b</b>/<b>HSA-5b NPs</b>; β-actin was used as the internal control. (E) Expression levels of STAT3, P-STAT3, PD-1, and TNF-α shown as percentages; β-actin was used as the internal control. (F) The level of M1 macrophage marker (CD86) in tumor tissue was determined by immunohistochemistry after the last injection. (G) Serum levels of M1 macrophage markers TNF-α and IL-12 were analyzed by an ELISA 24 h after the last injection. The asterisk indicates the difference between the treated group and the untreated group. *<i>p</i> < 0.05, **<i>p</i> < 0.02, ***<i>p</i> < 0.001, and ****<i>p</i> < 0.0001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00050&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">When TAMs are activated, they can release a variety of cytotoxic soluble factors (e.g., IL-12 and TNFα) that could consequently activate and recruit multiple effector cells (e.g., CD4<sup>+</sup>/CD8<sup>+</sup> T cells and NK cells). To evaluate the immunotherapeutic efficacy of the <b>5b</b>/<b>HSA-5b NPs</b><i>in vivo</i>, we used flow cytometry to analyze the percentage of activated CD8T cells (CD69<sup>+</sup>CD8<sup>+</sup>), CD4T cells (CD69<sup>+</sup>CD4<sup>+</sup>), and natural killer (NK) cells (CD69<sup>+</sup>NK<sup>+</sup>) in the tumors and tumor-draining lymph node (TDLN).<a onclick="showRef(event, 'ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref55 ref56">(55,56)</a> As shown in panels A and B of <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>, the <b>HSA-5b NPs</b> significantly increased the percentage of CD69<sup>+</sup>CD4<sup>+</sup>, CD69<sup>+</sup>CD8<sup>+</sup>, and CD69<sup>+</sup>NK<sup>+</sup> cells in the tumors and TDLN tissue ∼2–5-fold higher than that of <b>5b</b>. Furthermore, immunohistochemical staining indicated that the <b>5b</b>/<b>HSA-5b NPs</b> significantly upregulated PD-1 (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>D) and downregulated PD-L1 (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>C) in the tumor tissue, which indicated that T cells were activated. Together, these results revealed that the <b>HSA-5b NPs</b> significantly activated T cells and NK cells in the TME, consequently leading to tumor suppression.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/medium/jm1c00050_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Immune reaction of the <b>5b</b>/<b>HSA-5b NPs</b><i>in vivo</i>. (A and B) MFC tumor-bearing 615 mice were injected with <b>5b</b>, <b>HSA-5b NPs</b>, and negative control NaCl every 2 days for 28 days. The percentage of activated CD8 T cells (CD69<sup>+</sup>CD8<sup>+</sup>), activated CD4 T cells (CD69<sup>+</sup>CD4<sup>+</sup>), and activated NK cells (CD69<sup>+</sup>NK1.1<sup>+</sup>) in the (A) tumors and (B) TDLNs, analyzed by flow cytometry. (C and D) Tumor tissue with immune-associated protein PD-L1 and PD-1 immunohistochemical staining (400×). *<i>p</i> < 0.05, **<i>p</i> < 0.02, and ***<i>p</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00050&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">3.  Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06735" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06735" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">To overcome the deficiency of current immunotherapy strategies, we designed a novel Au agent capable of integrating chemotherapy and immunotherapy based on a new mechanism. Excitingly, we found that polarizing TAMs to the antitumor M1 phenotype by generating ROS <i>in vivo</i> was a novel and plausible approach for immunotherapy.<a onclick="showRef(event, 'ref19 ref30'); return false;" href="javascript:void(0);" class="ref ref19 ref30">(19,30)</a> Therefore, we proposed to develop a dual-function Au(III) agent to generate ROS,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> to polarize TAMs and induce cancer cell apoptosis at the same time. Indeed, our results fit well with our hypothesis because the Au α-N-heterocyclic thiosemicarbazone compound not only generated excess ROS to polarize macrophages but also induced cancer cell apoptosis directly <i>in vitro</i> and <i>in vivo</i>. Interestingly, the properties of Au α-N-heterocyclic thiosemicarbazone compounds can be optimized by substituting the hydrogen atom(s) in the N3 group of α-N-heterocyclic thiosemicarbazone with lipophilic group(s). Together, the Au α-N-heterocyclic thiosemicarbazone compound is a promising lead drug, which is worth developing as a novel next-generation anticancer dual-targeting metal agent for attacking the cellular components in the TME (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>).</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/medium/jm1c00050_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Au agent attacking the cellular components in the TME for integrating chemotherapy and immunotherapy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00050&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Currently, drugs are often encapsulated into HSA NPs to improve their ability to target cancer cells.<a onclick="showRef(event, 'ref31 ref32 ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref33 ref34 ref35">(31−35)</a> However, there are two potential disadvantages for such a drug delivery preparation method. First, HSA NPs may be disassembled in the circulation, which can allow the drug to be released from HSA NPs before it reaches the tumor. Second, the size of HSA NPs plays an important role in delivering the drug to the tumor, but it is difficult to synthesize a suitable size range of HSA NPs. If the size of HSA NPs is <30 nm, they are easily absorbed by the liver and eliminated by the kidney.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> When the size of HSA NPs is >200 nm, they are easily precipitated in the circulation and unlikely to have enhanced permeability and retention effect (EPR).<a onclick="showRef(event, 'ref58 ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref58 ref59 ref60">(58−60)</a> Thus, we proposed to develop HSA-metal agent complex NPs to avoid the problems mentioned above. Indeed, the X-ray crystallography results revealed that His146 replaced Cl in the Au agent bound to the HSA IB subdomain binding site and coordinated with Au<sup>3+</sup>, thus forming the HSA-Au agent complex. Furthermore, the SEM images showed that the HSA-Au agent complex NPs were structurally spheroidal and uniform in size, with an average particle size of 60.5 nm. Clearly, the size of HSA-Au agent complex NPs was effectively regulated because the Au agent did not occupy the center of the HSA NPs, but only bound to the hydrophobic cavity of the HSA IB subdomain by a coordination bond. Importantly, only a small amount of the Au agent (∼3%) was released from HSA NPs at pH 7.4 and DMEM, whereas ∼83% of the Au agent was released from the HSA-Au agent complex NPs at pH 4.7. This may be due to the fact that under the acidic conditions of the lysosome (pH 4.6–5.0), His146 in HSA is protonated and has a weakened ability to coordinate with the Au agent, thereby being released from HSA. The results of the release of the Au agent from the HSA-Au agent complex NPs suggested that HSA NPs were stable in the circulation, and that the Au agent was released from HSA NPs in cancer cells and TAMs.</div><div class="NLM_p last">The therapeutic efficiency of <b>HSA-5b NPs</b> was clearly superior to that of <b>5b</b> alone <i>in vivo</i>, as the rate of inhibition of the <b>HSA-5b NPs</b> (75.3%) was 1.5-fold higher than that of <b>5b</b> alone (51.1%). Furthermore, the immunotherapeutic efficiency of <b>HSA-5b NPs</b> was better than that of <b>5b</b> because <b>HSA-5b NPs</b> not only had the stronger capacity to activate NK cells in tumors and TDLNs than <b>5b</b> alone but also significantly downregulated PD-L1 and upregulated PD-1, which caused T cell activation. The results indicate that the HSA-Au(III) agent NPs can effectively activate T cells; in contrast, the gold(I) compound bound to HSA inhibits T cell proliferation.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> In addition, the <b>HSA-5b NPs</b> were well tolerated and produced few side effects <i>in vivo</i>, considering that they did not cause weight loss in mice and had low toxicity. Furthermore, the HSA NPs facilitated the selective accumulation of the Au agent into tumors and target cancer cells.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">4.  Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46688" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46688" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">To promote tumor regression to the maximum extent, we constructed an HSA-Au N-heterocyclic thiosemicarbazone agent complex nanoplatform to perform targeted cancer therapy. The HSA-Au agent complex NPs showed remarkable therapeutic efficacy by polarizing macrophages and inducing cancer cell apoptosis. The HSA NPs enhanced the targeting ability of the Au agent and decreased its side effects <i>in vivo</i>. Our experiments may pave the way for developing a promising dual-targeting Au N-heterocyclic thiosemicarbazone agent to integrate chemotherapy and immunotherapy for cancer patients by utilizing HSA complex NPs.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">5.  Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50460" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50460" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All of the chemical reagents were commercially available and used without further purification. The purity of all of the target agents used in the experiments was ≥95% (<a class="ref internalNav" href="#notes1" aria-label="Figures S5–S9">Figures S5–S9</a>), which was routinely verified by high-performance liquid chromatography. HSA (fatty acid content of <0.05%) was purchased from Sigma-Aldrich (Shanghai, China) and used for experiments without further purification. NaAuCl<sub>4</sub>·2H<sub>2</sub>O was purchased from Kunming (China) Platinum Rare Metal Material Co. All of the other chemicals and solvents were of analytical grade and provided by Alfa Aesar (Ward Hill, MA) or Sigma unless otherwise indicated. Secondary distilled water was used in the experiments. Elemental analyses (C, N, H, and S) were carried out by the PerkinElmer 2400 analyzer (PerkinElmer, Waltham, MA). The agent structure was determined using X-ray diffraction. <sup>1</sup>H and <sup>13</sup>C NMR analyses were conducted on the Bruker AVANCE III HD 400 MHz spectrophotometer at room temperature (298 K) in DMSO-<i>d</i><sub>6</sub>.</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23">5.1.  Synthesis and Characterization of Ligands (<b>1a–5a</b>)</h3><div class="NLM_p"><b>1a–5a</b> were synthesized by the reaction of 5-methylsalicylaldehyde with the N4 position of a thiosemicarbazone and the structural modification that can effectively increase the lipophilicity and produce superior antiproliferative activity. Synthesis and purification from Richardson et al., as previously described.<a onclick="showRef(event, 'ref61 ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref61 ref62 ref63">(61−63)</a></div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24">5.1.1.  2-Hydroxy-5-methylbenzaldehyde-thiosemicarbazide (<b>1a</b>)</h4><div class="NLM_p last">Yield: 89.3%. Anal. Calcd (%) for C<sub>9</sub>H<sub>11</sub>N<sub>3</sub>OS: C, 51.65; H, 5.30; N, 20.08; S, 15.32. Found: C, 51.69; H, 5.29; N, 20.07; S, 15.35. <sup>1</sup>H NMR (400 MHz, DMSO): δ 11.34 (s, 1 H, OH), 9.60 (s, 1 H, NH), 8.33 (s, 1 H, NCH), 8.10, 7.90 (2s, 2 H, NH2), 7.74 (s, 1 H), 7.01 (dd, <i>J</i> = 8.4, 2.3 Hz, 1 H), 6.75 (d, <i>J</i> = 8.3 Hz, 1 H), 2.20 (s, 3 H). <sup>13</sup>C NMR (100 MHz, DMSO): δ 177.59, 154.25, 139.74, 131.70, 127.80, 126.67, 119.87, 115.89, 20.00. ESI-MS: <i>m</i>/<i>z</i> 208.05 [M – H].</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25">5.1.2.  2-Hydroxy-5-methylbenzaldehyde-4-phenylthiosemicarbazide (<b>2a</b>)</h4><div class="NLM_p last">Yield: 79.5%. Anal. Calcd (%) for C<sub>15</sub>H<sub>15</sub>N<sub>3</sub>OS: C, 63.13; H, 5.30; N, 14.73; S, 11.24. Found: C, 63.16; H, 5.31; N, 14.70; S, 11.27. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.74 (s, 1 H, OH), 10.01 (s, 1 H, NH), 9.71 (s, 1 H, NH), 8.46 (s, 1 H, NCH), 7.86 (s, 1 H), 7.57–7.55 (m, 2 H), 7.39–7.35 (m, 2 H), 7.22–7.18 (m, 1 H), 7.04 (dd, <i>J</i> = 8.5, 2.2 Hz, 1 H), 6.78 (d, <i>J</i> = 8.2 Hz, 1 H), 4.35 (t, <i>J</i> = 5.0 Hz, 1 H), 2.23 (s, 3 H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 175.73, 154.47, 140.32, 139.15, 131.98, 128.00, 127.81, 126.84, 125.86, 125.20, 119.76, 115.91, 20.04. ESI-MS: <i>m</i>/<i>z</i> 284.09 [M – H].</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26">5.1.3.  2-Hydroxy-5-methylbenzaldehyde-3-(4-methylpiperidine)thiosemicarbazide (<b>3a</b>)</h4><div class="NLM_p last">Yield: 73.5%. Anal. Calcd (%) for C<sub>15</sub>H<sub>21</sub>N<sub>3</sub>OS: C, 61.82; H, 7.26; N, 14.42; S, 11.00. Found: C, 61.86; H, 7.23; N, 14.41; S, 11.01. <sup>1</sup>H NMR (400 MHz, DMSO): δ 11.39 (s, 1 H, OH), 11.35 (s, 1 H, NH), 8.40 (s, 1 H, NCH), 7.17 (d, <i>J</i> = 1.8 Hz, 1 H), 7.06 (dd, <i>J</i> = 8.3, 2.0 Hz, 1 H), 6.78 (d, <i>J</i> = 8.3 Hz, 1 H), 4.69 (d, <i>J</i> = 13.1 Hz, 2 H), 3.12–3.06 (m, 2 H), 2.24 (s, 3 H), 1.73–1.65 (m, 3 H), 1.19–1.05 (m, 2 H), 0.92 (d, <i>J</i> = 6.1 Hz, 3 H). <sup>13</sup>C NMR (100 MHz, DMSO): δ 178.60, 154.86, 145.86, 131.32, 129.80, 127.46, 118.13, 116.29, 48.78, 33.58, 30.20, 21.33, 19.88. ESI-MS: <i>m</i>/<i>z</i> 290.13 [M – H].</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27">5.1.4.  2-Hydroxy-5-methylbenzaldehyde-3-hexamethyleniminethiosemicarbazide (<b>4a</b>)</h4><div class="NLM_p last">Yield: 81.3%. Anal. Calcd (%) for C<sub>15</sub>H<sub>21</sub>N<sub>3</sub>OS: C, 61.82; H, 7.26; N, 14.42; S, 11.00. Found: C, 61.85; H, 7.25; N, 14.38; S, 11.01. <sup>1</sup>H NMR (400 MHz, DMSO): δ 11.58 (s, 1 H, OH), 11.17 (s, 1 H, NH), 8.52 (s, 1 H, NCH), 7.19 (d, <i>J</i> = 2.2 Hz, 1 H), 7.11 (dd, <i>J</i> = 8.4, 2.2 Hz, 1 H), 6.83 (d, <i>J</i> = 8.3 Hz, 1 H), 3.91 (s, 4 H), 2.28 (s, 3 H), 1.83–1.77 (m, 4 H), 1.55–1.53 (m, 4 H). <sup>13</sup>C NMR (100 MHz, DMSO): δ 178.43, 154.91, 146.37, 131.30, 130.02, 127.42, 118.04, 116.33, 50.87, 26.90, 26.13, 19.88. ESI-MS: <i>m</i>/<i>z</i> 290.13 [M – H].</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28">5.1.5.  2-Hydroxy-5-methylbenzaldehyde-4,4-dimethylthiosemicarbazide (<b>5a</b>)</h4><div class="NLM_p last">Yield: 84.4%. Anal. Calcd (%) for C<sub>11</sub>H<sub>15</sub>N<sub>3</sub>OS: C, 55.67; H, 6.37; N, 17.71; S, 13.51. Found: C, 55.69; H, 6.34; N, 17.70; S, 13.53. <sup>1</sup>H NMR (400 MHz, DMSO): δ 11.49 (s, 1 H, OH), 11.21 (s, 1 H, NH), 8.45 (s, 1 H, NCH), 7.16 (d, <i>J</i> = 2.1 Hz, 1 H), 7.07 (dd, <i>J</i> = 8.2, 2.2 Hz, 1 H), 6.79 (d, <i>J</i> = 8.3 Hz, 1 H), 3.29 (s, 6 H), 2.24 (s, 3 H). <sup>13</sup>C NMR (100 MHz, DMSO): δ 179.19, 154.91, 146.31, 131.33, 129.99, 127.46, 118.01, 116.32, 40.97, 19.87. ESI-MS: <i>m</i>/<i>z</i> 236.09 [M – H].</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29">5.2.  Synthesis and Characterization of Au(III) Compounds (<b>1b–5b</b>)</h3><div class="NLM_p"><b>1b–5b</b> were synthesized by the reaction of ligands <b>1a–5a</b> with Na[AuCl<sub>4</sub>]·2H<sub>2</sub>O. Ligands <b>1a–5a</b> (0.1 mmol) were dissolved in methanol (10 mL); Na[AuCl<sub>4</sub>]·2H<sub>2</sub>O (39.7 mg, 0.1 mmol) was added, and the reaction mixture was stirred at room temperature for 12 h, filtered, and vacuum-dried to obtain pale green solid. Solid complexes <b>1b–5b</b> were further recrystallized from CH<sub>2</sub>Cl<sub>2</sub>/<i>n</i>-hexane. The crystal complex (black crystal) was acquired by sealing and evaporating at room temperature. The spectroscopic characterization data are given below.</div><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30">5.2.1.  2-Hydroxy-5-methylbenzaldehyde-thiosemicarbazide-Au(III)-Chlorine (<b>1b</b>)</h4><div class="NLM_p last">Yield: 71.5%. CCDC 1934733. Anal. Calcd (%) for C<sub>9</sub>H<sub>9</sub>ClAuN<sub>3</sub>OS: C, 24.59; H, 2.06; N, 9.56; S, 7.29. Found: C, 24.61; H, 2.07; N, 9.54; S, 7.30. IR (cm<sup>–1</sup>): 3255 (s, amide), 3179 (s), 2914 (m, aromatic hydrogen), 1622 (s), 1593 (s), 1551 (s), 1473 (s, aromatic), 1389 (s, C═N), 1320 (s, thioamide), 1182 (s), 1154 (s), 1042 (m), 932 (m, C–H), 825 (S, C═S), 792 (s). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.77 (s, 1 H), 7.73 (s, 2 H), 7.52 (d, <i>J</i> = 1.8 Hz, 1 H), 7.41 (dd, <i>J</i> = 8.7, 2.3 Hz, 1 H), 6.94 (d, <i>J</i> = 8.6 Hz, 1 H), 2.25 (s, 3 H). ESI-MS: <i>m</i>/<i>z</i> 437.97 [M – H].</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31">5.2.2.  2-Hydroxy-5-methylbenzaldehyde-4-phenylthiosemicarbazide-Au(III)-Chlorine (<b>2b</b>)</h4><div class="NLM_p last">Yield: 59.6%, CCDC 1934730. Anal. Calcd (%) for C<sub>15</sub>H<sub>13</sub>ClAuN<sub>3</sub>OS: C, 34.93; H, 2.54; N, 8.15; S, 6.22. Found: C, 34.96; H, 2.55; N, 8.14; S, 6.21. IR (cm<sup>–1</sup>): 3451 (s, amide), 2916 (m, aromatic hydrogen), 1589 (s), 1536 (s), 1496 (s), 1444 (m, aromatic), 1385 (m, C═N), 1289 (s, thioamide), 1215 (s), 1166 (s), 1066 (m), 936 (m, C–H), 824 (s, C═S), 748 (s), 687 (s), 608 (m). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.87 (s, 1 H), 7.51 (d, <i>J</i> = 2.9 Hz, 1 H), 7.42 (dd, <i>J</i> = 8.6, 2.3 Hz, 1 H), 6.95 (d, <i>J</i> = 8.6 Hz, 1 H), 4.07 (d, <i>J</i> = 13.3 Hz, 2 H), 3.23–3.15 (m, 2 H), 2.24 (s, 3 H), 202–1.95 (m, 1 H), 1.72–1.61 (m, 4 H), 0.93 (d, <i>J</i> = 6.5 Hz, 3 H). ESI-MS: <i>m</i>/<i>z</i> 514.01 [M – H].</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32">5.2.3.  2-Hydroxy-5-methylbenzaldehyde-3-(4-methylpiperidine)thiosemicarbazide-Au(III)-Chlorine (<b>3b</b>)</h4><div class="NLM_p last">Yield: 70.1%. CCDC 1934729. Anal. Calcd (%) for C<sub>15</sub>H<sub>19</sub>ClAuN<sub>3</sub>OS: C, 34.57; H, 3.67; N, 8.05; S, 6.14. Found: C, 34.59; H, 3.66; N, 8.06; S, 6.15. IR (cm<sup>–1</sup>): 3436 (s, amide), 2923 (m, aromatic hydrogen), 1599 (s), 1529 (s), 1469 (s), 1452 (s, aromatic), 1358 (s, C═N), 1267 (s, thioamide), 1219 (s), 1172 (s), 970 (m, C–H), 820 (s, C═S), 796 (s). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.87 (s, 1 H), 7.51 (d, <i>J</i> = 2.9 Hz, 1 H), 7.42 (dd, <i>J</i> = 8.6, 2.3 Hz, 1 H), 6.95 (d, <i>J</i> = 8.6 Hz, 1 H), 4.07 (d, <i>J</i> = 13.3 Hz, 2 H), 3.23–3.15 (m, 2 H), 2.24 (s, 3 H), 1.72–1.69 (m, 3 H), 0.93 (d, <i>J</i> = 6.5 Hz, 3 H). ESI-MS: <i>m</i>/<i>z</i> 564.10 [M – Cl + DMSO].</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33">5.2.4.  2-Hydroxy-5-methylbenzaldehyde-3-hexamethyleniminethiosemicarbazide-Au(III)-Chlorine (<b>4b</b>)</h4><div class="NLM_p last">Yield: 55.6%. CCDC 1934732. Anal. Calcd (%) for C<sub>15</sub>H<sub>19</sub>ClAuN<sub>3</sub>OS: C, 34.57; H, 3.67; N, 8.05; S, 6.14. Found: C, 34.61; H, 3.68; N, 8.01; S, 6.16. IR (cm<sup>–1</sup>): 3424 (s, amide), 2921 (m, aromatic hydrogen), 1590 (s), 1528 (s), 1457 (s), 1457 (s, aromatic), 1391 (s, C═N), 1288 (s, thioamide), 1214 (s), 1139 (s), 972 (m, C–H), 824 (s, C═S), 794 (s). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.86 (s, 1 H), 7.53 (s, 1 H), 7.41 (dd, <i>J</i> = 8.7, 2.3 Hz, 1 H), 6.95 (d, <i>J</i> = 8.6 Hz, 1 H), 3.67 (t, <i>J</i> = 5.5 Hz, 4 H), 2.24 (s, 3H), 1.78–1.72 (m, 4 H), 1.56–1.52 (m, 4 H). ESI-MS: <i>m</i>/<i>z</i> 544.05 [M + Na].</div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34">5.2.5.  2-Hydroxy-5-methylbenzaldehyde-4,4-dimethylthiosemicarbazide-Au(III)-Chlorine (<b>5b</b>)</h4><div class="NLM_p last">Yield: 68.7%. CCDC 1934731. Anal. Calcd (%) for C<sub>11</sub>H<sub>13</sub>ClAuN<sub>3</sub>OS: C, 28.25; H, 2.80; N, 8.98; S, 6.86. Found: C, 28.29; H, 2.81; N, 8.97; S, 6.87. IR (cm<sup>–1</sup>): 3434 (s, amide), 2922 (m, aromatic hydrogen), 1590 (s), 1550 (s), 1432 (s, aromatic), 1414 (s, C═N), 1384 (s, thioamide), 1283 (s), 1261 (s), 1164 (m), 952 (m, C–H), 832 (s, C═S), 658 (m). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.84 (s, 1 H), 7.53 (d, <i>J</i> = 2.3 Hz, 1 H), 7.41 (dd, <i>J</i> = 8.6, 2.3 Hz, 1 H), 6.95 (d, <i>J</i> = 8.6 Hz, 1 H), 3.18 (s, 6 H), 2.24 (s, 3 H). ESI-MS: <i>m</i>/<i>z</i> 510.06 [M – Cl + DMSO].</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35">5.3.  X-ray Crystallography of the HSA-Au Agent Complex</h3><div class="NLM_p last">First, 243 μL of defatted HSA (41 mg/mL) and 390 μL of PA (2.5 mm) were incubated for 2 h at room temperature, followed by ultrafiltration washing with hyperpure H<sub>2</sub>O in triplicate, and then 20.05 μL of each Au agent (20 mM/L) was added to the mixture and incubated overnight. After ultrafiltration washing with hyperpure H<sub>2</sub>O, the mixture was concentrated to 100 g/L with a Millipore spin filter (10000 Da cutoff), and then crystallization was conducted as previously described.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The HSA-Au agent complex data were collected by a cryo-condition (100 K) with beamline BL17U of the Shanghai Synchrotron Radiation Facility, and then the data were processed with HKL2000. The HSA complex structure was determined by molecular replacement using PHASER in PHENIX suites with the initial model of the HSA-MYR structure, but the ligand was stripped in the initial search model. All of the ligands were built into the model by Ligand Fit in PHENIX and manually modified and adjusted in COOT.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36">5.4.  Preparation of the HSA-Au Agent Complex NPs</h3><div class="NLM_p last">The HSA-Au agent complex NPs were prepared by using a desolvation technique as previously described, with little modification. Briefly, 40 mg of HSA-Au agent complex powder dissolved in 2 mL of Milli-Q water was titrated to pH 8.2 using 0.1 N sodium hydroxide (NaOH), followed by dropwise addition of 8 mL of ethanol under stirring (800 rpm) at a rate of 1 mL/min. After the desolvation process, the nanoparticles were formed. Then, 23.5 μL of 8% glutaraldehyde was slowly added, and the solution was stirred for 24 h to cause particle cross-linking. The prepared nanoparticles were purified by two rounds of centrifugation (12000 rpm, 20 min). The pellet was redispersed to the original volume in water under ultrasonication over 10 min.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37">5.5.  Release of the Au Agent from HSA NPs</h3><div class="NLM_p last">First, buffers at pH 4.7, 7.4 and DMEM simulated the cell matrix, TME, interstitial space environment, and blood circulation, respectively. Then, the release of the Au agent from the HSA-Au agent complex NPs was determined by dialyzing the HSA-Au agent complex NPs in the dialysis pocket. Briefly, 2 mL of HSA-Au agent complex NPs in the dialysis pocket was dispersed in a beaker containing 100 mL of pH 4.7, 7.4 buffers and DMEM. To investigate the release behavior in different time intervals, seven tubes were prepared. The amount of the Au agent released from the HSA-Au agent complex NPs was determined by ICP-MS.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38">5.6.  <i>In Vivo</i> Animal Studies</h3><div class="NLM_p">Animal models were established. A total of 615 mice (6–7 weeks old) were used in the study. They were purchased from Beijing HFK Bioscience Co., Ltd. (Beijing, China). All of the animal experiments complied with the regulations from the People’s Republic of China’s Ministry of Health (Document 55, 2001) Committee’s Care and Use of Animals. The Institutional Animal Ethical Committee (IAEC) project number is SL-007-0.</div><div id="sec5_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39">5.6.1.  Acute Toxicity Assay</h4><div class="NLM_p last">The acute toxicity of the Au agent and HSA-Au agent complex NPs was assessed in healthy mice, as previously described. Eighteen healthy Kunming mice (with an equal number of males and females, 3–4 weeks old and weighing 18–22 g) were divided into three groups, with six mice in each group. Next, the different groups of mice were treated with the Au agent and HSA-Au agent complex NPs at doses of 2.5 μmol of Au/kg of body weight; NaCl was the control group. The serum samples were prepared from each group of mice 14 days after intravenous injection. The serum levels of the biochemical parameters, including BUN and CRE (renal function), CK, ALT, and AST, were determined.</div></div><div id="sec5_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40">5.6.2.  <i>In Vivo</i> Antitumor Behavior Assay</h4><div class="NLM_p last">A total of 615 mice (6–7 weeks old, female) were subcutaneously injected in the right dorsal region with 200 μL of a cell suspension containing 4 × 10<sup>6</sup> mouse gastric cancer cells (MFCs). When the tumor volume increased to approximately 100 mm<sup>3</sup>, the MFC tumor mice were divided into three groups, with three mice in each group. Depending on the group, each mouse was intravenously injected with NaCl, the Au agent, or HSA-Au agent complex NPs at doses of 2.5 μmol of Au/kg of body weight every 2 days. Each mouse in the different groups was tracked and labeled separately during the whole course of treatment. The tumor volume and weight of mice were measured and calculated with a Vernier caliper and analytical balance before each injection until the end of the experiment. The tumor volume was determined by the formula <i>V</i> = <sup>1</sup>/<sub>2</sub> × length × width<sup>2</sup>. After treatment for 28 days, the mice were killed. The correlation detection, involving serum detection, flow cytometry analysis, histopathological analysis, and immunohistochemical analysis staining of major organs and tumor tissues, was performed.</div></div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41">5.7.  Statistical Analysis</h3><div class="NLM_p last">Each experiment was repeated between three and five times. The significance of the difference was analyzed. The results were expressed as the mean ± the standard deviation, and <i>P</i> < 0.05 was considered to be statistically significant.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i42"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00050" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83112" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83112" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00050?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00050</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Experimental methods; crystal data and details of the structure refinement for Au agents; serological analysis of mice treated with NaCl, the Au agent, and HSA-Au agent complex NPs; cellular uptake of the Au agent and HSA-Au agent complex NPs; purity of compounds <b>1b–5b</b>, as characterized by HPLC; related primer lists; NMR spectra of ligands and Au agents; and ESI-MS spectra of ligands and Au agents (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00050/suppl_file/jm1c00050_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00050/suppl_file/jm1c00050_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00050/suppl_file/jm1c00050_si_001.pdf">jm1c00050_si_001.pdf (1.27 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00050/suppl_file/jm1c00050_si_002.csv">jm1c00050_si_002.csv (1.03 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Protein Data Bank entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7EEK">7EEK</a>, HSA-Au agent complex.</p><div class="testing" data-doi="10.1021/acs.jmedchem.1c00050" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11532" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11532" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Feng Yang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory for the Chemistry and Molecular Engineering of Medicinal
Resources, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin, Guangxi 541004, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-4201-1416" title="Orcid link">https://orcid.org/0000-0002-4201-1416</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b5d3ccd4dbd2f5d8d4dcd9d7dacd9bd2cddbc09bd0d1c09bd6db"><span class="__cf_email__" data-cfemail="96f0eff7f8f1d6fbf7fffaf4f9eeb8f1eef8e3b8f3f2e3b8f5f8">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong Liang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory for the Chemistry and Molecular Engineering of Medicinal
Resources, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin, Guangxi 541004, P. R. China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#5d3531343c333a1d303c34313f3225733a25332873383928733e33"><span class="__cf_email__" data-cfemail="620a0e0b030c05220f030b0e000d1a4c051a0c174c0706174c010c">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Juzheng Zhang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory for the Chemistry and Molecular Engineering of Medicinal
Resources, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin, Guangxi 541004, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ming Jiang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory for the Chemistry and Molecular Engineering of Medicinal
Resources, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin, Guangxi 541004, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shanhe Li</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory for the Chemistry and Molecular Engineering of Medicinal
Resources, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin, Guangxi 541004, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhenlei Zhang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory for the Chemistry and Molecular Engineering of Medicinal
Resources, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin, Guangxi 541004, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hongbin Sun</span> - <span class="hlFld-Affiliation affiliation">Jiangsu
Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, Nanjing, Jiangsu 210009, P. R. China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i44">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41611" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41611" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the Natural Science Foundation of China (22077021), the Natural Science Foundation of Guangxi (2017GXNSFEA198002 and AD17129007), and the Guangxi “Bagui” scholar program (H.S.) and the High-Level Innovation Team and Distinguished Scholar Program of Guangxi University (F.Y.).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">HSA</td><td class="NLM_def"><p class="first last">human serum albumin</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate-buffered saline</p></td></tr><tr><td class="NLM_term">TNF-α</td><td class="NLM_def"><p class="first last">tumor necrosis factor-α</p></td></tr><tr><td class="NLM_term">H<sub>2</sub>DCFDA</td><td class="NLM_def"><p class="first last">2′,7′-dichlorofluorescein diacetate</p></td></tr><tr><td class="NLM_term">JC-1</td><td class="NLM_def"><p class="first last">5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethyl-imidacarbocyanine iodide</p></td></tr><tr><td class="NLM_term">Mito-TEMPO</td><td class="NLM_def"><p class="first last">mitochondrion-targeted superoxide dismutase mimetic</p></td></tr><tr><td class="NLM_term">ROS</td><td class="NLM_def"><p class="first last">reactive oxygen species</p></td></tr><tr><td class="NLM_term">MALDI-TOF-MS</td><td class="NLM_def"><p class="first last">matrix-assisted laser desorption ionization time-of-flight mass spectrometry</p></td></tr><tr><td class="NLM_term">DLS</td><td class="NLM_def"><p class="first last">dynamic light scattering</p></td></tr><tr><td class="NLM_term">IRT</td><td class="NLM_def"><p class="first last">rate of inhibition of tumor growth</p></td></tr><tr><td class="NLM_term">PA</td><td class="NLM_def"><p class="first last">palmitic acid.</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i46">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35201" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35201" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 63 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span> <span> </span><span class="NLM_article-title">Cancer statistics</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.3322/caac.21332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.3322%2Fcaac.21332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=26742998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A280%3ADC%252BC28rot1Kjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2016&pages=7-30&author=R.+L.+Siegelauthor=K.+D.+Millerauthor=A.+Jemal&title=Cancer+statistics&doi=10.3322%2Fcaac.21332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer statistics, 2016</span></div><div class="casAuthors">Siegel Rebecca L; Miller Kimberly D; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival.  Incidence data were collected by the National Cancer Institute (Surveillance, Epidemiology, and End Results [SEER] Program), the Centers for Disease Control and Prevention (National Program of Cancer Registries), and the North American Association of Central Cancer Registries.  Mortality data were collected by the National Center for Health Statistics.  In 2016, 1,685,210 new cancer cases and 595,690 cancer deaths are projected to occur in the United States.  Overall cancer incidence trends (13 oldest SEER registries) are stable in women, but declining by 3.1% per year in men (from 2009-2012), much of which is because of recent rapid declines in prostate cancer diagnoses.  The cancer death rate has dropped by 23% since 1991, translating to more than 1.7 million deaths averted through 2012.  Despite this progress, death rates are increasing for cancers of the liver, pancreas, and uterine corpus, and cancer is now the leading cause of death in 21 states, primarily due to exceptionally large reductions in death from heart disease.  Among children and adolescents (aged birth-19 years), brain cancer has surpassed leukemia as the leading cause of cancer death because of the dramatic therapeutic advances against leukemia.  Accelerating progress against cancer requires both increased national investment in cancer research and the application of existing cancer control knowledge across all segments of the population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKAn5ROFAaRS86Js-BCLiifW6udTcc2eacrxJlq613Zrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rot1Kjug%253D%253D&md5=2d4030a531945c5ebaaab181bfd80457</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21332%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DMiller%26aufirst%3DK.%2BD.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DCancer%2520statistics%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2016%26volume%3D66%26spage%3D7%26epage%3D30%26doi%3D10.3322%2Fcaac.21332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span> <span> </span><span class="NLM_article-title">Photo-cross-linked scaffold with kartogenin-encapsulated nanoparticles for cartilage regeneration</span>. <i>ACS Nano</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1292</span>– <span class="NLM_lpage">1299</span>, <span class="refDoi"> DOI: 10.1021/acsnano.5b06663</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsnano.5b06663" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVKlsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=1292-1299&author=D.+Shiauthor=X.+Xuauthor=Y.+Yeauthor=K.+Songauthor=Y.+Chengauthor=J.+Diauthor=Q.+Huauthor=J.+Liauthor=H.+Juauthor=Q.+Jiangauthor=Z.+Gu&title=Photo-cross-linked+scaffold+with+kartogenin-encapsulated+nanoparticles+for+cartilage+regeneration&doi=10.1021%2Facsnano.5b06663"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Photo-Cross-Linked Scaffold with Kartogenin-Encapsulated Nanoparticles for Cartilage Regeneration</span></div><div class="casAuthors">Shi, Dongquan; Xu, Xingquan; Ye, Yanqi; Song, Kai; Cheng, Yixiang; Di, Jin; Hu, Quanyin; Li, Jianxin; Ju, Huangxian; Jiang, Qing; Gu, Zhen</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1292-1299</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The regeneration of cartilage, an aneural and avascular tissue, is often compromised by its lack of innate abilities to mount a sufficient healing response.  Kartogenin (KGN), a small mol. compd., can induce bone marrow-derived mesenchymal stem cells (BMSCs) into chondrocytes.  The previous in vitro study showed that kartogenin also had a chondrogenesis effect on synovium derived mesenchymal stem cells (SMSCs).  Herein, we present the effect of an UV-reactive, rapidly crosslinkable scaffold integrated with kartogenin-loaded nanoparticles using an innovational one-step technol.  In vivo studies showed its potential role for cell homing, esp. for recruiting the host's endogenous cells, including BMSCs and SMSCs, without cell transplantation.  Of note, the regenerated tissues were close to the natural hyaline cartilage based on the histol. tests, specific markers anal., and biomech. tests.  This innovative KGN release system makes the chondrogenesis efficient and persistent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-8sRc2vPm7bVg90H21EOLACvtfcHk0lgfbhNQZLvCCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVKlsLk%253D&md5=5cc651a480eb2b7f7b49768b52a77f6e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Facsnano.5b06663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsnano.5b06663%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DYe%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DDi%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DJu%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DGu%26aufirst%3DZ.%26atitle%3DPhoto-cross-linked%2520scaffold%2520with%2520kartogenin-encapsulated%2520nanoparticles%2520for%2520cartilage%2520regeneration%26jtitle%3DACS%2520Nano%26date%3D2016%26volume%3D10%26spage%3D1292%26epage%3D1299%26doi%3D10.1021%2Facsnano.5b06663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fesnak, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">June, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, B. L.</span></span> <span> </span><span class="NLM_article-title">Engineered T Cells: the promise and challenges of cancer immunotherapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">566</span>– <span class="NLM_lpage">581</span>, <span class="refDoi"> DOI: 10.1038/nrc.2016.97</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1038%2Fnrc.2016.97" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=27550819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlyqsbfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=566-581&author=A.+D.+Fesnakauthor=C.+H.+Juneauthor=B.+L.+Levine&title=Engineered+T+Cells%3A+the+promise+and+challenges+of+cancer+immunotherapy&doi=10.1038%2Fnrc.2016.97"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Engineered T cells: the promise and challenges of cancer immunotherapy</span></div><div class="casAuthors">Fesnak, Andrew D.; June, Carl H.; Levine, Bruce L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">566-581</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The immune system evolved to distinguish non-self from self to protect the organism.  As cancer is derived from our own cells, immune responses to dysregulated cell growth present a unique challenge.  This is compounded by mechanisms of immune evasion and immunosuppression that develop in the tumor microenvironment.  The modern genetic toolbox enables the adoptive transfer of engineered T cells to create enhanced anticancer immune functions where natural cancer-specific immune responses have failed.  Genetically engineered T cells, so-called 'living drugs', represent a new paradigm in anticancer therapy.  Recent clin. trials using T cells engineered to express chimeric antigen receptors (CARs) or engineered T cell receptors (TCRs) have produced stunning results in patients with relapsed or refractory hematol. malignancies.  In this Review we describe some of the most recent and promising advances in engineered T cell therapy with a particular emphasis on what the next generation of T cell therapy is likely to entail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwHuyW_V3JI7Vg90H21EOLACvtfcHk0lgfbhNQZLvCCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlyqsbfP&md5=9811eafadc8be8fcae3a25cbb30284a4</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2016.97&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2016.97%26sid%3Dliteratum%253Aachs%26aulast%3DFesnak%26aufirst%3DA.%2BD.%26aulast%3DJune%26aufirst%3DC.%2BH.%26aulast%3DLevine%26aufirst%3DB.%2BL.%26atitle%3DEngineered%2520T%2520Cells%253A%2520the%2520promise%2520and%2520challenges%2520of%2520cancer%2520immunotherapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2016%26volume%3D16%26spage%3D566%26epage%3D581%26doi%3D10.1038%2Fnrc.2016.97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span> <span> </span><span class="NLM_article-title">Cancer immunotherapy using checkpoint blockade</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>359</i></span>,  <span class="NLM_fpage">1350</span>– <span class="NLM_lpage">1355</span>, <span class="refDoi"> DOI: 10.1126/science.aar4060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1126%2Fscience.aar4060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=29567705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltFehtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2018&pages=1350-1355&author=A.+Ribasauthor=J.+D.+Wolchok&title=Cancer+immunotherapy+using+checkpoint+blockade&doi=10.1126%2Fscience.aar4060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer immunotherapy using checkpoint blockade</span></div><div class="casAuthors">Ribas, Antoni; Wolchok, Jedd D.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">6382</span>),
    <span class="NLM_cas:pages">1350-1355</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  The release of neg. regulators of immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates of long-lasting tumor responses in patients with a variety of cancers.  This can be achieved by antibodies blocking the cytotoxic T lymphocyte-assocd. protein 4 (CTLA-4) or the programmed cell death 1 (PD-1) pathway, either alone or in combination.  The main premise for inducing an immune response is the preexistence of antitumor T cells that were limited by specific immune checkpoints.  Most patients who have tumor responses maintain long-lasting disease control, yet one-third of patients relapse.  Mechanisms of acquired resistance are currently poorly understood, but evidence points to alterations that converge on the antigen presentation and interferon-γ signaling pathways.  New-generation combinatorial therapies may overcome resistance mechanisms to immune checkpoint therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHaFGKqeFnWLVg90H21EOLACvtfcHk0lgfbhNQZLvCCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltFehtb8%253D&md5=65120662af8a2c63425212b07e423939</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.aar4060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aar4060%26sid%3Dliteratum%253Aachs%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26atitle%3DCancer%2520immunotherapy%2520using%2520checkpoint%2520blockade%26jtitle%3DScience%26date%3D2018%26volume%3D359%26spage%3D1350%26epage%3D1355%26doi%3D10.1126%2Fscience.aar4060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dougan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dranoff, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougan, S. K.</span></span> <span> </span><span class="NLM_article-title">Cancer immunotherapy: beyond checkpoint blockade</span>. <i>Annu. Rev. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">75</span>, <span class="refDoi"> DOI: 10.1146/annurev-cancerbio-030518-055552</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1146%2Fannurev-cancerbio-030518-055552" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2019&pages=55-75&author=M.+Douganauthor=G.+Dranoffauthor=S.+K.+Dougan&title=Cancer+immunotherapy%3A+beyond+checkpoint+blockade&doi=10.1146%2Fannurev-cancerbio-030518-055552"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1146%2Fannurev-cancerbio-030518-055552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-cancerbio-030518-055552%26sid%3Dliteratum%253Aachs%26aulast%3DDougan%26aufirst%3DM.%26aulast%3DDranoff%26aufirst%3DG.%26aulast%3DDougan%26aufirst%3DS.%2BK.%26atitle%3DCancer%2520immunotherapy%253A%2520beyond%2520checkpoint%2520blockade%26jtitle%3DAnnu.%2520Rev.%2520Cancer%2520Biol.%26date%3D2019%26volume%3D3%26spage%3D55%26epage%3D75%26doi%3D10.1146%2Fannurev-cancerbio-030518-055552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maute, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dulken, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCracken, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ring, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissman, I. L.</span></span> <span> </span><span class="NLM_article-title">PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>545</i></span>,  <span class="NLM_fpage">495</span>– <span class="NLM_lpage">499</span>, <span class="refDoi"> DOI: 10.1038/nature22396</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1038%2Fnature22396" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=28514441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvVCrs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=545&publication_year=2017&pages=495-499&author=S.+R.+Gordonauthor=R.+L.+Mauteauthor=B.+W.+Dulkenauthor=G.+Hutterauthor=B.+M.+Georgeauthor=M.+N.+McCrackenauthor=R.+Guptaauthor=J.+M.+Tsaiauthor=R.+Sinhaauthor=D.+Coreyauthor=A.+M.+Ringauthor=A.+J.+Connollyauthor=I.+L.+Weissman&title=PD-1+expression+by+tumour-associated+macrophages+inhibits+phagocytosis+and+tumour+immunity&doi=10.1038%2Fnature22396"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity</span></div><div class="casAuthors">Gordon, Sydney R.; Maute, Roy L.; Dulken, Ben W.; Hutter, Gregor; George, Benson M.; McCracken, Melissa N.; Gupta, Rohit; Tsai, Jonathan M.; Sinha, Rahul; Corey, Daniel; Ring, Aaron M.; Connolly, Andrew J.; Weissman, Irving L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">545</span>
        (<span class="NLM_cas:issue">7655</span>),
    <span class="NLM_cas:pages">495-499</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor that is upregulated on activated T cells for the induction of immune tolerance.  Tumor cells frequently overexpress the ligand for PD-1, programmed cell death ligand 1 (PD-L1), facilitating their escape from the immune system.  Monoclonal antibodies that block the interaction between PD-1 and PD-L1, by binding to either the ligand or receptor, have shown notable clin. efficacy in patients with a variety of cancers, including melanoma, colorectal cancer, non-small-cell lung cancer and Hodgkin's lymphoma.  Although it is well established that PD-1-PD-L1 blockade activates T cells, little is known about the role that this pathway may have in tumor-assocd. macrophages (TAMs).  Here we show that both mouse and human TAMs express PD-1.  TAM PD-1 expression increases over time in mouse models of cancer and with increasing disease stage in primary human cancers.  TAM PD-1 expression correlates neg. with phagocytic potency against tumor cells, and blockade of PD-1-PD-L1 in vivo increases macrophage phagocytosis, reduces tumor growth and lengthens the survival of mice in mouse models of cancer in a macrophage-dependent fashion.  This suggests that PD-1-PD-L1 therapies may also function through a direct effect on macrophages, with substantial implications for the treatment of cancer with these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFC8j_ZPoELbVg90H21EOLACvtfcHk0liYsCqI4KqMKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvVCrs70%253D&md5=f428abc6d34ac6e3a18bfcf9371ea312</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnature22396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature22396%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DS.%2BR.%26aulast%3DMaute%26aufirst%3DR.%2BL.%26aulast%3DDulken%26aufirst%3DB.%2BW.%26aulast%3DHutter%26aufirst%3DG.%26aulast%3DGeorge%26aufirst%3DB.%2BM.%26aulast%3DMcCracken%26aufirst%3DM.%2BN.%26aulast%3DGupta%26aufirst%3DR.%26aulast%3DTsai%26aufirst%3DJ.%2BM.%26aulast%3DSinha%26aufirst%3DR.%26aulast%3DCorey%26aufirst%3DD.%26aulast%3DRing%26aufirst%3DA.%2BM.%26aulast%3DConnolly%26aufirst%3DA.%2BJ.%26aulast%3DWeissman%26aufirst%3DI.%2BL.%26atitle%3DPD-1%2520expression%2520by%2520tumour-associated%2520macrophages%2520inhibits%2520phagocytosis%2520and%2520tumour%2520immunity%26jtitle%3DNature%26date%3D2017%26volume%3D545%26spage%3D495%26epage%3D499%26doi%3D10.1038%2Fnature22396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nose, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span> <span> </span><span class="NLM_article-title">Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">151</span>, <span class="refDoi"> DOI: 10.1016/S1074-7613(00)80089-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1016%2FS1074-7613%2800%2980089-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10485649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADyaK1MXlvVShsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1999&pages=141-151&author=H.+Nishimuraauthor=M.+Noseauthor=H.+Hiaiauthor=N.+Minatoauthor=T.+Honjo&title=Development+of+lupus-like+autoimmune+diseases+by+disruption+of+the+PD-1+gene+encoding+an+ITIM+motif-carrying+immunoreceptor&doi=10.1016%2FS1074-7613%2800%2980089-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor</span></div><div class="casAuthors">Nishimura, Hiroyuki; Nose, Masato; Hiai, Hiroshi; Minato, Nagahiro; Honjo, Tasuku</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">141-151</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">PD-1, a 55 kDa transmembrane protein contg. an immunoreceptor tyrosine-based inhibitory motif, is induced in lymphocytes and monocytes following activation.  Aged C57BL/6(B6)-PD-1-/- congenic mice spontaneously developed characteristic lupus-like proliferative arthritis and glomerulonephritis with predominant IgG3 deposition, which were markedly accelerated by introduction of a Fas mutation (lpr).  Introduction of a PD-1 null mutation into the 2C-TCR (anti-H-2Ld) transgenic mice of the H-2b/d background resulted in the chronic and systemic graft-vs.- host-like disease.  Furthermore, CD8+2C-TCR+PD-1-/- T cells exhibited markedly augmented proliferation in vitro in response to H-2d allogeneic cells.  Collectively, it is suggested that PD-1 is involved in the maintenance of peripheral self-tolerance by serving as a neg. regulator of immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHFuMDDfhG3bVg90H21EOLACvtfcHk0liYsCqI4KqMKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvVShsb8%253D&md5=f627767082377fb523671a1635cb0a8f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS1074-7613%2800%2980089-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-7613%252800%252980089-8%26sid%3Dliteratum%253Aachs%26aulast%3DNishimura%26aufirst%3DH.%26aulast%3DNose%26aufirst%3DM.%26aulast%3DHiai%26aufirst%3DH.%26aulast%3DMinato%26aufirst%3DN.%26aulast%3DHonjo%26aufirst%3DT.%26atitle%3DDevelopment%2520of%2520lupus-like%2520autoimmune%2520diseases%2520by%2520disruption%2520of%2520the%2520PD-1%2520gene%2520encoding%2520an%2520ITIM%2520motif-carrying%2520immunoreceptor%26jtitle%3DImmunity%26date%3D1999%26volume%3D11%26spage%3D141%26epage%3D151%26doi%3D10.1016%2FS1074-7613%2800%2980089-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourque, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chernova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitz, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malenkovich, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horton, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fouser, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreno, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span> <span> </span><span class="NLM_article-title">Engagement of the Pd-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">1027</span>– <span class="NLM_lpage">1034</span>, <span class="refDoi"> DOI: 10.1084/jem.192.7.1027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1084%2Fjem.192.7.1027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=11015443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntFSlt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2000&pages=1027-1034&author=G.+J.+Freemanauthor=A.+J.+Longauthor=Y.+Iwaiauthor=K.+Bourqueauthor=T.+Chernovaauthor=H.+Nishimuraauthor=L.+J.+Fitzauthor=N.+Malenkovichauthor=T.+Okazakiauthor=M.+C.+Byrneauthor=H.+F.+Hortonauthor=L.+Fouserauthor=L.+Carterauthor=V.+Lingauthor=M.+R.+Bowmanauthor=B.+M.+Carrenoauthor=M.+Collinsauthor=C.+R.+Woodauthor=T.+Honjo&title=Engagement+of+the+Pd-1+immunoinhibitory+receptor+by+a+novel+B7+family+member+leads+to+negative+regulation+of+lymphocyte+activation&doi=10.1084%2Fjem.192.7.1027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation</span></div><div class="casAuthors">Freeman, Gordon J.; Long, Andrew J.; Iwai, Yoshiko; Bourque, Karen; Chernova, Tatyana; Nishimura, Hiroyuki; Fitz, Lori J.; Malenkovich, Nelly; Okazaki, Taku; Byrne, Michael C.; Horton, Heidi F.; Fouser, Lynette; Carter, Laura; Ling, Vincent; Bowman, Michael R.; Carreno, Beatriz M.; Collins, Mary; Wood, Clive R.; Honjo, Tasuku</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1027-1034</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">PD-1 is an immunoinhibitory receptor expressed by activated T cells, B cells, and myeloid cells.  Mice deficient in PD-1 exhibit a breakdown of peripheral tolerance and demonstrate multiple autoimmune features.  The authors report here that the ligand of PD-1 (PD-L1) is a member of the B7 gene family.  Engagement of PD-1 by PD-L1 leads to the inhibition of T cell receptor-mediated lymphocyte proliferation and cytokine secretion.  In addn., PD-1 signaling can inhibit at least suboptimal levels of CD28-mediated costimulation.  PD-L1 is expressed by antigen-presenting cells, including human peripheral blood monocytes stimulated with interferon γ, and activated human and murine dendritic cells.  In addn., PD-L1 is expressed in nonlymphoid tissues such as heart and lung.  The relative levels of inhibitory PD-L1 and costimulatory B7-1/B7-2 signals on antigen-presenting cells may det. the extent of T cell activation and consequently the threshold between tolerance and autoimmunity.  PD-L1 expression on nonlymphoid tissues and its potential interaction with PD-1 may subsequently det. the extent of immune responses at sites of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZIeEjiecqBbVg90H21EOLACvtfcHk0liYsCqI4KqMKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntFSlt7o%253D&md5=bc1499033282cd9dbfa396a4e2697f6e</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1084%2Fjem.192.7.1027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.192.7.1027%26sid%3Dliteratum%253Aachs%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26aulast%3DLong%26aufirst%3DA.%2BJ.%26aulast%3DIwai%26aufirst%3DY.%26aulast%3DBourque%26aufirst%3DK.%26aulast%3DChernova%26aufirst%3DT.%26aulast%3DNishimura%26aufirst%3DH.%26aulast%3DFitz%26aufirst%3DL.%2BJ.%26aulast%3DMalenkovich%26aufirst%3DN.%26aulast%3DOkazaki%26aufirst%3DT.%26aulast%3DByrne%26aufirst%3DM.%2BC.%26aulast%3DHorton%26aufirst%3DH.%2BF.%26aulast%3DFouser%26aufirst%3DL.%26aulast%3DCarter%26aufirst%3DL.%26aulast%3DLing%26aufirst%3DV.%26aulast%3DBowman%26aufirst%3DM.%2BR.%26aulast%3DCarreno%26aufirst%3DB.%2BM.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DWood%26aufirst%3DC.%2BR.%26aulast%3DHonjo%26aufirst%3DT.%26atitle%3DEngagement%2520of%2520the%2520Pd-1%2520immunoinhibitory%2520receptor%2520by%2520a%2520novel%2520B7%2520family%2520member%2520leads%2520to%2520negative%2520regulation%2520of%2520lymphocyte%2520activation%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2000%26volume%3D192%26spage%3D1027%26epage%3D1034%26doi%3D10.1084%2Fjem.192.7.1027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nanda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, L. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dees, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geva, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pusztai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pathiraja, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aktan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karantza, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buisseret, L.</span></span> <span> </span><span class="NLM_article-title">Pembrolizumab in patients with ad-vanced triple-negative breast cancer: phase ib keynote-012 study</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">2460</span>– <span class="NLM_lpage">2467</span>, <span class="refDoi"> DOI: 10.1200/JCO.2015.64.8931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1200%2FJCO.2015.64.8931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=27138582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFels7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=2460-2467&author=R.+Nandaauthor=L.+Q.+Chowauthor=E.+C.+Deesauthor=R.+Bergerauthor=S.+Guptaauthor=R.+Gevaauthor=L.+Pusztaiauthor=K.+Pathirajaauthor=G.+Aktanauthor=J.+D.+Chengauthor=V.+Karantzaauthor=L.+Buisseret&title=Pembrolizumab+in+patients+with+ad-vanced+triple-negative+breast+cancer%3A+phase+ib+keynote-012+study&doi=10.1200%2FJCO.2015.64.8931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study</span></div><div class="casAuthors">Nanda, Rita; Chow, Laura Q. M.; Dees, E. Claire; Berger, Raanan; Gupta, Shilpa; Geva, Ravit; Pusztai, Lajos; Pathiraja, Kumudu; Aktan, Gursel; Cheng, Jonathan D.; Karantza, Vassiliki; Buisseret, Laurence</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2460-2469</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Immune checkpoint inhibition has been demonstrated to be an effective anticancer strategy.  Several lines of evidence support the study of immunotherapy in triple-neg. breast cancer (TNBC).  We assessed the safety and antitumor activity of the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab in patients with advanced TNBC.  Methods KEYNOTE-012 (ClinicalTrials.gov identifier: NCT01848834) was amulticenter, nonrandomized phase Ib trial of single-agent pembrolizumab given i.v. at 10 mg/kg every 2 wk to patients with advanced PD-L1-pos. (expression in stroma or ≥ 1% of tumor cells by immunohistochem.) TNBC, gastric cancer, urothelial cancer, and head and neck cancer.  This report focuses on the TNBC cohort.  Results Among 111 patients with TNBC whose tumor samples were screened for PD-L1 expression, 58.6% had PD-L1-pos. tumors.  Thirty-two women (median age, 50.5 years; range, 29 to 72 years) were enrolled and assessed for safety and antitumor activity.  The median no. of doses administered was five (range, 1 to 36 doses).  Common toxicities were mild and similar to those obsd. in other tumor cohorts (eg, arthralgia, fatigue, myalgia, and nausea), and included five (15.6%) patients with grade ≥ 3 toxicity and one treatment-related death.  Among the 27 patients who were evaluable for antitumor activity, the overall response rate was 18.5%, the median time to response was 17.9 wk (range, 7.3 to 32.4 wk), and the median duration of response was not yet reached (range, 15.0 to ≥ 47.3 wk).  Conclusion This phase Ib study describes preliminary evidence of clin. activity and a potentially acceptable safety profile of pembrolizumab given every 2 wk to patients with heavily pretreated, advanced TNBC.  A single-agent phase II study examg. a 200-mg dose given once every 3 wk (ClinicalTrials.gov identifier: NCT02447003) is ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxATuIspigvrVg90H21EOLACvtfcHk0limxWF-VTCPIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFels7fM&md5=89877c871da52620104ee8bd8bac83fe</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1200%2FJCO.2015.64.8931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2015.64.8931%26sid%3Dliteratum%253Aachs%26aulast%3DNanda%26aufirst%3DR.%26aulast%3DChow%26aufirst%3DL.%2BQ.%26aulast%3DDees%26aufirst%3DE.%2BC.%26aulast%3DBerger%26aufirst%3DR.%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DGeva%26aufirst%3DR.%26aulast%3DPusztai%26aufirst%3DL.%26aulast%3DPathiraja%26aufirst%3DK.%26aulast%3DAktan%26aufirst%3DG.%26aulast%3DCheng%26aufirst%3DJ.%2BD.%26aulast%3DKarantza%26aufirst%3DV.%26aulast%3DBuisseret%26aufirst%3DL.%26atitle%3DPembrolizumab%2520in%2520patients%2520with%2520ad-vanced%2520triple-negative%2520breast%2520cancer%253A%2520phase%2520ib%2520keynote-012%2520study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D34%26spage%3D2460%26epage%3D2467%26doi%3D10.1200%2FJCO.2015.64.8931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braiteh, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eder, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolaney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuter, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassier, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delord, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ElGabry, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Hear, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fassò, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, P.</span></span> <span> </span><span class="NLM_article-title">Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study</span>. <i>JAMA Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">2986</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=2986&author=P.+Schmidauthor=C.+Cruzauthor=F.+S.+Braitehauthor=J.+P.+Ederauthor=S.+Tolaneyauthor=I.+Kuterauthor=R.+Nandaauthor=P.+A.+Cassierauthor=J.+P.+Delordauthor=M.+S.+Gordonauthor=E.+ElGabryauthor=C.+W.+Changauthor=I.+Sarkarauthor=W.+Grossmanauthor=C.+O%E2%80%99Hearauthor=M.+Fass%C3%B2author=L.+Molineroauthor=P.+Schmid&title=Long-term+clinical+outcomes+and+biomarker+analyses+of+atezolizumab+therapy+for+patients+with+metastatic+triple-negative+breast+cancer%3A+a+phase+1+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchmid%26aufirst%3DP.%26aulast%3DCruz%26aufirst%3DC.%26aulast%3DBraiteh%26aufirst%3DF.%2BS.%26aulast%3DEder%26aufirst%3DJ.%2BP.%26aulast%3DTolaney%26aufirst%3DS.%26aulast%3DKuter%26aufirst%3DI.%26aulast%3DNanda%26aufirst%3DR.%26aulast%3DCassier%26aufirst%3DP.%2BA.%26aulast%3DDelord%26aufirst%3DJ.%2BP.%26aulast%3DGordon%26aufirst%3DM.%2BS.%26aulast%3DElGabry%26aufirst%3DE.%26aulast%3DChang%26aufirst%3DC.%2BW.%26aulast%3DSarkar%26aufirst%3DI.%26aulast%3DGrossman%26aufirst%3DW.%26aulast%3DO%25E2%2580%2599Hear%26aufirst%3DC.%26aulast%3DFass%25C3%25B2%26aufirst%3DM.%26aulast%3DMolinero%26aufirst%3DL.%26aulast%3DSchmid%26aufirst%3DP.%26atitle%3DLong-term%2520clinical%2520outcomes%2520and%2520biomarker%2520analyses%2520of%2520atezolizumab%2520therapy%2520for%2520patients%2520with%2520metastatic%2520triple-negative%2520breast%2520cancer%253A%2520a%2520phase%25201%2520study%26jtitle%3DJAMA%2520Oncol.%26date%3D2017%26volume%3D77%26spage%3D2986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellman, I.</span></span> <span> </span><span class="NLM_article-title">Oncology meets immunology: the cancer-immunity cycle</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2013.07.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1016%2Fj.immuni.2013.07.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=23890059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOhs7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2013&pages=1-10&author=D.+Chenauthor=I.+Mellman&title=Oncology+meets+immunology%3A+the+cancer-immunity+cycle&doi=10.1016%2Fj.immuni.2013.07.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Oncology Meets Immunology: The Cancer-Immunity Cycle</span></div><div class="casAuthors">Chen, Daniel S.; Mellman, Ira</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The genetic and cellular alterations that define cancer provide the immune system with the means to generate T cell responses that recognize and eradicate cancer cells.  However, elimination of cancer by T cells is only one step in the Cancer-Immunity Cycle, which manages the delicate balance between the recognition of nonself and the prevention of autoimmunity.  Identification of cancer cell T cell inhibitory signals, including PD-L1, has prompted the development of a new class of cancer immunotherapy that specifically hinders immune effector inhibition, reinvigorating and potentially expanding preexisting anticancer immune responses.  The presence of suppressive factors in the tumor microenvironment may explain the limited activity obsd. with previous immune-based therapies and why these therapies may be more effective in combination with agents that target other steps of the cycle.  Emerging clin. data suggest that cancer immunotherapy is likely to become a key part of the clin. management of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbBQaWD_6lybVg90H21EOLACvtfcHk0limxWF-VTCPIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOhs7vL&md5=85f4befe58d8dc2e3901f4b2df0fdd6f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2013.07.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2013.07.012%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DD.%26aulast%3DMellman%26aufirst%3DI.%26atitle%3DOncology%2520meets%2520immunology%253A%2520the%2520cancer-immunity%2520cycle%26jtitle%3DImmunity%26date%3D2013%26volume%3D39%26spage%3D1%26epage%3D10%26doi%3D10.1016%2Fj.immuni.2013.07.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pohlmann, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolaney, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iizuka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powderly, J.</span></span> <span> </span><span class="NLM_article-title">Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: a phase 1b clinical trial</span>. <i>JAMA Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">334</span>– <span class="NLM_lpage">342</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2018.5152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1001%2Fjamaoncol.2018.5152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=30347025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A280%3ADC%252BB3cvhvFWgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=334-342&author=S.+Adamsauthor=J.+R.+Diamondauthor=E.+Hamiltonauthor=P.+R.+Pohlmannauthor=S.+M.+Tolaneyauthor=C.+W.+Changauthor=W.+Zhangauthor=K.+Iizukaauthor=P.+G.+Fosterauthor=L.+Molineroauthor=R.+Funkeauthor=J.+Powderly&title=Atezolizumab+plus+nab-paclitaxel+in+the+treatment+of+metastatic+triple-negative+breast+cancer+with+2-year+survival+follow-up%3A+a+phase+1b+clinical+trial&doi=10.1001%2Fjamaoncol.2018.5152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial</span></div><div class="casAuthors">Adams Sylvia; Diamond Jennifer R; Hamilton Erika; Pohlmann Paula R; Tolaney Sara M; Chang Ching-Wei; Zhang Wei; Iizuka Koho; Foster Paul G; Molinero Luciana; Funke Roel; Powderly John</div><div class="citationInfo"><span class="NLM_cas:title">JAMA oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">334-342</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Importance:  The humanized monoclonal antibody atezolizumab targets programmed death-ligand 1 and has demonstrated durable single-agent activity in a subset of metastatic triple-negative breast cancers.  To extend the observed activity, combinatorial approaches are being tested with standard cytotoxic chemotherapies known to induce immunogenic tumor cell death.  Objective:  To examine the safety, tolerability, and preliminary clinical activity of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancers.  Design, Setting, and Participants:  This phase 1b multicohort study enrolled 33 women with stage IV or locally recurrent triple-negative breast cancers and 0 to 2 lines of prior chemotherapy in the metastatic setting from December 8, 2014, to April 30, 2017, at 11 sites in the United States.  The median follow-up was 24.4 months (95% CI, 22.1-28.8 months).  Interventions:  Patients received concurrent intravenous atezolizumab and intravenous nab-paclitaxel (minimum 4 cycles).  Main Outcomes and Measures:  The primary end point was safety and tolerability.  Secondary end points included best overall response rate by Response Evaluation Criteria in Solid Tumors, version 1.1; objective response rate; duration of response; disease control rate; progression-free survival; overall survival; and biomarker analyses.  Results:  The 33 women had a median age of 55 years (range, 32-84 years) and received 1 or more doses of atezolizumab.  All patients (100%) experienced at least 1 treatment-related adverse event, 24 patients (73%) experienced grade 3/4 adverse events, and 7 patients (21%) had grade 3/4 adverse events of special interest.  No deaths were related to study treatment.  The objective response rate was 39.4% (95% CI, 22.9%-57.9%), and the median duration of response was 9.1 months (95% CI, 2.0-20.9 months).  The disease control rate was 51.5% (95% CI, 33.5%-69.2%).  Median progression-free survival and overall survival were 5.5 months (95% CI, 5.1-7.7 months) and 14.7 months (95% CI, 10.1-not estimable), respectively.  Concurrent nab-paclitaxel neither significantly changed biomarkers of the tumor immune microenvironment (programmed death-ligand 1, tumor-infiltrating lymphocytes, CD8) nor impaired atezolizumab systemic immune activation (expansion of proliferating CD8+ T cells, increase of CXCL10 chemokine).  Conclusions and Relevance:  In this phase 1b trial for metastatic triple-negative breast cancers, the combination of atezolizumab plus nab-paclitaxel had a manageable safety profile.  Antitumor responses were observed, including in patients previously treated with a taxane.  Trial Registration:  ClinicalTrials.gov identifier: NCT01633970.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRou_rsDK4nb7mQt-ICR3qNfW6udTcc2eYKpTOLQgrwxrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvhvFWgtQ%253D%253D&md5=a1dfd4fd703ab88ee3d768ff6cf7a622</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2018.5152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2018.5152%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DS.%26aulast%3DDiamond%26aufirst%3DJ.%2BR.%26aulast%3DHamilton%26aufirst%3DE.%26aulast%3DPohlmann%26aufirst%3DP.%2BR.%26aulast%3DTolaney%26aufirst%3DS.%2BM.%26aulast%3DChang%26aufirst%3DC.%2BW.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DIizuka%26aufirst%3DK.%26aulast%3DFoster%26aufirst%3DP.%2BG.%26aulast%3DMolinero%26aufirst%3DL.%26aulast%3DFunke%26aufirst%3DR.%26aulast%3DPowderly%26aufirst%3DJ.%26atitle%3DAtezolizumab%2520plus%2520nab-paclitaxel%2520in%2520the%2520treatment%2520of%2520metastatic%2520triple-negative%2520breast%2520cancer%2520with%25202-year%2520survival%2520follow-up%253A%2520a%2520phase%25201b%2520clinical%2520trial%26jtitle%3DJAMA%2520Oncol.%26date%3D2019%26volume%3D5%26spage%3D334%26epage%3D342%26doi%3D10.1001%2Fjamaoncol.2018.5152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span> <span> </span><span class="NLM_article-title">Tumor associated macrophage-targeted microRNA delivery with dual-responsive polypeptide nanovectors for anti-cancer therapy</span>. <i>Biomaterials</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">166</span>– <span class="NLM_lpage">179</span>, <span class="refDoi"> DOI: 10.1016/j.biomaterials.2017.04.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1016%2Fj.biomaterials.2017.04.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=28463694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvVGisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2017&pages=166-179&author=L.+Liuauthor=H.+Yiauthor=H.+Heauthor=H.+Panauthor=L.+Caiauthor=Y.+Ma&title=Tumor+associated+macrophage-targeted+microRNA+delivery+with+dual-responsive+polypeptide+nanovectors+for+anti-cancer+therapy&doi=10.1016%2Fj.biomaterials.2017.04.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor associated macrophage-targeted microRNA delivery with dual-responsive polypeptide nanovectors for anti-cancer therapy</span></div><div class="casAuthors">Liu, Lanlan; Yi, Huqiang; He, Huamei; Pan, Hong; Cai, Lintao; Ma, Yifan</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">166-179</span>CODEN:
                <span class="NLM_cas:coden">BIMADU</span>;
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Repolarizing Tumor-assocd. macrophages (TAMs) to anti-tumor M1 macrophages with microRNA (miR) is a plausible approach for cancer treatment.  However, how to achieve TAM-targeted miR delivery remains a challenge.  The present study generated redox/pH dual-responsive hybrid polypeptide nanovectors, which consisted of self-crosslinked redox-responsive nanoparticles based on galactose-functionalized n-butylamine-poly(L-lysine)-b-poly(L-cysteine) polypeptides (GLC) coated with DCA-grafted sheddable PEG-PLL (sPEG) copolymers.  The ex vivo study showed that sPEG shielded cationic GLC core at physiol. pH but quickly shed off to re-expose GLC due to it charge reversible property.  Encapsulation with sPEG/GLC nanovectors effectively facilitated macrophage-targeted miR delivery at the acidic condition but diminished miR uptake at neutral pH.  Administration of miR155-loaded sPEG/GLC (sPEG/GLC/155) nanocomplexes increased miR155 expression in TAMs about 100-400 folds both in vitro and in vivo. sPEG/GLC/155 also effectively repolarized immunosuppressive TAMs to anti-tumor M1 macrophages through elevating M1 macrophage markers (IL-12, iNOS, MHC II) and suppressing M2 macrophage markers (Msr2 and Arg1) in TAMs.  Moreover, the treatment of sPEG/GLC/155 significantly increased activated T lymphocytes and NK cells in tumors, which consequently led to robust tumor regression.  Hence, TAM-targeted delivery of miR with redox/pH dual-responsive sPEG/GLC nanovectors could be a promising approach to re-polarize TAMs to M1 macrophages in situ and induce tumor regression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbRBf33UjOp7Vg90H21EOLACvtfcHk0ljEcelzZaCcMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvVGisro%253D&md5=3ac17bd522d7f49fe811da3442a5feca</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2017.04.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2017.04.043%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DYi%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DPan%26aufirst%3DH.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DMa%26aufirst%3DY.%26atitle%3DTumor%2520associated%2520macrophage-targeted%2520microRNA%2520delivery%2520with%2520dual-responsive%2520polypeptide%2520nanovectors%2520for%2520anti-cancer%2520therapy%26jtitle%3DBiomaterials%26date%3D2017%26volume%3D134%26spage%3D166%26epage%3D179%26doi%3D10.1016%2Fj.biomaterials.2017.04.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, L.</span></span> <span> </span><span class="NLM_article-title">ROS-inducing micelles sensitize tumor-associated macrophages to TLR3 stimulation for potent immunotherapy</span>. <i>Biomacromolecules</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2146</span>– <span class="NLM_lpage">2155</span>, <span class="refDoi"> DOI: 10.1021/acs.biomac.8b00239</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biomac.8b00239" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnslKmtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=2146-2155&author=L.+Liuauthor=H.+Heauthor=R.+Liangauthor=H.+Yiauthor=X.+Mengauthor=Z.+Chenauthor=H.+Panauthor=Y.+Maauthor=L.+Cai&title=ROS-inducing+micelles+sensitize+tumor-associated+macrophages+to+TLR3+stimulation+for+potent+immunotherapy&doi=10.1021%2Facs.biomac.8b00239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">ROS-inducing micelles sensitize tumor-associated macrophages to TLR3 stimulation for potent immunotherapy</span></div><div class="casAuthors">Liu, Lanlan; He, Huamei; Liang, Ruijing; Yi, Huqiang; Meng, Xiaoqing; Chen, Zhikuan; Pan, Hong; Ma, Yifan; Cai, Lintao</div><div class="citationInfo"><span class="NLM_cas:title">Biomacromolecules</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2146-2155</span>CODEN:
                <span class="NLM_cas:coden">BOMAF6</span>;
        ISSN:<span class="NLM_cas:issn">1525-7797</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">One approach to cancer immunotherapy is the repolarization of immunosuppressive tumor-assocd. macrophages (TAMs) to antitumor M1 macrophages.  The present study developed galactose-functionalized zinc protoporphyrin IX (ZnPP) grafted poly(L-lysine)-b-poly(ethylene glycol) polypeptide micelles (ZnPP PM) for TAM-targeted immunopotentiator delivery, which aimed at in vivo repolarization of TAMs to antitumor M1 macrophages.  The outcomes revealed that ROS-inducing ZnPP PM demonstrated specificity for the in vitro and in vivo targeting of macrophages, elevated the level of ROS, and lowered STAT3 expression in BM-TAMs.  Poly I:C (PIC, a TLR3 agonist)-loaded ZnPP PM (ZnPP PM/PIC) efficiently repolarized TAMs to M1 macrophages, which were reliant on ROS generation.  Further, ZnPP PM/PIC substantially elevated the activated NK cells and T lymphocytes in B16-F10 melanoma tumors, which caused vigorous tumor regression.  Therefore, the TAM-targeted transport of an immunol. adjuvant with ZnPP-grafted nanovectors may be a potential strategy to repolarize TAMs to M1 macrophages in situ for effective cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH90CD71cMjrVg90H21EOLACvtfcHk0ljEcelzZaCcMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnslKmtLw%253D&md5=574e353538168791fb446a6b3c043125</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facs.biomac.8b00239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biomac.8b00239%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DLiang%26aufirst%3DR.%26aulast%3DYi%26aufirst%3DH.%26aulast%3DMeng%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DPan%26aufirst%3DH.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DL.%26atitle%3DROS-inducing%2520micelles%2520sensitize%2520tumor-associated%2520macrophages%2520to%2520TLR3%2520stimulation%2520for%2520potent%2520immunotherapy%26jtitle%3DBiomacromolecules%26date%3D2018%26volume%3D19%26spage%3D2146%26epage%3D2155%26doi%3D10.1021%2Facs.biomac.8b00239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuong, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span> <span> </span><span class="NLM_article-title">On the mechanism of iron oxide-induced macrophage activation: the impact of composition and the underlying signaling pathway</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">6122</span>– <span class="NLM_lpage">6126</span>, <span class="refDoi"> DOI: 10.1021/jacs.8b10904</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.8b10904" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtlWgsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2019&pages=6122-6126&author=Z.+Guauthor=T.+Liuauthor=J.+Tangauthor=Y.+Yangauthor=H.+Songauthor=Z.+K.+Tuongauthor=J.+Fuauthor=C.+Yu&title=On+the+mechanism+of+iron+oxide-induced+macrophage+activation%3A+the+impact+of+composition+and+the+underlying+signaling+pathway&doi=10.1021%2Fjacs.8b10904"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of iron oxide-induced macrophage activation: The impact of composition and the underlying signaling pathway</span></div><div class="casAuthors">Gu, Zhengying; Liu, Tianqing; Tang, Jie; Yang, Yannan; Song, Hao; Tuong, Zewen K.; Fu, Jianye; Yu, Chengzhong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6122-6126</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Iron oxide nanoparticles (IONPs) have emerging anticancer applications via polarizing tumor-assocd. macrophages from tumor-promoting phenotype (M2) to tumor-suppressing phenotype (M1).  However, the underlying mechanism and structure-function relationship remain unclear.  We report magnetite IONPs are more effective compared to hematite in M1 polarization and tumor suppression.  Moreover, magnetite IONPs specifically rely on interferon regulatory factor 5 signaling pathway for M1 polarization and down-regulate M2-assocd. arginase-1.  This study provides new understandings and paves the way for designing advanced iron-based anticancer technologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq36AZI0pj7nrVg90H21EOLACvtfcHk0ljEcelzZaCcMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtlWgsLg%253D&md5=fd99474a78bc8a19a7e8fa99eddf748b</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjacs.8b10904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.8b10904%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DTuong%26aufirst%3DZ.%2BK.%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DC.%26atitle%3DOn%2520the%2520mechanism%2520of%2520iron%2520oxide-induced%2520macrophage%2520activation%253A%2520the%2520impact%2520of%2520composition%2520and%2520the%2520underlying%2520signaling%2520pathway%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2019%26volume%3D141%26spage%3D6122%26epage%3D6126%26doi%3D10.1021%2Fjacs.8b10904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.-Z.</span></span> <span> </span><span class="NLM_article-title">Enhanced immunotherapy based on photodynamic therapy for both primary and lung metastasis tumor eradication</span>. <i>ACS Nano</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1978</span>– <span class="NLM_lpage">1989</span>, <span class="refDoi"> DOI: 10.1021/acsnano.7b09112</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsnano.7b09112" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFamu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=1978-1989&author=W.+Songauthor=J.+Kuangauthor=C.-X.+Liauthor=M.+Zhangauthor=D.+Zhengauthor=X.+Zengauthor=C.+Liuauthor=X.-Z.+Zhang&title=Enhanced+immunotherapy+based+on+photodynamic+therapy+for+both+primary+and+lung+metastasis+tumor+eradication&doi=10.1021%2Facsnano.7b09112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced Immunotherapy Based on Photodynamic Therapy for Both Primary and Lung Metastasis Tumor Eradication</span></div><div class="casAuthors">Song, Wen; Kuang, Jing; Li, Chu-Xin; Zhang, Mingkang; Zheng, Diwei; Zeng, Xuan; Liu, Chuanjun; Zhang, Xian-Zheng</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1978-1989</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Metastasis and recurrence are two unavoidable and intractable problems in cancer therapy, despite various robust therapeutic approaches.  Currently, it seems that immunotherapy is an effective approach to solve these problems, but the high heterogeneity of tumor tissue, inefficient presentation of tumor antigen, and deficient targeting ability of therapy usually blunt the efficacy of immunotherapy and hinder its clin. application.  Herein, an approach based on combining photodynamic and immunol. therapy was designed and developed.  We synthesized a chimeric peptide, PpIX-1MT, which integrates photosensitizer PpIX with immune checkpoint inhibitor 1MT via a caspase-responsive peptide sequence, Asp-Glu-Val-Asp (DEVD), to realize a cascaded synergistic effect.  The PpIX-1MT peptide could form nanoparticles in PBS and accumulate in tumor areas via the enhanced penetration retention effect.  Upon 630 nm light irradn., the PpIX-1MT nanoparticles produced reactive oxygen species, induced apoptosis of cancer cells, and thus facilitated the expression of caspase-3 and the prodn. of tumor antigens, which could trigger an intense immune response.  The subsequently released 1MT upon caspase-3 cleavage could further strengthen the immune system and help to activate CD8+ T cells effectively.  This cascaded synergistic effect could inhibit both primary and lung metastasis tumor effectively, which may provide the soln. for solving tumor recurrence and metastasis clin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2rf8jxw88ZbVg90H21EOLACvtfcHk0lgOqFGujJYZZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFamu70%253D&md5=c0853b57e48a2c49de211b01c5dd0360</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facsnano.7b09112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsnano.7b09112%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DW.%26aulast%3DKuang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.-X.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DZheng%26aufirst%3DD.%26aulast%3DZeng%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DX.-Z.%26atitle%3DEnhanced%2520immunotherapy%2520based%2520on%2520photodynamic%2520therapy%2520for%2520both%2520primary%2520and%2520lung%2520metastasis%2520tumor%2520eradication%26jtitle%3DACS%2520Nano%26date%3D2018%26volume%3D12%26spage%3D1978%26epage%3D1989%26doi%3D10.1021%2Facsnano.7b09112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen-Thanh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W.</span></span> <span> </span><span class="NLM_article-title">Sirt2 ameliorates lipopolysaccharide-induced inflammation in macrophages</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>450</i></span>,  <span class="NLM_fpage">1363</span>– <span class="NLM_lpage">1369</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2014.06.135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1016%2Fj.bbrc.2014.06.135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=25003320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Squ7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=450&publication_year=2014&pages=1363-1369&author=A.+S.+Leeauthor=Y.+J.+Jungauthor=D.+Kimauthor=T.+Nguyen-Thanhauthor=K.+P.+Kangauthor=S.+Leeauthor=S.+K.+Parkauthor=W.+Kim&title=Sirt2+ameliorates+lipopolysaccharide-induced+inflammation+in+macrophages&doi=10.1016%2Fj.bbrc.2014.06.135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">SIRT2 ameliorates lipopolysaccharide-induced inflammation in macrophages</span></div><div class="casAuthors">Lee, Ae Sin; Jung, Yu Jin; Kim, Dal; Nguyen-Thanh, Tung; Kang, Kyung Pyo; Lee, Sik; Park, Sung Kwang; Kim, Won</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">450</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1363-1369</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">SIRT2 is a NAD(+)-dependent deacetylases and assocd. with numerous processes such as infection, carcinogenesis, DNA damage and cell cycle regulation.  However, the role of SIRT2 in inflammatory process in macrophage remains unclear.In the present study, we have evaluated the regulatory effects of SIRT2 in lipopolysaccharide (LPS)-stimulated macrophages isolated from SIRT2 knockout (KO) and wild type (WT) mice or Raw264.7 macrophage cells.  As inflammatory parameters, expression of inducible nitric oxide synthase (iNOS), the productions of nitric oxide, reactive oxygen species (ROS) and M1-macrophage-related factors were evaluated.  We also examd. the effects of SIRT2 on activation of nuclear factor-kappaB (NFκB) signaling.SIRT2 deficiency inhibits LPS-induced iNOS mRNA and protein expression in bone marrow derived macrophages.  SIRT2-siRNA transfection also suppressed LPS-induced iNOS expression in Raw264.7 macrophage cells.  Bone marrow derived macrophages isolated from SIRT2 KO mice produced lower nitric oxide and expressed lower levels of M1-macrophage related markers including iNOS and CD86 in response to LPS than WT mice.  Decrease of SIRT2 reduced the LPS-induced reactive oxygen species prodn.  Deficiency of SIRT2 resulted in inhibition of NFκB activation through reducing the phosphorylation and degrdn. of IκBα.  The phosphorylation and nuclear translocation of p65 was significantly decreased in SIRT2-deficient macrophages after LPS stimulation.Our data suggested that deficiency of SIRT2 ameliorates iNOS, NO expression and reactive oxygen species prodn. with suppressing LPS-induced activation of NFκB in macrophages.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJd6E2kD7Xd7Vg90H21EOLACvtfcHk0lgOqFGujJYZZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Squ7vF&md5=74c9bcc76abb6f1581f40651acd6764c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2014.06.135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2014.06.135%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DA.%2BS.%26aulast%3DJung%26aufirst%3DY.%2BJ.%26aulast%3DKim%26aufirst%3DD.%26aulast%3DNguyen-Thanh%26aufirst%3DT.%26aulast%3DKang%26aufirst%3DK.%2BP.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DS.%2BK.%26aulast%3DKim%26aufirst%3DW.%26atitle%3DSirt2%2520ameliorates%2520lipopolysaccharide-induced%2520inflammation%2520in%2520macrophages%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2014%26volume%3D450%26spage%3D1363%26epage%3D1369%26doi%3D10.1016%2Fj.bbrc.2014.06.135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Padgett, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burg, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, W. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tse, H. M.</span></span> <span> </span><span class="NLM_article-title">Loss of nadph oxidase-derived superoxide skews macrophage phenotypes to delay type 1 diabetes</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">937</span>– <span class="NLM_lpage">946</span>, <span class="refDoi"> DOI: 10.2337/db14-0929</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.2337%2Fdb14-0929" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=25288672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFanurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2015&pages=937-946&author=L.+E.+Padgettauthor=A.+R.+Burgauthor=W.+Q.+Leiauthor=H.+M.+Tse&title=Loss+of+nadph+oxidase-derived+superoxide+skews+macrophage+phenotypes+to+delay+type+1+diabetes&doi=10.2337%2Fdb14-0929"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of NADPH oxidase-derived superoxide skews macrophage phenotypes to delay type 1 diabetes</span></div><div class="casAuthors">Padgett, Lindsey E.; Burg, Ashley R.; Lei, Weiqi; Tse, Hubert M.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">937-946</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">Macrophages are early islet-infiltrating cells seen in type 1 diabetes (T1D).  While proinflammatory M1 macrophages induce T1D, M2 macrophages have been shown to delay this autoimmune disease in nonobese diabetic (NOD) mice, but the environmental cues that govern macrophage polarization and differentiation remain unresolved.  We previously demonstrated the importance of reactive oxygen species (ROS) in T1D, as NOD mice deficient in NADPH oxidase (NOX)-derived superoxide (Ncf1m1J) were protected against T1D partly because of blunted Toll-like receptor-dependent macrophage responses.  We provide evidence that NOX-derived ROS contribute to macrophage differentiation in T1D.  During spontaneous diabetes progression, T1D-resistant NOD.Ncf1m1J islet-resident macrophages displayed a dampened M1 and increased M2 phenotype.  The transfer of diabetogenic T cells into NOX-deficient NOD.Rag.Ncf1m1J recipients resulted in decreased TNF-α+ and IL-1β+ islet-infiltrating M1 macrophages and a concomitant enhancement in arginase-1+ M2 macrophages.  Mechanistic anal. of superoxide-deficient bone marrow-derived macrophages revealed a marked diminution in a proinflammatory M1 phenotype due to decreased P-STAT1 (Y701) and interferon regulatory factor 5 compared with NOD mice.  We have therefore defined a novel mechanistic link between NOX-derived ROS and macrophage phenotypes, and implicated superoxide as an important factor in macrophage differentiation.  Thus, targeting macrophage redox status may represent a promising therapy in halting human T1D.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIF8q7R1nl1LVg90H21EOLACvtfcHk0lgOqFGujJYZZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFanurk%253D&md5=bd3bb94ac4c58194dd0166a5d6491fa6</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2337%2Fdb14-0929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb14-0929%26sid%3Dliteratum%253Aachs%26aulast%3DPadgett%26aufirst%3DL.%2BE.%26aulast%3DBurg%26aufirst%3DA.%2BR.%26aulast%3DLei%26aufirst%3DW.%2BQ.%26aulast%3DTse%26aufirst%3DH.%2BM.%26atitle%3DLoss%2520of%2520nadph%2520oxidase-derived%2520superoxide%2520skews%2520macrophage%2520phenotypes%2520to%2520delay%2520type%25201%2520diabetes%26jtitle%3DDiabetes%26date%3D2015%26volume%3D64%26spage%3D937%26epage%3D946%26doi%3D10.2337%2Fdb14-0929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Englinger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffeter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terenzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowol, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keppler, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, W.</span></span> <span> </span><span class="NLM_article-title">Metal drugs and the anticancer immune response</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">1519</span>– <span class="NLM_lpage">1624</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.8b00396</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.8b00396" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlakt7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2019&pages=1519-1624&author=B.+Englingerauthor=C.+Pirkerauthor=P.+Heffeterauthor=A.+Terenziauthor=C.+R.+Kowolauthor=B.+K.+Kepplerauthor=W.+Berger&title=Metal+drugs+and+the+anticancer+immune+response&doi=10.1021%2Facs.chemrev.8b00396"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Metal drugs and the anticancer immune response</span></div><div class="casAuthors">Englinger, Bernhard; Pirker, Christine; Heffeter, Petra; Terenzi, Alessio; Kowol, Christian R.; Keppler, Bernhard K.; Berger, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1519-1624</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The immune system deploys a multitude of innate and adaptive mechanisms not only to ward off pathogens but also to prevent malignant transformation ("immune surveillance").  Hence, a clin. apparent tumor already reflects selection for those malignant cell clones capable of evading immune recognition ("immune evasion").  Metal drugs, besides their well-investigated cytotoxic anticancer effects, massively interact with the cancer-immune interface and can reverse important aspects of immune evasion.  This topic has recently gained intense attention based on combination approaches with anticancer immunotherapy (e.g., immune checkpoint inhibitors), a strategy recently delivering first exciting results in clin. settings.  This review summarizes the promising but still extremely fragmentary knowledge on the interplay of metal drugs with the fidelity of anticancer immune responses but also their role in adverse effects.  It highlights that, at least in some cases, metal drugs can induce long-lasting anticancer immune responses.  Important steps in this process comprise altered visibility and susceptibility of cancer cells toward innate and adaptive immunity, as well as direct impacts on immune cell populations and the tumor microenvironment.  On the basis of the gathered information, we suggest initiating joint multidisciplinary programs to implement comprehensive immune analyses into strategies to develop novel and smart anticancer metal compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpduZa3EdGgurVg90H21EOLACvtfcHk0ljhzpnknXL-8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlakt7bO&md5=9cf67c2ef463cd26be88b178b5b6534a</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.8b00396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.8b00396%26sid%3Dliteratum%253Aachs%26aulast%3DEnglinger%26aufirst%3DB.%26aulast%3DPirker%26aufirst%3DC.%26aulast%3DHeffeter%26aufirst%3DP.%26aulast%3DTerenzi%26aufirst%3DA.%26aulast%3DKowol%26aufirst%3DC.%2BR.%26aulast%3DKeppler%26aufirst%3DB.%2BK.%26aulast%3DBerger%26aufirst%3DW.%26atitle%3DMetal%2520drugs%2520and%2520the%2520anticancer%2520immune%2520response%26jtitle%3DChem.%2520Rev.%26date%3D2019%26volume%3D119%26spage%3D1519%26epage%3D1624%26doi%3D10.1021%2Facs.chemrev.8b00396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mora, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gimeno, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visbal, R.</span></span> <span> </span><span class="NLM_article-title">Recent advances in gold-NHC complexes with biological properties</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">447</span>– <span class="NLM_lpage">462</span>, <span class="refDoi"> DOI: 10.1039/C8CS00570B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1039%2FC8CS00570B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=30474097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit12ks7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2019&pages=447-462&author=M.+Moraauthor=M.-C.+Gimenoauthor=R.+Visbal&title=Recent+advances+in+gold-NHC+complexes+with+biological+properties&doi=10.1039%2FC8CS00570B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in gold-NHC complexes with biological properties</span></div><div class="casAuthors">Mora, Malka; Gimeno, M. Concepcion; Visbal, Renso</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">447-462</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">This tutorial review covers the recent advances made in the study of gold complexes contg. N-heterocyclic carbene ligands with biol. properties.  The great stability, ease of modulation of the electronic properties and excellent σ-donating capacity displayed by NHCs allow gold-NHC derivs. to reach high stability in biol. media and relatively good internalization into cells and for that they have emerged as excellent potential chemotherapeutics.  The new gold-NHC derivs. show superior anticancer activity compared to other stds. such as Cisplatin or Auranofin.  In addn., the application of gold-NHC complexes in the treatment of other human diseases as antibacterial, antioxidant and antiparasitic agents is reviewed for the first time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0VvhC9V7eAbVg90H21EOLACvtfcHk0ljhzpnknXL-8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit12ks7zE&md5=a3da211b61b5414e1af3d38eca0b1302</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1039%2FC8CS00570B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8CS00570B%26sid%3Dliteratum%253Aachs%26aulast%3DMora%26aufirst%3DM.%26aulast%3DGimeno%26aufirst%3DM.-C.%26aulast%3DVisbal%26aufirst%3DR.%26atitle%3DRecent%2520advances%2520in%2520gold-NHC%2520complexes%2520with%2520biological%2520properties%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2019%26volume%3D48%26spage%3D447%26epage%3D462%26doi%3D10.1039%2FC8CS00570B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lum, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lok, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, C. M.</span></span> <span> </span><span class="NLM_article-title">Chemical biology of anticancer Au(III) and Au(I) complexes</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">8786</span>– <span class="NLM_lpage">8801</span>, <span class="refDoi"> DOI: 10.1039/C5CS00132C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1039%2FC5CS00132C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=25868756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsVChurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2015&pages=8786-8801&author=T.+Zouauthor=C.+T.+Lumauthor=C.+N.+Lokauthor=J.+J.+Zhangauthor=C.+M.+Che&title=Chemical+biology+of+anticancer+Au%28III%29+and+Au%28I%29+complexes&doi=10.1039%2FC5CS00132C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical biology of anticancer gold(III) and gold(I) complexes</span></div><div class="casAuthors">Zou, Taotao; Lum, Ching Tung; Lok, Chun-Nam; Zhang, Jing-Jing; Che, Chi-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8786-8801</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Gold complexes have recently gained increasing attention in the design of new metal-based anticancer therapeutics.  Gold(III) complexes are generally reactive/unstable under physiol. conditions via intracellular redox reactions, and the intracellular AuIII to AuI redn. reaction has recently been "traced" by the introduction of appropriate fluorescent ligands.  Similar to most Au(I) complexes, Au(III) complexes can inhibit the activities of thiol-contg. enzymes, including thioredoxin reductase, via ligand exchange reactions to form Au-S(Se) bonds.  Nonetheless, there are examples of physiol. stable Au(III) and Au(I) complexes, such as [Au(TPP)]Cl (H2TPP = 5,10,15,20-tetraphenylporphyrin) and [Au(dppe)2]Cl (dppe = 1,2-bis(diphenylphosphanyl)ethane), which are known to display highly potent in vitro and in vivo anticancer activities.  In this review, we summarize our current understanding of anticancer gold complexes, including their mechanisms of action and the approaches adopted to improve their anticancer efficiency.  Some recent examples of gold anticancer chemotherapeutics are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraSf5EPIPo8rVg90H21EOLACvtfcHk0ljhzpnknXL-8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsVChurg%253D&md5=6e546124df776ce9612fb8a4fdbcad37</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1039%2FC5CS00132C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5CS00132C%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DT.%26aulast%3DLum%26aufirst%3DC.%2BT.%26aulast%3DLok%26aufirst%3DC.%2BN.%26aulast%3DZhang%26aufirst%3DJ.%2BJ.%26aulast%3DChe%26aufirst%3DC.%2BM.%26atitle%3DChemical%2520biology%2520of%2520anticancer%2520Au%2528III%2529%2520and%2520Au%2528I%2529%2520complexes%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2015%26volume%3D44%26spage%3D8786%26epage%3D8801%26doi%3D10.1039%2FC5CS00132C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, H.</span></span> <span> </span><span class="NLM_article-title">Developing a novel gold(III) agent to treat glioma based on the unique properties of apoferritin nanoparticles: inducing lethal autophagy and apoptosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">13695</span>– <span class="NLM_lpage">13708</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c01257</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01257" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlertrrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=13695-13708&author=J.+Zhangauthor=Z.+Zhangauthor=M.+Jiangauthor=S.+Liauthor=H.+Yuanauthor=H.+Sunauthor=F.+Yangauthor=H.+Liang&title=Developing+a+novel+gold%28III%29+agent+to+treat+glioma+based+on+the+unique+properties+of+apoferritin+nanoparticles%3A+inducing+lethal+autophagy+and+apoptosis&doi=10.1021%2Facs.jmedchem.0c01257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Developing a Novel Gold(III) Agent to Treat Glioma Based on the Unique Properties of Apoferritin Nanoparticles: Inducing Lethal Autophagy and Apoptosis</span></div><div class="casAuthors">Zhang, Juzheng; Zhang, Zhenlei; Jiang, Ming; Li, Shanhe; Yuan, Haoliang; Sun, Hongbin; Yang, Feng; Liang, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">13695-13708</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Effective delivery of anticancer agents across the blood-brain barrier (BBB) required innovative strategies to achieve glioma regression.  To resolve this problem, we proposed to develop a metal agent that target and treat glioma based on the unique property of apoferritin (AFt) nanoparticles (NPs).  Thus, we synthesized a series of Au(III) 3-(4-metyl piperidine)thiosemicarbazides compds. and analyzed their structure-activity relationships, obtaining a Au agent (C6) with remarkable cytotoxicity in glioma.  Moreover, we confirmed that C6 kills glioma cells by inducing lethal autophagy and apoptosis.  Importantly, our results revealed that the successfully constructed apoferritin-C6 NPs (AFt-C6 NPs) can effectively cross the BBB, inhibit glioma growth, and selectively accumulate in tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_X0TvxpIJ8LVg90H21EOLACvtfcHk0ljhzpnknXL-8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlertrrO&md5=a7c40edae866d6824f5c300edb3d4755</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01257%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DLiang%26aufirst%3DH.%26atitle%3DDeveloping%2520a%2520novel%2520gold%2528III%2529%2520agent%2520to%2520treat%2520glioma%2520based%2520on%2520the%2520unique%2520properties%2520of%2520apoferritin%2520nanoparticles%253A%2520inducing%2520lethal%2520autophagy%2520and%2520apoptosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D13695%26epage%3D13708%26doi%3D10.1021%2Facs.jmedchem.0c01257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awuah, S. G.</span></span> <span> </span><span class="NLM_article-title">Gold(I/III)-phosphine complexes as potent antiproliferative agents</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">12335</span>, <span class="refDoi"> DOI: 10.1038/s41598-019-48584-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1038%2Fs41598-019-48584-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=31451718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A280%3ADC%252BB3MrhvVGrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=12335&author=J.+H.+Kimauthor=E.+Reederauthor=S.+Parkinauthor=S.+G.+Awuah&title=Gold%28I%2FIII%29-phosphine+complexes+as+potent+antiproliferative+agents&doi=10.1038%2Fs41598-019-48584-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Gold(I/III)-Phosphine Complexes as Potent Antiproliferative Agents</span></div><div class="casAuthors">Kim Jong Hyun; Reeder Evan; Parkin Sean; Awuah Samuel G</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12335</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The reaction of gold reagents [HAuCl4•3H2O], [AuCl(tht)], or cyclometalated gold(III) precursor, [C NAuCl2] with chiral ((R,R)-(-)-2,3-bis(t-butylmethylphosphino) quinoxaline) and non-chiral phosphine (1,2-Bis(diphenylphosphino)ethane, dppe) ligands lead to distorted Au(I), (1, 2, 4, 5) and novel cyclometalated Au(III) complexes (3, 6).  These gold compounds were characterized by multinuclear NMR, microanalysis, mass spectrometry, and X-ray crystallography.  The inherent electrochemical properties of the gold complexes were also studied by cyclic voltammetry and theoretical insight of the complexes was gained by density functional theory and TD-DFT calculations.  The complexes effectively kill cancer cells with IC50 in the range of ~0.10-2.53 μΜ across K562, H460, and OVCAR8 cell lines.  In addition, the retinal pigment epithelial cell line, RPE-Neo was used as a healthy cell line for comparison.  Differential cellular uptake in cancer cells was observed for the compounds by measuring the intracellular accumulation of gold using ICP-OES.  Furthermore, the compounds trigger early - late stage apoptosis through potential disruption of redox homeostasis.  Complexes 1 and 3 induce predominant G1 cell cycle arrest.  Results presented in this report suggest that stable gold-phosphine complexes with variable oxidation states hold promise in anticancer drug discovery and need further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS__ehwZ0OhMh0LsK7uFuY7fW6udTcc2ea1OxFY7V3vILntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrhvVGrsw%253D%253D&md5=1d0a70644aa1bd4626a76bb96bda8c47</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-48584-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-48584-5%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DReeder%26aufirst%3DE.%26aulast%3DParkin%26aufirst%3DS.%26aulast%3DAwuah%26aufirst%3DS.%2BG.%26atitle%3DGold%2528I%252FIII%2529-phosphine%2520complexes%2520as%2520potent%2520antiproliferative%2520agents%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26spage%3D12335%26doi%3D10.1038%2Fs41598-019-48584-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gukathasan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awuah, S. G.</span></span> <span> </span><span class="NLM_article-title">Cyclometalated gold(III) complexes bearing DACH ligands</span>. <i>Inorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">9326</span>– <span class="NLM_lpage">9340</span>, <span class="refDoi"> DOI: 10.1021/acs.inorgchem.9b01031</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.inorgchem.9b01031" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1eru7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=9326-9340&author=S.+Gukathasanauthor=S.+Parkinauthor=S.+G.+Awuah&title=Cyclometalated+gold%28III%29+complexes+bearing+DACH+ligands&doi=10.1021%2Facs.inorgchem.9b01031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclometalated Gold(III) Complexes Bearing DACH Ligands</span></div><div class="casAuthors">Gukathasan, Sailajah; Parkin, Sean; Awuah, Samuel G.</div><div class="citationInfo"><span class="NLM_cas:title">Inorganic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">9326-9340</span>CODEN:
                <span class="NLM_cas:coden">INOCAJ</span>;
        ISSN:<span class="NLM_cas:issn">0020-1669</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis of a novel class of cyclometalated gold(III) complexes supported by benzoylpyridine, benzylpyridine, and (1R,2R)-(+)-1,2-diaminocyclohexane (DACH) ligands, along with their crystal structures, is reported.  These compds. provide a new scaffold to investigate biol. properties of gold(III) complexes.  The six complexes were prepd. and characterized, following reactions of (C,N) cyclometalated gold(III) scaffolds, [Au(C N)Cl2] with DACH, which yielded a new series of cyclometaled gold(III), 3-5, of the type [Au(C NH)(DACH)2]+ and the nitrogen-substituted cyclometalated Au(III), 6-8, of the type [Au(C N)(DACH)]2+.  Antiproliferative activity of these complexes in a panel of cancer cells showed promising results with IC50 in the micromolar range and selectivity over normal epithelial cells, MRC5.  Whereas 8 shows minimal interaction with superhelical DNA except at high gold concns. of 500μM, complex 5 does not show interaction even at 1000μM.  The complexes display significant uptake in OVCAR8 cancer cells within 200-1200 pmol/million cells with the exception of complex 4.  Differential cellular uptake was obsd. for the complexes; for example, while 3 and 8 display significant uptake, 4 showed minimal uptake.  The compds. proved to be stable under physiol. conditions and were minimally affected by either glutathione or sodium ascorbate.  Cell cycle studies reveal a G1 arrest induced by representative complexes.  The results reveal that enhanced Au(III) stabilization promoted by combined cyclometalated and DACH ligands may offer ligand tuning insights for novel anticancer drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxUSNZnA3_YLVg90H21EOLACvtfcHk0ljs6mEeThnRFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1eru7jM&md5=2653b7cab5e02eca231c79b09061c995</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.inorgchem.9b01031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.inorgchem.9b01031%26sid%3Dliteratum%253Aachs%26aulast%3DGukathasan%26aufirst%3DS.%26aulast%3DParkin%26aufirst%3DS.%26aulast%3DAwuah%26aufirst%3DS.%2BG.%26atitle%3DCyclometalated%2520gold%2528III%2529%2520complexes%2520bearing%2520DACH%2520ligands%26jtitle%3DInorg.%2520Chem.%26date%3D2019%26volume%3D58%26spage%3D9326%26epage%3D9340%26doi%3D10.1021%2Facs.inorgchem.9b01031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tong, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lok, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung, Y. M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, C. M.</span></span> <span> </span><span class="NLM_article-title">An anticancer gold(III)-activated porphyrin scaffold that covalently modifies protein cysteine thiols</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">1321</span>– <span class="NLM_lpage">1329</span>, <span class="refDoi"> DOI: 10.1073/pnas.1915202117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1073%2Fpnas.1915202117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=31896586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFKktL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2020&pages=1321-1329&author=K.+C.+Tongauthor=C.+N.+Lokauthor=P.+K.+Wanauthor=D.+Huauthor=Y.+M.+E.+Fungauthor=X.+Y.+Changauthor=S.+Huangauthor=H.+Jiangauthor=C.+M.+Che&title=An+anticancer+gold%28III%29-activated+porphyrin+scaffold+that+covalently+modifies+protein+cysteine+thiols&doi=10.1073%2Fpnas.1915202117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">An anticancer gold(III)-activated porphyrin scaffold that covalently modifies protein cysteine thiols</span></div><div class="casAuthors">Tong, Ka-Chung; Lok, Chun-Nam; Wan, Pui-Ki; Hu, Di; Eva Fung, Yi Man; Chang, Xiao-Yong; Huang, Song; Jiang, Haibo; Che, Chi-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1321-1329</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Cysteine thiols of many cancer-assocd. proteins are attractive targets of anticancer agents.  Herein, we unequivocally demonstrate a distinct thiol-targeting property of gold(III) mesoporphyrin IX di-Me ester (AuMesoIX) and its anticancer activities.  While the binding of cysteine thiols with metal complexes usually occurs via M-S bond formation, AuMesoIX is unique in that the meso-carbon atom of the porphyrin ring is activated by the gold(III) ion to undergo nucleophilic arom. substitution with thiols.  AuMesoIX was shown to modify reactive cysteine residues and inhibit the activities of anticancer protein targets including thioredoxin, peroxiredoxin, and deubiquitinases.  Treatment of cancer cells with AuMesoIX resulted in the formation of gold-bound sulfur-rich protein aggregates, oxidative stress-mediated cytotoxicity, and accumulation of ubiquitinated proteins.  Importantly, AuMesoIX exhibited effective antitumor activity in mice.  Our study has uncovered a gold(III)-induced ligand scaffold reactivity for thiol targeting that can be exploited for anticancer applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJuhQj8AqhG7Vg90H21EOLACvtfcHk0ljs6mEeThnRFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFKktL4%253D&md5=58f9fb7cbcbb4da43df2f07f97b7d311</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1915202117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1915202117%26sid%3Dliteratum%253Aachs%26aulast%3DTong%26aufirst%3DK.%2BC.%26aulast%3DLok%26aufirst%3DC.%2BN.%26aulast%3DWan%26aufirst%3DP.%2BK.%26aulast%3DHu%26aufirst%3DD.%26aulast%3DFung%26aufirst%3DY.%2BM.%2BE.%26aulast%3DChang%26aufirst%3DX.%2BY.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DChe%26aufirst%3DC.%2BM.%26atitle%3DAn%2520anticancer%2520gold%2528III%2529-activated%2520porphyrin%2520scaffold%2520that%2520covalently%2520modifies%2520protein%2520cysteine%2520thiols%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2020%26volume%3D117%26spage%3D1321%26epage%3D1329%26doi%3D10.1073%2Fpnas.1915202117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mertens, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awuah, S. G.</span></span> <span> </span><span class="NLM_article-title">Cancer cell-selective modulation of mitochondrial respiration and metabolism by potent organogold(iii) dithiocarbamates</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">10465</span>– <span class="NLM_lpage">10482</span>, <span class="refDoi"> DOI: 10.1039/D0SC03628E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1039%2FD0SC03628E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVGgs7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=10465-10482&author=R.+T.+Mertensauthor=S.+Parkinauthor=S.+G.+Awuah&title=Cancer+cell-selective+modulation+of+mitochondrial+respiration+and+metabolism+by+potent+organogold%28iii%29+dithiocarbamates&doi=10.1039%2FD0SC03628E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer cell-selective modulation of mitochondrial respiration and metabolism by potent organogold(III) dithiocarbamates</span></div><div class="casAuthors">Mertens, Randall T.; Parkin, Sean; Awuah, Samuel G.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">10465-10482</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Metabolic reprogramming is a key cancer hallmark that has led to the therapeutic targeting of glycolysis.  However, agents that target dysfunctional mitochondrial respiration for targeted therapy remains underexplored.  We report the synthesis and characterization of ten (10) novel, highly potent organometallic gold(III) complexes supported by dithiocarbamate ligands as selective inhibitors of mitochondrial respiration.  The structure of dithiocarbamates employed dictates the biol. stability and cellular cytotoxicity.  Most of the compds. exhibit 50% inhibitory concn. (IC50) in the low-micromolar (0.50-2.9 μM) range when tested in a panel of aggressive cancer types with significant selectivity for cancer cells over normal cells.  Consequently, there is great interest in the mechanism of action of gold chemotherapeutics, particularly, considering that DNA is not the major target of most gold complexes.  We investigate the mechanism of action of representative complexes, 1a and 2a in the recalcitrant triple neg. breast cancer (TNBC) cell line, MDA-MB-231.  Whole-cell transcriptomics sequencing revealed genes related to three major pathways, namely: cell cycle, organelle fission, and oxidative phosphorylation. 2a irreversibly and rapidly inhibits maximal respiration in TNBC with no effect on normal epithelial cells, implicating mitochondrial OXPHOS as a potential target.  Furthermore, the modulation of cyclin dependent kinases and G1 cell cycle arrest induced by these compds. is promising for the treatment of cancer.  This work contributes to the need for mitochondrial respiration modulators in biomedical research and outlines a systematic approach to study the mechanism of action of metal-based agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy7PCLc_HGgrVg90H21EOLACvtfcHk0lhv_53FU5w5FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVGgs7zL&md5=bb3f230316d8b08686829a5b6fcc540d</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1039%2FD0SC03628E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FD0SC03628E%26sid%3Dliteratum%253Aachs%26aulast%3DMertens%26aufirst%3DR.%2BT.%26aulast%3DParkin%26aufirst%3DS.%26aulast%3DAwuah%26aufirst%3DS.%2BG.%26atitle%3DCancer%2520cell-selective%2520modulation%2520of%2520mitochondrial%2520respiration%2520and%2520metabolism%2520by%2520potent%2520organogold%2528iii%2529%2520dithiocarbamates%26jtitle%3DChem.%2520Sci.%26date%3D2020%26volume%3D11%26spage%3D10465%26epage%3D10482%26doi%3D10.1039%2FD0SC03628E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">da
S. Maia, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponader, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagenbach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergemann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gust, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deflon, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abram, U.</span></span> <span> </span><span class="NLM_article-title">Neutral gold complexes with tridentate SNS thiosemicarbazide ligands</span>. <i>Inorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1604</span>– <span class="NLM_lpage">1613</span>, <span class="refDoi"> DOI: 10.1021/ic201905t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ic201905t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=1604-1613&author=P.+I.+da%0AS.+Maiaauthor=H.+H.+Nguyenauthor=D.+Ponaderauthor=A.+Hagenbachauthor=S.+Bergemannauthor=R.+Gustauthor=V.+M.+Deflonauthor=U.+Abram&title=Neutral+gold+complexes+with+tridentate+SNS+thiosemicarbazide+ligands&doi=10.1021%2Fic201905t"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fic201905t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fic201905t%26sid%3Dliteratum%253Aachs%26aulast%3Dda%2BS.%2BMaia%26aufirst%3DP.%2BI.%26aulast%3DNguyen%26aufirst%3DH.%2BH.%26aulast%3DPonader%26aufirst%3DD.%26aulast%3DHagenbach%26aufirst%3DA.%26aulast%3DBergemann%26aufirst%3DS.%26aulast%3DGust%26aufirst%3DR.%26aulast%3DDeflon%26aufirst%3DV.%2BM.%26aulast%3DAbram%26aufirst%3DU.%26atitle%3DNeutral%2520gold%2520complexes%2520with%2520tridentate%2520SNS%2520thiosemicarbazide%2520ligands%26jtitle%3DInorg.%2520Chem.%26date%3D2012%26volume%3D51%26spage%3D1604%26epage%3D1613%26doi%3D10.1021%2Fic201905t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vela, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palomera, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azaceta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzo, I.</span></span> <span> </span><span class="NLM_article-title">Iminophosphorane-organogold(III) complexes induce cell death through mitochondrial ROS production</span>. <i>J. Inorg. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">1306</span>– <span class="NLM_lpage">1313</span>, <span class="refDoi"> DOI: 10.1016/j.jinorgbio.2011.06.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1016%2Fj.jinorgbio.2011.06.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=21864808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFymtrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2011&pages=1306-1313&author=L.+Velaauthor=M.+Contelauthor=L.+Palomeraauthor=G.+Azacetaauthor=I.+Marzo&title=Iminophosphorane-organogold%28III%29+complexes+induce+cell+death+through+mitochondrial+ROS+production&doi=10.1016%2Fj.jinorgbio.2011.06.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Iminophosphorane-organogold(III) complexes induce cell death through mitochondrial ROS production</span></div><div class="casAuthors">Vela, Laura; Contel, Maria; Palomera, Luis; Azaceta, Gemma; Marzo, Isabel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inorganic Biochemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1306-1313</span>CODEN:
                <span class="NLM_cas:coden">JIBIDJ</span>;
        ISSN:<span class="NLM_cas:issn">0162-0134</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Gold compds. are being investigated as potential antitumor drugs.  Some gold(III) derivs. have been shown to induce cell death in solid tumors but their mechanism of action differs from that of cisplatin, since most of these compds. do not bind to DNA.  The authors have explored cellular events triggered by three different iminophosphorane-organogold(III) compds. in leukemia cells (a) neutral compd. with two chloride ligands [Au{κ2-C,N-C6H4(PPh2 = N(C6H5))-2}Cl2] (1), and two cationic compds. with either a dithiocarbamate ligand [Au{κ2-C,N-C6H4(PPh2 = N(C6H5))-2}(S2CN-Me2)]PF6 (2), or a water-sol. phosphine and a chloride ligand [Au{κ2-C,N-C6H4(PPh2 = N(C6H5))-2}(P{Cp(m-C6H4-SO3Na)2}3)Cl]PF6(3).  All three compds. showed higher toxicity against leukemia cells when compared to normal T-lymphocytes.  Compds. 1 and 2 induced both necrosis and apoptosis, while 3 was mainly apoptotic.  Necrotic cell death induced by 1 and 2 was Bax/Bak- and caspase-independent, while apoptosis induced by 3 was Bax/Bak-dependent.  Reactive oxygen species (ROS) prodn. at the mitochondrial level was a crit. step in the antitumor effect of these compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg8Idbd1OVKrVg90H21EOLACvtfcHk0lhv_53FU5w5FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFymtrfK&md5=45228490d1eb548fa5d749535ab1da12</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2011.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2011.06.004%26sid%3Dliteratum%253Aachs%26aulast%3DVela%26aufirst%3DL.%26aulast%3DContel%26aufirst%3DM.%26aulast%3DPalomera%26aufirst%3DL.%26aulast%3DAzaceta%26aufirst%3DG.%26aulast%3DMarzo%26aufirst%3DI.%26atitle%3DIminophosphorane-organogold%2528III%2529%2520complexes%2520induce%2520cell%2520death%2520through%2520mitochondrial%2520ROS%2520production%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2011%26volume%3D105%26spage%3D1306%26epage%3D1313%26doi%3D10.1016%2Fj.jinorgbio.2011.06.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dean, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grayson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMartino, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furdui, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bierbach, U.</span></span> <span> </span><span class="NLM_article-title">Human serum albumin-delivered [Au(PEt<sub>3</sub>)]<sup>+</sup> is a potent inhibitor of T cell proliferation</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">572</span>– <span class="NLM_lpage">576</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00142</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00142" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmsFWrsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=572-576&author=T.+C.+Deanauthor=M.+Yangauthor=M.+Liuauthor=J.+M.+Graysonauthor=A.+W.+DeMartinoauthor=C.+S.+Dayauthor=J.+Leeauthor=C.+M.+Furduiauthor=U.+Bierbach&title=Human+serum+albumin-delivered+%5BAu%28PEt3%29%5D%2B+is+a+potent+inhibitor+of+T+cell+proliferation&doi=10.1021%2Facsmedchemlett.7b00142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Human serum albumin-delivered [Au(PEt3)]+ is a potent inhibitor of T cell proliferation</span></div><div class="casAuthors">Dean, Tyler C.; Yang, Mu; Liu, Mingyong; Grayson, Jason M.; DeMartino, Anthony W.; Day, Cynthia S.; Lee, Jingyun; Furdui, Cristina M.; Bierbach, Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">572-576</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Using a modular library format in conjunction with cell viability (MTS) and flow cytometry assays, 90 cationic complexes [AuPL]n+ (P = phosphine ligand; L = thiourea deriv. or chloride) were studied for their antiproliferative activity in CD8+ T lymphocyte cells.  The activity of the compds. correlates with the steric bulk of the phosphine ligands.  Thiourea serves as a leaving group that is readily replaced by cysteine thiol (NMR, ESI-MS).  Taking advantage of selective thiourea ligand exchange, the fragments [Au(PEt3)]+ and [Au(JohnPhos)]+ ((JohnPhos = 1,1'-biphenyl-2-yl)di-tert-butylphosphine) in compds. 1 and 2 were transferred to recombinant human serum albumin (rHSA).  PEt3 promoted efficient modification of Cys34 in HSA (HSA-1), whereas use of bulky JohnPhos as a carrier ligand led to serum protein nonspecifically modified with multiple gold adducts (HSA-2) (Ellman's test, ESI-TOF MS).  HSA-1, but not HSA-2, strongly inhibits T cell proliferation at nanomolar doses.  The potential role of HSA as a delivery vehicle in gold-based autoimmune disease treatment is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonxEIYrjLlMLVg90H21EOLACvtfcHk0lhv_53FU5w5FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmsFWrsL8%253D&md5=4dff57b4b7d7d363b3fe7ec578d5269c</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00142%26sid%3Dliteratum%253Aachs%26aulast%3DDean%26aufirst%3DT.%2BC.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DGrayson%26aufirst%3DJ.%2BM.%26aulast%3DDeMartino%26aufirst%3DA.%2BW.%26aulast%3DDay%26aufirst%3DC.%2BS.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DFurdui%26aufirst%3DC.%2BM.%26aulast%3DBierbach%26aufirst%3DU.%26atitle%3DHuman%2520serum%2520albumin-delivered%2520%255BAu%2528PEt3%2529%255D%252B%2520is%2520a%2520potent%2520inhibitor%2520of%2520T%2520cell%2520proliferation%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D572%26epage%3D576%26doi%3D10.1021%2Facsmedchemlett.7b00142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jurgens, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casini, A.</span></span> <span> </span><span class="NLM_article-title">Mechanistic insights into gold organometallic compounds and their biomedical applications</span>. <i>Chimia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">92</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.2533/chimia.2017.92</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.2533%2Fchimia.2017.92" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=28351454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFektbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2017&pages=92-101&author=S.+Jurgensauthor=A.+Casini&title=Mechanistic+insights+into+gold+organometallic+compounds+and+their+biomedical+applications&doi=10.2533%2Fchimia.2017.92"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic insights into gold organometallic compounds and their biomedical applications</span></div><div class="casAuthors">Jurgens, Sophie; Casini, Angela</div><div class="citationInfo"><span class="NLM_cas:title">Chimia</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">92-101</span>CODEN:
                <span class="NLM_cas:coden">CHIMAD</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Swiss Chemical Society</span>)
        </div><div class="casAbstract">A review.  The application of gold in medicine can be traced back several thousand years and Au(i) compds. have been used in the treatment of rheumatoid arthritis since the last century.  Recently research into gold-based drugs for a no. of human diseases has seen a renaissance due to their markedly different modes of action with respect to the classical platinum chemotherapeutic compds.  Within this research area, organometallic gold complexes have been particularly explored, mainly due to their higher stability in physiol. conditions guaranteed by the presence of a direct Au-C bond.  Thus, a no. of compds. have been tested for their uses as anticancer, antibacterial, antiprotozoal as well as anti-HIV agents.  In this review a selection of the main results obtained on the synthesis, chem. properties and biol. activities of two of the most explored families of organometallics - Au(i) N-heterocyclic carbenes (NHCs) and cyclometalated Au(iii) compds. - are summarized.  Their structure-activity relationships and modes of action at the cellular level are also discussed, which constitute the basis for future drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr44Y1pWKstfrVg90H21EOLACvtfcHk0lhqMH-m-bfxFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFektbzJ&md5=89ef4c3fb374c30ba49e1eef629ca826</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.2533%2Fchimia.2017.92&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2533%252Fchimia.2017.92%26sid%3Dliteratum%253Aachs%26aulast%3DJurgens%26aufirst%3DS.%26aulast%3DCasini%26aufirst%3DA.%26atitle%3DMechanistic%2520insights%2520into%2520gold%2520organometallic%2520compounds%2520and%2520their%2520biomedical%2520applications%26jtitle%3DChimia%26date%3D2017%26volume%3D71%26spage%3D92%26epage%3D101%26doi%3D10.2533%2Fchimia.2017.92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1432</span>– <span class="NLM_lpage">1456</span>, <span class="refDoi"> DOI: 10.1039/C5CS00158G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1039%2FC5CS00158G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=26771036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC28XovVKkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=1432-1456&author=Z.+Liuauthor=X.+Chen&title=Simple+bioconjugate+chemistry+serves+great+clinical+advances%3A+albumin+as+a+versatile+platform+for+diagnosis+and+precision+therapy&doi=10.1039%2FC5CS00158G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy</span></div><div class="casAuthors">Liu, Zhibo; Chen, Xiaoyuan</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1432-1456</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Albumin is the most abundant circulating protein in plasma and has recently emerged as a versatile protein carrier for drug targeting and for improving the pharmacokinetic profile of peptide or protein based drugs.  Three drug delivery technologies related to albumin have been developed, which include the coupling of low-mol. wt. drugs to exogenous or endogenous albumin, conjugating bioactive proteins by albumin fusion technol. (AFT), and encapsulation of drugs into albumin nanoparticles.  This review article starts with a brief introduction of human serum albumin (HSA), and then summarizes the mainstream chem. strategies of developing HSA binding mols. for coupling with drug mols.  Moreover, we also concisely condense the recent progress of the most important clin. applications of HSA-binding platforms, and specify the current challenges that need to be met for a bright future of HSA-binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX_KUb4v-V6LVg90H21EOLACvtfcHk0lhqMH-m-bfxFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XovVKkug%253D%253D&md5=6cbd8231b0f3dcdd776d464a835d535e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1039%2FC5CS00158G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5CS00158G%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DSimple%2520bioconjugate%2520chemistry%2520serves%2520great%2520clinical%2520advances%253A%2520albumin%2520as%2520a%2520versatile%2520platform%2520for%2520diagnosis%2520and%2520precision%2520therapy%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2016%26volume%3D45%26spage%3D1432%26epage%3D1456%26doi%3D10.1039%2FC5CS00158G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, X.</span></span> <span> </span><span class="NLM_article-title">Albumin-based nanotheranostic probe with hypoxia alleviating potentiates synchronous multimodal imaging and phototherapy for glioma</span>. <i>ACS Nano</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">6191</span>– <span class="NLM_lpage">6212</span>, <span class="refDoi"> DOI: 10.1021/acsnano.0c02249</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsnano.0c02249" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnslaqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2020&pages=6191-6212&author=Z.+Yangauthor=Y.+Duauthor=Q.+Sunauthor=Y.+Pengauthor=R.+Wangauthor=Y.+Zhouauthor=Y.+Wangauthor=C.+Zhangauthor=X.+Qi&title=Albumin-based+nanotheranostic+probe+with+hypoxia+alleviating+potentiates+synchronous+multimodal+imaging+and+phototherapy+for+glioma&doi=10.1021%2Facsnano.0c02249"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Albumin-Based Nanotheranostic Probe with Hypoxia Alleviating Potentiates Synchronous Multimodal Imaging and Phototherapy for Glioma</span></div><div class="casAuthors">Yang, Zhenzhen; Du, Yitian; Sun, Qi; Peng, Yiwei; Wang, Rudong; Zhou, Yu; Wang, Yuqi; Zhang, Chunli; Qi, Xianrong</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">6191-6212</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Highly infiltrative and invasive glioma cells obscure the boundary between tumor and normal brain tissue, making it extremely difficult to precisely diagnose and completely remove.  The combination of multimodal imaging with effective treatments to diagnose precisely and guide surgery and therapy accurately is desperately needed for glioma in the brain.  Here, we report a biomimetic catalase-integrated-albumin phototheranostic nanoprobe (ICG/<a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="df9eaa918d9f9d9c918f">[email protected]</a>) to realize multimodal imaging, amplify phototherapy, and guide surgery for glioma after penetrating the blood-brain barrier, accumulating into deep-seated glioma via albumin-binding protein mediated transportation.  The phototheranostic nanoprobe enabled fluorescence, photoacoustic, and IR thermal imaging with desirable detecting depth and high signal-to-background ratio for clearly differentiating brain tumors from surrounding tissues.  Meanwhile, the nanoprobe could effectively induce local hyperthermia and promote the level of singlet oxygen based on alleviated hypoxic glioma microenvironment by decompg. endogenous hydrogen peroxide to oxygen to amplify phototherapy.  Thus, significant inhibition of glioma growth, extended survival time, alleviated tumor hypoxia, improved apoptosis, and antiangiogenesis effects were exhibited in several animal models including the periphery and the brain through i.v. or intratumoral injection, meanwhile with low toxicity to normal tissue.  The phototherapy was also guided by the assistance of external bioluminescence, magnetic resonance, and positron emission tomog. imaging.  Moreover, the nanoprobe could accurately guide the glioma resection.  These results suggest that the phototheranostic nanoprobe is a promising nanoplatform specifically for glioma to achieve multimodal diagnosis, effective phototherapy, and accurate imaging-guided surgery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhf1pd_rRbzLVg90H21EOLACvtfcHk0lhqMH-m-bfxFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnslaqtbk%253D&md5=f4c6e564c95a27d986eb47983564950d</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facsnano.0c02249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsnano.0c02249%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DQi%26aufirst%3DX.%26atitle%3DAlbumin-based%2520nanotheranostic%2520probe%2520with%2520hypoxia%2520alleviating%2520potentiates%2520synchronous%2520multimodal%2520imaging%2520and%2520phototherapy%2520for%2520glioma%26jtitle%3DACS%2520Nano%26date%3D2020%26volume%3D14%26spage%3D6191%26epage%3D6212%26doi%3D10.1021%2Facsnano.0c02249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hyun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyle, L.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeo, Y.</span></span> <span> </span><span class="NLM_article-title">Surface modification of polymer nanoparticles with native albumin for enhancing drug delivery to solid tumors</span>. <i>Biomaterials</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>180</i></span>,  <span class="NLM_fpage">206</span>– <span class="NLM_lpage">224</span>, <span class="refDoi"> DOI: 10.1016/j.biomaterials.2018.07.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1016%2Fj.biomaterials.2018.07.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=30048910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlOitrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2018&pages=206-224&author=H.+Hyunauthor=J.+Parkauthor=K.+Willisauthor=J.-E.+Parkauthor=L.-T.+Lyleauthor=W.+Leeauthor=Y.+Yeo&title=Surface+modification+of+polymer+nanoparticles+with+native+albumin+for+enhancing+drug+delivery+to+solid+tumors&doi=10.1016%2Fj.biomaterials.2018.07.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Surface modification of polymer nanoparticles with native albumin for enhancing drug delivery to solid tumors</span></div><div class="casAuthors">Hyun, Hyesun; Park, Joonyoung; Willis, Kiela; Park, Ji Eun; Lyle, L. Tiffany; Lee, Wooin; Yeo, Yoon</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">206-224</span>CODEN:
                <span class="NLM_cas:coden">BIMADU</span>;
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Albumin is a promising surface modifier of nanoparticulate drug delivery systems.  Serving as a dysopsonin, albumin can protect circulating nanoparticles (NPs) from the recognition and clearance by the mononuclear phagocytic system (MPS).  Albumin may also help transport the NPs to solid tumors based on the increased consumption by cancer cells and interactions with the tumor microenvironment.  Several studies have explored the benefits of surface-bound albumin to enhance NP delivery to tumors.  However, it remains unknown how the surface modification process affects the conformation of albumin and the performance of the albumin-modified NPs.  We use three different surface modification methods including two prevalent approaches (physisorption and interfacial embedding) and a new method based on dopamine polymn. to modify the surface of poly(lactic-co-glycolic acid) NPs with albumin and compare the extent of albumin binding, conformation of the surface-bound albumin, and biol. performances of the albumin-coated NPs.  We find that the dopamine polymn. method preserves the albumin structure, forming a surface layer that facilitates NP transport and drug delivery into tumors via the interaction with albumin-binding proteins.  In contrast, the interfacial embedding method creates NPs with denatured albumin that offers no particular benefit to the interaction with cancer cells but rather promotes the MPS uptake via direct and indirect interactions with scavenger receptor A.  This study demonstrates that the surface-bound albumin can bring distinct effects according to the way they interact with NP surface and thus needs to be controlled in order to achieve favorable therapeutic outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZBVklIhgQBbVg90H21EOLACvtfcHk0ljJAIq6rirMyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlOitrfL&md5=a0ae5f81fdf22fb2c82c5b7a7336ebff</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2018.07.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2018.07.024%26sid%3Dliteratum%253Aachs%26aulast%3DHyun%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DWillis%26aufirst%3DK.%26aulast%3DPark%26aufirst%3DJ.-E.%26aulast%3DLyle%26aufirst%3DL.-T.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DYeo%26aufirst%3DY.%26atitle%3DSurface%2520modification%2520of%2520polymer%2520nanoparticles%2520with%2520native%2520albumin%2520for%2520enhancing%2520drug%2520delivery%2520to%2520solid%2520tumors%26jtitle%3DBiomaterials%26date%3D2018%26volume%3D180%26spage%3D206%26epage%3D224%26doi%3D10.1016%2Fj.biomaterials.2018.07.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.</span></span> <span> </span><span class="NLM_article-title">Ultrasound-enhanced chemo-photodynamic combination therapy by using albumin “nanoglue”-based nanotheranostics</span>. <i>ACS Nano</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">5560</span>– <span class="NLM_lpage">5569</span>, <span class="refDoi"> DOI: 10.1021/acsnano.9b09827</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsnano.9b09827" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BB3cXotFeht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2020&pages=5560-5569&author=Y.+Zhangauthor=Y.+Wanauthor=Y.+Chenauthor=N.+T.+Blumauthor=J.+Linauthor=P.+Huang&title=Ultrasound-enhanced+chemo-photodynamic+combination+therapy+by+using+albumin+%E2%80%9Cnanoglue%E2%80%9D-based+nanotheranostics&doi=10.1021%2Facsnano.9b09827"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Ultrasound-Enhanced Chemo-Photodynamic Combination Therapy by Using Albumin "Nanoglue"-Based Nanotheranostics</span></div><div class="casAuthors">Zhang, Yifan; Wan, Yilin; Chen, Yantao; Blum, Nicholas Thomas; Lin, Jing; Huang, Peng</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">5560-5569</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The combination of photodynamic therapy (PDT) and chemotherapy is considered to enhance the antitumor immunity and combat multidrug resistance.  Some preclin. studies have reported a pos. therapeutic outcome of using ultrasound (US) irradn. to enhance chemotherapy, but the combination of these three modalities has yet to be investigated.  On the basis of the discovery of a strong affinity between a photosensitizer sinoporphyrin sodium (DVDMS) and human serum albumin (HSA), a clin. used albumin-paclitaxel (HSA-PTX) nanoparticle is utilized as a "nanoglue" to load a large amt. of DVDMS by simple mixing.  The five conformations of HSA and DVDMS with highest affinity were calcd. using AutoDock Vina.  The obtained albumin "nanoglue"-based nanotheranostics, HSA-PTX-DVDMS (HPD), has better fluorescence imaging and PDT performance than free DVDMS, probably due to the reduced quenching of DVDMS after dispersion in albumin.  An efficacious tumor-targeting enhancement of chemotherapy by US irradn. is verified in a bilateral s.c. 4T1 tumors model.  With the aid of US irradn., the combined PDT and chemotherapy mediated by HPD achieve effective tumor growth inhibition.  Overall, this "nanoglue"-based nanotheranostics is composed of several clin. used elements and integrates three clin. modalities with application prospects in clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor-f57Xb7BbbVg90H21EOLACvtfcHk0ljJAIq6rirMyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXotFeht7g%253D&md5=a0e261f170fa74c4d99af2c8e0d37f5b</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facsnano.9b09827&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsnano.9b09827%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DBlum%26aufirst%3DN.%2BT.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DP.%26atitle%3DUltrasound-enhanced%2520chemo-photodynamic%2520combination%2520therapy%2520by%2520using%2520albumin%2520%25E2%2580%259Cnanoglue%25E2%2580%259D-based%2520nanotheranostics%26jtitle%3DACS%2520Nano%26date%3D2020%26volume%3D14%26spage%3D5560%26epage%3D5569%26doi%3D10.1021%2Facsnano.9b09827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span> <span> </span><span class="NLM_article-title">Blood-brain-barrier-penetrating albumin nanoparticles for biomimetic drug delivery via albumin-binding protein pathways for antiglioma therapy</span>. <i>ACS Nano</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">9999</span>– <span class="NLM_lpage">10012</span>, <span class="refDoi"> DOI: 10.1021/acsnano.6b04268</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsnano.6b04268" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhslykt7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=9999-10012&author=T.+Linauthor=P.+Zhaoauthor=Y.+Jiangauthor=Y.+Tangauthor=H.+Jinauthor=Z.+Panauthor=H.+Heauthor=V.+C.+Yangauthor=Y.+Huang&title=Blood-brain-barrier-penetrating+albumin+nanoparticles+for+biomimetic+drug+delivery+via+albumin-binding+protein+pathways+for+antiglioma+therapy&doi=10.1021%2Facsnano.6b04268"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Blood-Brain-Barrier-Penetrating Albumin Nanoparticles for Biomimetic Drug Delivery via Albumin-Binding Protein Pathways for Antiglioma Therapy</span></div><div class="casAuthors">Lin, Tingting; Zhao, Pengfei; Jiang, Yifan; Tang, Yisi; Jin, Hongyue; Pan, Zhenzhen; He, Huining; Yang, Victor C.; Huang, Yongzhuo</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">9999-10012</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nutrient transporters have been explored for biomimetic delivery targeting the brain.  The albumin-binding proteins (e.g., SPARC and gp60) are overexpressed in many tumors for transport of albumin as an amino acid and an energy source for fast-growing cancer cells.  However, their application in brain delivery has rarely been investigated.  In this work, SPARC and gp60 overexpression was found on glioma and tumor vessel endothelium; therefore, such pathways were explored for use in brain-targeting biomimetic delivery.  We developed a green method for blood-brain barrier (BBB)-penetrating albumin nanoparticle synthesis, with the capacity to coencapsulate different drugs and no need for crosslinkers.  The hydrophobic drugs (i.e., paclitaxel and fenretinide) yield synergistic effects to induce albumin self-assembly, forming dual drug-loaded nanoparticles.  The albumin nanoparticles can penetrate the BBB and target glioma cells via the mechanisms of SPARC- and gp60-mediated biomimetic transport.  Importantly, by modification with the cell-penetrating peptide LMWP, the albumin nanoparticles display enhanced BBB penetration, intratumoral infiltration, and cellular uptake.  The LMWP-modified nanoparticles exhibited improved treatment outcomes in both s.c. and intracranial glioma models, with reduced toxic side effects.  The therapeutic mechanisms were assocd. with induction of apoptosis, antiangiogenesis, and tumor immune microenvironment regulation.  It provides a facile method for dual drug-loaded albumin nanoparticle prepn. and a promising avenue for biomimetic delivery targeting the brain tumor based on combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQCxTZ5nRnwbVg90H21EOLACvtfcHk0ljJAIq6rirMyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhslykt7fP&md5=e8eac10ffbf7da065000fbd54f524ff9</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facsnano.6b04268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsnano.6b04268%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DV.%2BC.%26aulast%3DHuang%26aufirst%3DY.%26atitle%3DBlood-brain-barrier-penetrating%2520albumin%2520nanoparticles%2520for%2520biomimetic%2520drug%2520delivery%2520via%2520albumin-binding%2520protein%2520pathways%2520for%2520antiglioma%2520therapy%26jtitle%3DACS%2520Nano%26date%3D2016%26volume%3D10%26spage%3D9999%26epage%3D10012%26doi%3D10.1021%2Facsnano.6b04268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarkson, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imberti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadler, P. J.</span></span> <span> </span><span class="NLM_article-title">Nucleus-targeted organoiridium-albumin conjugate for photoactivated cancer therapy</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2350</span>– <span class="NLM_lpage">2354</span>, <span class="refDoi"> DOI: 10.1002/anie.201813002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1002%2Fanie.201813002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVOqsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=2350-2354&author=P.+Zhangauthor=H.+Huangauthor=S.+Banerjeeauthor=G.+J.+Clarksonauthor=C.+Geauthor=C.+Imbertiauthor=P.+J.+Sadler&title=Nucleus-targeted+organoiridium-albumin+conjugate+for+photoactivated+cancer+therapy&doi=10.1002%2Fanie.201813002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleus-Targeted Organoiridium-Albumin Conjugate for Photodynamic Cancer Therapy</span></div><div class="casAuthors">Zhang, Pingyu; Huang, Huaiyi; Banerjee, Samya; Clarkson, Guy J.; Ge, Chen; Imberti, Cinzia; Sadler, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2350-2354</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">An organoiridium-albumin bioconjugate (Ir1-HSA) was synthesized by reaction of a pendant maleimide ligand with human serum albumin.  The phosphorescence of Ir1-HSA was enhanced significantly compared to parent complex Ir1.  The long phosphorescence lifetime and high 1O2 quantum yield of Ir1-HSA are highly favorable properties for photodynamic therapy.  Ir1-HSA mainly accumulated in the nucleus of living cancer cells and showed remarkable photocytotoxicity against a range of cancer cell lines and tumor spheroids (light IC50; 0.8-5 μm, photo-cytotoxicity index PI=40-60), while remaining non-toxic to normal cells and normal cell spheroids, even after photo-irradn.  This nucleus-targeting organoiridium-albumin is a strong candidate photosensitizer for anticancer photodynamic therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjPniNhdl_Z7Vg90H21EOLACvtfcHk0ljJAIq6rirMyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVOqsr0%253D&md5=c312b9e6e6c55406b61ecacb74a9749d</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Fanie.201813002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201813002%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DBanerjee%26aufirst%3DS.%26aulast%3DClarkson%26aufirst%3DG.%2BJ.%26aulast%3DGe%26aufirst%3DC.%26aulast%3DImberti%26aufirst%3DC.%26aulast%3DSadler%26aufirst%3DP.%2BJ.%26atitle%3DNucleus-targeted%2520organoiridium-albumin%2520conjugate%2520for%2520photoactivated%2520cancer%2520therapy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2019%26volume%3D58%26spage%3D2350%26epage%3D2354%26doi%3D10.1002%2Fanie.201813002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span> <span> </span><span class="NLM_article-title">Albumin carriers for cancer theranostics: a conventional platform with new promise</span>. <i>Adv. Mater.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">10557</span>– <span class="NLM_lpage">10566</span>, <span class="refDoi"> DOI: 10.1002/adma.201600038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1002%2Fadma.201600038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=27111654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC28Xms1Oisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2016&pages=10557-10566&author=Q.+Chenauthor=Z.+Liu&title=Albumin+carriers+for+cancer+theranostics%3A+a+conventional+platform+with+new+promise&doi=10.1002%2Fadma.201600038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Albumin Carriers for Cancer Theranostics: A Conventional Platform with New Promise</span></div><div class="casAuthors">Chen, Qian; Liu, Zhuang</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Materials (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">10557-10566</span>CODEN:
                <span class="NLM_cas:coden">ADVMEW</span>;
        ISSN:<span class="NLM_cas:issn">0935-9648</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Theranostic nanoplatforms with integrated diagnostic and therapeutic functions, aiming at imaging-guided therapy to improve treatment planning, as well as combination therapy to enhance treatment efficacy, have received tremendous attention in recent years.  Among numerous types of functional nanomaterials explored in this field, protein-based nanocarriers with inherent biocompatibility have also been selected as building blocks to construct multifunctional theranostic platforms.  In particular, albumin, which has been extensively used as drug-delivery carriers for decades, has shown great new promise in the construction of novel imaging and therapeutic nanoagents, as demonstrated by a no. of recent studies.  IHere, the motivations of using albumins to build up nanoscale theranostics are discussed, and the latest progress/future perspectives in this direction are summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfL7VOZWFi_rVg90H21EOLACvtfcHk0lg0slcjAhkERw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xms1Oisr8%253D&md5=b750bf3e31eadade08d159137f9aa55f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2Fadma.201600038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadma.201600038%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DZ.%26atitle%3DAlbumin%2520carriers%2520for%2520cancer%2520theranostics%253A%2520a%2520conventional%2520platform%2520with%2520new%2520promise%26jtitle%3DAdv.%2520Mater.%26date%3D2016%26volume%3D28%26spage%3D10557%26epage%3D10566%26doi%3D10.1002%2Fadma.201600038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J. H.</span></span> <span> </span><span class="NLM_article-title">Self-assemblead PEGylated albumin nanoparticles (SPAN) as a platform for cancer chemotherapy and imaging</span>. <i>Drug Delivery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1570</span>– <span class="NLM_lpage">1578</span>, <span class="refDoi"> DOI: 10.1080/10717544.2018.1489430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1080%2F10717544.2018.1489430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=30044159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlyqsrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=1570-1578&author=J.+E.+Leeauthor=M.+G.+Kimauthor=Y.+L.+Jangauthor=M.+S.+Leeauthor=N.+W.+Kimauthor=Y.+Yinauthor=J.+H.+Leeauthor=S.+Y.+Limauthor=J.+W.+Parkauthor=J.+Kimauthor=D.+S.+Leeauthor=S.+H.+Kimauthor=J.+H.+Jeong&title=Self-assemblead+PEGylated+albumin+nanoparticles+%28SPAN%29+as+a+platform+for+cancer+chemotherapy+and+imaging&doi=10.1080%2F10717544.2018.1489430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Self-assembled PEGylated albumin nanoparticles (SPAN) as a platform for cancer chemotherapy and imaging</span></div><div class="casAuthors">Lee, Jung Eun; Kim, Myung Goo; Jang, Yeon Lim; Lee, Min Sang; Kim, Nak Won; Yin, Yue; Lee, Jong Han; Lim, Su Yeon; Park, Ji Won; Kim, Jaeyun; Lee, Doo Sung; Kim, Sun Hwa; Jeong, Ji Hoon</div><div class="citationInfo"><span class="NLM_cas:title">Drug Delivery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1570-1578</span>CODEN:
                <span class="NLM_cas:coden">DDELEB</span>;
        ISSN:<span class="NLM_cas:issn">1071-7544</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Paclitaxel (PTX) is used as a major antitumor agent for the treatment of recurrent and metastatic breast cancer.  For the clin. application of PTX, it needs to be dissolved in an oil/detergent-based solvent due to its poor soly. in an aq. medium.  However, the formulation often causes undesirable complications including hypersensitivity reactions and limited tumor distribution, resulting in a lower dose-dependent antitumor effect.  Herein, we introduce a facile and oil-free method to prep. albumin-based PTX nanoparticles for efficient systemic cancer therapy using a conjugate of human serum albumin (HSA) and poly(ethyleneglycol) (PEG).  PTX were efficiently incorporated in the self-assembled HSA-PEG nanoparticles (HSA-PEG/PTX) using a simple film casting and re-hydration procedure without addnl. processes such as application of high pressure/shear or chem. crosslinking.  The spherical HSA-PEG nanoparticle with a hydrodynamic diam. of ca. 280 nm mediates efficient cellular delivery, leading to comparable or even higher cytotoxicity in various breast cancer cells than that of the com. available Abraxane..  When systemically administered in a mouse xenograft model for human breast cancer, the HSA-PEG-based nanoparticle formulation exhibited an extended systemic circulation for more than 96 h and enhanced intratumoral accumulation, resulting in a remarkable anticancer effect and prolonged survival of the animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2P_t1NbxhtrVg90H21EOLACvtfcHk0lg0slcjAhkERw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlyqsrvO&md5=680751a493d4d5f9b3c40f0aeb7f9f7d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1080%2F10717544.2018.1489430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10717544.2018.1489430%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BE.%26aulast%3DKim%26aufirst%3DM.%2BG.%26aulast%3DJang%26aufirst%3DY.%2BL.%26aulast%3DLee%26aufirst%3DM.%2BS.%26aulast%3DKim%26aufirst%3DN.%2BW.%26aulast%3DYin%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DLim%26aufirst%3DS.%2BY.%26aulast%3DPark%26aufirst%3DJ.%2BW.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DD.%2BS.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DJeong%26aufirst%3DJ.%2BH.%26atitle%3DSelf-assemblead%2520PEGylated%2520albumin%2520nanoparticles%2520%2528SPAN%2529%2520as%2520a%2520platform%2520for%2520cancer%2520chemotherapy%2520and%2520imaging%26jtitle%3DDrug%2520Delivery%26date%3D2018%26volume%3D25%26spage%3D1570%26epage%3D1578%26doi%3D10.1080%2F10717544.2018.1489430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span> <span> </span><span class="NLM_article-title">Developing anticancer ferric prodrugs based on the N-Donor residues of human serum albumin carrier IIA subdomain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7497</span>– <span class="NLM_lpage">7511</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00509</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00509" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1SktLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7497-7511&author=J.+Qiauthor=Y.+Gouauthor=Y.+Zhangauthor=K.+Yangauthor=S.+Chenauthor=L.+Liuauthor=X.+Wuauthor=T.+Wangauthor=W.+Zhangauthor=F.+Yang&title=Developing+anticancer+ferric+prodrugs+based+on+the+N-Donor+residues+of+human+serum+albumin+carrier+IIA+subdomain&doi=10.1021%2Facs.jmedchem.6b00509"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Developing Anticancer Ferric Prodrugs Based on the N-Donor Residues of Human Serum Albumin Carrier IIA Subdomain</span></div><div class="casAuthors">Qi, Jinxu; Gou, Yi; Zhang, Yao; Yang, Kun; Chen, Shifang; Liu, Li; Wu, Xiaoyang; Wang, Tao; Zhang, Wei; Yang, Feng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7497-7511</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To improve the selectivity, delivery, and activity of ferric (Fe) anticancer agents, the authors design prodrugs based on N-donor residues of the human serum albumin (HSA) carrier IIA subdomain.  The authors synthesized six Fe(III) compds. derived from 2-hydroxy-1-naphthaldehyde thiosemicarbazone (7-12).  HSA complex structure revealed that Fe compd. binds to the hydrophobic cavity in the HSA IIA subdomain.  Lys199 and His242 of HSA replace the two Cl atoms of Fe compd., coordinating with Fe3+.  In vivo data revealed that compd. 12 and HSA-12 complex inhibit the growth of the liver tumor and that the HSA-12 complex has stronger targeting ability and therapeutic efficacy than compd. 12 alone.  The authors' results showed that compd. 12 and HSA-12 complex induce Bel-7402 cell death possible by several mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgWEKbMYrXyrVg90H21EOLACvtfcHk0lg0slcjAhkERw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1SktLrM&md5=6b9d962c4272056886c3525f2e7fcd1c</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00509%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DGou%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DF.%26atitle%3DDeveloping%2520anticancer%2520ferric%2520prodrugs%2520based%2520on%2520the%2520N-Donor%2520residues%2520of%2520human%2520serum%2520albumin%2520carrier%2520IIA%2520subdomain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7497%26epage%3D7511%26doi%3D10.1021%2Facs.jmedchem.6b00509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, H.</span></span> <span> </span><span class="NLM_article-title">Novel brain-tumor-inhibiting copper(II) compound based on a human serum albumin (HSA)-cell penetrating peptide conjugate</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">10630</span>– <span class="NLM_lpage">10644</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00939</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00939" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFWgs7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10630-10644&author=Z.+Zhangauthor=P.+Yuauthor=Y.+Gouauthor=J.+Zhangauthor=S.+Liauthor=M.+Caiauthor=H.+Sunauthor=F.+Yangauthor=H.+Liang&title=Novel+brain-tumor-inhibiting+copper%28II%29+compound+based+on+a+human+serum+albumin+%28HSA%29-cell+penetrating+peptide+conjugate&doi=10.1021%2Facs.jmedchem.9b00939"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Brain-Tumor-Inhibiting Copper(II) Compound Based on a Human Serum Albumin (HSA)-Cell Penetrating Peptide Conjugate</span></div><div class="casAuthors">Zhang, Zhenlei; Yu, Ping; Gou, Yi; Zhang, Juzheng; Li, Shanhe; Cai, Meiling; Sun, Hongbin; Yang, Feng; Liang, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10630-10644</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">It is a great challenge to design drugs that penetrate the blood-brain barrier to inhibit brain tumor growth by acting against multiple targets and also improve their delivery efficacy and targeting ability to cancer cells.  To overcome the above problems, the authors designed a multitarget metal agent for treating brain tumors based on an human serum albumin (HSA)-cell penetrating peptide conjugate.  Thus, the authors rationally screened copper (Cu) and 2-acetyl-3-ethylpyrazine thiosemicarbazones to synthesize six compds., and the authors investigated their structure-activity relations and confirmed multiple mechanisms for brain glioma cells.  The HSA-6b complex structure indicated that 6b binds to the IIA subdomain of HSA and His242 replaces the Br ligand in 6b in coordination with Cu2+.  In vivo data suggested that both 6b and the HSA-6b-peptide conjugate penetrate the blood-brain barrier and inhibit brain tumor growth with few side effects.  Also, the HSA-peptide conjugate also improved the delivery efficacy and targeting ability of 6b in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrunalWKT3Kz7Vg90H21EOLACvtfcHk0liW3RfeR5BXcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFWgs7fN&md5=ca872b0555a0b875720b4390d2b64539</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00939&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00939%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DGou%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DCai%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DLiang%26aufirst%3DH.%26atitle%3DNovel%2520brain-tumor-inhibiting%2520copper%2528II%2529%2520compound%2520based%2520on%2520a%2520human%2520serum%2520albumin%2520%2528HSA%2529-cell%2520penetrating%2520peptide%2520conjugate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D10630%26epage%3D10644%26doi%3D10.1021%2Facs.jmedchem.9b00939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajayi, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, H.</span></span> <span> </span><span class="NLM_article-title">Developing anticancer copper(II) prodrugs based on the nature of cancer cells and the human serum albumin carrier IIA subdomain</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">3597</span>– <span class="NLM_lpage">3609</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.5b00314</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.5b00314" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVOnsrbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=3597-3609&author=Y.+Gouauthor=J.+Qiauthor=J.-P.+Ajayiauthor=Y.+Zhangauthor=Z.+Zhouauthor=X.+Wuauthor=F.+Yangauthor=H.+Liang&title=Developing+anticancer+copper%28II%29+prodrugs+based+on+the+nature+of+cancer+cells+and+the+human+serum+albumin+carrier+IIA+subdomain&doi=10.1021%2Facs.molpharmaceut.5b00314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Developing Anticancer Copper(II) Pro-drugs Based on the Nature of Cancer Cells and the Human Serum Albumin Carrier IIA Subdomain</span></div><div class="casAuthors">Gou, Yi; Qi, Jinxu; Ajayi, Joshua-Paul; Zhang, Yao; Zhou, Zuping; Wu, Xiaoyang; Yang, Feng; Liang, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3597-3609</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To synergistically enhance the selectivity and efficiency of anticancer copper drugs, we proposed and built a model to develop anticancer copper pro-drugs based on the nature of human serum albumin (HSA) IIA subdomain and cancer cells.  Three copper(II) compds. of a 2-hydroxy-1-naphthaldehyde benzoyl hydrazone Schiff-base ligand in the presence pyridine, imidazole, or indazole ligands were synthesized (C1-C3).  The structures of three HSA complexes revealed that the Cu compds. bind to the hydrophobic cavity in the HSA IIA subdomain.  Among them, the pyridine and imidazole ligands of C1 and C2 are replaced by Lys199, and His242 directly coordinates with Cu(II).  The indazole and Br ligands of C3 are replaced by Lys199 and His242, resp.  Compared with the Cu(II) compds. alone, the HSA complexes enhance cytotoxicity in MCF-7 cells approx. 3-5-fold, but do not raise cytotoxicity levels in normal cells in vitro through selectively accumulating in cancer cells to some extent.  We find that the HSA complex has a stronger capacity for cell cycle arrest in the G2/M phase of MCF-7 by targeting cyclin-dependent kinase 1 (CDK1) and down-regulating the expression of CDK1 and cyclin B1.  Moreover, the HSA complex promotes MCF-7 cell apoptosis possibly through the intrinsic reactive oxygen species (ROS) mediated mitochondrial pathway, accompanied by the regulation of Bcl-2 family proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQC67vwTNSRLVg90H21EOLACvtfcHk0liW3RfeR5BXcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVOnsrbE&md5=c1977caff60b0d3a7ca3f47ce443c886</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.5b00314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.5b00314%26sid%3Dliteratum%253Aachs%26aulast%3DGou%26aufirst%3DY.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DAjayi%26aufirst%3DJ.-P.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DLiang%26aufirst%3DH.%26atitle%3DDeveloping%2520anticancer%2520copper%2528II%2529%2520prodrugs%2520based%2520on%2520the%2520nature%2520of%2520cancer%2520cells%2520and%2520the%2520human%2520serum%2520albumin%2520carrier%2520IIA%2520subdomain%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2015%26volume%3D12%26spage%3D3597%26epage%3D3609%26doi%3D10.1021%2Facs.molpharmaceut.5b00314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, H.</span></span> <span> </span><span class="NLM_article-title">Developing an anticancer copper(II) prodrug based on the His242 residue of the human serum albumin carrier IIA subdomain</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1501</span>– <span class="NLM_lpage">1507</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.5b00938</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.5b00938" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvVahurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=1501-1507&author=J.+Qiauthor=Y.+Zhangauthor=Y.+Gouauthor=Z.+Zhangauthor=Z.+Zhouauthor=X.+Wuauthor=F.+Yangauthor=H.+Liang&title=Developing+an+anticancer+copper%28II%29+prodrug+based+on+the+His242+residue+of+the+human+serum+albumin+carrier+IIA+subdomain&doi=10.1021%2Facs.molpharmaceut.5b00938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Developing an Anticancer Copper(II) Pro-Drug Based on the His242 Residue of the Human Serum Albumin Carrier IIA Subdomain</span></div><div class="casAuthors">Qi, Jinxu; Zhang, Yao; Gou, Yi; Zhang, Zhenlei; Zhou, Zuping; Wu, Xiaoyang; Yang, Feng; Liang, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1501-1507</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To increase delivery efficiency, anticancer activity, and selectivity of anticancer metal agents in vivo, we proposed to develop the anticancer metal pro-drug based on His242 residue of the human serum albumin (HSA) carrier IIA subdomain.  To confirm our hypothesis, we prepd. two Cu(II) compds. [Cu(P4 mT)Cl and Cu(Bp44 mT)Cl] by modifying Cu(II) compd. ligand structure.  Studies with two HSA complex structures revealed that Cu(P4 mT)Cl bound to the HSA subdomain IIA via hydrophobic interactions, but Cu(Bp44 mT)Cl bound to the HSA subdomain IIA via His242 replacement of a Cl atom of Cu(Bp44 mT)Cl, and a coordination to Cu2+.  Furthermore, Cu(II) compds. released from HSA could be regulated at different pHs.  In vivo data revealed that the HSA-Cu(Bp44 mT) complex increased copper's selectivity and capacity of inhibiting tumor growth compared to Cu(Bp44 mT)Cl alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHVA5oWe9GUbVg90H21EOLACvtfcHk0liW3RfeR5BXcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvVahurg%253D&md5=590fcfb50f0478829e3435277c6e8fd3</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.5b00938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.5b00938%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGou%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DLiang%26aufirst%3DH.%26atitle%3DDeveloping%2520an%2520anticancer%2520copper%2528II%2529%2520prodrug%2520based%2520on%2520the%2520His242%2520residue%2520of%2520the%2520human%2520serum%2520albumin%2520carrier%2520IIA%2520subdomain%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2016%26volume%3D13%26spage%3D1501%26epage%3D1507%26doi%3D10.1021%2Facs.molpharmaceut.5b00938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Z. W.</span></span> <span> </span><span class="NLM_article-title">Recoding the cancer epigenome by intervening in metabolism and iron homeostasis with mitochondria-targeted rhenium(I) complexes</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">18755</span>– <span class="NLM_lpage">18762</span>, <span class="refDoi"> DOI: 10.1002/anie.202008624</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1002%2Fanie.202008624" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFyht7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2020&pages=18755-18762&author=Z.-Y.+Panauthor=C.+P.+Tanauthor=L.+S.+Raoauthor=H.+Zhangauthor=Y.+Zhengauthor=L.+Haoauthor=L.+N.+Jiauthor=Z.+W.+Mao&title=Recoding+the+cancer+epigenome+by+intervening+in+metabolism+and+iron+homeostasis+with+mitochondria-targeted+rhenium%28I%29+complexes&doi=10.1002%2Fanie.202008624"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Recoding the Cancer Epigenome by Intervening in Metabolism and Iron Homeostasis with Mitochondria-Targeted Rhenium(I) Complexes</span></div><div class="casAuthors">Pan, Zheng-Yin; Tan, Cai-Ping; Rao, Lu-Si; Zhang, Hang; Zheng, Yue; Hao, Liang; Ji, Liang-Nian; Mao, Zong-Wan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">18755-18762</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The development and malignancy of cancer cells are closely related to the changes of the epigenome.  In this work, a mitochondria-targeted rhenium(I) complex (DFX-Re3), integrating the clin. iron chelating agent deferasirox (DFX), has been designed.  By relocating iron to the mitochondria and changing the key metabolic species related to epigenetic modifications, DFX-Re3 can elevate the methylation levels of histone, DNA, and RNA.  As a consequence, DFX-Re3 affects the events related to apoptosis, RNA polymerases, and T-cell receptor signaling pathways.  Finally, it is shown that DFX-Re3 induces immunogenic apoptotic cell death and exhibits potent antitumor activity in vivo.  This study provides a new approach for the design of novel epigenetic drugs that can recode the cancer epigenome by intervening in mitochondrial metab. and iron homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyFrV6Cler2rVg90H21EOLACvtfcHk0liAC0GQm_OgMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFyht7rE&md5=f4117f5ec75828dc97c5885b9f3698f1</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Fanie.202008624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.202008624%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.-Y.%26aulast%3DTan%26aufirst%3DC.%2BP.%26aulast%3DRao%26aufirst%3DL.%2BS.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DHao%26aufirst%3DL.%26aulast%3DJi%26aufirst%3DL.%2BN.%26aulast%3DMao%26aufirst%3DZ.%2BW.%26atitle%3DRecoding%2520the%2520cancer%2520epigenome%2520by%2520intervening%2520in%2520metabolism%2520and%2520iron%2520homeostasis%2520with%2520mitochondria-targeted%2520rhenium%2528I%2529%2520complexes%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2020%26volume%3D59%26spage%3D18755%26epage%3D18762%26doi%3D10.1002%2Fanie.202008624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Z.-W.</span></span> <span> </span><span class="NLM_article-title">CAIXplatins: highly potent platinum(IV) prodrugs selective against carbonic anhydrase IX for the treatment of hypoxic tumors</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">18556</span>– <span class="NLM_lpage">18562</span>, <span class="refDoi"> DOI: 10.1002/anie.202005362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1002%2Fanie.202005362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFyht7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2020&pages=18556-18562&author=Q.+Caoauthor=D.+J.+Zhouauthor=Z.+Y.+Panauthor=G.+G.+Yangauthor=H.+Zhangauthor=L.+N.+Jiauthor=Z.-W.+Mao&title=CAIXplatins%3A+highly+potent+platinum%28IV%29+prodrugs+selective+against+carbonic+anhydrase+IX+for+the+treatment+of+hypoxic+tumors&doi=10.1002%2Fanie.202005362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">CAIXplatins: Highly Potent Platinum(IV) Prodrugs Selective Against Carbonic Anhydrase IX for the Treatment of Hypoxic Tumors</span></div><div class="casAuthors">Cao, Qian; Zhou, Dan-Jie; Pan, Zheng-Yin; Yang, Gang-Gang; Zhang, Hang; Ji, Liang-Nian; Mao, Zong-Wan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">18556-18562</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Hypoxia and the acidic microenvironment play a vital role in tumor metastasis and angiogenesis, generally compromising the chemotherapeutic efficacy.  This provides a tantalizing angle for the design of platinum(IV) prodrugs for the effective and selective killing of solid tumors.  Herein, two carbonic anhydrase IX (CAIX)-targeting platinum(IV) prodrugs have been developed, named as CAIXplatins.  Based on their strong affinity for and inhibition of CAIX, CAIXplatins can not only overcome hypoxia and the acidic microenvironment, but also inhibit metabolic pathways of hypoxic cancer cells, resulting in a significantly enhanced therapeutic effect on hypoxic MDA-MB-231 tumors both in vitro and in vivo compared with cisplatin/oxaliplatin, accompanied with excellent anti-metastasis and anti-angiogenesis activities.  Furthermore, the cancer selectivity indexes of CAIXplatins are 70-90 times higher than those of cisplatin/oxaliplatin with effectively alleviated side-effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8xGTFjuUSd7Vg90H21EOLACvtfcHk0liAC0GQm_OgMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFyht7%252FF&md5=f345b238f8a0e15b33e795d24714097a</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2Fanie.202005362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.202005362%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DD.%2BJ.%26aulast%3DPan%26aufirst%3DZ.%2BY.%26aulast%3DYang%26aufirst%3DG.%2BG.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DJi%26aufirst%3DL.%2BN.%26aulast%3DMao%26aufirst%3DZ.-W.%26atitle%3DCAIXplatins%253A%2520highly%2520potent%2520platinum%2528IV%2529%2520prodrugs%2520selective%2520against%2520carbonic%2520anhydrase%2520IX%2520for%2520the%2520treatment%2520of%2520hypoxic%2520tumors%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2020%26volume%3D59%26spage%3D18556%26epage%3D18562%26doi%3D10.1002%2Fanie.202005362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brockman, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skipper, H. E.</span></span> <span> </span><span class="NLM_article-title">Observations on the antileukemic activity of pyridine-2-carboxalde-hyde thiosemicarbazone and thiocarbohydrazone</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1956</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">170</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=13293659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A280%3ADyaG28%252FksF2ntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1956&pages=167-170&author=R.+W.+Brockmanauthor=J.+R.+Thomsonauthor=M.+J.+Bellauthor=H.+E.+Skipper&title=Observations+on+the+antileukemic+activity+of+pyridine-2-carboxalde-hyde+thiosemicarbazone+and+thiocarbohydrazone"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Observations on the antileukemic activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone</span></div><div class="casAuthors">BROCKMAN R W; THOMSON J R; BELL M J; SKIPPER H E</div><div class="citationInfo"><span class="NLM_cas:title">Cancer research</span>
        (<span class="NLM_cas:date">1956</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-70</span>
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRN-1fIG0cy67JzI8owOhpDfW6udTcc2ebZyrv4BaJbTLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaG28%252FksF2ntw%253D%253D&md5=a96d785a0eb92ce711be35fce8f760d1</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrockman%26aufirst%3DR.%2BW.%26aulast%3DThomson%26aufirst%3DJ.%2BR.%26aulast%3DBell%26aufirst%3DM.%2BJ.%26aulast%3DSkipper%26aufirst%3DH.%2BE.%26atitle%3DObservations%2520on%2520the%2520antileukemic%2520activity%2520of%2520pyridine-2-carboxalde-hyde%2520thiosemicarbazone%2520and%2520thiocarbohydrazone%26jtitle%3DCancer%2520Res.%26date%3D1956%26volume%3D16%26spage%3D167%26epage%3D170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stacy, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palanimuthu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhardt, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalinowski, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. R.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships of di-2-pyridylketone, 2-benzoylpyridine, and 2-acetylpyridine thiosemicarbazones for overcoming pgp-mediated drug resistance</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8601</span>– <span class="NLM_lpage">8620</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01050</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01050" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtleiurbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8601-8620&author=A.+E.+Stacyauthor=D.+Palanimuthuauthor=P.+V.+Bernhardtauthor=D.+S.+Kalinowskiauthor=P.+J.+Janssonauthor=D.+R.+Richardson&title=Structure-activity+relationships+of+di-2-pyridylketone%2C+2-benzoylpyridine%2C+and+2-acetylpyridine+thiosemicarbazones+for+overcoming+pgp-mediated+drug+resistance&doi=10.1021%2Facs.jmedchem.6b01050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationships of Di-2-pyridylketone, 2-Benzoylpyridine, and 2-Acetylpyridine Thiosemicarbazones for Overcoming Pgp-Mediated Drug Resistance</span></div><div class="casAuthors">Stacy, Alexandra E.; Palanimuthu, Duraippandi; Bernhardt, Paul V.; Kalinowski, Danuta S.; Jansson, Patric J.; Richardson, Des R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8601-8620</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multidrug resistance (MDR) mediated by P-glycoprotein (Pgp) represents a significant impediment to successful cancer treatment.  The compd., di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT), has been shown to induce greater cytotoxicity against resistant cells than their nonresistant counterparts.  Herein, the structure-activity relationships of selected thiosemicarbazones are explored and the novel mechanism underlying their ability to overcome resistance is further elucidated.  Only thiosemicarbazones with electron-withdrawing substituents at the imine carbon mediated Pgp-dependent potentiated cytotoxicity, which was reversed by Pgp inhibition.  Treatment of resistant cells with these thiosemicarbazones resulted in Pgp-dependent lysosomal membrane permeabilization (LMP) that relied on copper (Cu) chelation, reactive oxygen species generation, and increased relative lipophilicity.  Hence, this study is the first to demonstrate the structural requirements of these thiosemicarbazones necessary to overcome MDR.  We also demonstrate the mechanism that enables the targeting of resistant tumors, whereby thiosemicarbazones "hijack" lysosomal Pgp and form redox-active Cu complexes that mediate LMP and potentiate cytotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoafsFvewets7Vg90H21EOLACvtfcHk0lh_E4OgqdyiOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtleiurbE&md5=db72435a4eeaa7f0b6035d406253251f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01050%26sid%3Dliteratum%253Aachs%26aulast%3DStacy%26aufirst%3DA.%2BE.%26aulast%3DPalanimuthu%26aufirst%3DD.%26aulast%3DBernhardt%26aufirst%3DP.%2BV.%26aulast%3DKalinowski%26aufirst%3DD.%2BS.%26aulast%3DJansson%26aufirst%3DP.%2BJ.%26aulast%3DRichardson%26aufirst%3DD.%2BR.%26atitle%3DStructure-activity%2520relationships%2520of%2520di-2-pyridylketone%252C%25202-benzoylpyridine%252C%2520and%25202-acetylpyridine%2520thiosemicarbazones%2520for%2520overcoming%2520pgp-mediated%2520drug%2520resistance%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8601%26epage%3D8620%26doi%3D10.1021%2Facs.jmedchem.6b01050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Danial, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korsmeyer, S. J.</span></span> <span> </span><span class="NLM_article-title">Cell death: critical control points</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(04)00046-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1016%2FS0092-8674%2804%2900046-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=14744432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtValsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2004&pages=205-219&author=N.+N.+Danialauthor=S.+J.+Korsmeyer&title=Cell+death%3A+critical+control+points&doi=10.1016%2FS0092-8674%2804%2900046-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Cell death: Critical control points</span></div><div class="casAuthors">Danial, Nika N.; Korsmeyer, Stanley J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">205-219</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review and discussion.  Programmed cell death (apoptosis) is a distinct genetic and biochem. pathway essential to metazoans.  An intact death pathway is required for successful embryonic development and the maintenance of normal tissue homeostasis.  Apoptosis has proven to be tightly interwoven with other essential cell pathways.  The identification of crit. control points in the cell death pathway has yielded fundamental insights for basic biol., as well as provided rational targets for new therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfuRt2EjV6WLVg90H21EOLACvtfcHk0lh_E4OgqdyiOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtValsrY%253D&md5=de853177ac091305b7f237e58108f579</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900046-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900046-7%26sid%3Dliteratum%253Aachs%26aulast%3DDanial%26aufirst%3DN.%2BN.%26aulast%3DKorsmeyer%26aufirst%3DS.%2BJ.%26atitle%3DCell%2520death%253A%2520critical%2520control%2520points%26jtitle%3DCell%26date%3D2004%26volume%3D116%26spage%3D205%26epage%3D219%26doi%3D10.1016%2FS0092-8674%2804%2900046-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stock, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. E.</span></span> <span> </span><span class="NLM_article-title">Molecular architecture of the rotary motor in ATP synthase</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">1700</span>– <span class="NLM_lpage">1705</span>, <span class="refDoi"> DOI: 10.1126/science.286.5445.1700</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1126%2Fscience.286.5445.1700" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10576729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADyaK1MXnslKntr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=1999&pages=1700-1705&author=D.+Stockauthor=A.+G.+Leslieauthor=J.+E.+Walker&title=Molecular+architecture+of+the+rotary+motor+in+ATP+synthase&doi=10.1126%2Fscience.286.5445.1700"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular architecture of the rotary motor in ATP synthase</span></div><div class="casAuthors">Stock, Daniela; Leslie, Andrew G. W.; Walker, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">5445</span>),
    <span class="NLM_cas:pages">1700-1705</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">ATP synthase contains a rotary motor involved in biol. energy conversion.  Its membrane-embedded F0 sector has a rotation generator fueled by protonmotive force, which provides the energy required for the synthesis of ATP by the F1 domain.  An electron d. map obtained from crystals of a subcomplex of yeast mitochondrial ATP synthase shows a ring of 10 c subunits.  Each c subunit forms an α-helical hairpin.  The interhelical loops of 6-7 of the c subunits are in close contact with the γ and δ subunits of the central stalk.  The extensive contact between the c ring and the stalk suggests that they may rotate as an ensemble during catalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojmVflzjYsVbVg90H21EOLACvtfcHk0lh_E4OgqdyiOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXnslKntr8%253D&md5=7ba1357b50d872513b7f0c4c3823019a</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1126%2Fscience.286.5445.1700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.286.5445.1700%26sid%3Dliteratum%253Aachs%26aulast%3DStock%26aufirst%3DD.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%26aulast%3DWalker%26aufirst%3DJ.%2BE.%26atitle%3DMolecular%2520architecture%2520of%2520the%2520rotary%2520motor%2520in%2520ATP%2520synthase%26jtitle%3DScience%26date%3D1999%26volume%3D286%26spage%3D1700%26epage%3D1705%26doi%3D10.1126%2Fscience.286.5445.1700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Du, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)00008-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1016%2FS0092-8674%2800%2900008-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10929711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkvFCrsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2000&pages=33-42&author=C.+Duauthor=M.+Fangauthor=Y.+Liauthor=L.+Liauthor=X.+Wang&title=Smac%2C+a+mitochondrial+protein+that+promotes+cytochrome+c-dependent+caspase+activation+by+eliminating+IAP+inhibition&doi=10.1016%2FS0092-8674%2800%2900008-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition</span></div><div class="casAuthors">Du, Chunying; Fang, Min; Li, Yucheng; Li, Lily; Wang, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-42</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We report here the identification of a novel protein, Smac, which promotes caspase activation in the cytochrome c/Apaf-1/caspase-9 pathway.  Smac promotes caspase-9 activation by binding to inhibitor of apoptosis proteins, IAPs, and removing their inhibitory activity.  Smac is normally a mitochondrial protein but is released into the cytosol when cells undergo apoptosis.  Mitochondrial import and cleavage of its signal peptide are required for Smac to gain its apoptotic activity.  Overexpression of Smac increases cells' sensitivity to apoptotic stimuli.  Smac is the second mitochondrial protein, along with cytochrome c, that promotes apoptosis by activating caspases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEUyaGmAsnprVg90H21EOLACvtfcHk0lh_E4OgqdyiOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkvFCrsbc%253D&md5=8321d44bed77ff7c2da398e1b02f9e20</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2900008-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252900008-8%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DC.%26aulast%3DFang%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DSmac%252C%2520a%2520mitochondrial%2520protein%2520that%2520promotes%2520cytochrome%2520c-dependent%2520caspase%2520activation%2520by%2520eliminating%2520IAP%2520inhibition%26jtitle%3DCell%26date%3D2000%26volume%3D102%26spage%3D33%26epage%3D42%26doi%3D10.1016%2FS0092-8674%2800%2900008-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shiozaki, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span> <span> </span><span class="NLM_article-title">Caspases, IAPs and Smac/DIABLO: mechanisms from structural biology</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">494</span>, <span class="refDoi"> DOI: 10.1016/j.tibs.2004.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1016%2Fj.tibs.2004.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=15337122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntFCjtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2004&pages=486-494&author=E.+N.+Shiozakiauthor=Y.+Shi&title=Caspases%2C+IAPs+and+Smac%2FDIABLO%3A+mechanisms+from+structural+biology&doi=10.1016%2Fj.tibs.2004.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Caspases, IAPs and Smac/DIABLO: mechanisms from structural biology</span></div><div class="casAuthors">Shiozaki, Eric N.; Shi, Yigong</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">486-494</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review and discussion.  Caspases are the central component of the apoptotic machinery that irreversibly commits a cell to die.  Whereas all caspases are structurally similar, those involved in apoptosis can be categorized functionally as either initiator or effector caspases, which are activated by distinct mechanisms.  The activated caspases are subject to inhibition by the inhibitor of apoptosis family of proteins (IAPs).  This inhibition can be removed by Smac/DIABLO during apoptosis.  The underlying mol. mechanisms of caspase regulation are discussed here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoit3MLouSJVbVg90H21EOLACvtfcHk0lhAWUmQDFTV4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntFCjtrs%253D&md5=c077897ad493facfdea3e061a169d810</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2004.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2004.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DShiozaki%26aufirst%3DE.%2BN.%26aulast%3DShi%26aufirst%3DY.%26atitle%3DCaspases%252C%2520IAPs%2520and%2520Smac%252FDIABLO%253A%2520mechanisms%2520from%2520structural%2520biology%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2004%26volume%3D29%26spage%3D486%26epage%3D494%26doi%3D10.1016%2Fj.tibs.2004.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verhagen, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekert, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pakusch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritz, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaux, D. L.</span></span> <span> </span><span class="NLM_article-title">Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)00009-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1016%2FS0092-8674%2800%2900009-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10929712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkvFCrtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2000&pages=43-53&author=A.+M.+Verhagenauthor=P.+G.+Ekertauthor=M.+Pakuschauthor=J.+Silkeauthor=L.+M.+Connollyauthor=G.+E.+Reidauthor=R.+L.+Moritzauthor=R.+J.+Simpsonauthor=D.+L.+Vaux&title=Identification+of+DIABLO%2C+a+mammalian+protein+that+promotes+apoptosis+by+binding+to+and+antagonizing+IAP+proteins&doi=10.1016%2FS0092-8674%2800%2900009-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins</span></div><div class="casAuthors">Verhagen, Anne M.; Ekert, Paul G.; Pakusch, Miha; Silke, John; Connolly, Lisa M.; Reid, Gavin E.; Moritz, Robert L.; Simpson, Richard J.; Vaux, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-53</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">To identify proteins that bind mammalian IAP homolog A (MIHA, also known as XIAP), we used coimmunopptn. and 2D immobilized pH gradient/SDS-PAGE, followed by electrospray ionization tandem mass spectrometry.  DIABLO (direct IAP binding protein with low pI) is a novel protein that can bind MIHA and can also interact with MIHB and MIHC and the baculoviral IAP, OpIAP.  The N-terminally processed, IAP-interacting form of DIABLO is concd. in membrane fractions in healthy cells but released into the MIHA-contg. cytosolic fractions upon UV irradn.  As transfection of cells with DIABLO was able to counter the protection afforded by MIHA against UV irradn., DIABLO may promote apoptosis by binding to IAPs and preventing them from inhibiting caspases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6-TYWHjxeE7Vg90H21EOLACvtfcHk0lhAWUmQDFTV4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkvFCrtr4%253D&md5=475519bd43e9d625b06b0293895d9693</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2900009-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252900009-X%26sid%3Dliteratum%253Aachs%26aulast%3DVerhagen%26aufirst%3DA.%2BM.%26aulast%3DEkert%26aufirst%3DP.%2BG.%26aulast%3DPakusch%26aufirst%3DM.%26aulast%3DSilke%26aufirst%3DJ.%26aulast%3DConnolly%26aufirst%3DL.%2BM.%26aulast%3DReid%26aufirst%3DG.%2BE.%26aulast%3DMoritz%26aufirst%3DR.%2BL.%26aulast%3DSimpson%26aufirst%3DR.%2BJ.%26aulast%3DVaux%26aufirst%3DD.%2BL.%26atitle%3DIdentification%2520of%2520DIABLO%252C%2520a%2520mammalian%2520protein%2520that%2520promotes%2520apoptosis%2520by%2520binding%2520to%2520and%2520antagonizing%2520IAP%2520proteins%26jtitle%3DCell%26date%3D2000%26volume%3D102%26spage%3D43%26epage%3D53%26doi%3D10.1016%2FS0092-8674%2800%2900009-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myszka, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span> <span> </span><span class="NLM_article-title">Requirement of both the second and third BIR domains for the relief of X-linked inhibitor of apoptosis protein (XIAP)-mediated caspase inhibition by Smac</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">49517</span>– <span class="NLM_lpage">49522</span>, <span class="refDoi"> DOI: 10.1074/jbc.M310061200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1074%2Fjbc.M310061200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=14512414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptlGrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=49517-49522&author=Y.+Huangauthor=R.+L.+Richauthor=D.+G.+Myszkaauthor=H.+Wu&title=Requirement+of+both+the+second+and+third+BIR+domains+for+the+relief+of+X-linked+inhibitor+of+apoptosis+protein+%28XIAP%29-mediated+caspase+inhibition+by+Smac&doi=10.1074%2Fjbc.M310061200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement of Both the Second and Third BIR Domains for the Relief of X-linked Inhibitor of Apoptosis Protein (XIAP)-mediated Caspase Inhibition by Smac</span></div><div class="casAuthors">Huang, Yihua; Rich, Rebecca L.; Myszka, David G.; Wu, Hao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">49517-49522</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The inhibitor of apoptosis proteins (IAP) are endogenous caspase inhibitors in the metazoan and characterized by the presence of baculoviral IAP repeats (BIR).  X-linked IAP (XIAP) contains three BIR domains and directly inhibits effector caspases such as caspase-7 via a linker BIR2 fragment and initiator caspases such as caspase-9 via the BIR3 domain.  A mitochondrial protein Smac/DIABLO, which is released during apoptosis, antagonizes XIAP-mediated caspase inhibition by interacting directly with XIAP.  Here, using glutathione S-transferase pulldown and caspase activity assay, we show that Smac is ineffective in relieving either caspase-7 or caspase-9 inhibition by XIAP domain fragments.  In addn., Smac forms a ternary complex with caspase-7 and linker BIR2, suggesting that Smac/linker BIR2 interaction does not sterically exclude linker BIR2/caspase-7 interaction.  However, Smac is effective in removing caspase-7 and caspase-9 inhibition by XIAP fragments contg. both the BIR2 and BIR3 domains.  Surface plasmon resonance measurements show that Smac interacts with the BIR2 or BIR3 domain in micromolar dissocn. consts.  On the other hand, Smac interacts with an XIAP construct contg. both BIR2 and BIR3 domains in a subnanomolar dissocn. const. by the simultaneous interaction of the Smac dimer with the BIR2 and BIR3 domains of a single XIAP mol.  This 2:1 Smac/XIAP interaction not only possesses enhanced affinity but also sterically excludes XIAP/caspase-7 interaction, demonstrating the requirement of both BIR2 and BIR3 domains for Smac to relieve XIAP-mediated caspase inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlkdgJwimDMLVg90H21EOLACvtfcHk0lhAWUmQDFTV4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptlGrtL8%253D&md5=10937a5499d990c1237753ed28cb9509</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M310061200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M310061200%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DRich%26aufirst%3DR.%2BL.%26aulast%3DMyszka%26aufirst%3DD.%2BG.%26aulast%3DWu%26aufirst%3DH.%26atitle%3DRequirement%2520of%2520both%2520the%2520second%2520and%2520third%2520BIR%2520domains%2520for%2520the%2520relief%2520of%2520X-linked%2520inhibitor%2520of%2520apoptosis%2520protein%2520%2528XIAP%2529-mediated%2520caspase%2520inhibition%2520by%2520Smac%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D49517%26epage%3D49522%26doi%3D10.1074%2Fjbc.M310061200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olejniczak, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meadows, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betz, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oost, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fesik, S. W.</span></span> <span> </span><span class="NLM_article-title">Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>408</i></span>,  <span class="NLM_fpage">1004</span>– <span class="NLM_lpage">1008</span>, <span class="refDoi"> DOI: 10.1038/35050006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1038%2F35050006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=11140637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhslaiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=408&publication_year=2000&pages=1004-1008&author=Z.+Liuauthor=C.+Sunauthor=E.+T.+Olejniczakauthor=R.+P.+Meadowsauthor=S.+F.+Betzauthor=T.+Oostauthor=J.+Herrmannauthor=J.+C.+Wuauthor=S.+W.+Fesik&title=Structural+basis+for+binding+of+Smac%2FDIABLO+to+the+XIAP+BIR3+domain&doi=10.1038%2F35050006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain</span></div><div class="casAuthors">Liu, Zhlhong; Sun, Chaohong; Olejniczak, Edward T.; Meadows, Robert P.; Betz, Stephen F.; Oost, Thorsten; Hemnann, Julia; Wu, Joe C.; Feslk, Stephen W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">408</span>
        (<span class="NLM_cas:issue">6815</span>),
    <span class="NLM_cas:pages">1004-1008</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The inhibitor-of-apoptosis proteins (IAPs) regulate programmed cell death by inhibiting members of the caspase family of enzymes.  Recently, a mammalian protein called Smac (also named DIABLO) was identified that binds to the LAPs and promotes caspase activation.  Although undefined in the x-ray structure, the amino-terminal residues of Smac are crit. for its function.  To understand the structural basis for mol. recognition between Smac and the IAPs, we detd. the soln. structure of the BIR3 domain of X-linked IAP (XIAP) complexed with a functionally active nine-residue peptide derived from the N terminus of Smac.  The peptide binds across the third β-strand of the BIR3 domain in an extended conformation with only the first four residues contacting the protein.  The complex is stabilized by four intermol. hydrogen bonds, an electrostatic interaction involving the N terminus of the peptide, and several hydrophobic interactions.  This structural information, along with the binding data from BIR3 and Smac peptide mutants reported here, should aid in the design of small mols. that may be used for the treatment of cancers that overexpress IAPs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM4pZbM96xmrVg90H21EOLACvtfcHk0ljwI374q3arxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhslaiug%253D%253D&md5=d81bd94ecd9cf9c11d96ee228ff371aa</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2F35050006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35050006%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DOlejniczak%26aufirst%3DE.%2BT.%26aulast%3DMeadows%26aufirst%3DR.%2BP.%26aulast%3DBetz%26aufirst%3DS.%2BF.%26aulast%3DOost%26aufirst%3DT.%26aulast%3DHerrmann%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DJ.%2BC.%26aulast%3DFesik%26aufirst%3DS.%2BW.%26atitle%3DStructural%2520basis%2520for%2520binding%2520of%2520Smac%252FDIABLO%2520to%2520the%2520XIAP%2520BIR3%2520domain%26jtitle%3DNature%26date%3D2000%26volume%3D408%26spage%3D1004%26epage%3D1008%26doi%3D10.1038%2F35050006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suber, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span> <span> </span><span class="NLM_article-title">Structural basis of IAP recognition by Smac/DIABLO</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>408</i></span>,  <span class="NLM_fpage">1008</span>– <span class="NLM_lpage">1012</span>, <span class="refDoi"> DOI: 10.1038/35050012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1038%2F35050012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=11140638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhslahsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=408&publication_year=2000&pages=1008-1012&author=G.+Wuauthor=J.+Chaiauthor=T.+L.+Suberauthor=J.+W.+Wuauthor=C.+Duauthor=X.+Wangauthor=Y.+Shi&title=Structural+basis+of+IAP+recognition+by+Smac%2FDIABLO&doi=10.1038%2F35050012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of IAP recognition by Smac/DIABLO</span></div><div class="casAuthors">Wu, Geng; Chai, Jijie; Suber, Tomeka L.; Wu, Jia-Wel; Du, Chunying; Wang, Xiaodong; Shi, Yigong</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">408</span>
        (<span class="NLM_cas:issue">6815</span>),
    <span class="NLM_cas:pages">1008-1012</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Apoptosis is an essential process in the development and homeostasis of all metazoans.  The inhibitor-of-apoptosis (IAP) proteins suppress cell death by inhibiting the activity of caspases; this inhibition is performed by the zinc-binding BIR domains of the IAP proteins.  The mitochondrial protein Smac/DIABLO promotes apoptosis by eliminating the inhibitory effect of IAPs through phys. interactions.  Amino-terminal sequences in Smac/DIABLO are required for this function, as mutation of the very first amino acid leads to loss of interaction with LAPs and concomitant loss of Smac/DIABLO function.  Here we report the high-resoln. crystal structure of Smac/DIABLO complexed with the third BIR domain (BIR3) of XIAP.  Our results show that the N-terminal four residues (Ala-Val-Pro-Ile) in Smac/DIABLO recognize a surface groove on BIR3, with the first residue Ala binding a hydrophobic pocket and making five hydrogen bonds to neighboring residues on BIR3.  These observations provide a structural explanation for the roles of the Smac N terminus as well as the conserved N-terminal sequences in the Drosophila proteins Hid/Grim/Reaper.  In conjunction with other observations, our results reveal how Smac may relieve IAP inhibition of caspase-9 activity.  In addn. to explaining a no. of biol. observations, our structural anal. identifies potential targets for drug screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV3qy8uKazsrVg90H21EOLACvtfcHk0ljwI374q3arxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhslahsQ%253D%253D&md5=fab609edfb1833053eeb78dd2d4ed536</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2F35050012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35050012%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DG.%26aulast%3DChai%26aufirst%3DJ.%26aulast%3DSuber%26aufirst%3DT.%2BL.%26aulast%3DWu%26aufirst%3DJ.%2BW.%26aulast%3DDu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26atitle%3DStructural%2520basis%2520of%2520IAP%2520recognition%2520by%2520Smac%252FDIABLO%26jtitle%3DNature%26date%3D2000%26volume%3D408%26spage%3D1008%26epage%3D1012%26doi%3D10.1038%2F35050012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Potent and selective small-molecule inhibitors of cIAP1/2 proteins reveal that the binding of smac mimetics to XIAP BIR3 is not required for their effective induction of cell death in tumor cells</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">994</span>– <span class="NLM_lpage">1002</span>, <span class="refDoi"> DOI: 10.1021/cb400889a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb400889a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC2cXit1yls74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=994-1002&author=H.+Sunauthor=J.+Luauthor=L.+Liuauthor=C.+Y.+Yangauthor=S.+Wang&title=Potent+and+selective+small-molecule+inhibitors+of+cIAP1%2F2+proteins+reveal+that+the+binding+of+smac+mimetics+to+XIAP+BIR3+is+not+required+for+their+effective+induction+of+cell+death+in+tumor+cells&doi=10.1021%2Fcb400889a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and Selective Small-Molecule Inhibitors of cIAP1/2 Proteins Reveal That the Binding of Smac Mimetics to XIAP BIR3 Is Not Required for Their Effective Induction of Cell Death in Tumor Cells</span></div><div class="casAuthors">Sun, Haiying; Lu, Jianfeng; Liu, Liu; Yang, Chao-Yie; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">994-1002</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cellular inhibitor of apoptosis protein 1 and 2 (cIAP1/2) and X-linked inhibitor of apoptosis protein (XIAP) are key apoptosis regulators and promising new cancer therapeutic targets.  This study describes a set of non-peptide, small-mol. Smac (second mitochondria-derived activator of caspases) mimetics that are selective inhibitors of cIAP1/2 over XIAP.  The most potent and most selective compds. bind to cIAP1/2 with affinities in the low nanomolar range and show >1,000-fold selectivity for cIAP1 over XIAP.  These selective cIAP inhibitors effectively induce degrdn. of the cIAP1 protein in cancer cells at low nanomolar concns. and do not antagonize XIAP in a cell-free functional assay.  They potently inhibit cell growth and effectively induce apoptosis at low nanomolar concns. in cancer cells with a mechanism of action similar to that of other known Smac mimetics.  Our study shows that binding of Smac mimetics to XIAP BIR3 is not required for effective induction of apoptosis in tumor cells by Smac mimetics.  These potent and highly selective cIAP1/2 inhibitors are powerful tools in the investigation of the role of these IAP proteins in the regulation of apoptosis and other cellular processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVFuPpODQgO7Vg90H21EOLACvtfcHk0ljwI374q3arxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXit1yls74%253D&md5=c0aadbda28ed4e14aa31b58cb995b8af</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fcb400889a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb400889a%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DPotent%2520and%2520selective%2520small-molecule%2520inhibitors%2520of%2520cIAP1%252F2%2520proteins%2520reveal%2520that%2520the%2520binding%2520of%2520smac%2520mimetics%2520to%2520XIAP%2520BIR3%2520is%2520not%2520required%2520for%2520their%2520effective%2520induction%2520of%2520cell%2520death%2520in%2520tumor%2520cells%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D994%26epage%3D1002%26doi%3D10.1021%2Fcb400889a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, B. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. W.</span></span> <span> </span><span class="NLM_article-title">Macrophage diversity enhances tumor progression and metastasis</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2010.03.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1016%2Fj.cell.2010.03.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=20371344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsVSgtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2010&pages=39-51&author=B.+Z.+Qianauthor=J.+W.+Pollard&title=Macrophage+diversity+enhances+tumor+progression+and+metastasis&doi=10.1016%2Fj.cell.2010.03.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Macrophage diversity enhances tumor progression and metastasis</span></div><div class="casAuthors">Qian, Bin-Zhi; Pollard, Jeffrey W.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-51</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  There is persuasive clin. and exptl. evidence that macrophages promote cancer initiation and malignant progression.  During tumor initiation, they create an inflammatory environment that is mutagenic and promotes growth.  As tumors progress to malignancy, macrophages stimulate angiogenesis, enhance tumor cell migration and invasion, and suppress antitumor immunity.  At metastatic sites, macrophages prep. the target tissue for arrival of tumor cells, and then a different subpopulation of macrophages promotes tumor cell extravasation, survival, and subsequent growth.  Specialized subpopulations of macrophages may represent important new therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlTr5UED5Br7Vg90H21EOLACvtfcHk0ljwI374q3arxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsVSgtLc%253D&md5=2d71fd59e10a43120dca111cb216302e</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2010.03.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2010.03.014%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DB.%2BZ.%26aulast%3DPollard%26aufirst%3DJ.%2BW.%26atitle%3DMacrophage%2520diversity%2520enhances%2520tumor%2520progression%2520and%2520metastasis%26jtitle%3DCell%26date%3D2010%26volume%3D141%26spage%3D39%26epage%3D51%26doi%3D10.1016%2Fj.cell.2010.03.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fransen, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melief, C. J.</span></span> <span> </span><span class="NLM_article-title">Local targets for immune therapy to cancer: tumor draining lymph nodes and tumor microenvironment</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">1971</span>– <span class="NLM_lpage">1976</span>, <span class="refDoi"> DOI: 10.1002/ijc.27755</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1002%2Fijc.27755" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=22858832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1SktLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2013&pages=1971-1976&author=M.+F.+Fransenauthor=R.+Arensauthor=C.+J.+Melief&title=Local+targets+for+immune+therapy+to+cancer%3A+tumor+draining+lymph+nodes+and+tumor+microenvironment&doi=10.1002%2Fijc.27755"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Local targets for immune therapy to cancer: Tumor draining lymph nodes and tumor microenvironment</span></div><div class="casAuthors">Fransen, Marieke F.; Arens, Ramon; Melief, Cornelis J. M.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1971-1976</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  In recent years, it has become apparent that immunoregulatory processes influence cancer development.  The key players in tumor progression are mainly present in the microenvironment of the tumor and the draining lymph nodes.  Interventions aimed at shifting tumor-promoting actions toward effective tumor-eradicating immunity are thus foremost required locally.  As immune-modulating therapy has been shown to cause many adverse side effects when administered systemically, we strongly advocate the further development of local treatment for cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9uvNpxlgLd7Vg90H21EOLACvtfcHk0lifDo2f-nzV9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1SktLbL&md5=706be587c23fe0326fd48bb5878b002a</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2Fijc.27755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.27755%26sid%3Dliteratum%253Aachs%26aulast%3DFransen%26aufirst%3DM.%2BF.%26aulast%3DArens%26aufirst%3DR.%26aulast%3DMelief%26aufirst%3DC.%2BJ.%26atitle%3DLocal%2520targets%2520for%2520immune%2520therapy%2520to%2520cancer%253A%2520tumor%2520draining%2520lymph%2520nodes%2520and%2520tumor%2520microenvironment%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2013%26volume%3D132%26spage%3D1971%26epage%3D1976%26doi%3D10.1002%2Fijc.27755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakaoka, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaoka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikada, Y.</span></span> <span> </span><span class="NLM_article-title">Prolongation of theplasma half-life period of superoxide dismutase by poly(ethylene glycol) modification</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">261</span>, <span class="refDoi"> DOI: 10.1016/S0168-3659(96)01605-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1016%2FS0168-3659%2896%2901605-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADyaK2sXhtlyhsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=1997&pages=253-261&author=R.+Nakaokaauthor=Y.+Tabataauthor=T.+Yamaokaauthor=Y.+Ikada&title=Prolongation+of+theplasma+half-life+period+of+superoxide+dismutase+by+poly%28ethylene+glycol%29+modification&doi=10.1016%2FS0168-3659%2896%2901605-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Prolongation of the serum half-life period of superoxide dismutase by poly(ethylene glycol) modification</span></div><div class="casAuthors">Nakaoka, Ryusuke; Tabata, Yasuhiko; Yamaoka, Tetsuji; Ikada, Yoshito</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">253-261</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Superoxide dismutase (SOD) was chem. modified using PEG with different mol. wts. to prep. PEG-SOD conjugates with different extents of modification.  The body distribution of the conjugates i.v. injected to mice was investigated to assess the influence of modification on the serum half-life period of SOD.  The SOD modification with PEG was effective in lowering the elimination rate of SOD from the blood circulation without any change in the distribution pattern of organs other than the kidney.  The mol. wt. of PEG used for modification and the modification extent have a min. effect on the half-life of the SOD.  The half-life of the SOD and its PEG conjugates have a similar dependency on the apparent mol. wt. as the PEG mols.  This indicates that the half-life of SOD and the PEG conjugates are mainly detd. by their mol. size.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0QwXLr5fw9bVg90H21EOLACvtfcHk0lifDo2f-nzV9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhtlyhsbk%253D&md5=b9fce58df8d23005a111b309cfc97e65</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2FS0168-3659%2896%2901605-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0168-3659%252896%252901605-7%26sid%3Dliteratum%253Aachs%26aulast%3DNakaoka%26aufirst%3DR.%26aulast%3DTabata%26aufirst%3DY.%26aulast%3DYamaoka%26aufirst%3DT.%26aulast%3DIkada%26aufirst%3DY.%26atitle%3DProlongation%2520of%2520theplasma%2520half-life%2520period%2520of%2520superoxide%2520dismutase%2520by%2520poly%2528ethylene%2520glycol%2529%2520modification%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D1997%26volume%3D46%26spage%3D253%26epage%3D261%26doi%3D10.1016%2FS0168-3659%2896%2901605-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moghimi, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muir, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illum, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, S. S.</span></span> <span> </span><span class="NLM_article-title">Non-phagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>177</i></span>,  <span class="NLM_fpage">861</span>– <span class="NLM_lpage">866</span>, <span class="refDoi"> DOI: 10.1016/0006-291X(91)91869-E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1016%2F0006-291X%2891%2991869-E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=2049107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADyaK3MXksFOjt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=1991&pages=861-866&author=S.+M.+Moghimiauthor=C.+J.+Porterauthor=I.+S.+Muirauthor=L.+Illumauthor=S.+S.+Davis&title=Non-phagocytic+uptake+of+intravenously+injected+microspheres+in+rat+spleen%3A+influence+of+particle+size+and+hydrophilic+coating&doi=10.1016%2F0006-291X%2891%2991869-E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Non-phagocytic uptake of intravenously injected microspheres in rat spleen:  influence of particle size and hydrophilic coating</span></div><div class="casAuthors">Moghimi, S. M.; Porter, C. J. H.; Muir, I. S.; Illum, L.; Davis, S. S.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">861-6</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    </div><div class="casAbstract">A recent development in prolonging the circulation time of drug carriers, such as liposomes and microspheres, has been to minimize their removal by macrophages of the reticuloendothelial system by covering their surface with hydrophilic polymers such as poloxamers, poloxamines and polyethylene glycols.  It was demonstrated that this strategy may not necessarily prolong the circulatory half-life of drug carriers in all animal models.  In rats, as opposed to rabbits, a nonphagocytic mechanism in the spleen may be triggered to remove efficiently from the blood drug carriers coated with hydrophilic coatings.  Both the size of particle and its hydrophilic coating may act synergistically to trigger this non-phagocytic mechanism.  In rats, a remarkable log to log relation between particle size and spleen uptake was obsd. for both uncoated and polymeric coated microspheres.  The potential implication of these observations in site-specific delivery of drug carriers is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvej2zQqn3VbVg90H21EOLACvtfcHk0lifDo2f-nzV9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXksFOjt7w%253D&md5=586dd854c9b08fe3ab5e5325ce7db290</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2F0006-291X%2891%2991869-E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-291X%252891%252991869-E%26sid%3Dliteratum%253Aachs%26aulast%3DMoghimi%26aufirst%3DS.%2BM.%26aulast%3DPorter%26aufirst%3DC.%2BJ.%26aulast%3DMuir%26aufirst%3DI.%2BS.%26aulast%3DIllum%26aufirst%3DL.%26aulast%3DDavis%26aufirst%3DS.%2BS.%26atitle%3DNon-phagocytic%2520uptake%2520of%2520intravenously%2520injected%2520microspheres%2520in%2520rat%2520spleen%253A%2520influence%2520of%2520particle%2520size%2520and%2520hydrophilic%2520coating%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1991%26volume%3D177%26spage%3D861%26epage%3D866%26doi%3D10.1016%2F0006-291X%2891%2991869-E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moghimi, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. C.</span></span> <span> </span><span class="NLM_article-title">Long-circulating and target-specific nanoparticles: theory to practice</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">283</span>– <span class="NLM_lpage">318</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=11356986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkt1Gnurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2001&pages=283-318&author=S.+M.+Moghimiauthor=A.+C.+Hunterauthor=J.+C.+Murray&title=Long-circulating+and+target-specific+nanoparticles%3A+theory+to+practice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Long-circulating and target-specific nanoparticles: Theory to practice</span></div><div class="casAuthors">Moghimi, S. Moein; Hunter, A. Christy; Murray, J. Clifford</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">283-318</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review with refs.  The rapid recognition of i.v. injected colloidal carriers, such as liposomes and polymeric nanospheres from the blood by Kupffer cells, has initiated a surge of development for "Kupffer cell-evading" or long-circulating particles.  Such carriers have applications in vascular drug delivery and release, site-specific targeting (passive as well as active targeting), as well as transfusion medicine.  In this article, we have critically reviewed and assessed the rational approaches in the design as well as the biol. performance of such constructs.  For engineering and design of long-circulating carriers, we have taken a lead from nature.  Here, we have explored the surface mechanisms, which affords red blood cells long-circulatory lives and the ability of specific microorganisms to evade macrophage recognition.  Our anal. is then centered where such strategies have been translated and fabricated to design a wide range of particulate carriers (e.g., nanospheres, liposomes, micelles, oil-in-water emulsions) with prolonged circulation and/or target specificity.  With regard to the targeting issues, attention is particularly focused on the importance of physiol. barriers and disease states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMLAfVpWVgl7Vg90H21EOLACvtfcHk0lifDo2f-nzV9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkt1Gnurc%253D&md5=88ac5651465c777f2e492237328d0b36</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoghimi%26aufirst%3DS.%2BM.%26aulast%3DHunter%26aufirst%3DA.%2BC.%26aulast%3DMurray%26aufirst%3DJ.%2BC.%26atitle%3DLong-circulating%2520and%2520target-specific%2520nanoparticles%253A%2520theory%2520to%2520practice%26jtitle%3DPharmacol.%2520Rev.%26date%3D2001%26volume%3D53%26spage%3D283%26epage%3D318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bormio
Nunes, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathuber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pósa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enyedy, É. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keppler, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffeter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowol, C. R.</span></span> <span> </span><span class="NLM_article-title">Cancer cell resistance against the clinically investigated thiosemicarbazone COTI-2 is based on formation of intracellular copper complex glutathione adducts and ABCC1-mediated efflux</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">13719</span>– <span class="NLM_lpage">13732</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c01277</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01277" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlWrur3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=13719-13732&author=J.+H.+Bormio%0ANunesauthor=S.+Hagerauthor=M.+Mathuberauthor=V.+P%C3%B3saauthor=A.+Rollerauthor=%C3%89.+A.+Enyedyauthor=A.+Stefanelliauthor=W.+Bergerauthor=B.+K.+Kepplerauthor=P.+Heffeterauthor=C.+R.+Kowol&title=Cancer+cell+resistance+against+the+clinically+investigated+thiosemicarbazone+COTI-2+is+based+on+formation+of+intracellular+copper+complex+glutathione+adducts+and+ABCC1-mediated+efflux&doi=10.1021%2Facs.jmedchem.0c01277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer Cell Resistance Against the Clinically Investigated Thiosemicarbazone COTI-2 Is Based on Formation of Intracellular Copper Complex Glutathione Adducts and ABCC1-Mediated Efflux</span></div><div class="casAuthors">Bormio Nunes, Julia H.; Hager, Sonja; Mathuber, Marlene; Posa, Vivien; Roller, Alexander; Enyedy, Eva A.; Stefanelli, Alessia; Berger, Walter; Keppler, Bernhard K.; Heffeter, Petra; Kowol, Christian R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">13719-13732</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">COTI-2 is a novel anticancer thiosemicarbazone in phase I clin. trial.  However, the effects of metal complexation (a main characteristic of thiosemicarbazones) and acquired resistance mechanisms are widely unknown.  Therefore, in this study, the copper and iron complexes of COTI-2 were synthesized and evaluated for their anticancer activity and impact on drug resistance in comparison to metal-free thiosemicarbazones.  Investigations using Triapine-resistant SW480/Tria and newly established COTI-2-resistant SW480/Coti cells revealed distinct structure-activity relationships.  SW480/Coti cells were found to overexpress ABCC1, and COTI-2 being a substrate for this efflux pump.  This was unexpected, as ABCC1 has strong selectivity for glutathione adducts.  The recognition by ABCC1 could be explained by the redn. kinetics of a ternary Cu-COTI-2 complex with glutathione.  Thus, only thiosemicarbazones forming stable, nonreducible copper(II)-glutathione adducts are recognized and, in turn, effluxed by ABCC1.  This reveals a crucial connection between copper complex chem., glutathione interaction, and the resistance profile of clin. relevant thiosemicarbazones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbICe_bVcd8LVg90H21EOLACvtfcHk0ljZKaLywi9l1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlWrur3I&md5=bf35acbade982334ebd64e89978d2e3a</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01277%26sid%3Dliteratum%253Aachs%26aulast%3DBormio%2BNunes%26aufirst%3DJ.%2BH.%26aulast%3DHager%26aufirst%3DS.%26aulast%3DMathuber%26aufirst%3DM.%26aulast%3DP%25C3%25B3sa%26aufirst%3DV.%26aulast%3DRoller%26aufirst%3DA.%26aulast%3DEnyedy%26aufirst%3D%25C3%2589.%2BA.%26aulast%3DStefanelli%26aufirst%3DA.%26aulast%3DBerger%26aufirst%3DW.%26aulast%3DKeppler%26aufirst%3DB.%2BK.%26aulast%3DHeffeter%26aufirst%3DP.%26aulast%3DKowol%26aufirst%3DC.%2BR.%26atitle%3DCancer%2520cell%2520resistance%2520against%2520the%2520clinically%2520investigated%2520thiosemicarbazone%2520COTI-2%2520is%2520based%2520on%2520formation%2520of%2520intracellular%2520copper%2520complex%2520glutathione%2520adducts%2520and%2520ABCC1-mediated%2520efflux%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D13719%26epage%3D13732%26doi%3D10.1021%2Facs.jmedchem.0c01277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kowol, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichinger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakupec, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arion, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keppler, B. K.</span></span> <span> </span><span class="NLM_article-title">Gallium(III) and iron(III) complexes of r-n-heterocyclic thiosemicarbazones: synthesis, characterization, cytotoxicity, and interaction with ribonucleotide reductase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1254</span>– <span class="NLM_lpage">1265</span>, <span class="refDoi"> DOI: 10.1021/jm0612618</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0612618" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvFags7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1254-1265&author=C.+R.+Kowolauthor=R.+Bergerauthor=R.+Eichingerauthor=A.+Rollerauthor=M.+A.+Jakupecauthor=P.+P.+Schmidtauthor=V.+B.+Arionauthor=B.+K.+Keppler&title=Gallium%28III%29+and+iron%28III%29+complexes+of+r-n-heterocyclic+thiosemicarbazones%3A+synthesis%2C+characterization%2C+cytotoxicity%2C+and+interaction+with+ribonucleotide+reductase&doi=10.1021%2Fjm0612618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Gallium(III) and Iron(III) Complexes of α-N-Heterocyclic Thiosemicarbazones: Synthesis, Characterization, Cytotoxicity, and Interaction with Ribonucleotide Reductase</span></div><div class="casAuthors">Kowol, Christian R.; Berger, Roland; Eichinger, Rene; Roller, Alexander; Jakupec, Michael A.; Schmidt, Peter P.; Arion, Vladimir B.; Keppler, Bernhard K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1254-1265</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ga(III) and Fe(III) complexes with five different 4N-substituted α-N-heterocyclic thiosemicarbazones, viz., 2-acetylpyridine N,N-dimethylthiosemicarbazone (1), 2-acetylpyridine N-pyrrolidinylthiosemicarbazone (2), acetylpyrazine N,N-dimethylthiosemicarbazone (3), acetylpyrazine N-pyrrolidinylthiosemicarbazone (4), and acetylpyrazine N-piperidinylthiosemicarbazone (5), [GaLCl2] (HL = 1 and 2) and [ML2][Y] (M = Ga, HL = 1-5, Y = PF6; M = Fe, HL = 1-5, Y = FeCl4 and PF6) were synthesized and characterized by elemental anal., a no. of spectroscopic methods (NMR, IR, UV-visible), mass spectrometry, and x-ray crystallog.  In vitro antitumor potency was studied in human cancer cell lines (41M and SK-BR-3).  The central metal ions exert pronounced effects in a divergent manner: Ga(III) enhances, whereas Fe(III) weakens the cytotoxicity of the ligands.  The capacity of ligand 1 and its Ga(III) and Fe(III) complexes to destroy the tyrosyl radical of the presumed target ribonucleotide reductase is reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK0rY8cgonJLVg90H21EOLACvtfcHk0ljZKaLywi9l1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvFags7g%253D&md5=18ea78354426cd88f574be43934eee27</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm0612618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0612618%26sid%3Dliteratum%253Aachs%26aulast%3DKowol%26aufirst%3DC.%2BR.%26aulast%3DBerger%26aufirst%3DR.%26aulast%3DEichinger%26aufirst%3DR.%26aulast%3DRoller%26aufirst%3DA.%26aulast%3DJakupec%26aufirst%3DM.%2BA.%26aulast%3DSchmidt%26aufirst%3DP.%2BP.%26aulast%3DArion%26aufirst%3DV.%2BB.%26aulast%3DKeppler%26aufirst%3DB.%2BK.%26atitle%3DGallium%2528III%2529%2520and%2520iron%2528III%2529%2520complexes%2520of%2520r-n-heterocyclic%2520thiosemicarbazones%253A%2520synthesis%252C%2520characterization%252C%2520cytotoxicity%252C%2520and%2520interaction%2520with%2520ribonucleotide%2520reductase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D1254%26epage%3D1265%26doi%3D10.1021%2Fjm0612618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jansson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhardt, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. R.</span></span> <span> </span><span class="NLM_article-title">Novel Thiosemicarbazones of the ApT and DpT series and their copper complexes: identification of pronounced redox activity and characterization of their antitumor activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">5759</span>– <span class="NLM_lpage">5769</span>, <span class="refDoi"> DOI: 10.1021/jm100561b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100561b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC3cXotlSnsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5759-5769&author=P.+J.+Janssonauthor=P.+C.+Sharpeauthor=P.+V.+Bernhardtauthor=D.+R.+Richardson&title=Novel+Thiosemicarbazones+of+the+ApT+and+DpT+series+and+their+copper+complexes%3A+identification+of+pronounced+redox+activity+and+characterization+of+their+antitumor+activity&doi=10.1021%2Fjm100561b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Thiosemicarbazones of the ApT and DpT Series and Their Copper Complexes: Identification of Pronounced Redox Activity and Characterization of Their Antitumor Activity</span></div><div class="casAuthors">Jansson, Patric J.; Sharpe, Philip C.; Bernhardt, Paul V.; Richardson, Des R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5759-5769</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The novel chelators 2-acetylpyridine-4,4-dimethyl-3-thiosemicarbazone (HAp44mT) and di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (HDp44mT) have been examd. to elucidate the structure-activity relationships necessary to form copper (Cu) complexes with pronounced antitumor activity.  Electrochem. studies demonstrated that the Cu complexes of these ligands had lower redox potentials than their iron complexes.  Moreover, the Cu complexes where the ligand/metal ratio was 1:1 rather than 2:1 had significantly higher intracellular oxidative properties and antitumor efficacy.  Interestingly, the 2:1 complex was shown to dissoc. to give significant amts. of the 1:1 complex that could be the major cytotoxic effector.  Both types of Cu complex showed significantly more antiproliferative activity than the ligand alone.  We also demonstrate the importance of the inductive effects of substituents on the carbonyl group of the parent ketone, which influence the CuII/I redox potentials because of their proximity to the metal center.  The structure-activity relationships described are important for the design of potent thiosemicarbazone Cu complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhryQ9dAB5CLVg90H21EOLACvtfcHk0ljZKaLywi9l1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXotlSnsr4%253D&md5=7417f8c18eed7edddd542da369ecb5ab</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fjm100561b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100561b%26sid%3Dliteratum%253Aachs%26aulast%3DJansson%26aufirst%3DP.%2BJ.%26aulast%3DSharpe%26aufirst%3DP.%2BC.%26aulast%3DBernhardt%26aufirst%3DP.%2BV.%26aulast%3DRichardson%26aufirst%3DD.%2BR.%26atitle%3DNovel%2520Thiosemicarbazones%2520of%2520the%2520ApT%2520and%2520DpT%2520series%2520and%2520their%2520copper%2520complexes%253A%2520identification%2520of%2520pronounced%2520redox%2520activity%2520and%2520characterization%2520of%2520their%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5759%26epage%3D5769%26doi%3D10.1021%2Fjm100561b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/medium/jm1c00050_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00050&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/medium/jm1c00050_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Construction of HSA-Au agent complex NPs to integrate chemotherapy and immunotherapy of cancer by dual targeting of two different cellular components in the TME.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00050&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/medium/jm1c00050_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design and structures of 5-methylbenzaldehyde-thiosemicarbazide ligands (<b>1a–5a</b>) and the corresponding Au compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00050&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/medium/jm1c00050_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structural basis of the HSA-Au agent complex. (A) SPR of the Au agent bound to HSA. (B) MALDI-TOF-MS spectrum of HSA and the HSA-Au agent complex. (C) Experimental σA-weighted 2<i>F</i><sub>o</sub> – <i>F</i><sub>c</sub> electron density map of the Au agent in the IB subdomain. The Protein Data Bank entry is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7EEK">7EEK</a>. (D) Au agent bound to the hydrophobic cavity in the IB subdomain. (E) Environment for binding of the Au agent to the IB subdomain of HSA. (F) Overall structure of the HSA-Au agent complex.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00050&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/medium/jm1c00050_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Feasibility of constructing the HSA-Au agent complex NP delivery system. (A) Size and SEM of purified protein NPs. Scale bar, 200 nm. (B) <i>In vitro</i> release of the <b>HSA-5b complex NPs</b>. (C) <b>HSA-5b complex NPs</b> absorbed by MGC-803, HL-7702, and M2 macrophages, as determined by Western blotting. (D) Cellular uptake of the <b>5b</b>/<b>HSA-5b complex NPs</b> and accumulation of the Au agents in the cells, as determined by ICP-MS in HL-7702, MGC-803, and M2 macrophages at different time intervals during the treatment with <b>5b</b>/<b>HSA-5b complex NPs</b> at 8 μM. (E–G) Fluorescence images of the intracellular uptake of Cy5.5-<b>HSA-5b complex NPs</b> in MGC-803 tumor cells, HL-7702 cells, and M2 macrophages, respectively, using fluorescence microscopy. MGC-803 cells, HL-7702 cells, and M2 macrophages were incubated at 37 °C with Cy5.5-<b>HSA-5b complex NPs</b> for the times indicated, followed by staining with a lysosomal marker to show the process of Cy5.5-<b>HSA-5b complex NP</b> cellular trafficking.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00050&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/medium/jm1c00050_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Antitumor behavior of the <b>5b</b>/<b>HSA-5b complex NPs</b><i>in vivo</i>. (A) The tumor volume of mouse gastric cancer cell (MFC) tumor-bearing 615 mice after administration of the vehicle control, <b>5b</b>, and <b>HSA-5b complex NPs</b> was measured every 2 days. (B) Tumor weight and tissue 2 days after the last treatment. (C) The average body weight was measured every 2 days for 28 days. (D) The major organs (heart, liver, spleen, lungs, and kidneys) were sliced for histopathological analysis of the H&E-stained sections (400×) 2 days after the last injection. (E) The average organ weight was measured 2 days after the last injection. (F) Au content of specific organs and tumors of the mice treated with <b>5b</b> and <b>HSA-5b complex NPs</b> 2 days after the last injection. *<i>p</i> < 0.05, **<i>p</i> < 0.02, and ***<i>p</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00050&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/medium/jm1c00050_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. <i>In vivo</i> fluorescence imaging of the mice bearing MFC tumors after the injection of free Cy5.5 or Cy5.5-<b>HSA-5b complex NPs</b>. <i>In vivo</i> fluorescence imaging results of (A) free Cy5.5 and (B) Cy5.5-<b>HSA-5b complex NPs</b> at different time intervals. (C) <i>Ex vivo</i> fluorescence images of major organs and tumors after the injection of free Cy5.5 and Cy5.5-<b>HSA-5b complex NPs</b> at 48 h. (D) Fluorescence intensity analysis of panels A and B. *<i>p</i> < 0.05, **<i>p</i> < 0.02, and ***<i>p</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00050&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/medium/jm1c00050_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. <b>5b</b>/<b>HSA-5b complex NPs</b> inducing MGC-803 cell apoptosis <i>in vivo</i>. Tumor tissue stained with (A) the TUNEL and (B) the H&E assay (400×) in different groups. (C) Immunohistochemical analysis of caspase-3 levels in the tumor tissue 2 days after the last injections.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00050&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/medium/jm1c00050_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Mechanism by which the <b>5b</b>/<b>HSA-5b NPs</b> induce MGC-803 cell apoptosis. (A) Effect of apoptosis of MGC-803 cells treated with 0.6 μM <b>5b</b>/<b>HSA-5b NPs</b> for 24 h compared with the untreated cells. (B) Fluorescence microscopy of the MGC-803 cells treated with 0.6 μM <b>5b</b>/<b>HSA-5b NPs</b> for 24 h. AO/EB images were determined by using a fluorescence microscope. (C) Loss of mitochondrial membrane protein after treatment with the <b>5b</b>/<b>HSA-5b NPs</b>. The cells were incubated with 0.6 μM <b>5b</b>/<b>HSA-5b NPs</b> for 24 h, treated with JC-1, and examined by confocal microscopy (JC-1 indicator, green). (D) Decrease in cellular ATP levels in MGC-803 cells incubated with <b>5b</b>/<b>HSA-5b complex NPs</b>. The cells were treated with the indicated concentrations of the <b>5b</b>/<b>HSA-5b NPs</b> for 24 h. The luminescence intensity was measured in a microplate reader. (E) Enrichment of ROS in MGC-803 cells treated with the <b>5b</b>/<b>HSA-5b complex NPs</b>. The cells were incubated with 0.6 μM <b>5b</b>/<b>HSA-5b NPs</b> for 24 h, treated with DCFH, and examined by fluorescence microscopy (ROS indicator, green, 20×). (F) Cell death induced by <b>5b</b>/<b>HSA-5b NPs</b> was prevented by Mito-TEMPO. (G) Western blotting analysis of mitochondrion-mediated apoptosis markers in MGC-803 cells treated with 0.6 μM <b>5b</b>/<b>HSA-5b NPs</b> for 48 h. β-Actin was used as the internal control. (H) Expression levels of mitochondrion-mediated apoptosis markers shown as percentages; the values are relative to the control. *<i>p</i> < 0.05, **<i>p</i> < 0.02, and ***<i>p</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00050&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/medium/jm1c00050_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Mechanism by which the <b>5b</b>/<b>HSA-5b NPs</b> polarized macrophages <i>in vivo</i> and <i>in vitro</i>. (A) Enrichment of ROS in M2 macrophages (RAW264.7) treated with the <b>5b</b>/<b>HSA-5b NPs</b>. M2 macrophages were obtained by IL-4 treatment (20 ng/mL). The cells were incubated with the <b>5b</b>/<b>HSA-5b NPs</b> for 24 h, treated with DCFH, and examined by fluorescence microscopy (ROS indicator, green, 20×). (B and C) Signaling pathway study of M2 macrophages <i>in vitro</i> and <i>in vivo</i> treated with the <b>5b</b>/<b>HSA-5b NPs</b>. Gene expression levels were examined by quantitative RT-PCR (qPCR) relative to the untreated control. (D) Western blot analysis of STAT3, P-STAT3, PD-1, and TNF-α in M2 macrophages treated with the <b>5b</b>/<b>HSA-5b NPs</b>; β-actin was used as the internal control. (E) Expression levels of STAT3, P-STAT3, PD-1, and TNF-α shown as percentages; β-actin was used as the internal control. (F) The level of M1 macrophage marker (CD86) in tumor tissue was determined by immunohistochemistry after the last injection. (G) Serum levels of M1 macrophage markers TNF-α and IL-12 were analyzed by an ELISA 24 h after the last injection. The asterisk indicates the difference between the treated group and the untreated group. *<i>p</i> < 0.05, **<i>p</i> < 0.02, ***<i>p</i> < 0.001, and ****<i>p</i> < 0.0001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00050&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/medium/jm1c00050_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Immune reaction of the <b>5b</b>/<b>HSA-5b NPs</b><i>in vivo</i>. (A and B) MFC tumor-bearing 615 mice were injected with <b>5b</b>, <b>HSA-5b NPs</b>, and negative control NaCl every 2 days for 28 days. The percentage of activated CD8 T cells (CD69<sup>+</sup>CD8<sup>+</sup>), activated CD4 T cells (CD69<sup>+</sup>CD4<sup>+</sup>), and activated NK cells (CD69<sup>+</sup>NK1.1<sup>+</sup>) in the (A) tumors and (B) TDLNs, analyzed by flow cytometry. (C and D) Tumor tissue with immune-associated protein PD-L1 and PD-1 immunohistochemical staining (400×). *<i>p</i> < 0.05, **<i>p</i> < 0.02, and ***<i>p</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00050&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/medium/jm1c00050_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Au agent attacking the cellular components in the TME for integrating chemotherapy and immunotherapy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-10/acs.jmedchem.1c00050/20210520/images/large/jm1c00050_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00050&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i46">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43313" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43313" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 63 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span> <span> </span><span class="NLM_article-title">Cancer statistics</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.3322/caac.21332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.3322%2Fcaac.21332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=26742998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A280%3ADC%252BC28rot1Kjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2016&pages=7-30&author=R.+L.+Siegelauthor=K.+D.+Millerauthor=A.+Jemal&title=Cancer+statistics&doi=10.3322%2Fcaac.21332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer statistics, 2016</span></div><div class="casAuthors">Siegel Rebecca L; Miller Kimberly D; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival.  Incidence data were collected by the National Cancer Institute (Surveillance, Epidemiology, and End Results [SEER] Program), the Centers for Disease Control and Prevention (National Program of Cancer Registries), and the North American Association of Central Cancer Registries.  Mortality data were collected by the National Center for Health Statistics.  In 2016, 1,685,210 new cancer cases and 595,690 cancer deaths are projected to occur in the United States.  Overall cancer incidence trends (13 oldest SEER registries) are stable in women, but declining by 3.1% per year in men (from 2009-2012), much of which is because of recent rapid declines in prostate cancer diagnoses.  The cancer death rate has dropped by 23% since 1991, translating to more than 1.7 million deaths averted through 2012.  Despite this progress, death rates are increasing for cancers of the liver, pancreas, and uterine corpus, and cancer is now the leading cause of death in 21 states, primarily due to exceptionally large reductions in death from heart disease.  Among children and adolescents (aged birth-19 years), brain cancer has surpassed leukemia as the leading cause of cancer death because of the dramatic therapeutic advances against leukemia.  Accelerating progress against cancer requires both increased national investment in cancer research and the application of existing cancer control knowledge across all segments of the population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKAn5ROFAaRS86Js-BCLiifW6udTcc2eZziu8A8hhWALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rot1Kjug%253D%253D&md5=2d4030a531945c5ebaaab181bfd80457</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21332%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DMiller%26aufirst%3DK.%2BD.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DCancer%2520statistics%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2016%26volume%3D66%26spage%3D7%26epage%3D30%26doi%3D10.3322%2Fcaac.21332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span> <span> </span><span class="NLM_article-title">Photo-cross-linked scaffold with kartogenin-encapsulated nanoparticles for cartilage regeneration</span>. <i>ACS Nano</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1292</span>– <span class="NLM_lpage">1299</span>, <span class="refDoi"> DOI: 10.1021/acsnano.5b06663</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsnano.5b06663" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVKlsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=1292-1299&author=D.+Shiauthor=X.+Xuauthor=Y.+Yeauthor=K.+Songauthor=Y.+Chengauthor=J.+Diauthor=Q.+Huauthor=J.+Liauthor=H.+Juauthor=Q.+Jiangauthor=Z.+Gu&title=Photo-cross-linked+scaffold+with+kartogenin-encapsulated+nanoparticles+for+cartilage+regeneration&doi=10.1021%2Facsnano.5b06663"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Photo-Cross-Linked Scaffold with Kartogenin-Encapsulated Nanoparticles for Cartilage Regeneration</span></div><div class="casAuthors">Shi, Dongquan; Xu, Xingquan; Ye, Yanqi; Song, Kai; Cheng, Yixiang; Di, Jin; Hu, Quanyin; Li, Jianxin; Ju, Huangxian; Jiang, Qing; Gu, Zhen</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1292-1299</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The regeneration of cartilage, an aneural and avascular tissue, is often compromised by its lack of innate abilities to mount a sufficient healing response.  Kartogenin (KGN), a small mol. compd., can induce bone marrow-derived mesenchymal stem cells (BMSCs) into chondrocytes.  The previous in vitro study showed that kartogenin also had a chondrogenesis effect on synovium derived mesenchymal stem cells (SMSCs).  Herein, we present the effect of an UV-reactive, rapidly crosslinkable scaffold integrated with kartogenin-loaded nanoparticles using an innovational one-step technol.  In vivo studies showed its potential role for cell homing, esp. for recruiting the host's endogenous cells, including BMSCs and SMSCs, without cell transplantation.  Of note, the regenerated tissues were close to the natural hyaline cartilage based on the histol. tests, specific markers anal., and biomech. tests.  This innovative KGN release system makes the chondrogenesis efficient and persistent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-8sRc2vPm7bVg90H21EOLACvtfcHk0liccJeLdp5y6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVKlsLk%253D&md5=5cc651a480eb2b7f7b49768b52a77f6e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Facsnano.5b06663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsnano.5b06663%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DYe%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DDi%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DJu%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DGu%26aufirst%3DZ.%26atitle%3DPhoto-cross-linked%2520scaffold%2520with%2520kartogenin-encapsulated%2520nanoparticles%2520for%2520cartilage%2520regeneration%26jtitle%3DACS%2520Nano%26date%3D2016%26volume%3D10%26spage%3D1292%26epage%3D1299%26doi%3D10.1021%2Facsnano.5b06663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fesnak, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">June, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, B. L.</span></span> <span> </span><span class="NLM_article-title">Engineered T Cells: the promise and challenges of cancer immunotherapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">566</span>– <span class="NLM_lpage">581</span>, <span class="refDoi"> DOI: 10.1038/nrc.2016.97</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1038%2Fnrc.2016.97" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=27550819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlyqsbfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=566-581&author=A.+D.+Fesnakauthor=C.+H.+Juneauthor=B.+L.+Levine&title=Engineered+T+Cells%3A+the+promise+and+challenges+of+cancer+immunotherapy&doi=10.1038%2Fnrc.2016.97"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Engineered T cells: the promise and challenges of cancer immunotherapy</span></div><div class="casAuthors">Fesnak, Andrew D.; June, Carl H.; Levine, Bruce L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">566-581</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The immune system evolved to distinguish non-self from self to protect the organism.  As cancer is derived from our own cells, immune responses to dysregulated cell growth present a unique challenge.  This is compounded by mechanisms of immune evasion and immunosuppression that develop in the tumor microenvironment.  The modern genetic toolbox enables the adoptive transfer of engineered T cells to create enhanced anticancer immune functions where natural cancer-specific immune responses have failed.  Genetically engineered T cells, so-called 'living drugs', represent a new paradigm in anticancer therapy.  Recent clin. trials using T cells engineered to express chimeric antigen receptors (CARs) or engineered T cell receptors (TCRs) have produced stunning results in patients with relapsed or refractory hematol. malignancies.  In this Review we describe some of the most recent and promising advances in engineered T cell therapy with a particular emphasis on what the next generation of T cell therapy is likely to entail.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwHuyW_V3JI7Vg90H21EOLACvtfcHk0li4UNPIYOizsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlyqsbfP&md5=9811eafadc8be8fcae3a25cbb30284a4</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2016.97&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2016.97%26sid%3Dliteratum%253Aachs%26aulast%3DFesnak%26aufirst%3DA.%2BD.%26aulast%3DJune%26aufirst%3DC.%2BH.%26aulast%3DLevine%26aufirst%3DB.%2BL.%26atitle%3DEngineered%2520T%2520Cells%253A%2520the%2520promise%2520and%2520challenges%2520of%2520cancer%2520immunotherapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2016%26volume%3D16%26spage%3D566%26epage%3D581%26doi%3D10.1038%2Fnrc.2016.97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span> <span> </span><span class="NLM_article-title">Cancer immunotherapy using checkpoint blockade</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>359</i></span>,  <span class="NLM_fpage">1350</span>– <span class="NLM_lpage">1355</span>, <span class="refDoi"> DOI: 10.1126/science.aar4060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1126%2Fscience.aar4060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=29567705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltFehtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2018&pages=1350-1355&author=A.+Ribasauthor=J.+D.+Wolchok&title=Cancer+immunotherapy+using+checkpoint+blockade&doi=10.1126%2Fscience.aar4060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer immunotherapy using checkpoint blockade</span></div><div class="casAuthors">Ribas, Antoni; Wolchok, Jedd D.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">6382</span>),
    <span class="NLM_cas:pages">1350-1355</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  The release of neg. regulators of immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates of long-lasting tumor responses in patients with a variety of cancers.  This can be achieved by antibodies blocking the cytotoxic T lymphocyte-assocd. protein 4 (CTLA-4) or the programmed cell death 1 (PD-1) pathway, either alone or in combination.  The main premise for inducing an immune response is the preexistence of antitumor T cells that were limited by specific immune checkpoints.  Most patients who have tumor responses maintain long-lasting disease control, yet one-third of patients relapse.  Mechanisms of acquired resistance are currently poorly understood, but evidence points to alterations that converge on the antigen presentation and interferon-γ signaling pathways.  New-generation combinatorial therapies may overcome resistance mechanisms to immune checkpoint therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHaFGKqeFnWLVg90H21EOLACvtfcHk0li4UNPIYOizsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltFehtb8%253D&md5=65120662af8a2c63425212b07e423939</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.aar4060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aar4060%26sid%3Dliteratum%253Aachs%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26atitle%3DCancer%2520immunotherapy%2520using%2520checkpoint%2520blockade%26jtitle%3DScience%26date%3D2018%26volume%3D359%26spage%3D1350%26epage%3D1355%26doi%3D10.1126%2Fscience.aar4060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dougan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dranoff, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougan, S. K.</span></span> <span> </span><span class="NLM_article-title">Cancer immunotherapy: beyond checkpoint blockade</span>. <i>Annu. Rev. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">75</span>, <span class="refDoi"> DOI: 10.1146/annurev-cancerbio-030518-055552</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1146%2Fannurev-cancerbio-030518-055552" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2019&pages=55-75&author=M.+Douganauthor=G.+Dranoffauthor=S.+K.+Dougan&title=Cancer+immunotherapy%3A+beyond+checkpoint+blockade&doi=10.1146%2Fannurev-cancerbio-030518-055552"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1146%2Fannurev-cancerbio-030518-055552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-cancerbio-030518-055552%26sid%3Dliteratum%253Aachs%26aulast%3DDougan%26aufirst%3DM.%26aulast%3DDranoff%26aufirst%3DG.%26aulast%3DDougan%26aufirst%3DS.%2BK.%26atitle%3DCancer%2520immunotherapy%253A%2520beyond%2520checkpoint%2520blockade%26jtitle%3DAnnu.%2520Rev.%2520Cancer%2520Biol.%26date%3D2019%26volume%3D3%26spage%3D55%26epage%3D75%26doi%3D10.1146%2Fannurev-cancerbio-030518-055552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maute, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dulken, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCracken, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ring, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissman, I. L.</span></span> <span> </span><span class="NLM_article-title">PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>545</i></span>,  <span class="NLM_fpage">495</span>– <span class="NLM_lpage">499</span>, <span class="refDoi"> DOI: 10.1038/nature22396</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1038%2Fnature22396" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=28514441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvVCrs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=545&publication_year=2017&pages=495-499&author=S.+R.+Gordonauthor=R.+L.+Mauteauthor=B.+W.+Dulkenauthor=G.+Hutterauthor=B.+M.+Georgeauthor=M.+N.+McCrackenauthor=R.+Guptaauthor=J.+M.+Tsaiauthor=R.+Sinhaauthor=D.+Coreyauthor=A.+M.+Ringauthor=A.+J.+Connollyauthor=I.+L.+Weissman&title=PD-1+expression+by+tumour-associated+macrophages+inhibits+phagocytosis+and+tumour+immunity&doi=10.1038%2Fnature22396"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity</span></div><div class="casAuthors">Gordon, Sydney R.; Maute, Roy L.; Dulken, Ben W.; Hutter, Gregor; George, Benson M.; McCracken, Melissa N.; Gupta, Rohit; Tsai, Jonathan M.; Sinha, Rahul; Corey, Daniel; Ring, Aaron M.; Connolly, Andrew J.; Weissman, Irving L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">545</span>
        (<span class="NLM_cas:issue">7655</span>),
    <span class="NLM_cas:pages">495-499</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor that is upregulated on activated T cells for the induction of immune tolerance.  Tumor cells frequently overexpress the ligand for PD-1, programmed cell death ligand 1 (PD-L1), facilitating their escape from the immune system.  Monoclonal antibodies that block the interaction between PD-1 and PD-L1, by binding to either the ligand or receptor, have shown notable clin. efficacy in patients with a variety of cancers, including melanoma, colorectal cancer, non-small-cell lung cancer and Hodgkin's lymphoma.  Although it is well established that PD-1-PD-L1 blockade activates T cells, little is known about the role that this pathway may have in tumor-assocd. macrophages (TAMs).  Here we show that both mouse and human TAMs express PD-1.  TAM PD-1 expression increases over time in mouse models of cancer and with increasing disease stage in primary human cancers.  TAM PD-1 expression correlates neg. with phagocytic potency against tumor cells, and blockade of PD-1-PD-L1 in vivo increases macrophage phagocytosis, reduces tumor growth and lengthens the survival of mice in mouse models of cancer in a macrophage-dependent fashion.  This suggests that PD-1-PD-L1 therapies may also function through a direct effect on macrophages, with substantial implications for the treatment of cancer with these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFC8j_ZPoELbVg90H21EOLACvtfcHk0li4UNPIYOizsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvVCrs70%253D&md5=f428abc6d34ac6e3a18bfcf9371ea312</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnature22396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature22396%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DS.%2BR.%26aulast%3DMaute%26aufirst%3DR.%2BL.%26aulast%3DDulken%26aufirst%3DB.%2BW.%26aulast%3DHutter%26aufirst%3DG.%26aulast%3DGeorge%26aufirst%3DB.%2BM.%26aulast%3DMcCracken%26aufirst%3DM.%2BN.%26aulast%3DGupta%26aufirst%3DR.%26aulast%3DTsai%26aufirst%3DJ.%2BM.%26aulast%3DSinha%26aufirst%3DR.%26aulast%3DCorey%26aufirst%3DD.%26aulast%3DRing%26aufirst%3DA.%2BM.%26aulast%3DConnolly%26aufirst%3DA.%2BJ.%26aulast%3DWeissman%26aufirst%3DI.%2BL.%26atitle%3DPD-1%2520expression%2520by%2520tumour-associated%2520macrophages%2520inhibits%2520phagocytosis%2520and%2520tumour%2520immunity%26jtitle%3DNature%26date%3D2017%26volume%3D545%26spage%3D495%26epage%3D499%26doi%3D10.1038%2Fnature22396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nose, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span> <span> </span><span class="NLM_article-title">Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">151</span>, <span class="refDoi"> DOI: 10.1016/S1074-7613(00)80089-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1016%2FS1074-7613%2800%2980089-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10485649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADyaK1MXlvVShsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1999&pages=141-151&author=H.+Nishimuraauthor=M.+Noseauthor=H.+Hiaiauthor=N.+Minatoauthor=T.+Honjo&title=Development+of+lupus-like+autoimmune+diseases+by+disruption+of+the+PD-1+gene+encoding+an+ITIM+motif-carrying+immunoreceptor&doi=10.1016%2FS1074-7613%2800%2980089-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor</span></div><div class="casAuthors">Nishimura, Hiroyuki; Nose, Masato; Hiai, Hiroshi; Minato, Nagahiro; Honjo, Tasuku</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">141-151</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">PD-1, a 55 kDa transmembrane protein contg. an immunoreceptor tyrosine-based inhibitory motif, is induced in lymphocytes and monocytes following activation.  Aged C57BL/6(B6)-PD-1-/- congenic mice spontaneously developed characteristic lupus-like proliferative arthritis and glomerulonephritis with predominant IgG3 deposition, which were markedly accelerated by introduction of a Fas mutation (lpr).  Introduction of a PD-1 null mutation into the 2C-TCR (anti-H-2Ld) transgenic mice of the H-2b/d background resulted in the chronic and systemic graft-vs.- host-like disease.  Furthermore, CD8+2C-TCR+PD-1-/- T cells exhibited markedly augmented proliferation in vitro in response to H-2d allogeneic cells.  Collectively, it is suggested that PD-1 is involved in the maintenance of peripheral self-tolerance by serving as a neg. regulator of immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHFuMDDfhG3bVg90H21EOLACvtfcHk0lh7FOw1wSX_JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvVShsb8%253D&md5=f627767082377fb523671a1635cb0a8f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS1074-7613%2800%2980089-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-7613%252800%252980089-8%26sid%3Dliteratum%253Aachs%26aulast%3DNishimura%26aufirst%3DH.%26aulast%3DNose%26aufirst%3DM.%26aulast%3DHiai%26aufirst%3DH.%26aulast%3DMinato%26aufirst%3DN.%26aulast%3DHonjo%26aufirst%3DT.%26atitle%3DDevelopment%2520of%2520lupus-like%2520autoimmune%2520diseases%2520by%2520disruption%2520of%2520the%2520PD-1%2520gene%2520encoding%2520an%2520ITIM%2520motif-carrying%2520immunoreceptor%26jtitle%3DImmunity%26date%3D1999%26volume%3D11%26spage%3D141%26epage%3D151%26doi%3D10.1016%2FS1074-7613%2800%2980089-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourque, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chernova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitz, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malenkovich, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horton, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fouser, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreno, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span> <span> </span><span class="NLM_article-title">Engagement of the Pd-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">1027</span>– <span class="NLM_lpage">1034</span>, <span class="refDoi"> DOI: 10.1084/jem.192.7.1027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1084%2Fjem.192.7.1027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=11015443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntFSlt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2000&pages=1027-1034&author=G.+J.+Freemanauthor=A.+J.+Longauthor=Y.+Iwaiauthor=K.+Bourqueauthor=T.+Chernovaauthor=H.+Nishimuraauthor=L.+J.+Fitzauthor=N.+Malenkovichauthor=T.+Okazakiauthor=M.+C.+Byrneauthor=H.+F.+Hortonauthor=L.+Fouserauthor=L.+Carterauthor=V.+Lingauthor=M.+R.+Bowmanauthor=B.+M.+Carrenoauthor=M.+Collinsauthor=C.+R.+Woodauthor=T.+Honjo&title=Engagement+of+the+Pd-1+immunoinhibitory+receptor+by+a+novel+B7+family+member+leads+to+negative+regulation+of+lymphocyte+activation&doi=10.1084%2Fjem.192.7.1027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation</span></div><div class="casAuthors">Freeman, Gordon J.; Long, Andrew J.; Iwai, Yoshiko; Bourque, Karen; Chernova, Tatyana; Nishimura, Hiroyuki; Fitz, Lori J.; Malenkovich, Nelly; Okazaki, Taku; Byrne, Michael C.; Horton, Heidi F.; Fouser, Lynette; Carter, Laura; Ling, Vincent; Bowman, Michael R.; Carreno, Beatriz M.; Collins, Mary; Wood, Clive R.; Honjo, Tasuku</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1027-1034</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">PD-1 is an immunoinhibitory receptor expressed by activated T cells, B cells, and myeloid cells.  Mice deficient in PD-1 exhibit a breakdown of peripheral tolerance and demonstrate multiple autoimmune features.  The authors report here that the ligand of PD-1 (PD-L1) is a member of the B7 gene family.  Engagement of PD-1 by PD-L1 leads to the inhibition of T cell receptor-mediated lymphocyte proliferation and cytokine secretion.  In addn., PD-1 signaling can inhibit at least suboptimal levels of CD28-mediated costimulation.  PD-L1 is expressed by antigen-presenting cells, including human peripheral blood monocytes stimulated with interferon γ, and activated human and murine dendritic cells.  In addn., PD-L1 is expressed in nonlymphoid tissues such as heart and lung.  The relative levels of inhibitory PD-L1 and costimulatory B7-1/B7-2 signals on antigen-presenting cells may det. the extent of T cell activation and consequently the threshold between tolerance and autoimmunity.  PD-L1 expression on nonlymphoid tissues and its potential interaction with PD-1 may subsequently det. the extent of immune responses at sites of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZIeEjiecqBbVg90H21EOLACvtfcHk0lh7FOw1wSX_JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntFSlt7o%253D&md5=bc1499033282cd9dbfa396a4e2697f6e</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1084%2Fjem.192.7.1027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.192.7.1027%26sid%3Dliteratum%253Aachs%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26aulast%3DLong%26aufirst%3DA.%2BJ.%26aulast%3DIwai%26aufirst%3DY.%26aulast%3DBourque%26aufirst%3DK.%26aulast%3DChernova%26aufirst%3DT.%26aulast%3DNishimura%26aufirst%3DH.%26aulast%3DFitz%26aufirst%3DL.%2BJ.%26aulast%3DMalenkovich%26aufirst%3DN.%26aulast%3DOkazaki%26aufirst%3DT.%26aulast%3DByrne%26aufirst%3DM.%2BC.%26aulast%3DHorton%26aufirst%3DH.%2BF.%26aulast%3DFouser%26aufirst%3DL.%26aulast%3DCarter%26aufirst%3DL.%26aulast%3DLing%26aufirst%3DV.%26aulast%3DBowman%26aufirst%3DM.%2BR.%26aulast%3DCarreno%26aufirst%3DB.%2BM.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DWood%26aufirst%3DC.%2BR.%26aulast%3DHonjo%26aufirst%3DT.%26atitle%3DEngagement%2520of%2520the%2520Pd-1%2520immunoinhibitory%2520receptor%2520by%2520a%2520novel%2520B7%2520family%2520member%2520leads%2520to%2520negative%2520regulation%2520of%2520lymphocyte%2520activation%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2000%26volume%3D192%26spage%3D1027%26epage%3D1034%26doi%3D10.1084%2Fjem.192.7.1027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nanda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, L. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dees, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geva, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pusztai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pathiraja, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aktan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karantza, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buisseret, L.</span></span> <span> </span><span class="NLM_article-title">Pembrolizumab in patients with ad-vanced triple-negative breast cancer: phase ib keynote-012 study</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">2460</span>– <span class="NLM_lpage">2467</span>, <span class="refDoi"> DOI: 10.1200/JCO.2015.64.8931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1200%2FJCO.2015.64.8931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=27138582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFels7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=2460-2467&author=R.+Nandaauthor=L.+Q.+Chowauthor=E.+C.+Deesauthor=R.+Bergerauthor=S.+Guptaauthor=R.+Gevaauthor=L.+Pusztaiauthor=K.+Pathirajaauthor=G.+Aktanauthor=J.+D.+Chengauthor=V.+Karantzaauthor=L.+Buisseret&title=Pembrolizumab+in+patients+with+ad-vanced+triple-negative+breast+cancer%3A+phase+ib+keynote-012+study&doi=10.1200%2FJCO.2015.64.8931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study</span></div><div class="casAuthors">Nanda, Rita; Chow, Laura Q. M.; Dees, E. Claire; Berger, Raanan; Gupta, Shilpa; Geva, Ravit; Pusztai, Lajos; Pathiraja, Kumudu; Aktan, Gursel; Cheng, Jonathan D.; Karantza, Vassiliki; Buisseret, Laurence</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2460-2469</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Immune checkpoint inhibition has been demonstrated to be an effective anticancer strategy.  Several lines of evidence support the study of immunotherapy in triple-neg. breast cancer (TNBC).  We assessed the safety and antitumor activity of the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab in patients with advanced TNBC.  Methods KEYNOTE-012 (ClinicalTrials.gov identifier: NCT01848834) was amulticenter, nonrandomized phase Ib trial of single-agent pembrolizumab given i.v. at 10 mg/kg every 2 wk to patients with advanced PD-L1-pos. (expression in stroma or ≥ 1% of tumor cells by immunohistochem.) TNBC, gastric cancer, urothelial cancer, and head and neck cancer.  This report focuses on the TNBC cohort.  Results Among 111 patients with TNBC whose tumor samples were screened for PD-L1 expression, 58.6% had PD-L1-pos. tumors.  Thirty-two women (median age, 50.5 years; range, 29 to 72 years) were enrolled and assessed for safety and antitumor activity.  The median no. of doses administered was five (range, 1 to 36 doses).  Common toxicities were mild and similar to those obsd. in other tumor cohorts (eg, arthralgia, fatigue, myalgia, and nausea), and included five (15.6%) patients with grade ≥ 3 toxicity and one treatment-related death.  Among the 27 patients who were evaluable for antitumor activity, the overall response rate was 18.5%, the median time to response was 17.9 wk (range, 7.3 to 32.4 wk), and the median duration of response was not yet reached (range, 15.0 to ≥ 47.3 wk).  Conclusion This phase Ib study describes preliminary evidence of clin. activity and a potentially acceptable safety profile of pembrolizumab given every 2 wk to patients with heavily pretreated, advanced TNBC.  A single-agent phase II study examg. a 200-mg dose given once every 3 wk (ClinicalTrials.gov identifier: NCT02447003) is ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxATuIspigvrVg90H21EOLACvtfcHk0lh7FOw1wSX_JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFels7fM&md5=89877c871da52620104ee8bd8bac83fe</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1200%2FJCO.2015.64.8931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2015.64.8931%26sid%3Dliteratum%253Aachs%26aulast%3DNanda%26aufirst%3DR.%26aulast%3DChow%26aufirst%3DL.%2BQ.%26aulast%3DDees%26aufirst%3DE.%2BC.%26aulast%3DBerger%26aufirst%3DR.%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DGeva%26aufirst%3DR.%26aulast%3DPusztai%26aufirst%3DL.%26aulast%3DPathiraja%26aufirst%3DK.%26aulast%3DAktan%26aufirst%3DG.%26aulast%3DCheng%26aufirst%3DJ.%2BD.%26aulast%3DKarantza%26aufirst%3DV.%26aulast%3DBuisseret%26aufirst%3DL.%26atitle%3DPembrolizumab%2520in%2520patients%2520with%2520ad-vanced%2520triple-negative%2520breast%2520cancer%253A%2520phase%2520ib%2520keynote-012%2520study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D34%26spage%3D2460%26epage%3D2467%26doi%3D10.1200%2FJCO.2015.64.8931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braiteh, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eder, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolaney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuter, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassier, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delord, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ElGabry, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Hear, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fassò, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, P.</span></span> <span> </span><span class="NLM_article-title">Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study</span>. <i>JAMA Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">2986</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=2986&author=P.+Schmidauthor=C.+Cruzauthor=F.+S.+Braitehauthor=J.+P.+Ederauthor=S.+Tolaneyauthor=I.+Kuterauthor=R.+Nandaauthor=P.+A.+Cassierauthor=J.+P.+Delordauthor=M.+S.+Gordonauthor=E.+ElGabryauthor=C.+W.+Changauthor=I.+Sarkarauthor=W.+Grossmanauthor=C.+O%E2%80%99Hearauthor=M.+Fass%C3%B2author=L.+Molineroauthor=P.+Schmid&title=Long-term+clinical+outcomes+and+biomarker+analyses+of+atezolizumab+therapy+for+patients+with+metastatic+triple-negative+breast+cancer%3A+a+phase+1+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchmid%26aufirst%3DP.%26aulast%3DCruz%26aufirst%3DC.%26aulast%3DBraiteh%26aufirst%3DF.%2BS.%26aulast%3DEder%26aufirst%3DJ.%2BP.%26aulast%3DTolaney%26aufirst%3DS.%26aulast%3DKuter%26aufirst%3DI.%26aulast%3DNanda%26aufirst%3DR.%26aulast%3DCassier%26aufirst%3DP.%2BA.%26aulast%3DDelord%26aufirst%3DJ.%2BP.%26aulast%3DGordon%26aufirst%3DM.%2BS.%26aulast%3DElGabry%26aufirst%3DE.%26aulast%3DChang%26aufirst%3DC.%2BW.%26aulast%3DSarkar%26aufirst%3DI.%26aulast%3DGrossman%26aufirst%3DW.%26aulast%3DO%25E2%2580%2599Hear%26aufirst%3DC.%26aulast%3DFass%25C3%25B2%26aufirst%3DM.%26aulast%3DMolinero%26aufirst%3DL.%26aulast%3DSchmid%26aufirst%3DP.%26atitle%3DLong-term%2520clinical%2520outcomes%2520and%2520biomarker%2520analyses%2520of%2520atezolizumab%2520therapy%2520for%2520patients%2520with%2520metastatic%2520triple-negative%2520breast%2520cancer%253A%2520a%2520phase%25201%2520study%26jtitle%3DJAMA%2520Oncol.%26date%3D2017%26volume%3D77%26spage%3D2986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellman, I.</span></span> <span> </span><span class="NLM_article-title">Oncology meets immunology: the cancer-immunity cycle</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2013.07.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1016%2Fj.immuni.2013.07.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=23890059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOhs7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2013&pages=1-10&author=D.+Chenauthor=I.+Mellman&title=Oncology+meets+immunology%3A+the+cancer-immunity+cycle&doi=10.1016%2Fj.immuni.2013.07.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Oncology Meets Immunology: The Cancer-Immunity Cycle</span></div><div class="casAuthors">Chen, Daniel S.; Mellman, Ira</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The genetic and cellular alterations that define cancer provide the immune system with the means to generate T cell responses that recognize and eradicate cancer cells.  However, elimination of cancer by T cells is only one step in the Cancer-Immunity Cycle, which manages the delicate balance between the recognition of nonself and the prevention of autoimmunity.  Identification of cancer cell T cell inhibitory signals, including PD-L1, has prompted the development of a new class of cancer immunotherapy that specifically hinders immune effector inhibition, reinvigorating and potentially expanding preexisting anticancer immune responses.  The presence of suppressive factors in the tumor microenvironment may explain the limited activity obsd. with previous immune-based therapies and why these therapies may be more effective in combination with agents that target other steps of the cycle.  Emerging clin. data suggest that cancer immunotherapy is likely to become a key part of the clin. management of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbBQaWD_6lybVg90H21EOLACvtfcHk0ljw8TNdYZOEbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOhs7vL&md5=85f4befe58d8dc2e3901f4b2df0fdd6f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2013.07.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2013.07.012%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DD.%26aulast%3DMellman%26aufirst%3DI.%26atitle%3DOncology%2520meets%2520immunology%253A%2520the%2520cancer-immunity%2520cycle%26jtitle%3DImmunity%26date%3D2013%26volume%3D39%26spage%3D1%26epage%3D10%26doi%3D10.1016%2Fj.immuni.2013.07.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pohlmann, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolaney, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iizuka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinero, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powderly, J.</span></span> <span> </span><span class="NLM_article-title">Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: a phase 1b clinical trial</span>. <i>JAMA Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">334</span>– <span class="NLM_lpage">342</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2018.5152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1001%2Fjamaoncol.2018.5152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=30347025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A280%3ADC%252BB3cvhvFWgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=334-342&author=S.+Adamsauthor=J.+R.+Diamondauthor=E.+Hamiltonauthor=P.+R.+Pohlmannauthor=S.+M.+Tolaneyauthor=C.+W.+Changauthor=W.+Zhangauthor=K.+Iizukaauthor=P.+G.+Fosterauthor=L.+Molineroauthor=R.+Funkeauthor=J.+Powderly&title=Atezolizumab+plus+nab-paclitaxel+in+the+treatment+of+metastatic+triple-negative+breast+cancer+with+2-year+survival+follow-up%3A+a+phase+1b+clinical+trial&doi=10.1001%2Fjamaoncol.2018.5152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial</span></div><div class="casAuthors">Adams Sylvia; Diamond Jennifer R; Hamilton Erika; Pohlmann Paula R; Tolaney Sara M; Chang Ching-Wei; Zhang Wei; Iizuka Koho; Foster Paul G; Molinero Luciana; Funke Roel; Powderly John</div><div class="citationInfo"><span class="NLM_cas:title">JAMA oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">334-342</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Importance:  The humanized monoclonal antibody atezolizumab targets programmed death-ligand 1 and has demonstrated durable single-agent activity in a subset of metastatic triple-negative breast cancers.  To extend the observed activity, combinatorial approaches are being tested with standard cytotoxic chemotherapies known to induce immunogenic tumor cell death.  Objective:  To examine the safety, tolerability, and preliminary clinical activity of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancers.  Design, Setting, and Participants:  This phase 1b multicohort study enrolled 33 women with stage IV or locally recurrent triple-negative breast cancers and 0 to 2 lines of prior chemotherapy in the metastatic setting from December 8, 2014, to April 30, 2017, at 11 sites in the United States.  The median follow-up was 24.4 months (95% CI, 22.1-28.8 months).  Interventions:  Patients received concurrent intravenous atezolizumab and intravenous nab-paclitaxel (minimum 4 cycles).  Main Outcomes and Measures:  The primary end point was safety and tolerability.  Secondary end points included best overall response rate by Response Evaluation Criteria in Solid Tumors, version 1.1; objective response rate; duration of response; disease control rate; progression-free survival; overall survival; and biomarker analyses.  Results:  The 33 women had a median age of 55 years (range, 32-84 years) and received 1 or more doses of atezolizumab.  All patients (100%) experienced at least 1 treatment-related adverse event, 24 patients (73%) experienced grade 3/4 adverse events, and 7 patients (21%) had grade 3/4 adverse events of special interest.  No deaths were related to study treatment.  The objective response rate was 39.4% (95% CI, 22.9%-57.9%), and the median duration of response was 9.1 months (95% CI, 2.0-20.9 months).  The disease control rate was 51.5% (95% CI, 33.5%-69.2%).  Median progression-free survival and overall survival were 5.5 months (95% CI, 5.1-7.7 months) and 14.7 months (95% CI, 10.1-not estimable), respectively.  Concurrent nab-paclitaxel neither significantly changed biomarkers of the tumor immune microenvironment (programmed death-ligand 1, tumor-infiltrating lymphocytes, CD8) nor impaired atezolizumab systemic immune activation (expansion of proliferating CD8+ T cells, increase of CXCL10 chemokine).  Conclusions and Relevance:  In this phase 1b trial for metastatic triple-negative breast cancers, the combination of atezolizumab plus nab-paclitaxel had a manageable safety profile.  Antitumor responses were observed, including in patients previously treated with a taxane.  Trial Registration:  ClinicalTrials.gov identifier: NCT01633970.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRou_rsDK4nb7mQt-ICR3qNfW6udTcc2eZZJ8Jzi4aQH7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvhvFWgtQ%253D%253D&md5=a1dfd4fd703ab88ee3d768ff6cf7a622</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2018.5152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2018.5152%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DS.%26aulast%3DDiamond%26aufirst%3DJ.%2BR.%26aulast%3DHamilton%26aufirst%3DE.%26aulast%3DPohlmann%26aufirst%3DP.%2BR.%26aulast%3DTolaney%26aufirst%3DS.%2BM.%26aulast%3DChang%26aufirst%3DC.%2BW.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DIizuka%26aufirst%3DK.%26aulast%3DFoster%26aufirst%3DP.%2BG.%26aulast%3DMolinero%26aufirst%3DL.%26aulast%3DFunke%26aufirst%3DR.%26aulast%3DPowderly%26aufirst%3DJ.%26atitle%3DAtezolizumab%2520plus%2520nab-paclitaxel%2520in%2520the%2520treatment%2520of%2520metastatic%2520triple-negative%2520breast%2520cancer%2520with%25202-year%2520survival%2520follow-up%253A%2520a%2520phase%25201b%2520clinical%2520trial%26jtitle%3DJAMA%2520Oncol.%26date%3D2019%26volume%3D5%26spage%3D334%26epage%3D342%26doi%3D10.1001%2Fjamaoncol.2018.5152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span> <span> </span><span class="NLM_article-title">Tumor associated macrophage-targeted microRNA delivery with dual-responsive polypeptide nanovectors for anti-cancer therapy</span>. <i>Biomaterials</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">166</span>– <span class="NLM_lpage">179</span>, <span class="refDoi"> DOI: 10.1016/j.biomaterials.2017.04.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1016%2Fj.biomaterials.2017.04.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=28463694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvVGisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2017&pages=166-179&author=L.+Liuauthor=H.+Yiauthor=H.+Heauthor=H.+Panauthor=L.+Caiauthor=Y.+Ma&title=Tumor+associated+macrophage-targeted+microRNA+delivery+with+dual-responsive+polypeptide+nanovectors+for+anti-cancer+therapy&doi=10.1016%2Fj.biomaterials.2017.04.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor associated macrophage-targeted microRNA delivery with dual-responsive polypeptide nanovectors for anti-cancer therapy</span></div><div class="casAuthors">Liu, Lanlan; Yi, Huqiang; He, Huamei; Pan, Hong; Cai, Lintao; Ma, Yifan</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">166-179</span>CODEN:
                <span class="NLM_cas:coden">BIMADU</span>;
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Repolarizing Tumor-assocd. macrophages (TAMs) to anti-tumor M1 macrophages with microRNA (miR) is a plausible approach for cancer treatment.  However, how to achieve TAM-targeted miR delivery remains a challenge.  The present study generated redox/pH dual-responsive hybrid polypeptide nanovectors, which consisted of self-crosslinked redox-responsive nanoparticles based on galactose-functionalized n-butylamine-poly(L-lysine)-b-poly(L-cysteine) polypeptides (GLC) coated with DCA-grafted sheddable PEG-PLL (sPEG) copolymers.  The ex vivo study showed that sPEG shielded cationic GLC core at physiol. pH but quickly shed off to re-expose GLC due to it charge reversible property.  Encapsulation with sPEG/GLC nanovectors effectively facilitated macrophage-targeted miR delivery at the acidic condition but diminished miR uptake at neutral pH.  Administration of miR155-loaded sPEG/GLC (sPEG/GLC/155) nanocomplexes increased miR155 expression in TAMs about 100-400 folds both in vitro and in vivo. sPEG/GLC/155 also effectively repolarized immunosuppressive TAMs to anti-tumor M1 macrophages through elevating M1 macrophage markers (IL-12, iNOS, MHC II) and suppressing M2 macrophage markers (Msr2 and Arg1) in TAMs.  Moreover, the treatment of sPEG/GLC/155 significantly increased activated T lymphocytes and NK cells in tumors, which consequently led to robust tumor regression.  Hence, TAM-targeted delivery of miR with redox/pH dual-responsive sPEG/GLC nanovectors could be a promising approach to re-polarize TAMs to M1 macrophages in situ and induce tumor regression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbRBf33UjOp7Vg90H21EOLACvtfcHk0lhdxYnZ3yYp0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvVGisro%253D&md5=3ac17bd522d7f49fe811da3442a5feca</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2017.04.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2017.04.043%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DYi%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DPan%26aufirst%3DH.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DMa%26aufirst%3DY.%26atitle%3DTumor%2520associated%2520macrophage-targeted%2520microRNA%2520delivery%2520with%2520dual-responsive%2520polypeptide%2520nanovectors%2520for%2520anti-cancer%2520therapy%26jtitle%3DBiomaterials%26date%3D2017%26volume%3D134%26spage%3D166%26epage%3D179%26doi%3D10.1016%2Fj.biomaterials.2017.04.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, L.</span></span> <span> </span><span class="NLM_article-title">ROS-inducing micelles sensitize tumor-associated macrophages to TLR3 stimulation for potent immunotherapy</span>. <i>Biomacromolecules</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2146</span>– <span class="NLM_lpage">2155</span>, <span class="refDoi"> DOI: 10.1021/acs.biomac.8b00239</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biomac.8b00239" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnslKmtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=2146-2155&author=L.+Liuauthor=H.+Heauthor=R.+Liangauthor=H.+Yiauthor=X.+Mengauthor=Z.+Chenauthor=H.+Panauthor=Y.+Maauthor=L.+Cai&title=ROS-inducing+micelles+sensitize+tumor-associated+macrophages+to+TLR3+stimulation+for+potent+immunotherapy&doi=10.1021%2Facs.biomac.8b00239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">ROS-inducing micelles sensitize tumor-associated macrophages to TLR3 stimulation for potent immunotherapy</span></div><div class="casAuthors">Liu, Lanlan; He, Huamei; Liang, Ruijing; Yi, Huqiang; Meng, Xiaoqing; Chen, Zhikuan; Pan, Hong; Ma, Yifan; Cai, Lintao</div><div class="citationInfo"><span class="NLM_cas:title">Biomacromolecules</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2146-2155</span>CODEN:
                <span class="NLM_cas:coden">BOMAF6</span>;
        ISSN:<span class="NLM_cas:issn">1525-7797</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">One approach to cancer immunotherapy is the repolarization of immunosuppressive tumor-assocd. macrophages (TAMs) to antitumor M1 macrophages.  The present study developed galactose-functionalized zinc protoporphyrin IX (ZnPP) grafted poly(L-lysine)-b-poly(ethylene glycol) polypeptide micelles (ZnPP PM) for TAM-targeted immunopotentiator delivery, which aimed at in vivo repolarization of TAMs to antitumor M1 macrophages.  The outcomes revealed that ROS-inducing ZnPP PM demonstrated specificity for the in vitro and in vivo targeting of macrophages, elevated the level of ROS, and lowered STAT3 expression in BM-TAMs.  Poly I:C (PIC, a TLR3 agonist)-loaded ZnPP PM (ZnPP PM/PIC) efficiently repolarized TAMs to M1 macrophages, which were reliant on ROS generation.  Further, ZnPP PM/PIC substantially elevated the activated NK cells and T lymphocytes in B16-F10 melanoma tumors, which caused vigorous tumor regression.  Therefore, the TAM-targeted transport of an immunol. adjuvant with ZnPP-grafted nanovectors may be a potential strategy to repolarize TAMs to M1 macrophages in situ for effective cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH90CD71cMjrVg90H21EOLACvtfcHk0lhdxYnZ3yYp0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnslKmtLw%253D&md5=574e353538168791fb446a6b3c043125</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facs.biomac.8b00239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biomac.8b00239%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DLiang%26aufirst%3DR.%26aulast%3DYi%26aufirst%3DH.%26aulast%3DMeng%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DPan%26aufirst%3DH.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DL.%26atitle%3DROS-inducing%2520micelles%2520sensitize%2520tumor-associated%2520macrophages%2520to%2520TLR3%2520stimulation%2520for%2520potent%2520immunotherapy%26jtitle%3DBiomacromolecules%26date%3D2018%26volume%3D19%26spage%3D2146%26epage%3D2155%26doi%3D10.1021%2Facs.biomac.8b00239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuong, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span> <span> </span><span class="NLM_article-title">On the mechanism of iron oxide-induced macrophage activation: the impact of composition and the underlying signaling pathway</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">6122</span>– <span class="NLM_lpage">6126</span>, <span class="refDoi"> DOI: 10.1021/jacs.8b10904</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.8b10904" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtlWgsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2019&pages=6122-6126&author=Z.+Guauthor=T.+Liuauthor=J.+Tangauthor=Y.+Yangauthor=H.+Songauthor=Z.+K.+Tuongauthor=J.+Fuauthor=C.+Yu&title=On+the+mechanism+of+iron+oxide-induced+macrophage+activation%3A+the+impact+of+composition+and+the+underlying+signaling+pathway&doi=10.1021%2Fjacs.8b10904"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of iron oxide-induced macrophage activation: The impact of composition and the underlying signaling pathway</span></div><div class="casAuthors">Gu, Zhengying; Liu, Tianqing; Tang, Jie; Yang, Yannan; Song, Hao; Tuong, Zewen K.; Fu, Jianye; Yu, Chengzhong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6122-6126</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Iron oxide nanoparticles (IONPs) have emerging anticancer applications via polarizing tumor-assocd. macrophages from tumor-promoting phenotype (M2) to tumor-suppressing phenotype (M1).  However, the underlying mechanism and structure-function relationship remain unclear.  We report magnetite IONPs are more effective compared to hematite in M1 polarization and tumor suppression.  Moreover, magnetite IONPs specifically rely on interferon regulatory factor 5 signaling pathway for M1 polarization and down-regulate M2-assocd. arginase-1.  This study provides new understandings and paves the way for designing advanced iron-based anticancer technologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq36AZI0pj7nrVg90H21EOLACvtfcHk0lhdxYnZ3yYp0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtlWgsLg%253D&md5=fd99474a78bc8a19a7e8fa99eddf748b</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjacs.8b10904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.8b10904%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DTuong%26aufirst%3DZ.%2BK.%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DC.%26atitle%3DOn%2520the%2520mechanism%2520of%2520iron%2520oxide-induced%2520macrophage%2520activation%253A%2520the%2520impact%2520of%2520composition%2520and%2520the%2520underlying%2520signaling%2520pathway%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2019%26volume%3D141%26spage%3D6122%26epage%3D6126%26doi%3D10.1021%2Fjacs.8b10904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.-Z.</span></span> <span> </span><span class="NLM_article-title">Enhanced immunotherapy based on photodynamic therapy for both primary and lung metastasis tumor eradication</span>. <i>ACS Nano</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1978</span>– <span class="NLM_lpage">1989</span>, <span class="refDoi"> DOI: 10.1021/acsnano.7b09112</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsnano.7b09112" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFamu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=1978-1989&author=W.+Songauthor=J.+Kuangauthor=C.-X.+Liauthor=M.+Zhangauthor=D.+Zhengauthor=X.+Zengauthor=C.+Liuauthor=X.-Z.+Zhang&title=Enhanced+immunotherapy+based+on+photodynamic+therapy+for+both+primary+and+lung+metastasis+tumor+eradication&doi=10.1021%2Facsnano.7b09112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced Immunotherapy Based on Photodynamic Therapy for Both Primary and Lung Metastasis Tumor Eradication</span></div><div class="casAuthors">Song, Wen; Kuang, Jing; Li, Chu-Xin; Zhang, Mingkang; Zheng, Diwei; Zeng, Xuan; Liu, Chuanjun; Zhang, Xian-Zheng</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1978-1989</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Metastasis and recurrence are two unavoidable and intractable problems in cancer therapy, despite various robust therapeutic approaches.  Currently, it seems that immunotherapy is an effective approach to solve these problems, but the high heterogeneity of tumor tissue, inefficient presentation of tumor antigen, and deficient targeting ability of therapy usually blunt the efficacy of immunotherapy and hinder its clin. application.  Herein, an approach based on combining photodynamic and immunol. therapy was designed and developed.  We synthesized a chimeric peptide, PpIX-1MT, which integrates photosensitizer PpIX with immune checkpoint inhibitor 1MT via a caspase-responsive peptide sequence, Asp-Glu-Val-Asp (DEVD), to realize a cascaded synergistic effect.  The PpIX-1MT peptide could form nanoparticles in PBS and accumulate in tumor areas via the enhanced penetration retention effect.  Upon 630 nm light irradn., the PpIX-1MT nanoparticles produced reactive oxygen species, induced apoptosis of cancer cells, and thus facilitated the expression of caspase-3 and the prodn. of tumor antigens, which could trigger an intense immune response.  The subsequently released 1MT upon caspase-3 cleavage could further strengthen the immune system and help to activate CD8+ T cells effectively.  This cascaded synergistic effect could inhibit both primary and lung metastasis tumor effectively, which may provide the soln. for solving tumor recurrence and metastasis clin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2rf8jxw88ZbVg90H21EOLACvtfcHk0lgoFBoV21uGSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFamu70%253D&md5=c0853b57e48a2c49de211b01c5dd0360</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facsnano.7b09112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsnano.7b09112%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DW.%26aulast%3DKuang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.-X.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DZheng%26aufirst%3DD.%26aulast%3DZeng%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DX.-Z.%26atitle%3DEnhanced%2520immunotherapy%2520based%2520on%2520photodynamic%2520therapy%2520for%2520both%2520primary%2520and%2520lung%2520metastasis%2520tumor%2520eradication%26jtitle%3DACS%2520Nano%26date%3D2018%26volume%3D12%26spage%3D1978%26epage%3D1989%26doi%3D10.1021%2Facsnano.7b09112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen-Thanh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W.</span></span> <span> </span><span class="NLM_article-title">Sirt2 ameliorates lipopolysaccharide-induced inflammation in macrophages</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>450</i></span>,  <span class="NLM_fpage">1363</span>– <span class="NLM_lpage">1369</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2014.06.135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1016%2Fj.bbrc.2014.06.135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=25003320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Squ7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=450&publication_year=2014&pages=1363-1369&author=A.+S.+Leeauthor=Y.+J.+Jungauthor=D.+Kimauthor=T.+Nguyen-Thanhauthor=K.+P.+Kangauthor=S.+Leeauthor=S.+K.+Parkauthor=W.+Kim&title=Sirt2+ameliorates+lipopolysaccharide-induced+inflammation+in+macrophages&doi=10.1016%2Fj.bbrc.2014.06.135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">SIRT2 ameliorates lipopolysaccharide-induced inflammation in macrophages</span></div><div class="casAuthors">Lee, Ae Sin; Jung, Yu Jin; Kim, Dal; Nguyen-Thanh, Tung; Kang, Kyung Pyo; Lee, Sik; Park, Sung Kwang; Kim, Won</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">450</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1363-1369</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">SIRT2 is a NAD(+)-dependent deacetylases and assocd. with numerous processes such as infection, carcinogenesis, DNA damage and cell cycle regulation.  However, the role of SIRT2 in inflammatory process in macrophage remains unclear.In the present study, we have evaluated the regulatory effects of SIRT2 in lipopolysaccharide (LPS)-stimulated macrophages isolated from SIRT2 knockout (KO) and wild type (WT) mice or Raw264.7 macrophage cells.  As inflammatory parameters, expression of inducible nitric oxide synthase (iNOS), the productions of nitric oxide, reactive oxygen species (ROS) and M1-macrophage-related factors were evaluated.  We also examd. the effects of SIRT2 on activation of nuclear factor-kappaB (NFκB) signaling.SIRT2 deficiency inhibits LPS-induced iNOS mRNA and protein expression in bone marrow derived macrophages.  SIRT2-siRNA transfection also suppressed LPS-induced iNOS expression in Raw264.7 macrophage cells.  Bone marrow derived macrophages isolated from SIRT2 KO mice produced lower nitric oxide and expressed lower levels of M1-macrophage related markers including iNOS and CD86 in response to LPS than WT mice.  Decrease of SIRT2 reduced the LPS-induced reactive oxygen species prodn.  Deficiency of SIRT2 resulted in inhibition of NFκB activation through reducing the phosphorylation and degrdn. of IκBα.  The phosphorylation and nuclear translocation of p65 was significantly decreased in SIRT2-deficient macrophages after LPS stimulation.Our data suggested that deficiency of SIRT2 ameliorates iNOS, NO expression and reactive oxygen species prodn. with suppressing LPS-induced activation of NFκB in macrophages.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJd6E2kD7Xd7Vg90H21EOLACvtfcHk0lgoFBoV21uGSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Squ7vF&md5=74c9bcc76abb6f1581f40651acd6764c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2014.06.135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2014.06.135%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DA.%2BS.%26aulast%3DJung%26aufirst%3DY.%2BJ.%26aulast%3DKim%26aufirst%3DD.%26aulast%3DNguyen-Thanh%26aufirst%3DT.%26aulast%3DKang%26aufirst%3DK.%2BP.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DS.%2BK.%26aulast%3DKim%26aufirst%3DW.%26atitle%3DSirt2%2520ameliorates%2520lipopolysaccharide-induced%2520inflammation%2520in%2520macrophages%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2014%26volume%3D450%26spage%3D1363%26epage%3D1369%26doi%3D10.1016%2Fj.bbrc.2014.06.135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Padgett, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burg, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, W. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tse, H. M.</span></span> <span> </span><span class="NLM_article-title">Loss of nadph oxidase-derived superoxide skews macrophage phenotypes to delay type 1 diabetes</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">937</span>– <span class="NLM_lpage">946</span>, <span class="refDoi"> DOI: 10.2337/db14-0929</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.2337%2Fdb14-0929" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=25288672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFanurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2015&pages=937-946&author=L.+E.+Padgettauthor=A.+R.+Burgauthor=W.+Q.+Leiauthor=H.+M.+Tse&title=Loss+of+nadph+oxidase-derived+superoxide+skews+macrophage+phenotypes+to+delay+type+1+diabetes&doi=10.2337%2Fdb14-0929"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of NADPH oxidase-derived superoxide skews macrophage phenotypes to delay type 1 diabetes</span></div><div class="casAuthors">Padgett, Lindsey E.; Burg, Ashley R.; Lei, Weiqi; Tse, Hubert M.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">937-946</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">Macrophages are early islet-infiltrating cells seen in type 1 diabetes (T1D).  While proinflammatory M1 macrophages induce T1D, M2 macrophages have been shown to delay this autoimmune disease in nonobese diabetic (NOD) mice, but the environmental cues that govern macrophage polarization and differentiation remain unresolved.  We previously demonstrated the importance of reactive oxygen species (ROS) in T1D, as NOD mice deficient in NADPH oxidase (NOX)-derived superoxide (Ncf1m1J) were protected against T1D partly because of blunted Toll-like receptor-dependent macrophage responses.  We provide evidence that NOX-derived ROS contribute to macrophage differentiation in T1D.  During spontaneous diabetes progression, T1D-resistant NOD.Ncf1m1J islet-resident macrophages displayed a dampened M1 and increased M2 phenotype.  The transfer of diabetogenic T cells into NOX-deficient NOD.Rag.Ncf1m1J recipients resulted in decreased TNF-α+ and IL-1β+ islet-infiltrating M1 macrophages and a concomitant enhancement in arginase-1+ M2 macrophages.  Mechanistic anal. of superoxide-deficient bone marrow-derived macrophages revealed a marked diminution in a proinflammatory M1 phenotype due to decreased P-STAT1 (Y701) and interferon regulatory factor 5 compared with NOD mice.  We have therefore defined a novel mechanistic link between NOX-derived ROS and macrophage phenotypes, and implicated superoxide as an important factor in macrophage differentiation.  Thus, targeting macrophage redox status may represent a promising therapy in halting human T1D.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIF8q7R1nl1LVg90H21EOLACvtfcHk0lgoFBoV21uGSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFanurk%253D&md5=bd3bb94ac4c58194dd0166a5d6491fa6</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2337%2Fdb14-0929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdb14-0929%26sid%3Dliteratum%253Aachs%26aulast%3DPadgett%26aufirst%3DL.%2BE.%26aulast%3DBurg%26aufirst%3DA.%2BR.%26aulast%3DLei%26aufirst%3DW.%2BQ.%26aulast%3DTse%26aufirst%3DH.%2BM.%26atitle%3DLoss%2520of%2520nadph%2520oxidase-derived%2520superoxide%2520skews%2520macrophage%2520phenotypes%2520to%2520delay%2520type%25201%2520diabetes%26jtitle%3DDiabetes%26date%3D2015%26volume%3D64%26spage%3D937%26epage%3D946%26doi%3D10.2337%2Fdb14-0929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Englinger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffeter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terenzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowol, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keppler, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, W.</span></span> <span> </span><span class="NLM_article-title">Metal drugs and the anticancer immune response</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">1519</span>– <span class="NLM_lpage">1624</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.8b00396</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.8b00396" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlakt7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2019&pages=1519-1624&author=B.+Englingerauthor=C.+Pirkerauthor=P.+Heffeterauthor=A.+Terenziauthor=C.+R.+Kowolauthor=B.+K.+Kepplerauthor=W.+Berger&title=Metal+drugs+and+the+anticancer+immune+response&doi=10.1021%2Facs.chemrev.8b00396"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Metal drugs and the anticancer immune response</span></div><div class="casAuthors">Englinger, Bernhard; Pirker, Christine; Heffeter, Petra; Terenzi, Alessio; Kowol, Christian R.; Keppler, Bernhard K.; Berger, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1519-1624</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The immune system deploys a multitude of innate and adaptive mechanisms not only to ward off pathogens but also to prevent malignant transformation ("immune surveillance").  Hence, a clin. apparent tumor already reflects selection for those malignant cell clones capable of evading immune recognition ("immune evasion").  Metal drugs, besides their well-investigated cytotoxic anticancer effects, massively interact with the cancer-immune interface and can reverse important aspects of immune evasion.  This topic has recently gained intense attention based on combination approaches with anticancer immunotherapy (e.g., immune checkpoint inhibitors), a strategy recently delivering first exciting results in clin. settings.  This review summarizes the promising but still extremely fragmentary knowledge on the interplay of metal drugs with the fidelity of anticancer immune responses but also their role in adverse effects.  It highlights that, at least in some cases, metal drugs can induce long-lasting anticancer immune responses.  Important steps in this process comprise altered visibility and susceptibility of cancer cells toward innate and adaptive immunity, as well as direct impacts on immune cell populations and the tumor microenvironment.  On the basis of the gathered information, we suggest initiating joint multidisciplinary programs to implement comprehensive immune analyses into strategies to develop novel and smart anticancer metal compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpduZa3EdGgurVg90H21EOLACvtfcHk0liEM4DErN-uhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlakt7bO&md5=9cf67c2ef463cd26be88b178b5b6534a</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.8b00396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.8b00396%26sid%3Dliteratum%253Aachs%26aulast%3DEnglinger%26aufirst%3DB.%26aulast%3DPirker%26aufirst%3DC.%26aulast%3DHeffeter%26aufirst%3DP.%26aulast%3DTerenzi%26aufirst%3DA.%26aulast%3DKowol%26aufirst%3DC.%2BR.%26aulast%3DKeppler%26aufirst%3DB.%2BK.%26aulast%3DBerger%26aufirst%3DW.%26atitle%3DMetal%2520drugs%2520and%2520the%2520anticancer%2520immune%2520response%26jtitle%3DChem.%2520Rev.%26date%3D2019%26volume%3D119%26spage%3D1519%26epage%3D1624%26doi%3D10.1021%2Facs.chemrev.8b00396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mora, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gimeno, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visbal, R.</span></span> <span> </span><span class="NLM_article-title">Recent advances in gold-NHC complexes with biological properties</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">447</span>– <span class="NLM_lpage">462</span>, <span class="refDoi"> DOI: 10.1039/C8CS00570B</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1039%2FC8CS00570B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=30474097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit12ks7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2019&pages=447-462&author=M.+Moraauthor=M.-C.+Gimenoauthor=R.+Visbal&title=Recent+advances+in+gold-NHC+complexes+with+biological+properties&doi=10.1039%2FC8CS00570B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in gold-NHC complexes with biological properties</span></div><div class="casAuthors">Mora, Malka; Gimeno, M. Concepcion; Visbal, Renso</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">447-462</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">This tutorial review covers the recent advances made in the study of gold complexes contg. N-heterocyclic carbene ligands with biol. properties.  The great stability, ease of modulation of the electronic properties and excellent σ-donating capacity displayed by NHCs allow gold-NHC derivs. to reach high stability in biol. media and relatively good internalization into cells and for that they have emerged as excellent potential chemotherapeutics.  The new gold-NHC derivs. show superior anticancer activity compared to other stds. such as Cisplatin or Auranofin.  In addn., the application of gold-NHC complexes in the treatment of other human diseases as antibacterial, antioxidant and antiparasitic agents is reviewed for the first time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0VvhC9V7eAbVg90H21EOLACvtfcHk0liEM4DErN-uhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit12ks7zE&md5=a3da211b61b5414e1af3d38eca0b1302</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1039%2FC8CS00570B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8CS00570B%26sid%3Dliteratum%253Aachs%26aulast%3DMora%26aufirst%3DM.%26aulast%3DGimeno%26aufirst%3DM.-C.%26aulast%3DVisbal%26aufirst%3DR.%26atitle%3DRecent%2520advances%2520in%2520gold-NHC%2520complexes%2520with%2520biological%2520properties%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2019%26volume%3D48%26spage%3D447%26epage%3D462%26doi%3D10.1039%2FC8CS00570B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lum, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lok, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, C. M.</span></span> <span> </span><span class="NLM_article-title">Chemical biology of anticancer Au(III) and Au(I) complexes</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">8786</span>– <span class="NLM_lpage">8801</span>, <span class="refDoi"> DOI: 10.1039/C5CS00132C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1039%2FC5CS00132C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=25868756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsVChurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2015&pages=8786-8801&author=T.+Zouauthor=C.+T.+Lumauthor=C.+N.+Lokauthor=J.+J.+Zhangauthor=C.+M.+Che&title=Chemical+biology+of+anticancer+Au%28III%29+and+Au%28I%29+complexes&doi=10.1039%2FC5CS00132C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical biology of anticancer gold(III) and gold(I) complexes</span></div><div class="casAuthors">Zou, Taotao; Lum, Ching Tung; Lok, Chun-Nam; Zhang, Jing-Jing; Che, Chi-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8786-8801</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Gold complexes have recently gained increasing attention in the design of new metal-based anticancer therapeutics.  Gold(III) complexes are generally reactive/unstable under physiol. conditions via intracellular redox reactions, and the intracellular AuIII to AuI redn. reaction has recently been "traced" by the introduction of appropriate fluorescent ligands.  Similar to most Au(I) complexes, Au(III) complexes can inhibit the activities of thiol-contg. enzymes, including thioredoxin reductase, via ligand exchange reactions to form Au-S(Se) bonds.  Nonetheless, there are examples of physiol. stable Au(III) and Au(I) complexes, such as [Au(TPP)]Cl (H2TPP = 5,10,15,20-tetraphenylporphyrin) and [Au(dppe)2]Cl (dppe = 1,2-bis(diphenylphosphanyl)ethane), which are known to display highly potent in vitro and in vivo anticancer activities.  In this review, we summarize our current understanding of anticancer gold complexes, including their mechanisms of action and the approaches adopted to improve their anticancer efficiency.  Some recent examples of gold anticancer chemotherapeutics are highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraSf5EPIPo8rVg90H21EOLACvtfcHk0liEM4DErN-uhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsVChurg%253D&md5=6e546124df776ce9612fb8a4fdbcad37</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1039%2FC5CS00132C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5CS00132C%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DT.%26aulast%3DLum%26aufirst%3DC.%2BT.%26aulast%3DLok%26aufirst%3DC.%2BN.%26aulast%3DZhang%26aufirst%3DJ.%2BJ.%26aulast%3DChe%26aufirst%3DC.%2BM.%26atitle%3DChemical%2520biology%2520of%2520anticancer%2520Au%2528III%2529%2520and%2520Au%2528I%2529%2520complexes%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2015%26volume%3D44%26spage%3D8786%26epage%3D8801%26doi%3D10.1039%2FC5CS00132C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, H.</span></span> <span> </span><span class="NLM_article-title">Developing a novel gold(III) agent to treat glioma based on the unique properties of apoferritin nanoparticles: inducing lethal autophagy and apoptosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">13695</span>– <span class="NLM_lpage">13708</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c01257</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01257" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlertrrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=13695-13708&author=J.+Zhangauthor=Z.+Zhangauthor=M.+Jiangauthor=S.+Liauthor=H.+Yuanauthor=H.+Sunauthor=F.+Yangauthor=H.+Liang&title=Developing+a+novel+gold%28III%29+agent+to+treat+glioma+based+on+the+unique+properties+of+apoferritin+nanoparticles%3A+inducing+lethal+autophagy+and+apoptosis&doi=10.1021%2Facs.jmedchem.0c01257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Developing a Novel Gold(III) Agent to Treat Glioma Based on the Unique Properties of Apoferritin Nanoparticles: Inducing Lethal Autophagy and Apoptosis</span></div><div class="casAuthors">Zhang, Juzheng; Zhang, Zhenlei; Jiang, Ming; Li, Shanhe; Yuan, Haoliang; Sun, Hongbin; Yang, Feng; Liang, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">13695-13708</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Effective delivery of anticancer agents across the blood-brain barrier (BBB) required innovative strategies to achieve glioma regression.  To resolve this problem, we proposed to develop a metal agent that target and treat glioma based on the unique property of apoferritin (AFt) nanoparticles (NPs).  Thus, we synthesized a series of Au(III) 3-(4-metyl piperidine)thiosemicarbazides compds. and analyzed their structure-activity relationships, obtaining a Au agent (C6) with remarkable cytotoxicity in glioma.  Moreover, we confirmed that C6 kills glioma cells by inducing lethal autophagy and apoptosis.  Importantly, our results revealed that the successfully constructed apoferritin-C6 NPs (AFt-C6 NPs) can effectively cross the BBB, inhibit glioma growth, and selectively accumulate in tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_X0TvxpIJ8LVg90H21EOLACvtfcHk0liEM4DErN-uhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlertrrO&md5=a7c40edae866d6824f5c300edb3d4755</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01257%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DLiang%26aufirst%3DH.%26atitle%3DDeveloping%2520a%2520novel%2520gold%2528III%2529%2520agent%2520to%2520treat%2520glioma%2520based%2520on%2520the%2520unique%2520properties%2520of%2520apoferritin%2520nanoparticles%253A%2520inducing%2520lethal%2520autophagy%2520and%2520apoptosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D13695%26epage%3D13708%26doi%3D10.1021%2Facs.jmedchem.0c01257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awuah, S. G.</span></span> <span> </span><span class="NLM_article-title">Gold(I/III)-phosphine complexes as potent antiproliferative agents</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">12335</span>, <span class="refDoi"> DOI: 10.1038/s41598-019-48584-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1038%2Fs41598-019-48584-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=31451718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A280%3ADC%252BB3MrhvVGrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=12335&author=J.+H.+Kimauthor=E.+Reederauthor=S.+Parkinauthor=S.+G.+Awuah&title=Gold%28I%2FIII%29-phosphine+complexes+as+potent+antiproliferative+agents&doi=10.1038%2Fs41598-019-48584-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Gold(I/III)-Phosphine Complexes as Potent Antiproliferative Agents</span></div><div class="casAuthors">Kim Jong Hyun; Reeder Evan; Parkin Sean; Awuah Samuel G</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12335</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The reaction of gold reagents [HAuCl4•3H2O], [AuCl(tht)], or cyclometalated gold(III) precursor, [C NAuCl2] with chiral ((R,R)-(-)-2,3-bis(t-butylmethylphosphino) quinoxaline) and non-chiral phosphine (1,2-Bis(diphenylphosphino)ethane, dppe) ligands lead to distorted Au(I), (1, 2, 4, 5) and novel cyclometalated Au(III) complexes (3, 6).  These gold compounds were characterized by multinuclear NMR, microanalysis, mass spectrometry, and X-ray crystallography.  The inherent electrochemical properties of the gold complexes were also studied by cyclic voltammetry and theoretical insight of the complexes was gained by density functional theory and TD-DFT calculations.  The complexes effectively kill cancer cells with IC50 in the range of ~0.10-2.53 μΜ across K562, H460, and OVCAR8 cell lines.  In addition, the retinal pigment epithelial cell line, RPE-Neo was used as a healthy cell line for comparison.  Differential cellular uptake in cancer cells was observed for the compounds by measuring the intracellular accumulation of gold using ICP-OES.  Furthermore, the compounds trigger early - late stage apoptosis through potential disruption of redox homeostasis.  Complexes 1 and 3 induce predominant G1 cell cycle arrest.  Results presented in this report suggest that stable gold-phosphine complexes with variable oxidation states hold promise in anticancer drug discovery and need further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS__ehwZ0OhMh0LsK7uFuY7fW6udTcc2eYFTnfAME_Qjbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrhvVGrsw%253D%253D&md5=1d0a70644aa1bd4626a76bb96bda8c47</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-48584-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-48584-5%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DReeder%26aufirst%3DE.%26aulast%3DParkin%26aufirst%3DS.%26aulast%3DAwuah%26aufirst%3DS.%2BG.%26atitle%3DGold%2528I%252FIII%2529-phosphine%2520complexes%2520as%2520potent%2520antiproliferative%2520agents%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26spage%3D12335%26doi%3D10.1038%2Fs41598-019-48584-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gukathasan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awuah, S. G.</span></span> <span> </span><span class="NLM_article-title">Cyclometalated gold(III) complexes bearing DACH ligands</span>. <i>Inorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">9326</span>– <span class="NLM_lpage">9340</span>, <span class="refDoi"> DOI: 10.1021/acs.inorgchem.9b01031</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.inorgchem.9b01031" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1eru7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=9326-9340&author=S.+Gukathasanauthor=S.+Parkinauthor=S.+G.+Awuah&title=Cyclometalated+gold%28III%29+complexes+bearing+DACH+ligands&doi=10.1021%2Facs.inorgchem.9b01031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclometalated Gold(III) Complexes Bearing DACH Ligands</span></div><div class="casAuthors">Gukathasan, Sailajah; Parkin, Sean; Awuah, Samuel G.</div><div class="citationInfo"><span class="NLM_cas:title">Inorganic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">9326-9340</span>CODEN:
                <span class="NLM_cas:coden">INOCAJ</span>;
        ISSN:<span class="NLM_cas:issn">0020-1669</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis of a novel class of cyclometalated gold(III) complexes supported by benzoylpyridine, benzylpyridine, and (1R,2R)-(+)-1,2-diaminocyclohexane (DACH) ligands, along with their crystal structures, is reported.  These compds. provide a new scaffold to investigate biol. properties of gold(III) complexes.  The six complexes were prepd. and characterized, following reactions of (C,N) cyclometalated gold(III) scaffolds, [Au(C N)Cl2] with DACH, which yielded a new series of cyclometaled gold(III), 3-5, of the type [Au(C NH)(DACH)2]+ and the nitrogen-substituted cyclometalated Au(III), 6-8, of the type [Au(C N)(DACH)]2+.  Antiproliferative activity of these complexes in a panel of cancer cells showed promising results with IC50 in the micromolar range and selectivity over normal epithelial cells, MRC5.  Whereas 8 shows minimal interaction with superhelical DNA except at high gold concns. of 500μM, complex 5 does not show interaction even at 1000μM.  The complexes display significant uptake in OVCAR8 cancer cells within 200-1200 pmol/million cells with the exception of complex 4.  Differential cellular uptake was obsd. for the complexes; for example, while 3 and 8 display significant uptake, 4 showed minimal uptake.  The compds. proved to be stable under physiol. conditions and were minimally affected by either glutathione or sodium ascorbate.  Cell cycle studies reveal a G1 arrest induced by representative complexes.  The results reveal that enhanced Au(III) stabilization promoted by combined cyclometalated and DACH ligands may offer ligand tuning insights for novel anticancer drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxUSNZnA3_YLVg90H21EOLACvtfcHk0ljNbIe6d0v-QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1eru7jM&md5=2653b7cab5e02eca231c79b09061c995</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.inorgchem.9b01031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.inorgchem.9b01031%26sid%3Dliteratum%253Aachs%26aulast%3DGukathasan%26aufirst%3DS.%26aulast%3DParkin%26aufirst%3DS.%26aulast%3DAwuah%26aufirst%3DS.%2BG.%26atitle%3DCyclometalated%2520gold%2528III%2529%2520complexes%2520bearing%2520DACH%2520ligands%26jtitle%3DInorg.%2520Chem.%26date%3D2019%26volume%3D58%26spage%3D9326%26epage%3D9340%26doi%3D10.1021%2Facs.inorgchem.9b01031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tong, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lok, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung, Y. M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, C. M.</span></span> <span> </span><span class="NLM_article-title">An anticancer gold(III)-activated porphyrin scaffold that covalently modifies protein cysteine thiols</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">1321</span>– <span class="NLM_lpage">1329</span>, <span class="refDoi"> DOI: 10.1073/pnas.1915202117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1073%2Fpnas.1915202117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=31896586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFKktL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2020&pages=1321-1329&author=K.+C.+Tongauthor=C.+N.+Lokauthor=P.+K.+Wanauthor=D.+Huauthor=Y.+M.+E.+Fungauthor=X.+Y.+Changauthor=S.+Huangauthor=H.+Jiangauthor=C.+M.+Che&title=An+anticancer+gold%28III%29-activated+porphyrin+scaffold+that+covalently+modifies+protein+cysteine+thiols&doi=10.1073%2Fpnas.1915202117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">An anticancer gold(III)-activated porphyrin scaffold that covalently modifies protein cysteine thiols</span></div><div class="casAuthors">Tong, Ka-Chung; Lok, Chun-Nam; Wan, Pui-Ki; Hu, Di; Eva Fung, Yi Man; Chang, Xiao-Yong; Huang, Song; Jiang, Haibo; Che, Chi-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1321-1329</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Cysteine thiols of many cancer-assocd. proteins are attractive targets of anticancer agents.  Herein, we unequivocally demonstrate a distinct thiol-targeting property of gold(III) mesoporphyrin IX di-Me ester (AuMesoIX) and its anticancer activities.  While the binding of cysteine thiols with metal complexes usually occurs via M-S bond formation, AuMesoIX is unique in that the meso-carbon atom of the porphyrin ring is activated by the gold(III) ion to undergo nucleophilic arom. substitution with thiols.  AuMesoIX was shown to modify reactive cysteine residues and inhibit the activities of anticancer protein targets including thioredoxin, peroxiredoxin, and deubiquitinases.  Treatment of cancer cells with AuMesoIX resulted in the formation of gold-bound sulfur-rich protein aggregates, oxidative stress-mediated cytotoxicity, and accumulation of ubiquitinated proteins.  Importantly, AuMesoIX exhibited effective antitumor activity in mice.  Our study has uncovered a gold(III)-induced ligand scaffold reactivity for thiol targeting that can be exploited for anticancer applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJuhQj8AqhG7Vg90H21EOLACvtfcHk0ljNbIe6d0v-QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFKktL4%253D&md5=58f9fb7cbcbb4da43df2f07f97b7d311</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1915202117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1915202117%26sid%3Dliteratum%253Aachs%26aulast%3DTong%26aufirst%3DK.%2BC.%26aulast%3DLok%26aufirst%3DC.%2BN.%26aulast%3DWan%26aufirst%3DP.%2BK.%26aulast%3DHu%26aufirst%3DD.%26aulast%3DFung%26aufirst%3DY.%2BM.%2BE.%26aulast%3DChang%26aufirst%3DX.%2BY.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DChe%26aufirst%3DC.%2BM.%26atitle%3DAn%2520anticancer%2520gold%2528III%2529-activated%2520porphyrin%2520scaffold%2520that%2520covalently%2520modifies%2520protein%2520cysteine%2520thiols%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2020%26volume%3D117%26spage%3D1321%26epage%3D1329%26doi%3D10.1073%2Fpnas.1915202117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mertens, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awuah, S. G.</span></span> <span> </span><span class="NLM_article-title">Cancer cell-selective modulation of mitochondrial respiration and metabolism by potent organogold(iii) dithiocarbamates</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">10465</span>– <span class="NLM_lpage">10482</span>, <span class="refDoi"> DOI: 10.1039/D0SC03628E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1039%2FD0SC03628E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVGgs7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=10465-10482&author=R.+T.+Mertensauthor=S.+Parkinauthor=S.+G.+Awuah&title=Cancer+cell-selective+modulation+of+mitochondrial+respiration+and+metabolism+by+potent+organogold%28iii%29+dithiocarbamates&doi=10.1039%2FD0SC03628E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer cell-selective modulation of mitochondrial respiration and metabolism by potent organogold(III) dithiocarbamates</span></div><div class="casAuthors">Mertens, Randall T.; Parkin, Sean; Awuah, Samuel G.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">10465-10482</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Metabolic reprogramming is a key cancer hallmark that has led to the therapeutic targeting of glycolysis.  However, agents that target dysfunctional mitochondrial respiration for targeted therapy remains underexplored.  We report the synthesis and characterization of ten (10) novel, highly potent organometallic gold(III) complexes supported by dithiocarbamate ligands as selective inhibitors of mitochondrial respiration.  The structure of dithiocarbamates employed dictates the biol. stability and cellular cytotoxicity.  Most of the compds. exhibit 50% inhibitory concn. (IC50) in the low-micromolar (0.50-2.9 μM) range when tested in a panel of aggressive cancer types with significant selectivity for cancer cells over normal cells.  Consequently, there is great interest in the mechanism of action of gold chemotherapeutics, particularly, considering that DNA is not the major target of most gold complexes.  We investigate the mechanism of action of representative complexes, 1a and 2a in the recalcitrant triple neg. breast cancer (TNBC) cell line, MDA-MB-231.  Whole-cell transcriptomics sequencing revealed genes related to three major pathways, namely: cell cycle, organelle fission, and oxidative phosphorylation. 2a irreversibly and rapidly inhibits maximal respiration in TNBC with no effect on normal epithelial cells, implicating mitochondrial OXPHOS as a potential target.  Furthermore, the modulation of cyclin dependent kinases and G1 cell cycle arrest induced by these compds. is promising for the treatment of cancer.  This work contributes to the need for mitochondrial respiration modulators in biomedical research and outlines a systematic approach to study the mechanism of action of metal-based agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy7PCLc_HGgrVg90H21EOLACvtfcHk0ljNbIe6d0v-QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVGgs7zL&md5=bb3f230316d8b08686829a5b6fcc540d</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1039%2FD0SC03628E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FD0SC03628E%26sid%3Dliteratum%253Aachs%26aulast%3DMertens%26aufirst%3DR.%2BT.%26aulast%3DParkin%26aufirst%3DS.%26aulast%3DAwuah%26aufirst%3DS.%2BG.%26atitle%3DCancer%2520cell-selective%2520modulation%2520of%2520mitochondrial%2520respiration%2520and%2520metabolism%2520by%2520potent%2520organogold%2528iii%2529%2520dithiocarbamates%26jtitle%3DChem.%2520Sci.%26date%3D2020%26volume%3D11%26spage%3D10465%26epage%3D10482%26doi%3D10.1039%2FD0SC03628E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">da
S. Maia, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponader, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagenbach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergemann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gust, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deflon, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abram, U.</span></span> <span> </span><span class="NLM_article-title">Neutral gold complexes with tridentate SNS thiosemicarbazide ligands</span>. <i>Inorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1604</span>– <span class="NLM_lpage">1613</span>, <span class="refDoi"> DOI: 10.1021/ic201905t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ic201905t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=1604-1613&author=P.+I.+da%0AS.+Maiaauthor=H.+H.+Nguyenauthor=D.+Ponaderauthor=A.+Hagenbachauthor=S.+Bergemannauthor=R.+Gustauthor=V.+M.+Deflonauthor=U.+Abram&title=Neutral+gold+complexes+with+tridentate+SNS+thiosemicarbazide+ligands&doi=10.1021%2Fic201905t"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fic201905t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fic201905t%26sid%3Dliteratum%253Aachs%26aulast%3Dda%2BS.%2BMaia%26aufirst%3DP.%2BI.%26aulast%3DNguyen%26aufirst%3DH.%2BH.%26aulast%3DPonader%26aufirst%3DD.%26aulast%3DHagenbach%26aufirst%3DA.%26aulast%3DBergemann%26aufirst%3DS.%26aulast%3DGust%26aufirst%3DR.%26aulast%3DDeflon%26aufirst%3DV.%2BM.%26aulast%3DAbram%26aufirst%3DU.%26atitle%3DNeutral%2520gold%2520complexes%2520with%2520tridentate%2520SNS%2520thiosemicarbazide%2520ligands%26jtitle%3DInorg.%2520Chem.%26date%3D2012%26volume%3D51%26spage%3D1604%26epage%3D1613%26doi%3D10.1021%2Fic201905t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vela, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palomera, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azaceta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzo, I.</span></span> <span> </span><span class="NLM_article-title">Iminophosphorane-organogold(III) complexes induce cell death through mitochondrial ROS production</span>. <i>J. Inorg. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">1306</span>– <span class="NLM_lpage">1313</span>, <span class="refDoi"> DOI: 10.1016/j.jinorgbio.2011.06.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1016%2Fj.jinorgbio.2011.06.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=21864808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFymtrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2011&pages=1306-1313&author=L.+Velaauthor=M.+Contelauthor=L.+Palomeraauthor=G.+Azacetaauthor=I.+Marzo&title=Iminophosphorane-organogold%28III%29+complexes+induce+cell+death+through+mitochondrial+ROS+production&doi=10.1016%2Fj.jinorgbio.2011.06.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Iminophosphorane-organogold(III) complexes induce cell death through mitochondrial ROS production</span></div><div class="casAuthors">Vela, Laura; Contel, Maria; Palomera, Luis; Azaceta, Gemma; Marzo, Isabel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inorganic Biochemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1306-1313</span>CODEN:
                <span class="NLM_cas:coden">JIBIDJ</span>;
        ISSN:<span class="NLM_cas:issn">0162-0134</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Gold compds. are being investigated as potential antitumor drugs.  Some gold(III) derivs. have been shown to induce cell death in solid tumors but their mechanism of action differs from that of cisplatin, since most of these compds. do not bind to DNA.  The authors have explored cellular events triggered by three different iminophosphorane-organogold(III) compds. in leukemia cells (a) neutral compd. with two chloride ligands [Au{κ2-C,N-C6H4(PPh2 = N(C6H5))-2}Cl2] (1), and two cationic compds. with either a dithiocarbamate ligand [Au{κ2-C,N-C6H4(PPh2 = N(C6H5))-2}(S2CN-Me2)]PF6 (2), or a water-sol. phosphine and a chloride ligand [Au{κ2-C,N-C6H4(PPh2 = N(C6H5))-2}(P{Cp(m-C6H4-SO3Na)2}3)Cl]PF6(3).  All three compds. showed higher toxicity against leukemia cells when compared to normal T-lymphocytes.  Compds. 1 and 2 induced both necrosis and apoptosis, while 3 was mainly apoptotic.  Necrotic cell death induced by 1 and 2 was Bax/Bak- and caspase-independent, while apoptosis induced by 3 was Bax/Bak-dependent.  Reactive oxygen species (ROS) prodn. at the mitochondrial level was a crit. step in the antitumor effect of these compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg8Idbd1OVKrVg90H21EOLACvtfcHk0lgczlGhyOnvtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFymtrfK&md5=45228490d1eb548fa5d749535ab1da12</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2011.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2011.06.004%26sid%3Dliteratum%253Aachs%26aulast%3DVela%26aufirst%3DL.%26aulast%3DContel%26aufirst%3DM.%26aulast%3DPalomera%26aufirst%3DL.%26aulast%3DAzaceta%26aufirst%3DG.%26aulast%3DMarzo%26aufirst%3DI.%26atitle%3DIminophosphorane-organogold%2528III%2529%2520complexes%2520induce%2520cell%2520death%2520through%2520mitochondrial%2520ROS%2520production%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2011%26volume%3D105%26spage%3D1306%26epage%3D1313%26doi%3D10.1016%2Fj.jinorgbio.2011.06.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dean, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grayson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMartino, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furdui, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bierbach, U.</span></span> <span> </span><span class="NLM_article-title">Human serum albumin-delivered [Au(PEt<sub>3</sub>)]<sup>+</sup> is a potent inhibitor of T cell proliferation</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">572</span>– <span class="NLM_lpage">576</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00142</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00142" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmsFWrsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=572-576&author=T.+C.+Deanauthor=M.+Yangauthor=M.+Liuauthor=J.+M.+Graysonauthor=A.+W.+DeMartinoauthor=C.+S.+Dayauthor=J.+Leeauthor=C.+M.+Furduiauthor=U.+Bierbach&title=Human+serum+albumin-delivered+%5BAu%28PEt3%29%5D%2B+is+a+potent+inhibitor+of+T+cell+proliferation&doi=10.1021%2Facsmedchemlett.7b00142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Human serum albumin-delivered [Au(PEt3)]+ is a potent inhibitor of T cell proliferation</span></div><div class="casAuthors">Dean, Tyler C.; Yang, Mu; Liu, Mingyong; Grayson, Jason M.; DeMartino, Anthony W.; Day, Cynthia S.; Lee, Jingyun; Furdui, Cristina M.; Bierbach, Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">572-576</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Using a modular library format in conjunction with cell viability (MTS) and flow cytometry assays, 90 cationic complexes [AuPL]n+ (P = phosphine ligand; L = thiourea deriv. or chloride) were studied for their antiproliferative activity in CD8+ T lymphocyte cells.  The activity of the compds. correlates with the steric bulk of the phosphine ligands.  Thiourea serves as a leaving group that is readily replaced by cysteine thiol (NMR, ESI-MS).  Taking advantage of selective thiourea ligand exchange, the fragments [Au(PEt3)]+ and [Au(JohnPhos)]+ ((JohnPhos = 1,1'-biphenyl-2-yl)di-tert-butylphosphine) in compds. 1 and 2 were transferred to recombinant human serum albumin (rHSA).  PEt3 promoted efficient modification of Cys34 in HSA (HSA-1), whereas use of bulky JohnPhos as a carrier ligand led to serum protein nonspecifically modified with multiple gold adducts (HSA-2) (Ellman's test, ESI-TOF MS).  HSA-1, but not HSA-2, strongly inhibits T cell proliferation at nanomolar doses.  The potential role of HSA as a delivery vehicle in gold-based autoimmune disease treatment is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonxEIYrjLlMLVg90H21EOLACvtfcHk0lgczlGhyOnvtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmsFWrsL8%253D&md5=4dff57b4b7d7d363b3fe7ec578d5269c</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00142%26sid%3Dliteratum%253Aachs%26aulast%3DDean%26aufirst%3DT.%2BC.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DGrayson%26aufirst%3DJ.%2BM.%26aulast%3DDeMartino%26aufirst%3DA.%2BW.%26aulast%3DDay%26aufirst%3DC.%2BS.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DFurdui%26aufirst%3DC.%2BM.%26aulast%3DBierbach%26aufirst%3DU.%26atitle%3DHuman%2520serum%2520albumin-delivered%2520%255BAu%2528PEt3%2529%255D%252B%2520is%2520a%2520potent%2520inhibitor%2520of%2520T%2520cell%2520proliferation%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D572%26epage%3D576%26doi%3D10.1021%2Facsmedchemlett.7b00142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jurgens, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casini, A.</span></span> <span> </span><span class="NLM_article-title">Mechanistic insights into gold organometallic compounds and their biomedical applications</span>. <i>Chimia</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">92</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.2533/chimia.2017.92</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.2533%2Fchimia.2017.92" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=28351454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFektbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2017&pages=92-101&author=S.+Jurgensauthor=A.+Casini&title=Mechanistic+insights+into+gold+organometallic+compounds+and+their+biomedical+applications&doi=10.2533%2Fchimia.2017.92"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic insights into gold organometallic compounds and their biomedical applications</span></div><div class="casAuthors">Jurgens, Sophie; Casini, Angela</div><div class="citationInfo"><span class="NLM_cas:title">Chimia</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">92-101</span>CODEN:
                <span class="NLM_cas:coden">CHIMAD</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Swiss Chemical Society</span>)
        </div><div class="casAbstract">A review.  The application of gold in medicine can be traced back several thousand years and Au(i) compds. have been used in the treatment of rheumatoid arthritis since the last century.  Recently research into gold-based drugs for a no. of human diseases has seen a renaissance due to their markedly different modes of action with respect to the classical platinum chemotherapeutic compds.  Within this research area, organometallic gold complexes have been particularly explored, mainly due to their higher stability in physiol. conditions guaranteed by the presence of a direct Au-C bond.  Thus, a no. of compds. have been tested for their uses as anticancer, antibacterial, antiprotozoal as well as anti-HIV agents.  In this review a selection of the main results obtained on the synthesis, chem. properties and biol. activities of two of the most explored families of organometallics - Au(i) N-heterocyclic carbenes (NHCs) and cyclometalated Au(iii) compds. - are summarized.  Their structure-activity relationships and modes of action at the cellular level are also discussed, which constitute the basis for future drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr44Y1pWKstfrVg90H21EOLACvtfcHk0lgczlGhyOnvtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFektbzJ&md5=89ef4c3fb374c30ba49e1eef629ca826</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.2533%2Fchimia.2017.92&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2533%252Fchimia.2017.92%26sid%3Dliteratum%253Aachs%26aulast%3DJurgens%26aufirst%3DS.%26aulast%3DCasini%26aufirst%3DA.%26atitle%3DMechanistic%2520insights%2520into%2520gold%2520organometallic%2520compounds%2520and%2520their%2520biomedical%2520applications%26jtitle%3DChimia%26date%3D2017%26volume%3D71%26spage%3D92%26epage%3D101%26doi%3D10.2533%2Fchimia.2017.92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1432</span>– <span class="NLM_lpage">1456</span>, <span class="refDoi"> DOI: 10.1039/C5CS00158G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1039%2FC5CS00158G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=26771036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC28XovVKkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=1432-1456&author=Z.+Liuauthor=X.+Chen&title=Simple+bioconjugate+chemistry+serves+great+clinical+advances%3A+albumin+as+a+versatile+platform+for+diagnosis+and+precision+therapy&doi=10.1039%2FC5CS00158G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy</span></div><div class="casAuthors">Liu, Zhibo; Chen, Xiaoyuan</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1432-1456</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Albumin is the most abundant circulating protein in plasma and has recently emerged as a versatile protein carrier for drug targeting and for improving the pharmacokinetic profile of peptide or protein based drugs.  Three drug delivery technologies related to albumin have been developed, which include the coupling of low-mol. wt. drugs to exogenous or endogenous albumin, conjugating bioactive proteins by albumin fusion technol. (AFT), and encapsulation of drugs into albumin nanoparticles.  This review article starts with a brief introduction of human serum albumin (HSA), and then summarizes the mainstream chem. strategies of developing HSA binding mols. for coupling with drug mols.  Moreover, we also concisely condense the recent progress of the most important clin. applications of HSA-binding platforms, and specify the current challenges that need to be met for a bright future of HSA-binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX_KUb4v-V6LVg90H21EOLACvtfcHk0lg_KDCWXNk_RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XovVKkug%253D%253D&md5=6cbd8231b0f3dcdd776d464a835d535e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1039%2FC5CS00158G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5CS00158G%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DSimple%2520bioconjugate%2520chemistry%2520serves%2520great%2520clinical%2520advances%253A%2520albumin%2520as%2520a%2520versatile%2520platform%2520for%2520diagnosis%2520and%2520precision%2520therapy%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2016%26volume%3D45%26spage%3D1432%26epage%3D1456%26doi%3D10.1039%2FC5CS00158G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, X.</span></span> <span> </span><span class="NLM_article-title">Albumin-based nanotheranostic probe with hypoxia alleviating potentiates synchronous multimodal imaging and phototherapy for glioma</span>. <i>ACS Nano</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">6191</span>– <span class="NLM_lpage">6212</span>, <span class="refDoi"> DOI: 10.1021/acsnano.0c02249</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsnano.0c02249" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnslaqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2020&pages=6191-6212&author=Z.+Yangauthor=Y.+Duauthor=Q.+Sunauthor=Y.+Pengauthor=R.+Wangauthor=Y.+Zhouauthor=Y.+Wangauthor=C.+Zhangauthor=X.+Qi&title=Albumin-based+nanotheranostic+probe+with+hypoxia+alleviating+potentiates+synchronous+multimodal+imaging+and+phototherapy+for+glioma&doi=10.1021%2Facsnano.0c02249"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Albumin-Based Nanotheranostic Probe with Hypoxia Alleviating Potentiates Synchronous Multimodal Imaging and Phototherapy for Glioma</span></div><div class="casAuthors">Yang, Zhenzhen; Du, Yitian; Sun, Qi; Peng, Yiwei; Wang, Rudong; Zhou, Yu; Wang, Yuqi; Zhang, Chunli; Qi, Xianrong</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">6191-6212</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Highly infiltrative and invasive glioma cells obscure the boundary between tumor and normal brain tissue, making it extremely difficult to precisely diagnose and completely remove.  The combination of multimodal imaging with effective treatments to diagnose precisely and guide surgery and therapy accurately is desperately needed for glioma in the brain.  Here, we report a biomimetic catalase-integrated-albumin phototheranostic nanoprobe (ICG/<a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="0e4f7b405c4e4c4d405e">[email protected]</a>) to realize multimodal imaging, amplify phototherapy, and guide surgery for glioma after penetrating the blood-brain barrier, accumulating into deep-seated glioma via albumin-binding protein mediated transportation.  The phototheranostic nanoprobe enabled fluorescence, photoacoustic, and IR thermal imaging with desirable detecting depth and high signal-to-background ratio for clearly differentiating brain tumors from surrounding tissues.  Meanwhile, the nanoprobe could effectively induce local hyperthermia and promote the level of singlet oxygen based on alleviated hypoxic glioma microenvironment by decompg. endogenous hydrogen peroxide to oxygen to amplify phototherapy.  Thus, significant inhibition of glioma growth, extended survival time, alleviated tumor hypoxia, improved apoptosis, and antiangiogenesis effects were exhibited in several animal models including the periphery and the brain through i.v. or intratumoral injection, meanwhile with low toxicity to normal tissue.  The phototherapy was also guided by the assistance of external bioluminescence, magnetic resonance, and positron emission tomog. imaging.  Moreover, the nanoprobe could accurately guide the glioma resection.  These results suggest that the phototheranostic nanoprobe is a promising nanoplatform specifically for glioma to achieve multimodal diagnosis, effective phototherapy, and accurate imaging-guided surgery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhf1pd_rRbzLVg90H21EOLACvtfcHk0lg_KDCWXNk_RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnslaqtbk%253D&md5=f4c6e564c95a27d986eb47983564950d</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facsnano.0c02249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsnano.0c02249%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DQi%26aufirst%3DX.%26atitle%3DAlbumin-based%2520nanotheranostic%2520probe%2520with%2520hypoxia%2520alleviating%2520potentiates%2520synchronous%2520multimodal%2520imaging%2520and%2520phototherapy%2520for%2520glioma%26jtitle%3DACS%2520Nano%26date%3D2020%26volume%3D14%26spage%3D6191%26epage%3D6212%26doi%3D10.1021%2Facsnano.0c02249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hyun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyle, L.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeo, Y.</span></span> <span> </span><span class="NLM_article-title">Surface modification of polymer nanoparticles with native albumin for enhancing drug delivery to solid tumors</span>. <i>Biomaterials</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>180</i></span>,  <span class="NLM_fpage">206</span>– <span class="NLM_lpage">224</span>, <span class="refDoi"> DOI: 10.1016/j.biomaterials.2018.07.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1016%2Fj.biomaterials.2018.07.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=30048910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlOitrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2018&pages=206-224&author=H.+Hyunauthor=J.+Parkauthor=K.+Willisauthor=J.-E.+Parkauthor=L.-T.+Lyleauthor=W.+Leeauthor=Y.+Yeo&title=Surface+modification+of+polymer+nanoparticles+with+native+albumin+for+enhancing+drug+delivery+to+solid+tumors&doi=10.1016%2Fj.biomaterials.2018.07.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Surface modification of polymer nanoparticles with native albumin for enhancing drug delivery to solid tumors</span></div><div class="casAuthors">Hyun, Hyesun; Park, Joonyoung; Willis, Kiela; Park, Ji Eun; Lyle, L. Tiffany; Lee, Wooin; Yeo, Yoon</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">206-224</span>CODEN:
                <span class="NLM_cas:coden">BIMADU</span>;
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Albumin is a promising surface modifier of nanoparticulate drug delivery systems.  Serving as a dysopsonin, albumin can protect circulating nanoparticles (NPs) from the recognition and clearance by the mononuclear phagocytic system (MPS).  Albumin may also help transport the NPs to solid tumors based on the increased consumption by cancer cells and interactions with the tumor microenvironment.  Several studies have explored the benefits of surface-bound albumin to enhance NP delivery to tumors.  However, it remains unknown how the surface modification process affects the conformation of albumin and the performance of the albumin-modified NPs.  We use three different surface modification methods including two prevalent approaches (physisorption and interfacial embedding) and a new method based on dopamine polymn. to modify the surface of poly(lactic-co-glycolic acid) NPs with albumin and compare the extent of albumin binding, conformation of the surface-bound albumin, and biol. performances of the albumin-coated NPs.  We find that the dopamine polymn. method preserves the albumin structure, forming a surface layer that facilitates NP transport and drug delivery into tumors via the interaction with albumin-binding proteins.  In contrast, the interfacial embedding method creates NPs with denatured albumin that offers no particular benefit to the interaction with cancer cells but rather promotes the MPS uptake via direct and indirect interactions with scavenger receptor A.  This study demonstrates that the surface-bound albumin can bring distinct effects according to the way they interact with NP surface and thus needs to be controlled in order to achieve favorable therapeutic outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZBVklIhgQBbVg90H21EOLACvtfcHk0lg_KDCWXNk_RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlOitrfL&md5=a0ae5f81fdf22fb2c82c5b7a7336ebff</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2018.07.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2018.07.024%26sid%3Dliteratum%253Aachs%26aulast%3DHyun%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DWillis%26aufirst%3DK.%26aulast%3DPark%26aufirst%3DJ.-E.%26aulast%3DLyle%26aufirst%3DL.-T.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DYeo%26aufirst%3DY.%26atitle%3DSurface%2520modification%2520of%2520polymer%2520nanoparticles%2520with%2520native%2520albumin%2520for%2520enhancing%2520drug%2520delivery%2520to%2520solid%2520tumors%26jtitle%3DBiomaterials%26date%3D2018%26volume%3D180%26spage%3D206%26epage%3D224%26doi%3D10.1016%2Fj.biomaterials.2018.07.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.</span></span> <span> </span><span class="NLM_article-title">Ultrasound-enhanced chemo-photodynamic combination therapy by using albumin “nanoglue”-based nanotheranostics</span>. <i>ACS Nano</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">5560</span>– <span class="NLM_lpage">5569</span>, <span class="refDoi"> DOI: 10.1021/acsnano.9b09827</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsnano.9b09827" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BB3cXotFeht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2020&pages=5560-5569&author=Y.+Zhangauthor=Y.+Wanauthor=Y.+Chenauthor=N.+T.+Blumauthor=J.+Linauthor=P.+Huang&title=Ultrasound-enhanced+chemo-photodynamic+combination+therapy+by+using+albumin+%E2%80%9Cnanoglue%E2%80%9D-based+nanotheranostics&doi=10.1021%2Facsnano.9b09827"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Ultrasound-Enhanced Chemo-Photodynamic Combination Therapy by Using Albumin "Nanoglue"-Based Nanotheranostics</span></div><div class="casAuthors">Zhang, Yifan; Wan, Yilin; Chen, Yantao; Blum, Nicholas Thomas; Lin, Jing; Huang, Peng</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">5560-5569</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The combination of photodynamic therapy (PDT) and chemotherapy is considered to enhance the antitumor immunity and combat multidrug resistance.  Some preclin. studies have reported a pos. therapeutic outcome of using ultrasound (US) irradn. to enhance chemotherapy, but the combination of these three modalities has yet to be investigated.  On the basis of the discovery of a strong affinity between a photosensitizer sinoporphyrin sodium (DVDMS) and human serum albumin (HSA), a clin. used albumin-paclitaxel (HSA-PTX) nanoparticle is utilized as a "nanoglue" to load a large amt. of DVDMS by simple mixing.  The five conformations of HSA and DVDMS with highest affinity were calcd. using AutoDock Vina.  The obtained albumin "nanoglue"-based nanotheranostics, HSA-PTX-DVDMS (HPD), has better fluorescence imaging and PDT performance than free DVDMS, probably due to the reduced quenching of DVDMS after dispersion in albumin.  An efficacious tumor-targeting enhancement of chemotherapy by US irradn. is verified in a bilateral s.c. 4T1 tumors model.  With the aid of US irradn., the combined PDT and chemotherapy mediated by HPD achieve effective tumor growth inhibition.  Overall, this "nanoglue"-based nanotheranostics is composed of several clin. used elements and integrates three clin. modalities with application prospects in clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor-f57Xb7BbbVg90H21EOLACvtfcHk0lgt9-TE6WZKIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXotFeht7g%253D&md5=a0e261f170fa74c4d99af2c8e0d37f5b</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facsnano.9b09827&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsnano.9b09827%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DBlum%26aufirst%3DN.%2BT.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DP.%26atitle%3DUltrasound-enhanced%2520chemo-photodynamic%2520combination%2520therapy%2520by%2520using%2520albumin%2520%25E2%2580%259Cnanoglue%25E2%2580%259D-based%2520nanotheranostics%26jtitle%3DACS%2520Nano%26date%3D2020%26volume%3D14%26spage%3D5560%26epage%3D5569%26doi%3D10.1021%2Facsnano.9b09827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span> <span> </span><span class="NLM_article-title">Blood-brain-barrier-penetrating albumin nanoparticles for biomimetic drug delivery via albumin-binding protein pathways for antiglioma therapy</span>. <i>ACS Nano</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">9999</span>– <span class="NLM_lpage">10012</span>, <span class="refDoi"> DOI: 10.1021/acsnano.6b04268</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsnano.6b04268" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhslykt7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=9999-10012&author=T.+Linauthor=P.+Zhaoauthor=Y.+Jiangauthor=Y.+Tangauthor=H.+Jinauthor=Z.+Panauthor=H.+Heauthor=V.+C.+Yangauthor=Y.+Huang&title=Blood-brain-barrier-penetrating+albumin+nanoparticles+for+biomimetic+drug+delivery+via+albumin-binding+protein+pathways+for+antiglioma+therapy&doi=10.1021%2Facsnano.6b04268"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Blood-Brain-Barrier-Penetrating Albumin Nanoparticles for Biomimetic Drug Delivery via Albumin-Binding Protein Pathways for Antiglioma Therapy</span></div><div class="casAuthors">Lin, Tingting; Zhao, Pengfei; Jiang, Yifan; Tang, Yisi; Jin, Hongyue; Pan, Zhenzhen; He, Huining; Yang, Victor C.; Huang, Yongzhuo</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">9999-10012</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nutrient transporters have been explored for biomimetic delivery targeting the brain.  The albumin-binding proteins (e.g., SPARC and gp60) are overexpressed in many tumors for transport of albumin as an amino acid and an energy source for fast-growing cancer cells.  However, their application in brain delivery has rarely been investigated.  In this work, SPARC and gp60 overexpression was found on glioma and tumor vessel endothelium; therefore, such pathways were explored for use in brain-targeting biomimetic delivery.  We developed a green method for blood-brain barrier (BBB)-penetrating albumin nanoparticle synthesis, with the capacity to coencapsulate different drugs and no need for crosslinkers.  The hydrophobic drugs (i.e., paclitaxel and fenretinide) yield synergistic effects to induce albumin self-assembly, forming dual drug-loaded nanoparticles.  The albumin nanoparticles can penetrate the BBB and target glioma cells via the mechanisms of SPARC- and gp60-mediated biomimetic transport.  Importantly, by modification with the cell-penetrating peptide LMWP, the albumin nanoparticles display enhanced BBB penetration, intratumoral infiltration, and cellular uptake.  The LMWP-modified nanoparticles exhibited improved treatment outcomes in both s.c. and intracranial glioma models, with reduced toxic side effects.  The therapeutic mechanisms were assocd. with induction of apoptosis, antiangiogenesis, and tumor immune microenvironment regulation.  It provides a facile method for dual drug-loaded albumin nanoparticle prepn. and a promising avenue for biomimetic delivery targeting the brain tumor based on combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQCxTZ5nRnwbVg90H21EOLACvtfcHk0lgt9-TE6WZKIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhslykt7fP&md5=e8eac10ffbf7da065000fbd54f524ff9</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facsnano.6b04268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsnano.6b04268%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DV.%2BC.%26aulast%3DHuang%26aufirst%3DY.%26atitle%3DBlood-brain-barrier-penetrating%2520albumin%2520nanoparticles%2520for%2520biomimetic%2520drug%2520delivery%2520via%2520albumin-binding%2520protein%2520pathways%2520for%2520antiglioma%2520therapy%26jtitle%3DACS%2520Nano%26date%3D2016%26volume%3D10%26spage%3D9999%26epage%3D10012%26doi%3D10.1021%2Facsnano.6b04268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarkson, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imberti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadler, P. J.</span></span> <span> </span><span class="NLM_article-title">Nucleus-targeted organoiridium-albumin conjugate for photoactivated cancer therapy</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2350</span>– <span class="NLM_lpage">2354</span>, <span class="refDoi"> DOI: 10.1002/anie.201813002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1002%2Fanie.201813002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVOqsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=2350-2354&author=P.+Zhangauthor=H.+Huangauthor=S.+Banerjeeauthor=G.+J.+Clarksonauthor=C.+Geauthor=C.+Imbertiauthor=P.+J.+Sadler&title=Nucleus-targeted+organoiridium-albumin+conjugate+for+photoactivated+cancer+therapy&doi=10.1002%2Fanie.201813002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleus-Targeted Organoiridium-Albumin Conjugate for Photodynamic Cancer Therapy</span></div><div class="casAuthors">Zhang, Pingyu; Huang, Huaiyi; Banerjee, Samya; Clarkson, Guy J.; Ge, Chen; Imberti, Cinzia; Sadler, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2350-2354</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">An organoiridium-albumin bioconjugate (Ir1-HSA) was synthesized by reaction of a pendant maleimide ligand with human serum albumin.  The phosphorescence of Ir1-HSA was enhanced significantly compared to parent complex Ir1.  The long phosphorescence lifetime and high 1O2 quantum yield of Ir1-HSA are highly favorable properties for photodynamic therapy.  Ir1-HSA mainly accumulated in the nucleus of living cancer cells and showed remarkable photocytotoxicity against a range of cancer cell lines and tumor spheroids (light IC50; 0.8-5 μm, photo-cytotoxicity index PI=40-60), while remaining non-toxic to normal cells and normal cell spheroids, even after photo-irradn.  This nucleus-targeting organoiridium-albumin is a strong candidate photosensitizer for anticancer photodynamic therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjPniNhdl_Z7Vg90H21EOLACvtfcHk0lgt9-TE6WZKIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVOqsr0%253D&md5=c312b9e6e6c55406b61ecacb74a9749d</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Fanie.201813002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201813002%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DBanerjee%26aufirst%3DS.%26aulast%3DClarkson%26aufirst%3DG.%2BJ.%26aulast%3DGe%26aufirst%3DC.%26aulast%3DImberti%26aufirst%3DC.%26aulast%3DSadler%26aufirst%3DP.%2BJ.%26atitle%3DNucleus-targeted%2520organoiridium-albumin%2520conjugate%2520for%2520photoactivated%2520cancer%2520therapy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2019%26volume%3D58%26spage%3D2350%26epage%3D2354%26doi%3D10.1002%2Fanie.201813002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span> <span> </span><span class="NLM_article-title">Albumin carriers for cancer theranostics: a conventional platform with new promise</span>. <i>Adv. Mater.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">10557</span>– <span class="NLM_lpage">10566</span>, <span class="refDoi"> DOI: 10.1002/adma.201600038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1002%2Fadma.201600038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=27111654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC28Xms1Oisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2016&pages=10557-10566&author=Q.+Chenauthor=Z.+Liu&title=Albumin+carriers+for+cancer+theranostics%3A+a+conventional+platform+with+new+promise&doi=10.1002%2Fadma.201600038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Albumin Carriers for Cancer Theranostics: A Conventional Platform with New Promise</span></div><div class="casAuthors">Chen, Qian; Liu, Zhuang</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Materials (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">10557-10566</span>CODEN:
                <span class="NLM_cas:coden">ADVMEW</span>;
        ISSN:<span class="NLM_cas:issn">0935-9648</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Theranostic nanoplatforms with integrated diagnostic and therapeutic functions, aiming at imaging-guided therapy to improve treatment planning, as well as combination therapy to enhance treatment efficacy, have received tremendous attention in recent years.  Among numerous types of functional nanomaterials explored in this field, protein-based nanocarriers with inherent biocompatibility have also been selected as building blocks to construct multifunctional theranostic platforms.  In particular, albumin, which has been extensively used as drug-delivery carriers for decades, has shown great new promise in the construction of novel imaging and therapeutic nanoagents, as demonstrated by a no. of recent studies.  IHere, the motivations of using albumins to build up nanoscale theranostics are discussed, and the latest progress/future perspectives in this direction are summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfL7VOZWFi_rVg90H21EOLACvtfcHk0lj9wWOUPzEq8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xms1Oisr8%253D&md5=b750bf3e31eadade08d159137f9aa55f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2Fadma.201600038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadma.201600038%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DZ.%26atitle%3DAlbumin%2520carriers%2520for%2520cancer%2520theranostics%253A%2520a%2520conventional%2520platform%2520with%2520new%2520promise%26jtitle%3DAdv.%2520Mater.%26date%3D2016%26volume%3D28%26spage%3D10557%26epage%3D10566%26doi%3D10.1002%2Fadma.201600038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J. H.</span></span> <span> </span><span class="NLM_article-title">Self-assemblead PEGylated albumin nanoparticles (SPAN) as a platform for cancer chemotherapy and imaging</span>. <i>Drug Delivery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1570</span>– <span class="NLM_lpage">1578</span>, <span class="refDoi"> DOI: 10.1080/10717544.2018.1489430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1080%2F10717544.2018.1489430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=30044159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlyqsrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=1570-1578&author=J.+E.+Leeauthor=M.+G.+Kimauthor=Y.+L.+Jangauthor=M.+S.+Leeauthor=N.+W.+Kimauthor=Y.+Yinauthor=J.+H.+Leeauthor=S.+Y.+Limauthor=J.+W.+Parkauthor=J.+Kimauthor=D.+S.+Leeauthor=S.+H.+Kimauthor=J.+H.+Jeong&title=Self-assemblead+PEGylated+albumin+nanoparticles+%28SPAN%29+as+a+platform+for+cancer+chemotherapy+and+imaging&doi=10.1080%2F10717544.2018.1489430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Self-assembled PEGylated albumin nanoparticles (SPAN) as a platform for cancer chemotherapy and imaging</span></div><div class="casAuthors">Lee, Jung Eun; Kim, Myung Goo; Jang, Yeon Lim; Lee, Min Sang; Kim, Nak Won; Yin, Yue; Lee, Jong Han; Lim, Su Yeon; Park, Ji Won; Kim, Jaeyun; Lee, Doo Sung; Kim, Sun Hwa; Jeong, Ji Hoon</div><div class="citationInfo"><span class="NLM_cas:title">Drug Delivery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1570-1578</span>CODEN:
                <span class="NLM_cas:coden">DDELEB</span>;
        ISSN:<span class="NLM_cas:issn">1071-7544</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Paclitaxel (PTX) is used as a major antitumor agent for the treatment of recurrent and metastatic breast cancer.  For the clin. application of PTX, it needs to be dissolved in an oil/detergent-based solvent due to its poor soly. in an aq. medium.  However, the formulation often causes undesirable complications including hypersensitivity reactions and limited tumor distribution, resulting in a lower dose-dependent antitumor effect.  Herein, we introduce a facile and oil-free method to prep. albumin-based PTX nanoparticles for efficient systemic cancer therapy using a conjugate of human serum albumin (HSA) and poly(ethyleneglycol) (PEG).  PTX were efficiently incorporated in the self-assembled HSA-PEG nanoparticles (HSA-PEG/PTX) using a simple film casting and re-hydration procedure without addnl. processes such as application of high pressure/shear or chem. crosslinking.  The spherical HSA-PEG nanoparticle with a hydrodynamic diam. of ca. 280 nm mediates efficient cellular delivery, leading to comparable or even higher cytotoxicity in various breast cancer cells than that of the com. available Abraxane..  When systemically administered in a mouse xenograft model for human breast cancer, the HSA-PEG-based nanoparticle formulation exhibited an extended systemic circulation for more than 96 h and enhanced intratumoral accumulation, resulting in a remarkable anticancer effect and prolonged survival of the animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2P_t1NbxhtrVg90H21EOLACvtfcHk0lj9wWOUPzEq8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlyqsrvO&md5=680751a493d4d5f9b3c40f0aeb7f9f7d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1080%2F10717544.2018.1489430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10717544.2018.1489430%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BE.%26aulast%3DKim%26aufirst%3DM.%2BG.%26aulast%3DJang%26aufirst%3DY.%2BL.%26aulast%3DLee%26aufirst%3DM.%2BS.%26aulast%3DKim%26aufirst%3DN.%2BW.%26aulast%3DYin%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DLim%26aufirst%3DS.%2BY.%26aulast%3DPark%26aufirst%3DJ.%2BW.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DD.%2BS.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DJeong%26aufirst%3DJ.%2BH.%26atitle%3DSelf-assemblead%2520PEGylated%2520albumin%2520nanoparticles%2520%2528SPAN%2529%2520as%2520a%2520platform%2520for%2520cancer%2520chemotherapy%2520and%2520imaging%26jtitle%3DDrug%2520Delivery%26date%3D2018%26volume%3D25%26spage%3D1570%26epage%3D1578%26doi%3D10.1080%2F10717544.2018.1489430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span> <span> </span><span class="NLM_article-title">Developing anticancer ferric prodrugs based on the N-Donor residues of human serum albumin carrier IIA subdomain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7497</span>– <span class="NLM_lpage">7511</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00509</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00509" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1SktLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7497-7511&author=J.+Qiauthor=Y.+Gouauthor=Y.+Zhangauthor=K.+Yangauthor=S.+Chenauthor=L.+Liuauthor=X.+Wuauthor=T.+Wangauthor=W.+Zhangauthor=F.+Yang&title=Developing+anticancer+ferric+prodrugs+based+on+the+N-Donor+residues+of+human+serum+albumin+carrier+IIA+subdomain&doi=10.1021%2Facs.jmedchem.6b00509"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Developing Anticancer Ferric Prodrugs Based on the N-Donor Residues of Human Serum Albumin Carrier IIA Subdomain</span></div><div class="casAuthors">Qi, Jinxu; Gou, Yi; Zhang, Yao; Yang, Kun; Chen, Shifang; Liu, Li; Wu, Xiaoyang; Wang, Tao; Zhang, Wei; Yang, Feng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7497-7511</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To improve the selectivity, delivery, and activity of ferric (Fe) anticancer agents, the authors design prodrugs based on N-donor residues of the human serum albumin (HSA) carrier IIA subdomain.  The authors synthesized six Fe(III) compds. derived from 2-hydroxy-1-naphthaldehyde thiosemicarbazone (7-12).  HSA complex structure revealed that Fe compd. binds to the hydrophobic cavity in the HSA IIA subdomain.  Lys199 and His242 of HSA replace the two Cl atoms of Fe compd., coordinating with Fe3+.  In vivo data revealed that compd. 12 and HSA-12 complex inhibit the growth of the liver tumor and that the HSA-12 complex has stronger targeting ability and therapeutic efficacy than compd. 12 alone.  The authors' results showed that compd. 12 and HSA-12 complex induce Bel-7402 cell death possible by several mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgWEKbMYrXyrVg90H21EOLACvtfcHk0lj9wWOUPzEq8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1SktLrM&md5=6b9d962c4272056886c3525f2e7fcd1c</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00509%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DGou%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DF.%26atitle%3DDeveloping%2520anticancer%2520ferric%2520prodrugs%2520based%2520on%2520the%2520N-Donor%2520residues%2520of%2520human%2520serum%2520albumin%2520carrier%2520IIA%2520subdomain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7497%26epage%3D7511%26doi%3D10.1021%2Facs.jmedchem.6b00509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, H.</span></span> <span> </span><span class="NLM_article-title">Novel brain-tumor-inhibiting copper(II) compound based on a human serum albumin (HSA)-cell penetrating peptide conjugate</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">10630</span>– <span class="NLM_lpage">10644</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00939</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00939" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFWgs7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10630-10644&author=Z.+Zhangauthor=P.+Yuauthor=Y.+Gouauthor=J.+Zhangauthor=S.+Liauthor=M.+Caiauthor=H.+Sunauthor=F.+Yangauthor=H.+Liang&title=Novel+brain-tumor-inhibiting+copper%28II%29+compound+based+on+a+human+serum+albumin+%28HSA%29-cell+penetrating+peptide+conjugate&doi=10.1021%2Facs.jmedchem.9b00939"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Brain-Tumor-Inhibiting Copper(II) Compound Based on a Human Serum Albumin (HSA)-Cell Penetrating Peptide Conjugate</span></div><div class="casAuthors">Zhang, Zhenlei; Yu, Ping; Gou, Yi; Zhang, Juzheng; Li, Shanhe; Cai, Meiling; Sun, Hongbin; Yang, Feng; Liang, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10630-10644</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">It is a great challenge to design drugs that penetrate the blood-brain barrier to inhibit brain tumor growth by acting against multiple targets and also improve their delivery efficacy and targeting ability to cancer cells.  To overcome the above problems, the authors designed a multitarget metal agent for treating brain tumors based on an human serum albumin (HSA)-cell penetrating peptide conjugate.  Thus, the authors rationally screened copper (Cu) and 2-acetyl-3-ethylpyrazine thiosemicarbazones to synthesize six compds., and the authors investigated their structure-activity relations and confirmed multiple mechanisms for brain glioma cells.  The HSA-6b complex structure indicated that 6b binds to the IIA subdomain of HSA and His242 replaces the Br ligand in 6b in coordination with Cu2+.  In vivo data suggested that both 6b and the HSA-6b-peptide conjugate penetrate the blood-brain barrier and inhibit brain tumor growth with few side effects.  Also, the HSA-peptide conjugate also improved the delivery efficacy and targeting ability of 6b in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrunalWKT3Kz7Vg90H21EOLACvtfcHk0lir3tIc7MBXhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFWgs7fN&md5=ca872b0555a0b875720b4390d2b64539</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00939&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00939%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DGou%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DCai%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DLiang%26aufirst%3DH.%26atitle%3DNovel%2520brain-tumor-inhibiting%2520copper%2528II%2529%2520compound%2520based%2520on%2520a%2520human%2520serum%2520albumin%2520%2528HSA%2529-cell%2520penetrating%2520peptide%2520conjugate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D10630%26epage%3D10644%26doi%3D10.1021%2Facs.jmedchem.9b00939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajayi, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, H.</span></span> <span> </span><span class="NLM_article-title">Developing anticancer copper(II) prodrugs based on the nature of cancer cells and the human serum albumin carrier IIA subdomain</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">3597</span>– <span class="NLM_lpage">3609</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.5b00314</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.5b00314" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVOnsrbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=3597-3609&author=Y.+Gouauthor=J.+Qiauthor=J.-P.+Ajayiauthor=Y.+Zhangauthor=Z.+Zhouauthor=X.+Wuauthor=F.+Yangauthor=H.+Liang&title=Developing+anticancer+copper%28II%29+prodrugs+based+on+the+nature+of+cancer+cells+and+the+human+serum+albumin+carrier+IIA+subdomain&doi=10.1021%2Facs.molpharmaceut.5b00314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Developing Anticancer Copper(II) Pro-drugs Based on the Nature of Cancer Cells and the Human Serum Albumin Carrier IIA Subdomain</span></div><div class="casAuthors">Gou, Yi; Qi, Jinxu; Ajayi, Joshua-Paul; Zhang, Yao; Zhou, Zuping; Wu, Xiaoyang; Yang, Feng; Liang, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3597-3609</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To synergistically enhance the selectivity and efficiency of anticancer copper drugs, we proposed and built a model to develop anticancer copper pro-drugs based on the nature of human serum albumin (HSA) IIA subdomain and cancer cells.  Three copper(II) compds. of a 2-hydroxy-1-naphthaldehyde benzoyl hydrazone Schiff-base ligand in the presence pyridine, imidazole, or indazole ligands were synthesized (C1-C3).  The structures of three HSA complexes revealed that the Cu compds. bind to the hydrophobic cavity in the HSA IIA subdomain.  Among them, the pyridine and imidazole ligands of C1 and C2 are replaced by Lys199, and His242 directly coordinates with Cu(II).  The indazole and Br ligands of C3 are replaced by Lys199 and His242, resp.  Compared with the Cu(II) compds. alone, the HSA complexes enhance cytotoxicity in MCF-7 cells approx. 3-5-fold, but do not raise cytotoxicity levels in normal cells in vitro through selectively accumulating in cancer cells to some extent.  We find that the HSA complex has a stronger capacity for cell cycle arrest in the G2/M phase of MCF-7 by targeting cyclin-dependent kinase 1 (CDK1) and down-regulating the expression of CDK1 and cyclin B1.  Moreover, the HSA complex promotes MCF-7 cell apoptosis possibly through the intrinsic reactive oxygen species (ROS) mediated mitochondrial pathway, accompanied by the regulation of Bcl-2 family proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQC67vwTNSRLVg90H21EOLACvtfcHk0lir3tIc7MBXhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVOnsrbE&md5=c1977caff60b0d3a7ca3f47ce443c886</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.5b00314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.5b00314%26sid%3Dliteratum%253Aachs%26aulast%3DGou%26aufirst%3DY.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DAjayi%26aufirst%3DJ.-P.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DLiang%26aufirst%3DH.%26atitle%3DDeveloping%2520anticancer%2520copper%2528II%2529%2520prodrugs%2520based%2520on%2520the%2520nature%2520of%2520cancer%2520cells%2520and%2520the%2520human%2520serum%2520albumin%2520carrier%2520IIA%2520subdomain%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2015%26volume%3D12%26spage%3D3597%26epage%3D3609%26doi%3D10.1021%2Facs.molpharmaceut.5b00314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, H.</span></span> <span> </span><span class="NLM_article-title">Developing an anticancer copper(II) prodrug based on the His242 residue of the human serum albumin carrier IIA subdomain</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1501</span>– <span class="NLM_lpage">1507</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.5b00938</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.5b00938" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvVahurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=1501-1507&author=J.+Qiauthor=Y.+Zhangauthor=Y.+Gouauthor=Z.+Zhangauthor=Z.+Zhouauthor=X.+Wuauthor=F.+Yangauthor=H.+Liang&title=Developing+an+anticancer+copper%28II%29+prodrug+based+on+the+His242+residue+of+the+human+serum+albumin+carrier+IIA+subdomain&doi=10.1021%2Facs.molpharmaceut.5b00938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Developing an Anticancer Copper(II) Pro-Drug Based on the His242 Residue of the Human Serum Albumin Carrier IIA Subdomain</span></div><div class="casAuthors">Qi, Jinxu; Zhang, Yao; Gou, Yi; Zhang, Zhenlei; Zhou, Zuping; Wu, Xiaoyang; Yang, Feng; Liang, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1501-1507</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To increase delivery efficiency, anticancer activity, and selectivity of anticancer metal agents in vivo, we proposed to develop the anticancer metal pro-drug based on His242 residue of the human serum albumin (HSA) carrier IIA subdomain.  To confirm our hypothesis, we prepd. two Cu(II) compds. [Cu(P4 mT)Cl and Cu(Bp44 mT)Cl] by modifying Cu(II) compd. ligand structure.  Studies with two HSA complex structures revealed that Cu(P4 mT)Cl bound to the HSA subdomain IIA via hydrophobic interactions, but Cu(Bp44 mT)Cl bound to the HSA subdomain IIA via His242 replacement of a Cl atom of Cu(Bp44 mT)Cl, and a coordination to Cu2+.  Furthermore, Cu(II) compds. released from HSA could be regulated at different pHs.  In vivo data revealed that the HSA-Cu(Bp44 mT) complex increased copper's selectivity and capacity of inhibiting tumor growth compared to Cu(Bp44 mT)Cl alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHVA5oWe9GUbVg90H21EOLACvtfcHk0lir3tIc7MBXhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvVahurg%253D&md5=590fcfb50f0478829e3435277c6e8fd3</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.5b00938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.5b00938%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DGou%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DLiang%26aufirst%3DH.%26atitle%3DDeveloping%2520an%2520anticancer%2520copper%2528II%2529%2520prodrug%2520based%2520on%2520the%2520His242%2520residue%2520of%2520the%2520human%2520serum%2520albumin%2520carrier%2520IIA%2520subdomain%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2016%26volume%3D13%26spage%3D1501%26epage%3D1507%26doi%3D10.1021%2Facs.molpharmaceut.5b00938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Z. W.</span></span> <span> </span><span class="NLM_article-title">Recoding the cancer epigenome by intervening in metabolism and iron homeostasis with mitochondria-targeted rhenium(I) complexes</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">18755</span>– <span class="NLM_lpage">18762</span>, <span class="refDoi"> DOI: 10.1002/anie.202008624</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1002%2Fanie.202008624" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFyht7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2020&pages=18755-18762&author=Z.-Y.+Panauthor=C.+P.+Tanauthor=L.+S.+Raoauthor=H.+Zhangauthor=Y.+Zhengauthor=L.+Haoauthor=L.+N.+Jiauthor=Z.+W.+Mao&title=Recoding+the+cancer+epigenome+by+intervening+in+metabolism+and+iron+homeostasis+with+mitochondria-targeted+rhenium%28I%29+complexes&doi=10.1002%2Fanie.202008624"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Recoding the Cancer Epigenome by Intervening in Metabolism and Iron Homeostasis with Mitochondria-Targeted Rhenium(I) Complexes</span></div><div class="casAuthors">Pan, Zheng-Yin; Tan, Cai-Ping; Rao, Lu-Si; Zhang, Hang; Zheng, Yue; Hao, Liang; Ji, Liang-Nian; Mao, Zong-Wan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">18755-18762</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The development and malignancy of cancer cells are closely related to the changes of the epigenome.  In this work, a mitochondria-targeted rhenium(I) complex (DFX-Re3), integrating the clin. iron chelating agent deferasirox (DFX), has been designed.  By relocating iron to the mitochondria and changing the key metabolic species related to epigenetic modifications, DFX-Re3 can elevate the methylation levels of histone, DNA, and RNA.  As a consequence, DFX-Re3 affects the events related to apoptosis, RNA polymerases, and T-cell receptor signaling pathways.  Finally, it is shown that DFX-Re3 induces immunogenic apoptotic cell death and exhibits potent antitumor activity in vivo.  This study provides a new approach for the design of novel epigenetic drugs that can recode the cancer epigenome by intervening in mitochondrial metab. and iron homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyFrV6Cler2rVg90H21EOLACvtfcHk0lir3tIc7MBXhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFyht7rE&md5=f4117f5ec75828dc97c5885b9f3698f1</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Fanie.202008624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.202008624%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.-Y.%26aulast%3DTan%26aufirst%3DC.%2BP.%26aulast%3DRao%26aufirst%3DL.%2BS.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DHao%26aufirst%3DL.%26aulast%3DJi%26aufirst%3DL.%2BN.%26aulast%3DMao%26aufirst%3DZ.%2BW.%26atitle%3DRecoding%2520the%2520cancer%2520epigenome%2520by%2520intervening%2520in%2520metabolism%2520and%2520iron%2520homeostasis%2520with%2520mitochondria-targeted%2520rhenium%2528I%2529%2520complexes%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2020%26volume%3D59%26spage%3D18755%26epage%3D18762%26doi%3D10.1002%2Fanie.202008624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Z.-W.</span></span> <span> </span><span class="NLM_article-title">CAIXplatins: highly potent platinum(IV) prodrugs selective against carbonic anhydrase IX for the treatment of hypoxic tumors</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">18556</span>– <span class="NLM_lpage">18562</span>, <span class="refDoi"> DOI: 10.1002/anie.202005362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1002%2Fanie.202005362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFyht7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2020&pages=18556-18562&author=Q.+Caoauthor=D.+J.+Zhouauthor=Z.+Y.+Panauthor=G.+G.+Yangauthor=H.+Zhangauthor=L.+N.+Jiauthor=Z.-W.+Mao&title=CAIXplatins%3A+highly+potent+platinum%28IV%29+prodrugs+selective+against+carbonic+anhydrase+IX+for+the+treatment+of+hypoxic+tumors&doi=10.1002%2Fanie.202005362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">CAIXplatins: Highly Potent Platinum(IV) Prodrugs Selective Against Carbonic Anhydrase IX for the Treatment of Hypoxic Tumors</span></div><div class="casAuthors">Cao, Qian; Zhou, Dan-Jie; Pan, Zheng-Yin; Yang, Gang-Gang; Zhang, Hang; Ji, Liang-Nian; Mao, Zong-Wan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">18556-18562</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Hypoxia and the acidic microenvironment play a vital role in tumor metastasis and angiogenesis, generally compromising the chemotherapeutic efficacy.  This provides a tantalizing angle for the design of platinum(IV) prodrugs for the effective and selective killing of solid tumors.  Herein, two carbonic anhydrase IX (CAIX)-targeting platinum(IV) prodrugs have been developed, named as CAIXplatins.  Based on their strong affinity for and inhibition of CAIX, CAIXplatins can not only overcome hypoxia and the acidic microenvironment, but also inhibit metabolic pathways of hypoxic cancer cells, resulting in a significantly enhanced therapeutic effect on hypoxic MDA-MB-231 tumors both in vitro and in vivo compared with cisplatin/oxaliplatin, accompanied with excellent anti-metastasis and anti-angiogenesis activities.  Furthermore, the cancer selectivity indexes of CAIXplatins are 70-90 times higher than those of cisplatin/oxaliplatin with effectively alleviated side-effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8xGTFjuUSd7Vg90H21EOLACvtfcHk0lgUuf7vkZ1RBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFyht7%252FF&md5=f345b238f8a0e15b33e795d24714097a</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2Fanie.202005362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.202005362%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DD.%2BJ.%26aulast%3DPan%26aufirst%3DZ.%2BY.%26aulast%3DYang%26aufirst%3DG.%2BG.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DJi%26aufirst%3DL.%2BN.%26aulast%3DMao%26aufirst%3DZ.-W.%26atitle%3DCAIXplatins%253A%2520highly%2520potent%2520platinum%2528IV%2529%2520prodrugs%2520selective%2520against%2520carbonic%2520anhydrase%2520IX%2520for%2520the%2520treatment%2520of%2520hypoxic%2520tumors%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2020%26volume%3D59%26spage%3D18556%26epage%3D18562%26doi%3D10.1002%2Fanie.202005362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brockman, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skipper, H. E.</span></span> <span> </span><span class="NLM_article-title">Observations on the antileukemic activity of pyridine-2-carboxalde-hyde thiosemicarbazone and thiocarbohydrazone</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1956</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">170</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=13293659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A280%3ADyaG28%252FksF2ntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1956&pages=167-170&author=R.+W.+Brockmanauthor=J.+R.+Thomsonauthor=M.+J.+Bellauthor=H.+E.+Skipper&title=Observations+on+the+antileukemic+activity+of+pyridine-2-carboxalde-hyde+thiosemicarbazone+and+thiocarbohydrazone"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Observations on the antileukemic activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone</span></div><div class="casAuthors">BROCKMAN R W; THOMSON J R; BELL M J; SKIPPER H E</div><div class="citationInfo"><span class="NLM_cas:title">Cancer research</span>
        (<span class="NLM_cas:date">1956</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-70</span>
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRN-1fIG0cy67JzI8owOhpDfW6udTcc2eYkSd7mTV7L37ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaG28%252FksF2ntw%253D%253D&md5=a96d785a0eb92ce711be35fce8f760d1</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrockman%26aufirst%3DR.%2BW.%26aulast%3DThomson%26aufirst%3DJ.%2BR.%26aulast%3DBell%26aufirst%3DM.%2BJ.%26aulast%3DSkipper%26aufirst%3DH.%2BE.%26atitle%3DObservations%2520on%2520the%2520antileukemic%2520activity%2520of%2520pyridine-2-carboxalde-hyde%2520thiosemicarbazone%2520and%2520thiocarbohydrazone%26jtitle%3DCancer%2520Res.%26date%3D1956%26volume%3D16%26spage%3D167%26epage%3D170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stacy, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palanimuthu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhardt, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalinowski, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. R.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships of di-2-pyridylketone, 2-benzoylpyridine, and 2-acetylpyridine thiosemicarbazones for overcoming pgp-mediated drug resistance</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8601</span>– <span class="NLM_lpage">8620</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01050</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01050" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtleiurbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8601-8620&author=A.+E.+Stacyauthor=D.+Palanimuthuauthor=P.+V.+Bernhardtauthor=D.+S.+Kalinowskiauthor=P.+J.+Janssonauthor=D.+R.+Richardson&title=Structure-activity+relationships+of+di-2-pyridylketone%2C+2-benzoylpyridine%2C+and+2-acetylpyridine+thiosemicarbazones+for+overcoming+pgp-mediated+drug+resistance&doi=10.1021%2Facs.jmedchem.6b01050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationships of Di-2-pyridylketone, 2-Benzoylpyridine, and 2-Acetylpyridine Thiosemicarbazones for Overcoming Pgp-Mediated Drug Resistance</span></div><div class="casAuthors">Stacy, Alexandra E.; Palanimuthu, Duraippandi; Bernhardt, Paul V.; Kalinowski, Danuta S.; Jansson, Patric J.; Richardson, Des R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8601-8620</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multidrug resistance (MDR) mediated by P-glycoprotein (Pgp) represents a significant impediment to successful cancer treatment.  The compd., di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT), has been shown to induce greater cytotoxicity against resistant cells than their nonresistant counterparts.  Herein, the structure-activity relationships of selected thiosemicarbazones are explored and the novel mechanism underlying their ability to overcome resistance is further elucidated.  Only thiosemicarbazones with electron-withdrawing substituents at the imine carbon mediated Pgp-dependent potentiated cytotoxicity, which was reversed by Pgp inhibition.  Treatment of resistant cells with these thiosemicarbazones resulted in Pgp-dependent lysosomal membrane permeabilization (LMP) that relied on copper (Cu) chelation, reactive oxygen species generation, and increased relative lipophilicity.  Hence, this study is the first to demonstrate the structural requirements of these thiosemicarbazones necessary to overcome MDR.  We also demonstrate the mechanism that enables the targeting of resistant tumors, whereby thiosemicarbazones "hijack" lysosomal Pgp and form redox-active Cu complexes that mediate LMP and potentiate cytotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoafsFvewets7Vg90H21EOLACvtfcHk0lgUuf7vkZ1RBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtleiurbE&md5=db72435a4eeaa7f0b6035d406253251f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01050%26sid%3Dliteratum%253Aachs%26aulast%3DStacy%26aufirst%3DA.%2BE.%26aulast%3DPalanimuthu%26aufirst%3DD.%26aulast%3DBernhardt%26aufirst%3DP.%2BV.%26aulast%3DKalinowski%26aufirst%3DD.%2BS.%26aulast%3DJansson%26aufirst%3DP.%2BJ.%26aulast%3DRichardson%26aufirst%3DD.%2BR.%26atitle%3DStructure-activity%2520relationships%2520of%2520di-2-pyridylketone%252C%25202-benzoylpyridine%252C%2520and%25202-acetylpyridine%2520thiosemicarbazones%2520for%2520overcoming%2520pgp-mediated%2520drug%2520resistance%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8601%26epage%3D8620%26doi%3D10.1021%2Facs.jmedchem.6b01050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Danial, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korsmeyer, S. J.</span></span> <span> </span><span class="NLM_article-title">Cell death: critical control points</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(04)00046-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1016%2FS0092-8674%2804%2900046-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=14744432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtValsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2004&pages=205-219&author=N.+N.+Danialauthor=S.+J.+Korsmeyer&title=Cell+death%3A+critical+control+points&doi=10.1016%2FS0092-8674%2804%2900046-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Cell death: Critical control points</span></div><div class="casAuthors">Danial, Nika N.; Korsmeyer, Stanley J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">205-219</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review and discussion.  Programmed cell death (apoptosis) is a distinct genetic and biochem. pathway essential to metazoans.  An intact death pathway is required for successful embryonic development and the maintenance of normal tissue homeostasis.  Apoptosis has proven to be tightly interwoven with other essential cell pathways.  The identification of crit. control points in the cell death pathway has yielded fundamental insights for basic biol., as well as provided rational targets for new therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfuRt2EjV6WLVg90H21EOLACvtfcHk0lhc-Kd9XhbgiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtValsrY%253D&md5=de853177ac091305b7f237e58108f579</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900046-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900046-7%26sid%3Dliteratum%253Aachs%26aulast%3DDanial%26aufirst%3DN.%2BN.%26aulast%3DKorsmeyer%26aufirst%3DS.%2BJ.%26atitle%3DCell%2520death%253A%2520critical%2520control%2520points%26jtitle%3DCell%26date%3D2004%26volume%3D116%26spage%3D205%26epage%3D219%26doi%3D10.1016%2FS0092-8674%2804%2900046-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stock, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. E.</span></span> <span> </span><span class="NLM_article-title">Molecular architecture of the rotary motor in ATP synthase</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">1700</span>– <span class="NLM_lpage">1705</span>, <span class="refDoi"> DOI: 10.1126/science.286.5445.1700</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1126%2Fscience.286.5445.1700" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10576729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADyaK1MXnslKntr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=1999&pages=1700-1705&author=D.+Stockauthor=A.+G.+Leslieauthor=J.+E.+Walker&title=Molecular+architecture+of+the+rotary+motor+in+ATP+synthase&doi=10.1126%2Fscience.286.5445.1700"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular architecture of the rotary motor in ATP synthase</span></div><div class="casAuthors">Stock, Daniela; Leslie, Andrew G. W.; Walker, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">5445</span>),
    <span class="NLM_cas:pages">1700-1705</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">ATP synthase contains a rotary motor involved in biol. energy conversion.  Its membrane-embedded F0 sector has a rotation generator fueled by protonmotive force, which provides the energy required for the synthesis of ATP by the F1 domain.  An electron d. map obtained from crystals of a subcomplex of yeast mitochondrial ATP synthase shows a ring of 10 c subunits.  Each c subunit forms an α-helical hairpin.  The interhelical loops of 6-7 of the c subunits are in close contact with the γ and δ subunits of the central stalk.  The extensive contact between the c ring and the stalk suggests that they may rotate as an ensemble during catalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojmVflzjYsVbVg90H21EOLACvtfcHk0lhc-Kd9XhbgiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXnslKntr8%253D&md5=7ba1357b50d872513b7f0c4c3823019a</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1126%2Fscience.286.5445.1700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.286.5445.1700%26sid%3Dliteratum%253Aachs%26aulast%3DStock%26aufirst%3DD.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%26aulast%3DWalker%26aufirst%3DJ.%2BE.%26atitle%3DMolecular%2520architecture%2520of%2520the%2520rotary%2520motor%2520in%2520ATP%2520synthase%26jtitle%3DScience%26date%3D1999%26volume%3D286%26spage%3D1700%26epage%3D1705%26doi%3D10.1126%2Fscience.286.5445.1700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Du, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)00008-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1016%2FS0092-8674%2800%2900008-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10929711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkvFCrsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2000&pages=33-42&author=C.+Duauthor=M.+Fangauthor=Y.+Liauthor=L.+Liauthor=X.+Wang&title=Smac%2C+a+mitochondrial+protein+that+promotes+cytochrome+c-dependent+caspase+activation+by+eliminating+IAP+inhibition&doi=10.1016%2FS0092-8674%2800%2900008-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition</span></div><div class="casAuthors">Du, Chunying; Fang, Min; Li, Yucheng; Li, Lily; Wang, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-42</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We report here the identification of a novel protein, Smac, which promotes caspase activation in the cytochrome c/Apaf-1/caspase-9 pathway.  Smac promotes caspase-9 activation by binding to inhibitor of apoptosis proteins, IAPs, and removing their inhibitory activity.  Smac is normally a mitochondrial protein but is released into the cytosol when cells undergo apoptosis.  Mitochondrial import and cleavage of its signal peptide are required for Smac to gain its apoptotic activity.  Overexpression of Smac increases cells' sensitivity to apoptotic stimuli.  Smac is the second mitochondrial protein, along with cytochrome c, that promotes apoptosis by activating caspases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEUyaGmAsnprVg90H21EOLACvtfcHk0lhc-Kd9XhbgiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkvFCrsbc%253D&md5=8321d44bed77ff7c2da398e1b02f9e20</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2900008-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252900008-8%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DC.%26aulast%3DFang%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DSmac%252C%2520a%2520mitochondrial%2520protein%2520that%2520promotes%2520cytochrome%2520c-dependent%2520caspase%2520activation%2520by%2520eliminating%2520IAP%2520inhibition%26jtitle%3DCell%26date%3D2000%26volume%3D102%26spage%3D33%26epage%3D42%26doi%3D10.1016%2FS0092-8674%2800%2900008-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shiozaki, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span> <span> </span><span class="NLM_article-title">Caspases, IAPs and Smac/DIABLO: mechanisms from structural biology</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">494</span>, <span class="refDoi"> DOI: 10.1016/j.tibs.2004.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1016%2Fj.tibs.2004.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=15337122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntFCjtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2004&pages=486-494&author=E.+N.+Shiozakiauthor=Y.+Shi&title=Caspases%2C+IAPs+and+Smac%2FDIABLO%3A+mechanisms+from+structural+biology&doi=10.1016%2Fj.tibs.2004.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Caspases, IAPs and Smac/DIABLO: mechanisms from structural biology</span></div><div class="casAuthors">Shiozaki, Eric N.; Shi, Yigong</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">486-494</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review and discussion.  Caspases are the central component of the apoptotic machinery that irreversibly commits a cell to die.  Whereas all caspases are structurally similar, those involved in apoptosis can be categorized functionally as either initiator or effector caspases, which are activated by distinct mechanisms.  The activated caspases are subject to inhibition by the inhibitor of apoptosis family of proteins (IAPs).  This inhibition can be removed by Smac/DIABLO during apoptosis.  The underlying mol. mechanisms of caspase regulation are discussed here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoit3MLouSJVbVg90H21EOLACvtfcHk0lhc-Kd9XhbgiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntFCjtrs%253D&md5=c077897ad493facfdea3e061a169d810</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2004.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2004.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DShiozaki%26aufirst%3DE.%2BN.%26aulast%3DShi%26aufirst%3DY.%26atitle%3DCaspases%252C%2520IAPs%2520and%2520Smac%252FDIABLO%253A%2520mechanisms%2520from%2520structural%2520biology%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2004%26volume%3D29%26spage%3D486%26epage%3D494%26doi%3D10.1016%2Fj.tibs.2004.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verhagen, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekert, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pakusch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritz, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaux, D. L.</span></span> <span> </span><span class="NLM_article-title">Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)00009-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1016%2FS0092-8674%2800%2900009-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10929712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkvFCrtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2000&pages=43-53&author=A.+M.+Verhagenauthor=P.+G.+Ekertauthor=M.+Pakuschauthor=J.+Silkeauthor=L.+M.+Connollyauthor=G.+E.+Reidauthor=R.+L.+Moritzauthor=R.+J.+Simpsonauthor=D.+L.+Vaux&title=Identification+of+DIABLO%2C+a+mammalian+protein+that+promotes+apoptosis+by+binding+to+and+antagonizing+IAP+proteins&doi=10.1016%2FS0092-8674%2800%2900009-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins</span></div><div class="casAuthors">Verhagen, Anne M.; Ekert, Paul G.; Pakusch, Miha; Silke, John; Connolly, Lisa M.; Reid, Gavin E.; Moritz, Robert L.; Simpson, Richard J.; Vaux, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-53</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">To identify proteins that bind mammalian IAP homolog A (MIHA, also known as XIAP), we used coimmunopptn. and 2D immobilized pH gradient/SDS-PAGE, followed by electrospray ionization tandem mass spectrometry.  DIABLO (direct IAP binding protein with low pI) is a novel protein that can bind MIHA and can also interact with MIHB and MIHC and the baculoviral IAP, OpIAP.  The N-terminally processed, IAP-interacting form of DIABLO is concd. in membrane fractions in healthy cells but released into the MIHA-contg. cytosolic fractions upon UV irradn.  As transfection of cells with DIABLO was able to counter the protection afforded by MIHA against UV irradn., DIABLO may promote apoptosis by binding to IAPs and preventing them from inhibiting caspases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6-TYWHjxeE7Vg90H21EOLACvtfcHk0lgUQZh6qOkUwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkvFCrtr4%253D&md5=475519bd43e9d625b06b0293895d9693</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2900009-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252900009-X%26sid%3Dliteratum%253Aachs%26aulast%3DVerhagen%26aufirst%3DA.%2BM.%26aulast%3DEkert%26aufirst%3DP.%2BG.%26aulast%3DPakusch%26aufirst%3DM.%26aulast%3DSilke%26aufirst%3DJ.%26aulast%3DConnolly%26aufirst%3DL.%2BM.%26aulast%3DReid%26aufirst%3DG.%2BE.%26aulast%3DMoritz%26aufirst%3DR.%2BL.%26aulast%3DSimpson%26aufirst%3DR.%2BJ.%26aulast%3DVaux%26aufirst%3DD.%2BL.%26atitle%3DIdentification%2520of%2520DIABLO%252C%2520a%2520mammalian%2520protein%2520that%2520promotes%2520apoptosis%2520by%2520binding%2520to%2520and%2520antagonizing%2520IAP%2520proteins%26jtitle%3DCell%26date%3D2000%26volume%3D102%26spage%3D43%26epage%3D53%26doi%3D10.1016%2FS0092-8674%2800%2900009-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myszka, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span> <span> </span><span class="NLM_article-title">Requirement of both the second and third BIR domains for the relief of X-linked inhibitor of apoptosis protein (XIAP)-mediated caspase inhibition by Smac</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">49517</span>– <span class="NLM_lpage">49522</span>, <span class="refDoi"> DOI: 10.1074/jbc.M310061200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1074%2Fjbc.M310061200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=14512414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptlGrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=49517-49522&author=Y.+Huangauthor=R.+L.+Richauthor=D.+G.+Myszkaauthor=H.+Wu&title=Requirement+of+both+the+second+and+third+BIR+domains+for+the+relief+of+X-linked+inhibitor+of+apoptosis+protein+%28XIAP%29-mediated+caspase+inhibition+by+Smac&doi=10.1074%2Fjbc.M310061200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement of Both the Second and Third BIR Domains for the Relief of X-linked Inhibitor of Apoptosis Protein (XIAP)-mediated Caspase Inhibition by Smac</span></div><div class="casAuthors">Huang, Yihua; Rich, Rebecca L.; Myszka, David G.; Wu, Hao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">49517-49522</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The inhibitor of apoptosis proteins (IAP) are endogenous caspase inhibitors in the metazoan and characterized by the presence of baculoviral IAP repeats (BIR).  X-linked IAP (XIAP) contains three BIR domains and directly inhibits effector caspases such as caspase-7 via a linker BIR2 fragment and initiator caspases such as caspase-9 via the BIR3 domain.  A mitochondrial protein Smac/DIABLO, which is released during apoptosis, antagonizes XIAP-mediated caspase inhibition by interacting directly with XIAP.  Here, using glutathione S-transferase pulldown and caspase activity assay, we show that Smac is ineffective in relieving either caspase-7 or caspase-9 inhibition by XIAP domain fragments.  In addn., Smac forms a ternary complex with caspase-7 and linker BIR2, suggesting that Smac/linker BIR2 interaction does not sterically exclude linker BIR2/caspase-7 interaction.  However, Smac is effective in removing caspase-7 and caspase-9 inhibition by XIAP fragments contg. both the BIR2 and BIR3 domains.  Surface plasmon resonance measurements show that Smac interacts with the BIR2 or BIR3 domain in micromolar dissocn. consts.  On the other hand, Smac interacts with an XIAP construct contg. both BIR2 and BIR3 domains in a subnanomolar dissocn. const. by the simultaneous interaction of the Smac dimer with the BIR2 and BIR3 domains of a single XIAP mol.  This 2:1 Smac/XIAP interaction not only possesses enhanced affinity but also sterically excludes XIAP/caspase-7 interaction, demonstrating the requirement of both BIR2 and BIR3 domains for Smac to relieve XIAP-mediated caspase inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlkdgJwimDMLVg90H21EOLACvtfcHk0lgUQZh6qOkUwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptlGrtL8%253D&md5=10937a5499d990c1237753ed28cb9509</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M310061200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M310061200%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DRich%26aufirst%3DR.%2BL.%26aulast%3DMyszka%26aufirst%3DD.%2BG.%26aulast%3DWu%26aufirst%3DH.%26atitle%3DRequirement%2520of%2520both%2520the%2520second%2520and%2520third%2520BIR%2520domains%2520for%2520the%2520relief%2520of%2520X-linked%2520inhibitor%2520of%2520apoptosis%2520protein%2520%2528XIAP%2529-mediated%2520caspase%2520inhibition%2520by%2520Smac%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D49517%26epage%3D49522%26doi%3D10.1074%2Fjbc.M310061200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olejniczak, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meadows, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betz, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oost, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fesik, S. W.</span></span> <span> </span><span class="NLM_article-title">Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>408</i></span>,  <span class="NLM_fpage">1004</span>– <span class="NLM_lpage">1008</span>, <span class="refDoi"> DOI: 10.1038/35050006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1038%2F35050006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=11140637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhslaiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=408&publication_year=2000&pages=1004-1008&author=Z.+Liuauthor=C.+Sunauthor=E.+T.+Olejniczakauthor=R.+P.+Meadowsauthor=S.+F.+Betzauthor=T.+Oostauthor=J.+Herrmannauthor=J.+C.+Wuauthor=S.+W.+Fesik&title=Structural+basis+for+binding+of+Smac%2FDIABLO+to+the+XIAP+BIR3+domain&doi=10.1038%2F35050006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain</span></div><div class="casAuthors">Liu, Zhlhong; Sun, Chaohong; Olejniczak, Edward T.; Meadows, Robert P.; Betz, Stephen F.; Oost, Thorsten; Hemnann, Julia; Wu, Joe C.; Feslk, Stephen W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">408</span>
        (<span class="NLM_cas:issue">6815</span>),
    <span class="NLM_cas:pages">1004-1008</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The inhibitor-of-apoptosis proteins (IAPs) regulate programmed cell death by inhibiting members of the caspase family of enzymes.  Recently, a mammalian protein called Smac (also named DIABLO) was identified that binds to the LAPs and promotes caspase activation.  Although undefined in the x-ray structure, the amino-terminal residues of Smac are crit. for its function.  To understand the structural basis for mol. recognition between Smac and the IAPs, we detd. the soln. structure of the BIR3 domain of X-linked IAP (XIAP) complexed with a functionally active nine-residue peptide derived from the N terminus of Smac.  The peptide binds across the third β-strand of the BIR3 domain in an extended conformation with only the first four residues contacting the protein.  The complex is stabilized by four intermol. hydrogen bonds, an electrostatic interaction involving the N terminus of the peptide, and several hydrophobic interactions.  This structural information, along with the binding data from BIR3 and Smac peptide mutants reported here, should aid in the design of small mols. that may be used for the treatment of cancers that overexpress IAPs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM4pZbM96xmrVg90H21EOLACvtfcHk0lgUQZh6qOkUwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhslaiug%253D%253D&md5=d81bd94ecd9cf9c11d96ee228ff371aa</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2F35050006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35050006%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DOlejniczak%26aufirst%3DE.%2BT.%26aulast%3DMeadows%26aufirst%3DR.%2BP.%26aulast%3DBetz%26aufirst%3DS.%2BF.%26aulast%3DOost%26aufirst%3DT.%26aulast%3DHerrmann%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DJ.%2BC.%26aulast%3DFesik%26aufirst%3DS.%2BW.%26atitle%3DStructural%2520basis%2520for%2520binding%2520of%2520Smac%252FDIABLO%2520to%2520the%2520XIAP%2520BIR3%2520domain%26jtitle%3DNature%26date%3D2000%26volume%3D408%26spage%3D1004%26epage%3D1008%26doi%3D10.1038%2F35050006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suber, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span> <span> </span><span class="NLM_article-title">Structural basis of IAP recognition by Smac/DIABLO</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>408</i></span>,  <span class="NLM_fpage">1008</span>– <span class="NLM_lpage">1012</span>, <span class="refDoi"> DOI: 10.1038/35050012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1038%2F35050012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=11140638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhslahsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=408&publication_year=2000&pages=1008-1012&author=G.+Wuauthor=J.+Chaiauthor=T.+L.+Suberauthor=J.+W.+Wuauthor=C.+Duauthor=X.+Wangauthor=Y.+Shi&title=Structural+basis+of+IAP+recognition+by+Smac%2FDIABLO&doi=10.1038%2F35050012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of IAP recognition by Smac/DIABLO</span></div><div class="casAuthors">Wu, Geng; Chai, Jijie; Suber, Tomeka L.; Wu, Jia-Wel; Du, Chunying; Wang, Xiaodong; Shi, Yigong</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">408</span>
        (<span class="NLM_cas:issue">6815</span>),
    <span class="NLM_cas:pages">1008-1012</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Apoptosis is an essential process in the development and homeostasis of all metazoans.  The inhibitor-of-apoptosis (IAP) proteins suppress cell death by inhibiting the activity of caspases; this inhibition is performed by the zinc-binding BIR domains of the IAP proteins.  The mitochondrial protein Smac/DIABLO promotes apoptosis by eliminating the inhibitory effect of IAPs through phys. interactions.  Amino-terminal sequences in Smac/DIABLO are required for this function, as mutation of the very first amino acid leads to loss of interaction with LAPs and concomitant loss of Smac/DIABLO function.  Here we report the high-resoln. crystal structure of Smac/DIABLO complexed with the third BIR domain (BIR3) of XIAP.  Our results show that the N-terminal four residues (Ala-Val-Pro-Ile) in Smac/DIABLO recognize a surface groove on BIR3, with the first residue Ala binding a hydrophobic pocket and making five hydrogen bonds to neighboring residues on BIR3.  These observations provide a structural explanation for the roles of the Smac N terminus as well as the conserved N-terminal sequences in the Drosophila proteins Hid/Grim/Reaper.  In conjunction with other observations, our results reveal how Smac may relieve IAP inhibition of caspase-9 activity.  In addn. to explaining a no. of biol. observations, our structural anal. identifies potential targets for drug screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV3qy8uKazsrVg90H21EOLACvtfcHk0lgdBVrO-2Om8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhslahsQ%253D%253D&md5=fab609edfb1833053eeb78dd2d4ed536</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2F35050012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35050012%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DG.%26aulast%3DChai%26aufirst%3DJ.%26aulast%3DSuber%26aufirst%3DT.%2BL.%26aulast%3DWu%26aufirst%3DJ.%2BW.%26aulast%3DDu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26atitle%3DStructural%2520basis%2520of%2520IAP%2520recognition%2520by%2520Smac%252FDIABLO%26jtitle%3DNature%26date%3D2000%26volume%3D408%26spage%3D1008%26epage%3D1012%26doi%3D10.1038%2F35050012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Potent and selective small-molecule inhibitors of cIAP1/2 proteins reveal that the binding of smac mimetics to XIAP BIR3 is not required for their effective induction of cell death in tumor cells</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">994</span>– <span class="NLM_lpage">1002</span>, <span class="refDoi"> DOI: 10.1021/cb400889a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb400889a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC2cXit1yls74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=994-1002&author=H.+Sunauthor=J.+Luauthor=L.+Liuauthor=C.+Y.+Yangauthor=S.+Wang&title=Potent+and+selective+small-molecule+inhibitors+of+cIAP1%2F2+proteins+reveal+that+the+binding+of+smac+mimetics+to+XIAP+BIR3+is+not+required+for+their+effective+induction+of+cell+death+in+tumor+cells&doi=10.1021%2Fcb400889a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and Selective Small-Molecule Inhibitors of cIAP1/2 Proteins Reveal That the Binding of Smac Mimetics to XIAP BIR3 Is Not Required for Their Effective Induction of Cell Death in Tumor Cells</span></div><div class="casAuthors">Sun, Haiying; Lu, Jianfeng; Liu, Liu; Yang, Chao-Yie; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">994-1002</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cellular inhibitor of apoptosis protein 1 and 2 (cIAP1/2) and X-linked inhibitor of apoptosis protein (XIAP) are key apoptosis regulators and promising new cancer therapeutic targets.  This study describes a set of non-peptide, small-mol. Smac (second mitochondria-derived activator of caspases) mimetics that are selective inhibitors of cIAP1/2 over XIAP.  The most potent and most selective compds. bind to cIAP1/2 with affinities in the low nanomolar range and show >1,000-fold selectivity for cIAP1 over XIAP.  These selective cIAP inhibitors effectively induce degrdn. of the cIAP1 protein in cancer cells at low nanomolar concns. and do not antagonize XIAP in a cell-free functional assay.  They potently inhibit cell growth and effectively induce apoptosis at low nanomolar concns. in cancer cells with a mechanism of action similar to that of other known Smac mimetics.  Our study shows that binding of Smac mimetics to XIAP BIR3 is not required for effective induction of apoptosis in tumor cells by Smac mimetics.  These potent and highly selective cIAP1/2 inhibitors are powerful tools in the investigation of the role of these IAP proteins in the regulation of apoptosis and other cellular processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVFuPpODQgO7Vg90H21EOLACvtfcHk0lgdBVrO-2Om8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXit1yls74%253D&md5=c0aadbda28ed4e14aa31b58cb995b8af</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fcb400889a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb400889a%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DPotent%2520and%2520selective%2520small-molecule%2520inhibitors%2520of%2520cIAP1%252F2%2520proteins%2520reveal%2520that%2520the%2520binding%2520of%2520smac%2520mimetics%2520to%2520XIAP%2520BIR3%2520is%2520not%2520required%2520for%2520their%2520effective%2520induction%2520of%2520cell%2520death%2520in%2520tumor%2520cells%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D994%26epage%3D1002%26doi%3D10.1021%2Fcb400889a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, B. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. W.</span></span> <span> </span><span class="NLM_article-title">Macrophage diversity enhances tumor progression and metastasis</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2010.03.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1016%2Fj.cell.2010.03.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=20371344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsVSgtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2010&pages=39-51&author=B.+Z.+Qianauthor=J.+W.+Pollard&title=Macrophage+diversity+enhances+tumor+progression+and+metastasis&doi=10.1016%2Fj.cell.2010.03.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Macrophage diversity enhances tumor progression and metastasis</span></div><div class="casAuthors">Qian, Bin-Zhi; Pollard, Jeffrey W.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-51</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  There is persuasive clin. and exptl. evidence that macrophages promote cancer initiation and malignant progression.  During tumor initiation, they create an inflammatory environment that is mutagenic and promotes growth.  As tumors progress to malignancy, macrophages stimulate angiogenesis, enhance tumor cell migration and invasion, and suppress antitumor immunity.  At metastatic sites, macrophages prep. the target tissue for arrival of tumor cells, and then a different subpopulation of macrophages promotes tumor cell extravasation, survival, and subsequent growth.  Specialized subpopulations of macrophages may represent important new therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlTr5UED5Br7Vg90H21EOLACvtfcHk0lgdBVrO-2Om8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsVSgtLc%253D&md5=2d71fd59e10a43120dca111cb216302e</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2010.03.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2010.03.014%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DB.%2BZ.%26aulast%3DPollard%26aufirst%3DJ.%2BW.%26atitle%3DMacrophage%2520diversity%2520enhances%2520tumor%2520progression%2520and%2520metastasis%26jtitle%3DCell%26date%3D2010%26volume%3D141%26spage%3D39%26epage%3D51%26doi%3D10.1016%2Fj.cell.2010.03.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fransen, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melief, C. J.</span></span> <span> </span><span class="NLM_article-title">Local targets for immune therapy to cancer: tumor draining lymph nodes and tumor microenvironment</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">1971</span>– <span class="NLM_lpage">1976</span>, <span class="refDoi"> DOI: 10.1002/ijc.27755</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1002%2Fijc.27755" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=22858832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1SktLbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2013&pages=1971-1976&author=M.+F.+Fransenauthor=R.+Arensauthor=C.+J.+Melief&title=Local+targets+for+immune+therapy+to+cancer%3A+tumor+draining+lymph+nodes+and+tumor+microenvironment&doi=10.1002%2Fijc.27755"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Local targets for immune therapy to cancer: Tumor draining lymph nodes and tumor microenvironment</span></div><div class="casAuthors">Fransen, Marieke F.; Arens, Ramon; Melief, Cornelis J. M.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1971-1976</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  In recent years, it has become apparent that immunoregulatory processes influence cancer development.  The key players in tumor progression are mainly present in the microenvironment of the tumor and the draining lymph nodes.  Interventions aimed at shifting tumor-promoting actions toward effective tumor-eradicating immunity are thus foremost required locally.  As immune-modulating therapy has been shown to cause many adverse side effects when administered systemically, we strongly advocate the further development of local treatment for cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9uvNpxlgLd7Vg90H21EOLACvtfcHk0lgdBVrO-2Om8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1SktLbL&md5=706be587c23fe0326fd48bb5878b002a</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2Fijc.27755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.27755%26sid%3Dliteratum%253Aachs%26aulast%3DFransen%26aufirst%3DM.%2BF.%26aulast%3DArens%26aufirst%3DR.%26aulast%3DMelief%26aufirst%3DC.%2BJ.%26atitle%3DLocal%2520targets%2520for%2520immune%2520therapy%2520to%2520cancer%253A%2520tumor%2520draining%2520lymph%2520nodes%2520and%2520tumor%2520microenvironment%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2013%26volume%3D132%26spage%3D1971%26epage%3D1976%26doi%3D10.1002%2Fijc.27755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakaoka, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaoka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikada, Y.</span></span> <span> </span><span class="NLM_article-title">Prolongation of theplasma half-life period of superoxide dismutase by poly(ethylene glycol) modification</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">261</span>, <span class="refDoi"> DOI: 10.1016/S0168-3659(96)01605-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1016%2FS0168-3659%2896%2901605-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADyaK2sXhtlyhsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=1997&pages=253-261&author=R.+Nakaokaauthor=Y.+Tabataauthor=T.+Yamaokaauthor=Y.+Ikada&title=Prolongation+of+theplasma+half-life+period+of+superoxide+dismutase+by+poly%28ethylene+glycol%29+modification&doi=10.1016%2FS0168-3659%2896%2901605-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Prolongation of the serum half-life period of superoxide dismutase by poly(ethylene glycol) modification</span></div><div class="casAuthors">Nakaoka, Ryusuke; Tabata, Yasuhiko; Yamaoka, Tetsuji; Ikada, Yoshito</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">253-261</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Superoxide dismutase (SOD) was chem. modified using PEG with different mol. wts. to prep. PEG-SOD conjugates with different extents of modification.  The body distribution of the conjugates i.v. injected to mice was investigated to assess the influence of modification on the serum half-life period of SOD.  The SOD modification with PEG was effective in lowering the elimination rate of SOD from the blood circulation without any change in the distribution pattern of organs other than the kidney.  The mol. wt. of PEG used for modification and the modification extent have a min. effect on the half-life of the SOD.  The half-life of the SOD and its PEG conjugates have a similar dependency on the apparent mol. wt. as the PEG mols.  This indicates that the half-life of SOD and the PEG conjugates are mainly detd. by their mol. size.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0QwXLr5fw9bVg90H21EOLACvtfcHk0ljGJs1T7IHo9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhtlyhsbk%253D&md5=b9fce58df8d23005a111b309cfc97e65</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2FS0168-3659%2896%2901605-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0168-3659%252896%252901605-7%26sid%3Dliteratum%253Aachs%26aulast%3DNakaoka%26aufirst%3DR.%26aulast%3DTabata%26aufirst%3DY.%26aulast%3DYamaoka%26aufirst%3DT.%26aulast%3DIkada%26aufirst%3DY.%26atitle%3DProlongation%2520of%2520theplasma%2520half-life%2520period%2520of%2520superoxide%2520dismutase%2520by%2520poly%2528ethylene%2520glycol%2529%2520modification%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D1997%26volume%3D46%26spage%3D253%26epage%3D261%26doi%3D10.1016%2FS0168-3659%2896%2901605-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moghimi, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muir, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illum, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, S. S.</span></span> <span> </span><span class="NLM_article-title">Non-phagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>177</i></span>,  <span class="NLM_fpage">861</span>– <span class="NLM_lpage">866</span>, <span class="refDoi"> DOI: 10.1016/0006-291X(91)91869-E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=10.1016%2F0006-291X%2891%2991869-E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=2049107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADyaK3MXksFOjt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=1991&pages=861-866&author=S.+M.+Moghimiauthor=C.+J.+Porterauthor=I.+S.+Muirauthor=L.+Illumauthor=S.+S.+Davis&title=Non-phagocytic+uptake+of+intravenously+injected+microspheres+in+rat+spleen%3A+influence+of+particle+size+and+hydrophilic+coating&doi=10.1016%2F0006-291X%2891%2991869-E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Non-phagocytic uptake of intravenously injected microspheres in rat spleen:  influence of particle size and hydrophilic coating</span></div><div class="casAuthors">Moghimi, S. M.; Porter, C. J. H.; Muir, I. S.; Illum, L.; Davis, S. S.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">861-6</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    </div><div class="casAbstract">A recent development in prolonging the circulation time of drug carriers, such as liposomes and microspheres, has been to minimize their removal by macrophages of the reticuloendothelial system by covering their surface with hydrophilic polymers such as poloxamers, poloxamines and polyethylene glycols.  It was demonstrated that this strategy may not necessarily prolong the circulatory half-life of drug carriers in all animal models.  In rats, as opposed to rabbits, a nonphagocytic mechanism in the spleen may be triggered to remove efficiently from the blood drug carriers coated with hydrophilic coatings.  Both the size of particle and its hydrophilic coating may act synergistically to trigger this non-phagocytic mechanism.  In rats, a remarkable log to log relation between particle size and spleen uptake was obsd. for both uncoated and polymeric coated microspheres.  The potential implication of these observations in site-specific delivery of drug carriers is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvej2zQqn3VbVg90H21EOLACvtfcHk0ljGJs1T7IHo9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXksFOjt7w%253D&md5=586dd854c9b08fe3ab5e5325ce7db290</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2F0006-291X%2891%2991869-E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-291X%252891%252991869-E%26sid%3Dliteratum%253Aachs%26aulast%3DMoghimi%26aufirst%3DS.%2BM.%26aulast%3DPorter%26aufirst%3DC.%2BJ.%26aulast%3DMuir%26aufirst%3DI.%2BS.%26aulast%3DIllum%26aufirst%3DL.%26aulast%3DDavis%26aufirst%3DS.%2BS.%26atitle%3DNon-phagocytic%2520uptake%2520of%2520intravenously%2520injected%2520microspheres%2520in%2520rat%2520spleen%253A%2520influence%2520of%2520particle%2520size%2520and%2520hydrophilic%2520coating%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1991%26volume%3D177%26spage%3D861%26epage%3D866%26doi%3D10.1016%2F0006-291X%2891%2991869-E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moghimi, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. C.</span></span> <span> </span><span class="NLM_article-title">Long-circulating and target-specific nanoparticles: theory to practice</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">283</span>– <span class="NLM_lpage">318</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=11356986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkt1Gnurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2001&pages=283-318&author=S.+M.+Moghimiauthor=A.+C.+Hunterauthor=J.+C.+Murray&title=Long-circulating+and+target-specific+nanoparticles%3A+theory+to+practice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Long-circulating and target-specific nanoparticles: Theory to practice</span></div><div class="casAuthors">Moghimi, S. Moein; Hunter, A. Christy; Murray, J. Clifford</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">283-318</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review with refs.  The rapid recognition of i.v. injected colloidal carriers, such as liposomes and polymeric nanospheres from the blood by Kupffer cells, has initiated a surge of development for "Kupffer cell-evading" or long-circulating particles.  Such carriers have applications in vascular drug delivery and release, site-specific targeting (passive as well as active targeting), as well as transfusion medicine.  In this article, we have critically reviewed and assessed the rational approaches in the design as well as the biol. performance of such constructs.  For engineering and design of long-circulating carriers, we have taken a lead from nature.  Here, we have explored the surface mechanisms, which affords red blood cells long-circulatory lives and the ability of specific microorganisms to evade macrophage recognition.  Our anal. is then centered where such strategies have been translated and fabricated to design a wide range of particulate carriers (e.g., nanospheres, liposomes, micelles, oil-in-water emulsions) with prolonged circulation and/or target specificity.  With regard to the targeting issues, attention is particularly focused on the importance of physiol. barriers and disease states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMLAfVpWVgl7Vg90H21EOLACvtfcHk0ljGJs1T7IHo9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkt1Gnurc%253D&md5=88ac5651465c777f2e492237328d0b36</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoghimi%26aufirst%3DS.%2BM.%26aulast%3DHunter%26aufirst%3DA.%2BC.%26aulast%3DMurray%26aufirst%3DJ.%2BC.%26atitle%3DLong-circulating%2520and%2520target-specific%2520nanoparticles%253A%2520theory%2520to%2520practice%26jtitle%3DPharmacol.%2520Rev.%26date%3D2001%26volume%3D53%26spage%3D283%26epage%3D318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bormio
Nunes, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathuber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pósa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enyedy, É. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keppler, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffeter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowol, C. R.</span></span> <span> </span><span class="NLM_article-title">Cancer cell resistance against the clinically investigated thiosemicarbazone COTI-2 is based on formation of intracellular copper complex glutathione adducts and ABCC1-mediated efflux</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">13719</span>– <span class="NLM_lpage">13732</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c01277</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01277" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlWrur3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=13719-13732&author=J.+H.+Bormio%0ANunesauthor=S.+Hagerauthor=M.+Mathuberauthor=V.+P%C3%B3saauthor=A.+Rollerauthor=%C3%89.+A.+Enyedyauthor=A.+Stefanelliauthor=W.+Bergerauthor=B.+K.+Kepplerauthor=P.+Heffeterauthor=C.+R.+Kowol&title=Cancer+cell+resistance+against+the+clinically+investigated+thiosemicarbazone+COTI-2+is+based+on+formation+of+intracellular+copper+complex+glutathione+adducts+and+ABCC1-mediated+efflux&doi=10.1021%2Facs.jmedchem.0c01277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer Cell Resistance Against the Clinically Investigated Thiosemicarbazone COTI-2 Is Based on Formation of Intracellular Copper Complex Glutathione Adducts and ABCC1-Mediated Efflux</span></div><div class="casAuthors">Bormio Nunes, Julia H.; Hager, Sonja; Mathuber, Marlene; Posa, Vivien; Roller, Alexander; Enyedy, Eva A.; Stefanelli, Alessia; Berger, Walter; Keppler, Bernhard K.; Heffeter, Petra; Kowol, Christian R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">13719-13732</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">COTI-2 is a novel anticancer thiosemicarbazone in phase I clin. trial.  However, the effects of metal complexation (a main characteristic of thiosemicarbazones) and acquired resistance mechanisms are widely unknown.  Therefore, in this study, the copper and iron complexes of COTI-2 were synthesized and evaluated for their anticancer activity and impact on drug resistance in comparison to metal-free thiosemicarbazones.  Investigations using Triapine-resistant SW480/Tria and newly established COTI-2-resistant SW480/Coti cells revealed distinct structure-activity relationships.  SW480/Coti cells were found to overexpress ABCC1, and COTI-2 being a substrate for this efflux pump.  This was unexpected, as ABCC1 has strong selectivity for glutathione adducts.  The recognition by ABCC1 could be explained by the redn. kinetics of a ternary Cu-COTI-2 complex with glutathione.  Thus, only thiosemicarbazones forming stable, nonreducible copper(II)-glutathione adducts are recognized and, in turn, effluxed by ABCC1.  This reveals a crucial connection between copper complex chem., glutathione interaction, and the resistance profile of clin. relevant thiosemicarbazones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbICe_bVcd8LVg90H21EOLACvtfcHk0liTLt0qOJYk-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlWrur3I&md5=bf35acbade982334ebd64e89978d2e3a</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01277%26sid%3Dliteratum%253Aachs%26aulast%3DBormio%2BNunes%26aufirst%3DJ.%2BH.%26aulast%3DHager%26aufirst%3DS.%26aulast%3DMathuber%26aufirst%3DM.%26aulast%3DP%25C3%25B3sa%26aufirst%3DV.%26aulast%3DRoller%26aufirst%3DA.%26aulast%3DEnyedy%26aufirst%3D%25C3%2589.%2BA.%26aulast%3DStefanelli%26aufirst%3DA.%26aulast%3DBerger%26aufirst%3DW.%26aulast%3DKeppler%26aufirst%3DB.%2BK.%26aulast%3DHeffeter%26aufirst%3DP.%26aulast%3DKowol%26aufirst%3DC.%2BR.%26atitle%3DCancer%2520cell%2520resistance%2520against%2520the%2520clinically%2520investigated%2520thiosemicarbazone%2520COTI-2%2520is%2520based%2520on%2520formation%2520of%2520intracellular%2520copper%2520complex%2520glutathione%2520adducts%2520and%2520ABCC1-mediated%2520efflux%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D13719%26epage%3D13732%26doi%3D10.1021%2Facs.jmedchem.0c01277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kowol, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichinger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakupec, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arion, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keppler, B. K.</span></span> <span> </span><span class="NLM_article-title">Gallium(III) and iron(III) complexes of r-n-heterocyclic thiosemicarbazones: synthesis, characterization, cytotoxicity, and interaction with ribonucleotide reductase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1254</span>– <span class="NLM_lpage">1265</span>, <span class="refDoi"> DOI: 10.1021/jm0612618</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0612618" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvFags7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1254-1265&author=C.+R.+Kowolauthor=R.+Bergerauthor=R.+Eichingerauthor=A.+Rollerauthor=M.+A.+Jakupecauthor=P.+P.+Schmidtauthor=V.+B.+Arionauthor=B.+K.+Keppler&title=Gallium%28III%29+and+iron%28III%29+complexes+of+r-n-heterocyclic+thiosemicarbazones%3A+synthesis%2C+characterization%2C+cytotoxicity%2C+and+interaction+with+ribonucleotide+reductase&doi=10.1021%2Fjm0612618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Gallium(III) and Iron(III) Complexes of α-N-Heterocyclic Thiosemicarbazones: Synthesis, Characterization, Cytotoxicity, and Interaction with Ribonucleotide Reductase</span></div><div class="casAuthors">Kowol, Christian R.; Berger, Roland; Eichinger, Rene; Roller, Alexander; Jakupec, Michael A.; Schmidt, Peter P.; Arion, Vladimir B.; Keppler, Bernhard K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1254-1265</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ga(III) and Fe(III) complexes with five different 4N-substituted α-N-heterocyclic thiosemicarbazones, viz., 2-acetylpyridine N,N-dimethylthiosemicarbazone (1), 2-acetylpyridine N-pyrrolidinylthiosemicarbazone (2), acetylpyrazine N,N-dimethylthiosemicarbazone (3), acetylpyrazine N-pyrrolidinylthiosemicarbazone (4), and acetylpyrazine N-piperidinylthiosemicarbazone (5), [GaLCl2] (HL = 1 and 2) and [ML2][Y] (M = Ga, HL = 1-5, Y = PF6; M = Fe, HL = 1-5, Y = FeCl4 and PF6) were synthesized and characterized by elemental anal., a no. of spectroscopic methods (NMR, IR, UV-visible), mass spectrometry, and x-ray crystallog.  In vitro antitumor potency was studied in human cancer cell lines (41M and SK-BR-3).  The central metal ions exert pronounced effects in a divergent manner: Ga(III) enhances, whereas Fe(III) weakens the cytotoxicity of the ligands.  The capacity of ligand 1 and its Ga(III) and Fe(III) complexes to destroy the tyrosyl radical of the presumed target ribonucleotide reductase is reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK0rY8cgonJLVg90H21EOLACvtfcHk0liTLt0qOJYk-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvFags7g%253D&md5=18ea78354426cd88f574be43934eee27</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm0612618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0612618%26sid%3Dliteratum%253Aachs%26aulast%3DKowol%26aufirst%3DC.%2BR.%26aulast%3DBerger%26aufirst%3DR.%26aulast%3DEichinger%26aufirst%3DR.%26aulast%3DRoller%26aufirst%3DA.%26aulast%3DJakupec%26aufirst%3DM.%2BA.%26aulast%3DSchmidt%26aufirst%3DP.%2BP.%26aulast%3DArion%26aufirst%3DV.%2BB.%26aulast%3DKeppler%26aufirst%3DB.%2BK.%26atitle%3DGallium%2528III%2529%2520and%2520iron%2528III%2529%2520complexes%2520of%2520r-n-heterocyclic%2520thiosemicarbazones%253A%2520synthesis%252C%2520characterization%252C%2520cytotoxicity%252C%2520and%2520interaction%2520with%2520ribonucleotide%2520reductase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D1254%26epage%3D1265%26doi%3D10.1021%2Fjm0612618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jansson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhardt, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. R.</span></span> <span> </span><span class="NLM_article-title">Novel Thiosemicarbazones of the ApT and DpT series and their copper complexes: identification of pronounced redox activity and characterization of their antitumor activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">5759</span>– <span class="NLM_lpage">5769</span>, <span class="refDoi"> DOI: 10.1021/jm100561b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100561b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;key=1%3ACAS%3A528%3ADC%252BC3cXotlSnsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5759-5769&author=P.+J.+Janssonauthor=P.+C.+Sharpeauthor=P.+V.+Bernhardtauthor=D.+R.+Richardson&title=Novel+Thiosemicarbazones+of+the+ApT+and+DpT+series+and+their+copper+complexes%3A+identification+of+pronounced+redox+activity+and+characterization+of+their+antitumor+activity&doi=10.1021%2Fjm100561b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Thiosemicarbazones of the ApT and DpT Series and Their Copper Complexes: Identification of Pronounced Redox Activity and Characterization of Their Antitumor Activity</span></div><div class="casAuthors">Jansson, Patric J.; Sharpe, Philip C.; Bernhardt, Paul V.; Richardson, Des R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5759-5769</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The novel chelators 2-acetylpyridine-4,4-dimethyl-3-thiosemicarbazone (HAp44mT) and di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (HDp44mT) have been examd. to elucidate the structure-activity relationships necessary to form copper (Cu) complexes with pronounced antitumor activity.  Electrochem. studies demonstrated that the Cu complexes of these ligands had lower redox potentials than their iron complexes.  Moreover, the Cu complexes where the ligand/metal ratio was 1:1 rather than 2:1 had significantly higher intracellular oxidative properties and antitumor efficacy.  Interestingly, the 2:1 complex was shown to dissoc. to give significant amts. of the 1:1 complex that could be the major cytotoxic effector.  Both types of Cu complex showed significantly more antiproliferative activity than the ligand alone.  We also demonstrate the importance of the inductive effects of substituents on the carbonyl group of the parent ketone, which influence the CuII/I redox potentials because of their proximity to the metal center.  The structure-activity relationships described are important for the design of potent thiosemicarbazone Cu complexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhryQ9dAB5CLVg90H21EOLACvtfcHk0liTLt0qOJYk-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXotlSnsr4%253D&md5=7417f8c18eed7edddd542da369ecb5ab</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fjm100561b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100561b%26sid%3Dliteratum%253Aachs%26aulast%3DJansson%26aufirst%3DP.%2BJ.%26aulast%3DSharpe%26aufirst%3DP.%2BC.%26aulast%3DBernhardt%26aufirst%3DP.%2BV.%26aulast%3DRichardson%26aufirst%3DD.%2BR.%26atitle%3DNovel%2520Thiosemicarbazones%2520of%2520the%2520ApT%2520and%2520DpT%2520series%2520and%2520their%2520copper%2520complexes%253A%2520identification%2520of%2520pronounced%2520redox%2520activity%2520and%2520characterization%2520of%2520their%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5759%26epage%3D5769%26doi%3D10.1021%2Fjm100561b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7EEK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7EEK','PDB','7EEK'); return false;">PDB: 7EEK</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i42"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00050">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_75564"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00050?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00050</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Experimental methods; crystal data and details of the structure refinement for Au agents; serological analysis of mice treated with NaCl, the Au agent, and HSA-Au agent complex NPs; cellular uptake of the Au agent and HSA-Au agent complex NPs; purity of compounds <b>1b–5b</b>, as characterized by HPLC; related primer lists; NMR spectra of ligands and Au agents; and ESI-MS spectra of ligands and Au agents (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00050/suppl_file/jm1c00050_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00050/suppl_file/jm1c00050_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00050/suppl_file/jm1c00050_si_001.pdf">jm1c00050_si_001.pdf (1.27 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00050/suppl_file/jm1c00050_si_002.csv">jm1c00050_si_002.csv (1.03 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Protein Data Bank entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7EEK">7EEK</a>, HSA-Au agent complex.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00050&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-10%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00050%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00050" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679ab9066939d187","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
